BRCA1	NNP	O
is	VBZ	O
secreted	VBN	O
and	CC	O
exhibits	JJ	O
properties	NNS	O
of	IN	O
a	DT	O
granin	NN	O
.	.	O

Germline	NNP	O
mutations	NNS	O
in	IN	O
BRCA1	NNP	O
are	VBP	O
responsible	JJ	O
for	IN	O
most	JJS	O
cases	NNS	O
of	IN	O
inherited	JJ	B_Disease
breast	NN	I_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
.	.	O

However	RB	O
,	,	O
the	DT	O
function	NN	O
of	IN	O
the	DT	O
BRCA1	NNP	O
protein	NN	O
has	VBZ	O
remained	VBN	O
elusive	JJ	O
.	.	O

We	PRP	O
now	RB	O
show	VBP	O
that	IN	O
BRCA1	NNP	O
encodes	VBZ	O
a	DT	O
190	CD	O
-	:	O
kD	NN	O
protein	NN	O
with	IN	O
sequence	NN	O
homology	NN	O
and	CC	O
biochemical	JJ	O
analogy	NN	O
to	TO	O
the	DT	O
granin	NN	O
protein	NN	O
family	NN	O
.	.	O

Interestingly	RB	O
,	,	O
BRCA2	NNP	O
also	RB	O
includes	VBZ	O
a	DT	O
motif	NN	O
similar	JJ	O
to	TO	O
the	DT	O
granin	NN	O
consensus	NN	O
at	IN	O
the	DT	O
C	NNP	O
terminus	NN	O
of	IN	O
the	DT	O
protein	NN	O
.	.	O

Both	DT	O
BRCA1	NNP	O
and	CC	O
the	DT	O
granins	NNS	O
localize	VBP	O
to	TO	O
secretory	JJ	O
vesicles	NNS	O
,	,	O
are	VBP	O
secreted	VBN	O
by	IN	O
a	DT	O
regulated	JJ	O
pathway	NN	O
,	,	O
are	VBP	O
post	VBN	O
-	:	O
translationally	RB	O
glycosylated	VBN	O
and	CC	O
are	VBP	O
responsive	JJ	O
to	TO	O
hormones	NNS	O
.	.	O

As	IN	O
a	DT	O
regulated	JJ	O
secretory	NN	O
protein	NN	O
,	,	O
BRCA1	NNP	O
appears	VBZ	O
to	TO	O
function	VB	O
by	IN	O
a	DT	O
mechanism	NN	O
not	RB	O
previously	RB	O
described	VBN	O
for	IN	O
tumour	NN	S_Disease
suppressor	NN	O
gene	NN	O
products	NNS	O
.	.	O
.	.	O

Ovarian	JJ	B_Disease
cancer	NN	E_Disease
risk	NN	O
in	IN	O
BRCA1	NNP	O
carriers	NNS	O
is	VBZ	O
modified	VBN	O
by	IN	O
the	DT	O
HRAS1	NNP	O
variable	JJ	O
number	NN	O
of	IN	O
tandem	JJ	O
repeat	NN	O
(	(	O
VNTR	NNP	O
)	)	O
locus	NN	O
.	.	O

Women	NNS	O
who	WP	O
carry	VBP	O
a	DT	O
mutation	NN	O
in	IN	O
the	DT	O
BRCA1	NNP	O
gene	NN	O
(	(	O
on	IN	O
chromosome	NN	O
17q21	CD	O
)	)	O
,	,	O
have	VBP	O
an	DT	O
80	CD	O
%	NN	O
risk	NN	O
of	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
and	CC	O
a	DT	O
40	CD	O
%	NN	O
risk	NN	O
of	IN	O
ovarian	JJ	B_Disease
cancer	NN	E_Disease
by	IN	O
the	DT	O
age	NN	O
of	IN	O
70	CD	O
(	(	O
ref	NN	O
.	.	O

1	CD	O
)	)	O
.	.	O

The	DT	O
variable	JJ	O
penetrance	NN	O
of	IN	O
BRCA1	NNP	O
suggests	VBZ	O
that	IN	O
other	JJ	O
genetic	JJ	O
and	CC	O
non	JJ	O
-	:	O
genetic	JJ	O
factors	NNS	O
play	VBP	O
a	DT	O
role	NN	O
in	IN	O
tumourigenesis	NN	O
in	IN	O
these	DT	O
individuals	NNS	O
.	.	O

The	DT	O
HRAS1	NNP	O
variable	JJ	O
number	NN	O
of	IN	O
tandem	JJ	O
repeats	NNS	O
(	(	O
VNTR	NNP	O
)	)	O
polymorphism	NN	O
,	,	O
located	VBN	O
1	CD	O
kilobase	NN	O
(	(	O
kb	NN	O
)	)	O
downstream	NN	O
of	IN	O
the	DT	O
HRAS1	NNP	O
proto	NN	O
-	:	O
oncogene	NN	O
(	(	O
chromosome	JJ	O
11p15	CD	O
.	.	O

5	CD	O
)	)	O
is	VBZ	O
one	CD	O
possible	JJ	O
genetic	JJ	O
modifier	NN	O
of	IN	O
cancer	NN	S_Disease
penetrance	NN	O
.	.	O

Individuals	NNS	O
who	WP	O
have	VBP	O
rare	JJ	O
alleles	NNS	O
of	IN	O
the	DT	O
VNTR	NNP	O
have	VBP	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
certain	JJ	O
types	NNS	O
of	IN	O
cancers	NNS	S_Disease
,	,	O
including	VBG	O
breast	NN	B_Disease
cancer	NN	E_Disease
(	(	O
2	CD	O
-	:	O
4	CD	O
)	)	O
.	.	O

To	TO	O
investigate	VB	O
whether	IN	O
the	DT	O
presence	NN	O
of	IN	O
rare	JJ	O
HRAS1	NNP	O
alleles	VBZ	O
increases	NNS	O
susceptibility	NN	O
to	TO	O
hereditary	VB	B_Disease
breast	NN	I_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
,	,	O
we	PRP	O
have	VBP	O
typed	VBN	O
a	DT	O
panel	NN	O
of	IN	O
307	CD	O
female	JJ	O
BRCA1	NNP	O
carriers	NNS	O
at	IN	O
this	DT	O
locus	NN	O
using	VBG	O
a	DT	O
PCR	NNP	O
-	:	O
based	VBN	O
technique	NN	O
.	.	O

The	DT	O
risk	NN	O
for	IN	O
ovarian	JJ	B_Disease
cancer	NN	E_Disease
was	VBD	O
2	CD	O
.	.	O

11	CD	O
times	NNS	O
greater	JJR	O
for	IN	O
BRCA1	NNP	O
carriers	NNS	O
harbouring	VBG	O
one	CD	O
or	CC	O
two	CD	O
rare	JJ	O
HRAS1	NNP	O
alleles	NNS	O
,	,	O
compared	VBN	O
to	TO	O
carriers	NNS	O
with	IN	O
only	JJ	O
common	JJ	O
alleles	NNS	O
(	(	O
P	NNP	O
=	VBZ	O
0	CD	O
.	.	O

015	CD	O
)	)	O
.	.	O

The	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
relative	JJ	O
risk	NN	O
associated	VBN	O
with	IN	O
a	DT	O
rare	JJ	O
HRAS1	NNP	O
allele	NN	O
was	VBD	O
not	RB	O
altered	VBN	O
by	IN	O
adjusting	VBG	O
for	IN	O
the	DT	O
other	JJ	O
known	VBN	O
risk	NN	O
factors	NNS	O
for	IN	O
hereditary	JJ	B_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
(	(	O
5	CD	O
)	)	O
.	.	O

Susceptibility	NN	O
to	TO	O
breast	VB	B_Disease
cancer	NN	E_Disease
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
be	VB	O
affected	VBN	O
by	IN	O
the	DT	O
presence	NN	O
of	IN	O
rare	JJ	O
HRAS1	NNP	O
alleles	NNS	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
the	DT	O
first	JJ	O
to	TO	O
show	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
modifying	VBG	O
gene	NN	O
on	IN	O
the	DT	O
penetrance	NN	O
of	IN	O
an	DT	O
inherited	JJ	B_Disease
cancer	NN	I_Disease
syndrome	NN	E_Disease

A	DT	O
novel	NN	O
homeodomain	NN	O
-	:	O
encoding	VBG	O
gene	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
large	JJ	O
CpG	NNP	O
island	NN	O
interrupted	VBN	O
by	IN	O
the	DT	O
myotonic	JJ	B_Disease
dystrophy	NN	E_Disease
unstable	JJ	O
(	(	O
CTG	NNP	O
)	)	O
n	RB	O
repeat	NN	O
.	.	O

Myotonic	JJ	B_Disease
dystrophy	NN	E_Disease
(	(	O
DM	NNP	S_Disease
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
(	(	O
CTG	NNP	O
)	)	O
n	FW	O
trinucleotide	JJ	O
repeat	NN	O
expansion	NN	O
in	IN	O
the	DT	O
3	CD	O
-	:	O
untranslated	JJ	O
region	NN	O
of	IN	O
a	DT	O
protein	NN	O
kinase	SYM	O
-	:	O
encoding	VBG	O
gene	NN	O
,	,	O
DMPK	NNP	O
,	,	O
which	WDT	O
maps	VBZ	O
to	TO	O
chromosome	VB	O
19q13	CD	O
.	.	O

3	CD	O
.	.	O

Characterisation	NN	O
of	IN	O
the	DT	O
expression	NN	O
of	IN	O
this	DT	O
gene	NN	O
in	IN	O
patient	JJ	O
tissues	NNS	O
has	VBZ	O
thus	RB	O
far	RB	O
generated	JJ	O
conflicting	VBG	O
data	NNS	O
on	IN	O
alterations	NNS	O
in	IN	O
the	DT	O
steady	JJ	O
state	NN	O
levels	NNS	O
of	IN	O
DMPK	NNP	O
mRNA	NN	O
,	,	O
and	CC	O
on	IN	O
the	DT	O
final	JJ	O
DMPK	NNP	O
protein	NN	O
levels	NNS	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
expansion	NN	O
.	.	O

The	DT	O
DM	NNP	S_Disease
region	NN	O
of	IN	O
chromosome	NN	O
19	CD	O
is	VBZ	O
gene	NN	O
rich	JJ	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
possible	JJ	O
that	IN	O
the	DT	O
repeat	NN	O
expansion	NN	O
may	MD	O
lead	VB	O
to	TO	O
dysfunction	NN	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
transcription	NN	O
units	NNS	O
in	IN	O
the	DT	O
vicinity	NN	O
,	,	O
perhaps	RB	O
as	IN	O
a	DT	O
consequence	NN	O
of	IN	O
chromatin	JJ	O
disruption	NN	O
.	.	O

We	PRP	O
have	VBP	O
searched	VBN	O
for	IN	O
genes	NNS	O
associated	VBN	O
with	IN	O
a	DT	O
CpG	NNP	O
island	NN	O
at	IN	O
the	DT	O
3	CD	O
end	NN	O
of	IN	O
DMPK	NNP	O
.	.	O

Sequencing	VBG	O
of	IN	O
this	DT	O
region	NN	O
shows	VBZ	O
that	IN	O
the	DT	O
island	NN	O
extends	VBZ	O
over	IN	O
3	CD	O
.	.	O

5	CD	O
kb	NN	O
and	CC	O
is	VBZ	O
interrupted	VBN	O
by	IN	O
the	DT	O
(	(	O
CTG	NNP	O
)	)	O
n	RB	O
repeat	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
genomic	JJ	O
sequences	NNS	O
downstream	NN	O
(	(	O
centromeric	JJ	O
)	)	O
of	IN	O
the	DT	O
repeat	NN	O
in	IN	O
human	JJ	O
and	CC	O
mouse	NN	O
identified	JJ	O
regions	NNS	O
of	IN	O
significant	JJ	O
homology	NN	O
.	.	O

These	DT	O
correspond	NN	O
to	TO	O
exons	NNS	O
of	IN	O
a	DT	O
gene	NN	O
predicted	VBN	O
to	TO	O
encode	VB	O
a	DT	O
homeodomain	NN	O
protein	NN	O
.	.	O

RT	NNP	O
-	:	O
PCR	NN	O
analysis	NN	O
shows	VBZ	O
that	IN	O
this	DT	O
gene	NN	O
,	,	O
which	WDT	O
we	PRP	O
have	VBP	O
called	VBN	O
DM	NNP	S_Disease
locus	SYM	O
-	:	O
associated	VBN	O
homeodomain	NN	O
protein	NN	O
(	(	O
DMAHP	NNP	O
)	)	O
,	,	O
is	VBZ	O
expressed	VBN	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
human	JJ	O
tissues	NNS	O
,	,	O
including	VBG	O
skeletal	JJ	O
muscle	NN	O
,	,	O
heart	NN	O
and	CC	O
brain	NN	O
.	.	O

Germline	NNP	O
mutations	NNS	O
in	IN	O
the	DT	O
RB1	NNP	O
gene	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hereditary	JJ	B_Disease
retinoblastoma	NN	E_Disease
.	.	O

We	PRP	O
have	VBP	O
analyzed	VBN	O
the	DT	O
27	CD	O
exons	NNS	O
and	CC	O
the	DT	O
promoter	NN	O
region	NN	O
of	IN	O
the	DT	O
RB1	NNP	O
gene	NN	O
in	IN	O
familial	JJ	B_Disease
or	CC	I_Disease
sporadic	JJ	I_Disease
bilateral	JJ	I_Disease
retinoblastoma	NN	E_Disease
by	IN	O
using	VBG	O
single	JJ	O
-	:	O
strand	NN	O
conformation	NN	O
polymorphism	NN	O
analysis	NN	O
.	.	O

For	IN	O
improvement	NN	O
over	IN	O
previous	JJ	O
studies	NNS	O
,	,	O
a	DT	O
new	JJ	O
set	NN	O
of	IN	O
primers	NNS	O
has	VBZ	O
been	VBN	O
designed	VBN	O
,	,	O
which	WDT	O
allow	VBP	O
for	IN	O
amplification	NN	O
of	IN	O
the	DT	O
coding	NN	O
and	CC	O
splicing	NN	O
sequences	NNS	O
only	RB	O
.	.	O

The	DT	O
positioning	NN	O
of	IN	O
the	DT	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
PCR	NNP	O
)	)	O
primers	NNS	O
was	VBD	O
such	JJ	O
that	IN	O
the	DT	O
resulting	VBG	O
PCR	NNP	O
products	NNS	O
were	VBD	O
of	IN	O
different	JJ	O
sizes	NNS	O
,	,	O
which	WDT	O
enabled	VBD	O
us	PRP	O
to	TO	O
analyze	VB	O
two	CD	O
different	JJ	O
exons	NNS	O
simultaneously	RB	O
and	CC	O
still	RB	O
distinguish	VB	O
between	IN	O
the	DT	O
banding	NN	O
profiles	NNS	O
for	IN	O
both	DT	O
(	(	O
biplex	JJ	O
analysis	NN	O
)	)	O
.	.	O

By	IN	O
using	VBG	O
this	DT	O
approach	NN	O
,	,	O
we	PRP	O
were	VBD	O
able	JJ	O
to	TO	O
identify	VB	O
mutation	NN	O
in	IN	O
22	CD	O
new	JJ	O
patients	NNS	O
,	,	O
but	CC	O
the	DT	O
overall	JJ	O
efficiency	NN	O
of	IN	O
the	DT	O
procedure	NN	O
when	WRB	O
we	PRP	O
used	VBD	O
a	DT	O
single	JJ	O
-	:	O
pass	NN	O
regimen	NN	O
was	VBD	O
only	RB	O
48	CD	O
%	NN	O
.	.	O

The	DT	O
mutations	NNS	O
were	VBD	O
small	JJ	O
insertions	NNS	O
and	CC	O
deletions	NNS	O
and	CC	O
point	NN	O
mutations	NNS	O
in	IN	O
roughly	RB	O
equal	JJ	O
proportions	NNS	O
.	.	O
.	.	O

Type	NNP	B_Disease
II	NNP	I_Disease
human	JJ	I_Disease
complement	NN	I_Disease
C2	NNP	I_Disease
deficiency	NN	E_Disease
.	.	O

Allele	NNP	O
-	:	O
specific	JJ	O
amino	NN	O
acid	JJ	O
substitutions	NNS	O
(	(	O
Ser189	NNP	O
-	:	O
-	:	O
>	NN	O
Phe	NNP	O
;	:	O
Gly444	NNP	O
-	:	O
-	:	O
>	NN	O
Arg	NNP	O
)	)	O
cause	NN	O
impaired	JJ	O
C2	NNP	O
secretion	NN	O
.	.	O

Type	NNP	B_Disease
II	NNP	I_Disease
complement	NN	I_Disease
protein	NN	I_Disease
C2	NNP	I_Disease
deficiency	NN	E_Disease
is	VBZ	O
characterized	VBN	O
by	IN	O
a	DT	O
selective	JJ	O
block	NN	O
in	IN	O
C2	NNP	O
secretion	NN	O
.	.	O

The	DT	O
Type	NNP	O
II	NNP	O
C2	NNP	O
null	JJ	O
allele	NN	O
(	(	O
C2Q0	NNP	O
)	)	O
is	VBZ	O
linked	VBN	O
to	TO	O
two	CD	O
major	JJ	O
histocompatibility	NN	O
haplotypes	NNS	O
(	(	O
MHC	NNP	O
)	)	O
that	WDT	O
differ	VBP	O
from	IN	O
the	DT	O
MHC	NNP	O
of	IN	O
the	DT	O
more	RBR	O
common	JJ	O
Type	NNP	B_Disease
I	PRP	I_Disease
C2	NNP	I_Disease
deficiency	NN	E_Disease
.	.	O

To	TO	O
determine	VB	O
the	DT	O
molecular	JJ	O
basis	NN	O
of	IN	O
Type	NNP	B_Disease
II	NNP	I_Disease
deficiency	VBZ	E_Disease
the	DT	O
two	CD	O
Type	NNP	O
II	NNP	O
C2Q0	NNP	O
genes	NNS	O
were	VBD	O
isolated	VBN	O
and	CC	O
transfected	VBN	O
separately	RB	O
into	IN	O
L	NNP	O
-	:	O
cells	NNS	O
.	.	O

Subsequent	JJ	O
molecular	JJ	O
biology	NN	O
,	,	O
biosynthetic	JJ	O
,	,	O
and	CC	O
immunofluorescence	NN	O
studies	NNS	O
demonstrated	VBD	O
that	IN	O
C2	NNP	O
secretion	NN	O
is	VBZ	O
impaired	VBN	O
in	IN	O
Type	NNP	B_Disease
II	NNP	I_Disease
C2	NNP	I_Disease
deficiency	NN	E_Disease
because	IN	O
of	IN	O
different	JJ	O
missense	NN	O
mutations	NNS	O
at	IN	O
highly	RB	O
conserved	VBN	O
residues	NNS	O
in	IN	O
each	DT	O
of	IN	O
the	DT	O
C2Q0	NNP	O
alleles	NNS	O
.	.	O

One	CD	O
is	VBZ	O
in	IN	O
exon	JJ	O
5	CD	O
(	(	O
nucleotide	JJ	O
C566	NNP	O
-	:	O
-	:	O
>	NN	O
T	NNP	O
;	:	O
Ser189	NNP	O
-	:	O
-	:	O
>	NN	O
Phe	NNP	O
)	)	O
of	IN	O
the	DT	O
C2Q0	NNP	O
gene	NN	O
linked	VBD	O
to	TO	O
the	DT	O
MHC	NNP	O
haplotype	NN	O
A11	NNP	O
,	,	O
B35	NNP	O
,	,	O
DRw1	NNP	O
,	,	O
BFS	NNP	O
,	,	O
C4A0B1	NNP	O
.	.	O

The	DT	O
other	JJ	O
is	VBZ	O
in	IN	O
exon	JJ	O
11	CD	O
(	(	O
G1930	NNP	O
-	:	O
-	:	O
>	VB	O
A	DT	O
;	:	O
Gly444	NNP	O
-	:	O
-	:	O
>	NN	O
Arg	NNP	O
)	)	O
of	IN	O
the	DT	O
C2Q0	NNP	O
gene	NN	O
linked	VBD	O
to	TO	O
the	DT	O
MHC	NNP	O
haplotype	NN	O
A2	NNP	O
,	,	O
B5	NNP	O
,	,	O
DRw4	NNP	O
,	,	O
BFS	NNP	O
,	,	O
C4A3B1	NNP	O
.	.	O

Each	DT	O
mutant	JJ	O
C2	NNP	O
gene	NN	O
product	NN	O
is	VBZ	O
retained	VBN	O
early	RB	O
in	IN	O
the	DT	O
secretory	JJ	O
pathway	NN	O
.	.	O

These	DT	O
mutants	NNS	O
provide	VBP	O
models	NNS	O
for	IN	O
elucidating	VBG	O
the	DT	O
C2	NNP	O
secretory	NN	O
pathway	NN	O
.	.	O
.	.	O

Defective	JJ	O
dimerization	NN	O
of	IN	O
von	JJ	B_Disease
Willebrand	NNP	E_Disease
factor	NN	O
subunits	NNS	O
due	JJ	O
to	TO	O
a	DT	O
Cys	NNP	O
-	:	O
>	NN	O
Arg	NNP	O
mutation	NN	O
in	IN	O
type	NN	B_Disease
IID	NNP	I_Disease
von	NNP	I_Disease
Willebrand	NNP	I_Disease
disease	NN	E_Disease
.	.	O

The	DT	O
same	JJ	O
heterozygous	JJ	O
T	NNP	O
-	:	O
>	NN	O
C	NNP	O
transition	NN	O
at	IN	O
nt	JJ	O
8567	CD	O
of	IN	O
the	DT	O
von	NN	B_Disease
Willebrand	NNP	E_Disease
factor	NN	O
(	(	O
vWF	NN	O
)	)	O
transcript	NN	O
was	VBD	O
found	VBN	O
in	IN	O
two	CD	O
unrelated	JJ	O
patients	NNS	O
with	IN	O
type	JJ	B_Disease
IID	NNP	I_Disease
von	NNP	I_Disease
Willebrand	NNP	I_Disease
disease	NN	E_Disease
,	,	O
with	IN	O
no	DT	O
other	JJ	O
apparent	JJ	O
abnormality	NN	O
.	.	O

In	IN	O
one	CD	O
family	NN	O
,	,	O
both	DT	O
alleles	NNS	O
were	VBD	O
normal	JJ	O
in	IN	O
the	DT	O
parents	NNS	O
and	CC	O
one	CD	O
sister	NN	O
;	:	O
thus	RB	O
,	,	O
the	DT	O
mutation	NN	O
originated	VBD	O
de	FW	O
novo	FW	O
in	IN	O
the	DT	O
proposita	NN	O
.	.	O

The	DT	O
second	JJ	O
patient	NN	O
also	RB	O
had	VBD	O
asymptomatic	JJ	O
parents	NNS	O
who	WP	O
,	,	O
however	RB	O
,	,	O
were	VBD	O
not	RB	O
available	JJ	O
for	IN	O
study	NN	O
.	.	O

The	DT	O
structural	JJ	O
consequences	NNS	O
of	IN	O
the	DT	O
identified	JJ	O
mutation	NN	O
,	,	O
resulting	VBG	O
in	IN	O
the	DT	O
CyS2010	NNP	O
-	:	O
>	NN	O
Arg	NNP	O
substitution	NN	O
,	,	O
were	VBD	O
evaluated	VBN	O
by	IN	O
expression	NN	O
of	IN	O
the	DT	O
vWF	NN	O
carboxyl	SYM	O
-	:	O
terminal	JJ	O
domain	NN	O
containing	VBG	O
residues	NNS	O
1366	CD	O
-	:	O
2050	CD	O
.	.	O

Insect	NNP	O
cells	NNS	O
infected	VBN	O
with	IN	O
recombinant	JJ	O
baculovirus	NN	O
expressing	VBG	O
normal	JJ	O
vWF	JJ	O
sequence	NN	O
secreted	VBD	O
a	DT	O
disulfide	NN	O
linked	VBN	O
dimeric	JJ	O
molecule	NN	O
with	IN	O
an	DT	O
apparent	JJ	O
molecular	JJ	O
mass	NN	O
of	IN	O
150	CD	O
kDa	NNS	O
before	IN	O
reduction	NN	O
,	,	O
yielding	VBG	O
a	DT	O
single	JJ	O
band	NN	O
of	IN	O
80	CD	O
kDa	NNS	O
after	IN	O
disulfide	JJ	O
bond	NN	O
reduction	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
cells	NNS	O
expressing	VBG	O
the	DT	O
mutant	JJ	O
fragment	NN	O
secreted	VBD	O
a	DT	O
monomeric	JJ	O
molecule	NN	O
of	IN	O
apparent	JJ	O
molecular	JJ	O
mass	NN	O
of	IN	O
80	CD	O
kDa	NNS	O
,	,	O
which	WDT	O
remained	VBD	O
unchanged	JJ	O
after	IN	O
reduction	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
CyS2010	NNP	O
is	VBZ	O
essential	JJ	O
for	IN	O
normal	JJ	O
dimerization	NN	O
of	IN	O
vWF	NN	O
subunits	NNS	O
through	IN	O
disulfide	JJ	O
bonding	NN	O
of	IN	O
carboxyl	NN	O
-	:	O
terminal	NN	O
domains	NNS	O
and	CC	O
that	IN	O
a	DT	O
heterozygous	JJ	O
mutation	NN	O
in	IN	O
the	DT	O
corresponding	JJ	O
codon	NN	O
is	VBZ	O
responsible	JJ	O
for	IN	O
defective	JJ	O
multimer	NN	O
formation	NN	O
in	IN	O
type	NN	B_Disease
IID	NNP	I_Disease
von	NNP	I_Disease
Willebrand	NNP	I_Disease
disease	NN	E_Disease
.	.	O
.	.	O

Wiskott	NNP	B_Disease
-	:	I_Disease
Aldrich	NNP	I_Disease
syndrome	VBD	E_Disease
protein	NN	O
,	,	O
a	DT	O
novel	JJ	O
effector	NN	O
for	IN	O
the	DT	O
GTPase	NNP	O
CDC42Hs	NNP	O
,	,	O
is	VBZ	O
implicated	VBN	O
in	IN	O
actin	JJ	O
polymerization	NN	O
.	.	O

The	DT	O
Rho	NNP	O
family	NN	O
of	IN	O
GTPases	NNP	O
control	NN	O
diverse	JJ	O
biological	JJ	O
processes	NNS	O
,	,	O
including	VBG	O
cell	NN	O
morphology	NN	O
and	CC	O
mitogenesis	NN	O
.	.	O

We	PRP	O
have	VBP	O
identified	VBN	O
WASP	NNP	O
,	,	O
the	DT	O
protein	NN	O
that	WDT	O
is	VBZ	O
defective	JJ	O
in	IN	O
Wiskott	NNP	B_Disease
-	:	I_Disease
Aldrich	NNP	I_Disease
syndrome	NN	E_Disease
(	(	O
WAS	NNP	S_Disease
)	)	O
,	,	O
as	IN	O
a	DT	O
novel	JJ	O
effector	NN	O
for	IN	O
CDC42Hs	NNP	O
,	,	O
but	CC	O
not	RB	O
for	IN	O
the	DT	O
other	JJ	O
Rho	NNP	O
family	NN	O
members	NNS	O
,	,	O
Rac	NNP	O
and	CC	O
Rho	NNP	O
.	.	O

This	DT	O
interaction	NN	O
is	VBZ	O
dependent	JJ	O
on	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
G	NNP	O
protein	SYM	O
-	:	O
binding	NN	O
domain	NN	O
.	.	O

Cellular	JJ	O
expression	NN	O
of	IN	O
epitope	NN	O
-	:	O
tagged	VBN	O
WASP	NNP	O
produces	VBZ	O
clusters	NNS	O
of	IN	O
WASP	NNP	O
that	WDT	O
are	VBP	O
highly	RB	O
enriched	VBN	O
in	IN	O
polymerized	JJ	O
actin	NN	O
.	.	O

This	DT	O
clustering	NN	O
is	VBZ	O
not	RB	O
observed	VBN	O
with	IN	O
a	DT	O
C	NNP	O
-	:	O
terminally	RB	O
deleted	VBN	O
WASP	NNP	O
and	CC	O
is	VBZ	O
inhibited	VBN	O
by	IN	O
coexpression	NN	O
with	IN	O
dominant	JJ	O
negative	JJ	O
CDC42Hs	NNP	O
-	:	O
N17	NN	O
,	,	O
but	CC	O
not	RB	O
with	IN	O
dominant	JJ	O
negative	JJ	O
forms	NNS	O
of	IN	O
Rac	NNP	O
or	CC	O
Rho	NNP	O
.	.	O

Thus	RB	O
,	,	O
WASP	NNP	O
provides	VBZ	O
a	DT	O
novel	JJ	O
link	NN	O
between	IN	O
CDC42Hs	NNP	O
and	CC	O
the	DT	O
actin	JJ	O
cytoskeleton	NN	O
,	,	O
which	WDT	O
suggests	VBZ	O
a	DT	O
molecular	JJ	O
mechanism	NN	O
for	IN	O
many	JJ	O
of	IN	O
the	DT	O
cellular	JJ	O
abnormalities	NNS	O
in	IN	O
WAS	NNP	S_Disease
.	.	O

The	DT	O
WASP	NNP	O
sequence	NN	O
contains	VBZ	O
two	CD	O
novel	NN	O
domains	NNS	O
that	WDT	O
are	VBP	O
homologous	JJ	O
to	TO	O
other	JJ	O
proteins	NNS	O
involved	VBN	O
in	IN	O
action	NN	O
organization	NN	O
.	.	O
.	.	O

X	LS	B_Disease
-	:	I_Disease
linked	VBN	I_Disease
adrenoleukodystrophy	NN	E_Disease
is	VBZ	O
a	DT	O
frequent	JJ	O
cause	NN	O
of	IN	O
idiopathic	JJ	O
Addison	NNP	B_Disease
'	POS	I_Disease
s	JJ	I_Disease
disease	NN	E_Disease
in	IN	O
young	JJ	O
adult	NN	O
male	JJ	O
patients	NNS	O
.	.	O

X	LS	B_Disease
-	:	I_Disease
Linked	VBN	I_Disease
adrenoleukodystrophy	NN	E_Disease
(	(	O
ALD	NNP	S_Disease
)	)	O
is	VBZ	O
a	DT	O
genetic	JJ	B_Disease
disease	NN	E_Disease
associated	VBN	O
with	IN	O
demyelination	NN	B_Disease
of	IN	I_Disease
the	DT	I_Disease
central	JJ	I_Disease
nervous	JJ	I_Disease
system	NN	E_Disease
,	,	O
adrenal	JJ	B_Disease
insufficiency	NN	E_Disease
,	,	O
and	CC	O
accumulation	NN	O
of	IN	O
very	RB	O
long	RB	O
chain	NN	O
fatty	JJ	O
acids	NNS	O
in	IN	O
tissue	NN	O
and	CC	O
body	NN	O
fluids	NNS	O
.	.	O

ALD	NNP	S_Disease
is	VBZ	O
due	JJ	O
to	TO	O
mutation	NN	O
of	IN	O
a	DT	O
gene	NN	O
located	VBN	O
in	IN	O
Xq28	NNP	O
that	WDT	O
encodes	VBZ	O
a	DT	O
peroxisomal	JJ	O
transporter	NN	O
protein	NN	O
of	IN	O
unknown	JJ	O
function	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
phenotype	NN	O
of	IN	O
ALD	NNP	S_Disease
is	VBZ	O
the	DT	O
cerebral	JJ	O
form	NN	O
(	(	O
45	CD	O
%	NN	O
)	)	O
that	WDT	O
develops	VBZ	O
in	IN	O
boys	NNS	O
between	IN	O
5	CD	O
-	:	O
12	CD	O
yr	NN	O
.	.	O

Adrenomyeloneuropathy	NNP	S_Disease
(	(	O
AMN	NNP	S_Disease
)	)	O
involves	VBZ	O
the	DT	O
spinal	JJ	O
cord	NN	O
and	CC	O
peripheral	JJ	O
nerves	NNS	O
in	IN	O
young	JJ	O
adults	NNS	O
(	(	O
35	CD	O
%	NN	O
)	)	O
.	.	O

Adrenal	JJ	B_Disease
insufficiency	NN	E_Disease
(	(	O
Addisons	NNP	B_Disease
disease	NN	E_Disease
)	)	O
is	VBZ	O
frequently	RB	O
associated	VBN	O
with	IN	O
AMN	NNP	S_Disease
or	CC	O
cerebral	JJ	B_Disease
ALD	NNP	E_Disease
and	CC	O
may	MD	O
remain	VB	O
the	DT	O
only	JJ	O
clinical	JJ	O
expression	NN	O
of	IN	O
ALD	NNP	S_Disease
(	(	O
8	CD	O
%	NN	O
of	IN	O
cases	NNS	O
)	)	O
.	.	O

The	DT	O
prevalence	NN	O
of	IN	O
ALD	NNP	S_Disease
among	IN	O
adults	NNS	O
with	IN	O
Addisons	NNP	B_Disease
disease	NN	E_Disease
remains	VBZ	O
unknown	JJ	O
.	.	O

To	TO	O
evaluate	VB	O
this	DT	O
prevalence	NN	O
,	,	O
we	PRP	O
performed	VBD	O
biochemical	JJ	O
analysis	NN	O
of	IN	O
very	RB	O
long	RB	O
chain	NN	O
fatty	JJ	O
acids	NNS	O
in	IN	O
14	CD	O
male	NN	O
patients	NNS	O
(	(	O
age	NN	O
ranging	VBG	O
from	IN	O
12	CD	O
-	:	O
45	CD	O
yr	NN	O
at	IN	O
diagnosis	NN	O
)	)	O
previously	RB	O
diagnosed	VBN	O
as	IN	O
having	VBG	O
primary	JJ	O
idiopathic	JJ	O
adrenocortical	JJ	B_Disease
insufficiency	NN	E_Disease
.	.	O

In	IN	O
5	CD	O
of	IN	O
14	CD	O
patients	NNS	O
(	(	O
35	CD	O
%	NN	O
)	)	O
,	,	O
elevated	VBD	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
very	RB	O
long	RB	O
chain	NN	O
fatty	JJ	O
acids	NNS	O
were	VBD	O
detected	VBN	O
.	.	O

None	NN	O
of	IN	O
these	DT	O
patients	NNS	O
had	VBD	O
adrenocortical	JJ	O
antibodies	NNS	O
.	.	O

By	IN	O
electrophysiological	JJ	O
tests	NNS	O
and	CC	O
magnetic	JJ	O
resonance	NN	O
imaging	VBG	O
it	PRP	O
was	VBD	O
determined	VBN	O
that	IN	O
two	CD	O
patients	NNS	O
had	VBD	O
cerebral	JJ	B_Disease
ALD	NNP	E_Disease
,	,	O
one	CD	O
had	VBD	O
adrenomyeloneuropathy	VBN	S_Disease
with	IN	O
cerebral	JJ	O
involvement	NN	O
,	,	O
and	CC	O
two	CD	O
had	VBD	O
preclinical	JJ	O
AMN	NNP	S_Disease
.	.	O

Our	PRP$	O
data	NNS	O
support	NN	O
the	DT	O
hypothesis	NN	O
that	IN	O
ALD	NNP	S_Disease
is	VBZ	O
a	DT	O
frequent	JJ	O
cause	NN	O
of	IN	O
idiopathic	JJ	O
Addisons	NNP	B_Disease
disease	NN	E_Disease
in	IN	O
children	NNS	O
and	CC	O
adults	NNS	O
.	.	O
.	.	O

Tumor	NNP	S_Disease
suppression	NN	O
and	CC	O
apoptosis	NN	O
of	IN	O
human	JJ	O
prostate	NN	B_Disease
carcinoma	NN	E_Disease
mediated	VBN	O
by	IN	O
a	DT	O
genetic	JJ	O
locus	NN	O
within	IN	O
human	JJ	O
chromosome	NN	O
10pter	CD	O
-	:	O
q11	NN	O
.	.	O

Prostate	NNP	B_Disease
cancer	NN	E_Disease
is	VBZ	O
the	DT	O
second	JJ	O
leading	JJ	O
cause	NN	O
of	IN	O
male	JJ	O
cancer	NN	S_Disease
deaths	NNS	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
.	.	O

Yet	RB	O
,	,	O
despite	IN	O
a	DT	O
large	JJ	O
international	JJ	O
effort	NN	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
molecular	JJ	O
mechanisms	NNS	O
that	WDT	O
underlie	VBP	O
this	DT	O
devastating	JJ	O
disease	NN	O
.	.	O

Prostate	NNP	O
secretory	NN	O
epithelial	JJ	O
cells	NNS	O
and	CC	O
androgen	NN	O
-	:	O
dependent	JJ	O
prostate	NN	B_Disease
carcinomas	NN	E_Disease
undergo	JJ	O
apoptosis	NN	O
in	IN	O
response	NN	O
to	TO	O
androgen	VB	O
deprivation	NN	O
and	CC	O
,	,	O
furthermore	RB	O
,	,	O
most	JJS	O
prostate	JJ	B_Disease
carcinomas	NN	E_Disease
become	VBN	O
androgen	JJ	O
independent	JJ	O
and	CC	O
refractory	NN	O
to	TO	O
further	RBR	O
therapeutic	JJ	O
manipulations	NNS	O
during	IN	O
disease	NN	O
progression	NN	O
.	.	O

Definition	NN	O
of	IN	O
the	DT	O
genetic	JJ	O
events	NNS	O
that	WDT	O
trigger	VBP	O
apoptosis	NN	O
in	IN	O
the	DT	O
prostate	NN	O
could	MD	O
provide	VB	O
important	JJ	O
insights	NNS	O
into	IN	O
critical	JJ	O
pathways	NNS	O
in	IN	O
normal	JJ	O
development	NN	O
as	RB	O
well	RB	O
as	IN	O
elucidate	NN	O
the	DT	O
perturbations	NNS	O
of	IN	O
those	DT	O
key	JJ	O
pathways	NNS	O
in	IN	O
neoplastic	JJ	O
transformation	NN	O
.	.	O

We	PRP	O
report	VBP	O
the	DT	O
functional	JJ	O
definition	NN	O
of	IN	O
a	DT	O
novel	JJ	O
genetic	JJ	O
locus	NN	O
within	IN	O
human	JJ	O
chromosome	NN	O
10pter	CD	O
-	:	O
q11	NN	O
that	WDT	O
mediates	VBZ	O
both	DT	O
in	IN	O
vivo	NN	O
tumor	NN	O
suppression	NN	O
and	CC	O
in	IN	O
vitro	JJ	O
apoptosis	NN	O
of	IN	O
prostatic	JJ	B_Disease
adenocarcinoma	NN	E_Disease
cells	NNS	O
.	.	O

A	DT	O
defined	JJ	O
fragment	NN	O
of	IN	O
human	JJ	O
chromosome	NN	O
10	CD	O
was	VBD	O
transferred	VBN	O
via	IN	O
microcell	NN	O
fusion	NN	O
into	IN	O
a	DT	O
prostate	JJ	B_Disease
adenocarcinoma	NN	E_Disease
cell	NN	O
line	NN	O
.	.	O

Microcell	NNP	O
hybrids	NNS	O
containing	VBG	O
only	RB	O
the	DT	O
region	NN	O
10pter	CD	O
-	:	O
q11	NN	O
were	VBD	O
suppressed	VBN	O
for	IN	O
tumorigenicity	NN	O
following	VBG	O
injection	NN	O
of	IN	O
microcell	NN	O
hybrids	NNS	O
into	IN	O
nude	JJ	O
mice	NN	O
.	.	O

Furthermore	RB	O
,	,	O
the	DT	O
complemented	JJ	O
hybrids	NNS	O
undergo	NN	O
programmed	VBD	O
cell	NN	O
death	NN	O
in	IN	O
vitro	NN	O
via	IN	O
a	DT	O
mechanism	NN	O
that	WDT	O
does	VBZ	O
not	RB	O
require	VB	O
nuclear	JJ	O
localization	NN	O
of	IN	O
p53	NN	O
.	.	O

These	DT	O
data	NNS	O
functionally	RB	O
define	VBP	O
a	DT	O
novel	JJ	O
genetic	JJ	O
locus	NN	O
,	,	O
designated	VBN	O
PAC1	NNP	O
,	,	O
for	IN	O
prostate	NN	O
adenocarcinoma	NN	O
1	CD	O
,	,	O
involved	VBN	O
in	IN	O
tumor	NN	O
suppression	NN	O
of	IN	O
human	JJ	O
prostate	NN	B_Disease
carcinoma	NN	E_Disease
and	CC	O
furthermore	RB	O
strongly	RB	O
suggest	VBP	O
that	IN	O
the	DT	O
cell	NN	O
death	NN	O
pathway	NN	O
can	MD	O
be	VB	O
functionally	RB	O
restored	VBN	O
in	IN	O
prostatic	JJ	B_Disease
adenocarcinoma	NN	E_Disease
.	.	O
.	.	O

Low	JJ	O
incidence	NN	O
of	IN	O
BRCA2	NNP	O
mutations	NNS	O
in	IN	O
breast	NN	B_Disease
carcinoma	NN	E_Disease
and	CC	O
other	JJ	O
cancers	NNS	S_Disease
.	.	O

Inherited	VBN	O
mutant	JJ	O
alleles	NNS	O
of	IN	O
familial	JJ	O
tumour	NN	S_Disease
suppressor	NN	O
genes	NNS	O
predispose	VBP	O
individuals	NNS	O
to	TO	O
particular	JJ	O
types	NNS	O
of	IN	O
cancer	NN	S_Disease
.	.	O

In	IN	O
addition	NN	O
to	TO	O
an	DT	O
involvement	NN	O
in	IN	O
inherited	JJ	O
susceptibility	NN	O
to	TO	O
cancer	NN	S_Disease
,	,	O
these	DT	O
tumour	NNS	S_Disease
suppressor	NN	O
genes	NNS	O
are	VBP	O
targets	NNS	O
for	IN	O
somatic	JJ	O
mutations	NNS	O
in	IN	O
sporadic	JJ	B_Disease
cancers	NNS	E_Disease
of	IN	O
the	DT	O
same	JJ	O
type	NN	O
found	VBD	O
in	IN	O
the	DT	O
familial	JJ	O
forms	NNS	O
.	.	O

An	DT	O
exception	NN	O
is	VBZ	O
BRCA1	NNP	O
,	,	O
which	WDT	O
contributes	VBZ	O
to	TO	O
a	DT	O
significant	JJ	O
fraction	NN	O
of	IN	O
familial	JJ	B_Disease
breast	NN	I_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
,	,	O
but	CC	O
undergoes	JJ	O
mutation	NN	O
at	IN	O
very	RB	O
low	JJ	O
rates	NNS	O
in	IN	O
sporadic	JJ	B_Disease
breast	NN	I_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancers	NNS	E_Disease
.	.	O

This	DT	O
finding	NN	O
suggests	VBZ	O
that	IN	O
other	JJ	O
genes	NNS	O
may	MD	O
be	VB	O
the	DT	O
principal	JJ	O
targets	NNS	O
for	IN	O
somatic	JJ	O
mutation	NN	O
in	IN	O
breast	NN	B_Disease
carcinoma	NN	E_Disease
.	.	O

A	DT	O
second	JJ	O
,	,	O
recently	RB	O
identified	VBN	O
familial	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
gene	NN	O
,	,	O
BRCA2	NNP	O
(	(	O
refs	VB	O
5	CD	O
-	:	O
8	CD	O
)	)	O
,	,	O
accounts	NNS	O
for	IN	O
a	DT	O
proportion	NN	O
of	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
roughly	RB	O
equal	JJ	O
to	TO	O
BRCA1	NNP	O
.	.	O

Like	IN	O
BRCA1	NNP	O
,	,	O
BRCA2	NNP	O
behaves	VBZ	O
as	IN	O
a	DT	O
dominantly	RB	O
inherited	VBN	O
tumour	NN	S_Disease
suppressor	NN	O
gene	NN	O
.	.	O

Individuals	NNS	O
who	WP	O
inherit	VBP	O
one	CD	O
mutant	NN	O
allele	NN	O
are	VBP	O
at	IN	O
increased	VBN	O
risk	NN	O
for	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
,	,	O
and	CC	O
the	DT	O
tumours	NN	S_Disease
they	PRP	O
develop	VBP	O
lose	VB	O
the	DT	O
wild	JJ	O
-	:	O
type	NN	O
allele	NN	O
by	IN	O
heterozygous	JJ	O
deletion	NN	O
.	.	O

The	DT	O
BRCA2	NNP	O
coding	NN	O
sequence	NN	O
is	VBZ	O
huge	JJ	O
,	,	O
composed	VBN	O
of	IN	O
26	CD	O
exons	NNS	O
that	IN	O
span	VBP	O
10	CD	O
,	,	O
443	CD	O
bp	NN	O
.	.	O

Here	RB	O
we	PRP	O
investigate	VBP	O
the	DT	O
rate	NN	O
of	IN	O
BRCA2	NNP	O
mutation	NN	O
in	IN	O
sporadic	JJ	B_Disease
breast	NN	I_Disease
cancers	NNS	E_Disease
and	CC	O
in	IN	O
a	DT	O
set	NN	O
of	IN	O
cell	NN	O
lines	NNS	O
that	WDT	O
represent	VBP	O
twelve	VB	O
other	JJ	O
tumour	JJ	S_Disease
types	NNS	O
.	.	O

Surprisingly	RB	O
,	,	O
mutations	NNS	O
in	IN	O
BRCA2	NNP	O
are	VBP	O
infrequent	JJ	O
in	IN	O
cancers	NNS	S_Disease
including	VBG	O
breast	NN	B_Disease
carcinoma	NN	E_Disease
.	.	O

However	RB	O
,	,	O
a	DT	O
probable	JJ	O
germline	NN	O
mutation	NN	O
in	IN	O
a	DT	O
pancreatic	JJ	B_Disease
tumour	NN	E_Disease
cell	NN	O
line	NN	O
suggests	VBZ	O
a	DT	O
role	NN	O
for	IN	O
BRCA2	NNP	O
in	IN	O
susceptibility	NN	O
to	TO	O
pancreatic	JJ	B_Disease
cancer	NN	E_Disease
.	.	O
.	.	O

Founding	VBG	O
BRCA1	NNP	O
mutations	NNS	O
in	IN	O
hereditary	JJ	B_Disease
breast	NN	I_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
in	IN	O
southern	JJ	O
Sweden	NNP	O
.	.	O

Nine	NNP	O
different	JJ	O
germ	NNS	O
-	:	O
line	NN	O
mutations	NNS	O
in	IN	O
the	DT	O
BRCA1	NNP	O
breast	NN	B_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
susceptibility	NN	O
gene	NN	O
were	VBD	O
identified	VBN	O
in	IN	O
15	CD	O
of	IN	O
47	CD	O
kindreds	NNS	O
from	IN	O
southern	JJ	O
Sweden	NNP	O
,	,	O
by	IN	O
use	NN	O
of	IN	O
SSCP	NNP	O
and	CC	O
heteroduplex	JJ	O
analysis	NN	O
of	IN	O
all	DT	O
exons	NNS	O
and	CC	O
flanking	VBG	O
intron	JJ	O
region	NN	O
and	CC	O
by	IN	O
a	DT	O
protein	NN	O
-	:	O
truncation	NN	O
test	NN	O
for	IN	O
exon	NN	O
11	CD	O
,	,	O
followed	VBN	O
by	IN	O
direct	JJ	O
sequencing	NN	O
.	.	O

All	DT	O
but	CC	O
one	CD	O
of	IN	O
the	DT	O
mutations	NNS	O
are	VBP	O
predicted	VBN	O
to	TO	O
give	VB	O
rise	NN	O
to	TO	O
premature	VB	O
translation	NN	O
termination	NN	O
and	CC	O
include	VBP	O
seven	CD	O
frameshift	JJ	O
insertions	NNS	O
or	CC	O
deletions	NNS	O
,	,	O
a	DT	O
nonsense	JJ	O
mutation	NN	O
,	,	O
and	CC	O
a	DT	O
splice	NN	O
acceptor	NN	O
site	NN	O
mutation	NN	O
.	.	O

The	DT	O
remaining	VBG	O
mutation	NN	O
is	VBZ	O
a	DT	O
missense	JJ	O
mutation	NN	O
(	(	O
Cys61Gly	NNP	O
)	)	O
in	IN	O
the	DT	O
zinc	NN	O
-	:	O
binding	NN	O
motif	NN	O
.	.	O

Four	CD	O
novel	JJ	O
Swedish	NNP	O
founding	NN	O
mutations	NNS	O
were	VBD	O
identified	VBN	O
the	DT	O
nucleotide	JJ	O
2595	CD	O
deletion	NN	O
A	DT	O
was	VBD	O
found	VBN	O
in	IN	O
five	CD	O
families	NNS	O
,	,	O
the	DT	O
C	NNP	O
1806	CD	O
T	NNP	O
nonsense	JJ	O
mutation	NN	O
in	IN	O
three	CD	O
families	NNS	O
,	,	O
the	DT	O
3166	CD	O
insertion	NN	O
TGAGA	NNP	O
in	IN	O
three	CD	O
families	NNS	O
,	,	O
and	CC	O
the	DT	O
nucleotide	JJ	O
1201	CD	O
deletion	NN	O
11	CD	O
in	IN	O
two	CD	O
families	NNS	O
.	.	O

Analysis	NN	O
of	IN	O
the	DT	O
intragenic	JJ	O
polymorphism	NN	O
D17S855	NNP	O
supports	VBZ	O
common	JJ	O
origins	NNS	O
of	IN	O
the	DT	O
mutations	NNS	O
.	.	O

Eleven	NNP	O
of	IN	O
the	DT	O
15	CD	O
kindreds	NNS	O
manifesting	VBG	O
BRCA1	NNP	O
mutations	NNS	O
were	VBD	O
breast	SYM	B_Disease
-	:	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
families	NNS	O
,	,	O
several	JJ	O
of	IN	O
them	PRP	O
with	IN	O
a	DT	O
predominant	JJ	O
ovarian	JJ	B_Disease
cancer	NN	E_Disease
phenotype	NN	O
.	.	O

The	DT	O
set	NN	O
of	IN	O
32	CD	O
families	NNS	O
in	IN	O
which	WDT	O
no	DT	O
BRCA1	NNP	O
alterations	NNS	O
were	VBD	O
detected	VBN	O
included	JJ	O
1	CD	O
breast	NN	B_Disease
-	:	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
kindred	VBD	O
manifesting	VBG	O
clear	JJ	O
linkage	NN	O
to	TO	O
the	DT	O
BRCA1	NNP	O
region	NN	O
and	CC	O
loss	NN	O
of	IN	O
the	DT	O
wild	JJ	O
-	:	O
type	NN	O
chromosome	NN	O
in	IN	O
associated	JJ	O
tumors	NNS	S_Disease
.	.	O

Other	JJ	O
tumor	NN	S_Disease
types	NNS	O
found	VBN	O
in	IN	O
BRCA1	NNP	O
mutation	NN	O
/	NNP	O
haplotype	NN	O
carriers	NNS	O
included	VBD	O
prostatic	JJ	B_Disease
,	,	I_Disease
pancreas	NNS	I_Disease
,	,	I_Disease
skin	NN	I_Disease
,	,	I_Disease
and	CC	I_Disease
lung	NN	I_Disease
cancer	NN	E_Disease
,	,	O
a	DT	O
malignant	JJ	B_Disease
melanoma	NN	E_Disease
,	,	O
an	DT	O
oligodendroglioma	NN	S_Disease
,	,	O
and	CC	O
a	DT	O
carcinosarcoma	NN	S_Disease
.	.	O

In	IN	O
all	DT	O
,	,	O
12	CD	O
of	IN	O
16	CD	O
kindreds	NNS	O
manifesting	VBG	O
BRCA1	NNP	O
mutation	NN	O
or	CC	O
linkage	NN	O
contained	VBN	O
ovarian	JJ	B_Disease
cancer	NN	E_Disease
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
only	RB	O
6	CD	O
of	IN	O
the	DT	O
remaining	VBG	O
31	CD	O
families	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.	.	O

001	CD	O
)	)	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
confirms	VBZ	O
the	DT	O
involvement	NN	O
of	IN	O
BRCA1	NNP	O
in	IN	O
disease	NN	O
predisposition	NN	O
for	IN	O
a	DT	O
subset	NN	O
of	IN	O
hereditary	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
families	NNS	O
often	RB	O
characterized	VBN	O
by	IN	O
ovarian	JJ	B_Disease
cancers	NNS	E_Disease
.	.	O

Rapid	JJ	O
detection	NN	O
of	IN	O
regionally	RB	O
clustered	VBN	O
germ	JJ	O
-	:	O
line	NN	O
BRCA1	NNP	O
mutations	NNS	O
by	IN	O
multiplex	JJ	O
heteroduplex	JJ	O
analysis	NN	O
.	.	O

UKCCCR	NNP	O
Familial	NNP	O
Ovarian	NNP	B_Disease
Cancer	NNP	E_Disease
Study	NNP	O
Group	NNP	O
.	.	O

Germ	NNP	O
-	:	O
line	NN	O
mutations	NNS	O
of	IN	O
the	DT	O
BRCA1	NNP	O
gene	NN	O
are	VBP	O
responsible	JJ	O
for	IN	O
a	DT	O
substantial	JJ	O
proportion	NN	O
of	IN	O
families	NNS	O
with	IN	O
multiple	JJ	O
cases	NNS	O
of	IN	O
early	JJ	O
-	:	O
onset	NN	O
breast	NN	B_Disease
and	CC	I_Disease
/	NN	I_Disease
or	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
.	.	O

Since	IN	O
the	DT	O
isolation	NN	O
of	IN	O
BRCA1	NNP	O
last	JJ	O
year	NN	O
,	,	O
>	VBP	O
65	CD	O
distinct	JJ	O
mutations	NNS	O
scattered	VBD	O
throughout	IN	O
the	DT	O
coding	VBG	O
region	NN	O
have	VBP	O
been	VBN	O
detected	VBN	O
,	,	O
making	VBG	O
analysis	NN	O
of	IN	O
the	DT	O
gene	NN	O
time	NN	O
consuming	VBG	O
and	CC	O
technically	RB	O
challenging	JJ	O
.	.	O

We	PRP	O
have	VBP	O
developed	VBN	O
a	DT	O
multiplex	JJ	O
heteroduplex	NN	O
analysis	NN	O
that	WDT	O
is	VBZ	O
designed	VBN	O
to	TO	O
analyze	VB	O
one	CD	O
-	:	O
quarter	NN	O
of	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
in	IN	O
a	DT	O
single	JJ	O
-	:	O
step	NN	O
screening	JJ	O
procedure	NN	O
and	CC	O
that	DT	O
will	MD	O
detect	VB	O
approximately	RB	O
50	CD	O
%	NN	O
of	IN	O
all	DT	O
BRCA1	NNP	O
mutations	NNS	O
so	RB	O
far	RB	O
reported	VBN	O
in	IN	O
breast	NN	B_Disease
/	NN	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
families	NNS	O
.	.	O

We	PRP	O
have	VBP	O
used	VBN	O
this	DT	O
technique	NN	O
to	TO	O
analyze	VB	O
BRCA1	NNP	O
in	IN	O
162	CD	O
families	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
breast	NN	B_Disease
and	CC	I_Disease
/	NN	I_Disease
or	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
and	CC	O
identified	VBD	O
12	CD	O
distinct	JJ	O
mutations	NNS	O
in	IN	O
35	CD	O
families	NNS	O
.	.	O
.	.	O

A	DT	O
previously	RB	O
undescribed	JJ	O
mutation	NN	O
within	IN	O
the	DT	O
tetramerisation	NN	O
domain	NN	O
of	IN	O
TP53	NNP	O
in	IN	O
a	DT	O
family	NN	O
with	IN	O
Li	NNP	B_Disease
-	:	I_Disease
Fraumeni	NNP	I_Disease
syndrome	NN	E_Disease
.	.	O

We	PRP	O
report	VBP	O
details	NNS	O
of	IN	O
a	DT	O
family	NN	O
with	IN	O
classic	JJ	O
Li	NNP	B_Disease
-	:	I_Disease
Fraumeni	NNP	I_Disease
syndrome	NN	E_Disease
in	IN	O
which	WDT	O
there	EX	O
is	VBZ	O
a	DT	O
mutation	NN	O
in	IN	O
codon	JJ	O
344	CD	O
of	IN	O
the	DT	O
tumour	NN	S_Disease
suppressor	NN	O
gene	NN	O
TP53	NNP	O
.	.	O

Codon	NNP	O
344	CD	O
is	VBZ	O
a	DT	O
key	JJ	O
residue	NN	O
within	IN	O
the	DT	O
tetramerisation	NN	O
domain	NN	O
,	,	O
and	CC	O
the	DT	O
amino	NN	O
acid	JJ	O
substitution	NN	O
of	IN	O
a	DT	O
proline	NN	O
for	IN	O
a	DT	O
leucine	NN	O
is	VBZ	O
predicted	VBN	O
to	TO	O
have	VB	O
profound	JJ	O
implications	NNS	O
for	IN	O
tetramerisation	NN	O
and	CC	O
potentially	RB	O
DNA	NNP	O
binding	NN	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
report	NN	O
of	IN	O
a	DT	O
mutation	NN	O
at	IN	O
this	DT	O
residue	NN	O
in	IN	O
either	DT	O
sporadic	JJ	B_Disease
tumours	NN	E_Disease
or	CC	O
in	IN	O
the	DT	O
germline	NN	O
and	CC	O
the	DT	O
first	JJ	O
report	NN	O
of	IN	O
a	DT	O
germline	JJ	O
mutation	NN	O
within	IN	O
the	DT	O
tetramerisation	NN	O
domain	NN	O
.	.	O

The	DT	O
family	NN	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
be	VB	O
remarkable	JJ	O
in	IN	O
the	DT	O
spectrum	NN	O
of	IN	O
tumours	NNS	S_Disease
,	,	O
and	CC	O
there	EX	O
is	VBZ	O
loss	NN	O
of	IN	O
the	DT	O
wild	JJ	O
-	:	O
type	NN	O
allele	NN	O
in	IN	O
a	DT	O
leiomyosarcoma	NN	S_Disease
from	IN	O
the	DT	O
proband	NN	O
.	.	O

A	DT	O
cell	NN	O
line	NN	O
has	VBZ	O
been	VBN	O
established	VBN	O
from	IN	O
the	DT	O
tumour	NN	S_Disease
of	IN	O
the	DT	O
proband	NN	O
and	CC	O
cytogenetic	JJ	O
and	CC	O
molecular	JJ	O
studies	NNS	O
carried	VBD	O
out	RP	O
,	,	O
providing	VBG	O
an	DT	O
extensive	JJ	O
analysis	NN	O
in	IN	O
this	DT	O
family	NN	O
.	.	O
.	.	O

The	DT	O
spectrum	NN	O
of	IN	O
RB1	NNP	O
germ	FW	O
-	:	O
line	NN	O
mutations	NNS	O
in	IN	O
hereditary	JJ	B_Disease
retinoblastoma	NN	E_Disease
.	.	O

We	PRP	O
have	VBP	O
searched	VBN	O
for	IN	O
germ	JJ	O
-	:	O
line	NN	O
RB1	NNP	O
mutations	NNS	O
in	IN	O
119	CD	O
patients	NNS	O
with	IN	O
hereditary	JJ	B_Disease
retinoblastoma	NN	E_Disease
.	.	O

Previous	JJ	O
investigations	NNS	O
by	IN	O
Southern	NNP	O
blot	NN	O
hybridization	NN	O
and	CC	O
PCR	NNP	O
fragment	VBD	O
-	:	O
length	NN	O
analysis	NN	O
had	VBD	O
revealed	VBN	O
mutations	NNS	O
in	IN	O
48	CD	O
patients	NNS	O
.	.	O

Here	RB	O
we	PRP	O
report	VBP	O
on	IN	O
the	DT	O
analysis	NN	O
of	IN	O
the	DT	O
remaining	VBG	O
71	CD	O
patients	NNS	O
.	.	O

By	IN	O
applying	VBG	O
heteroduplex	JJ	O
analysis	NN	O
,	,	O
nonisotopic	JJ	O
SSCP	NNP	O
,	,	O
and	CC	O
direct	JJ	O
sequencing	NN	O
,	,	O
we	PRP	O
detected	VBD	O
germ	JJ	O
-	:	O
line	NN	O
mutations	NNS	O
resulting	VBG	O
in	IN	O
premature	NN	O
termination	NN	O
codons	NNS	O
or	CC	O
disruption	NN	O
of	IN	O
splice	NN	O
signals	NNS	O
in	IN	O
51	CD	O
(	(	O
72	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
71	CD	O
patients	NNS	O
.	.	O

Four	CD	O
patients	NNS	O
also	RB	O
showed	VBD	O
rare	JJ	O
sequence	NN	O
variants	NNS	O
.	.	O

No	DT	O
region	NN	O
of	IN	O
the	DT	O
RB1	NNP	O
gene	NN	O
was	VBD	O
preferentially	RB	O
involved	VBN	O
in	IN	O
single	JJ	O
base	NN	O
substitutions	NNS	O
.	.	O

Recurrent	JJ	O
transitions	NNS	O
were	VBD	O
observed	VBN	O
at	IN	O
most	JJS	O
of	IN	O
the	DT	O
14	CD	O
codons	NNS	O
within	IN	O
the	DT	O
RB1	NNP	O
.	.	O

No	DT	O
mutation	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
exons	NNS	O
25	CD	O
-	:	O
27	CD	O
,	,	O
although	IN	O
this	DT	O
region	NN	O
contains	VBZ	O
two	CD	O
CGA	NNP	O
codons	NNS	O
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
mutations	NNS	O
within	IN	O
the	DT	O
3	CD	O
-	:	O
terminal	JJ	O
region	NN	O
of	IN	O
the	DT	O
RB1	NNP	O
gene	NN	O
may	MD	O
not	RB	O
be	VB	O
oncogenic	JJ	O
.	.	O

When	WRB	O
these	DT	O
data	NNS	O
were	VBD	O
combined	VBN	O
with	IN	O
the	DT	O
results	NNS	O
of	IN	O
our	PRP$	O
previous	JJ	O
investigations	NNS	O
,	,	O
mutations	NNS	O
were	VBD	O
identified	VBN	O
in	IN	O
a	DT	O
total	NN	O
of	IN	O
99	CD	O
(	(	O
83	CD	O
%	NN	O
)	)	O
of	IN	O
119	CD	O
patients	NNS	O
.	.	O

The	DT	O
spectrum	NN	O
comprises	VBZ	O
15	CD	O
%	NN	O
large	JJ	O
deletions	NNS	O
,	,	O
26	CD	O
%	NN	O
small	JJ	O
length	NN	O
alterations	NNS	O
,	,	O
and	CC	O
42	CD	O
%	NN	O
base	NN	O
substitutions	NNS	O
.	.	O

No	DT	O
correlation	NN	O
between	IN	O
the	DT	O
location	NN	O
of	IN	O
frameshift	NN	O
or	CC	O
nonsense	JJ	O
mutations	NNS	O
and	CC	O
phenotypic	NN	O
features	NNS	O
,	,	O
including	VBG	O
age	NN	O
at	IN	O
diagnosis	NN	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
tumor	NN	S_Disease
foci	NN	O
,	,	O
and	CC	O
manifestation	NN	O
of	IN	O
nonocular	JJ	B_Disease
tumors	NNS	E_Disease
was	VBD	O
observed	VBN	O
.	.	O
.	.	O

Phenotypic	NNP	O
characterization	NN	O
of	IN	O
individuals	NNS	O
with	IN	O
30	CD	O
-	:	O
40	CD	O
CAG	NNP	O
repeats	NNS	O
in	IN	O
the	DT	O
Huntington	NNP	B_Disease
disease	NN	E_Disease
(	(	O
HD	NNP	S_Disease
)	)	O
gene	NN	O
reveals	NNS	O
HD	NNP	S_Disease
cases	NNS	O
with	IN	O
36	CD	O
repeats	NNS	O
and	CC	O
apparently	RB	O
normal	JJ	O
elderly	JJ	O
individuals	NNS	O
with	IN	O
36	CD	O
-	:	O
39	CD	O
repeats	NNS	O
.	.	O

Abnormal	NNP	O
CAG	NNP	O
expansions	NNS	O
in	IN	O
the	DT	O
IT	NNP	O
-	:	O
15	CD	O
gene	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
Huntington	NNP	B_Disease
disease	NN	E_Disease
(	(	O
HD	NNP	S_Disease
)	)	O
.	.	O

In	IN	O
the	DT	O
diagnostic	JJ	O
setting	NN	O
it	PRP	O
is	VBZ	O
necessary	JJ	O
to	TO	O
define	VB	O
the	DT	O
limits	NNS	O
of	IN	O
the	DT	O
CAG	NNP	O
size	NN	O
ranges	VBZ	O
on	IN	O
normal	JJ	O
and	CC	O
HD	NNP	S_Disease
-	:	O
associated	VBN	O
chromosomes	NNS	O
.	.	O

Most	JJS	O
large	JJ	O
analyses	NNS	O
that	WDT	O
defined	VBD	O
the	DT	O
limits	NNS	O
of	IN	O
the	DT	O
normal	JJ	O
and	CC	O
pathological	JJ	O
size	NN	O
ranges	VBZ	O
employed	VBN	O
PCR	NNP	O
assays	NNS	O
,	,	O
which	WDT	O
included	VBD	O
the	DT	O
CAG	NNP	O
repeats	NNS	O
and	CC	O
a	DT	O
CCG	NNP	O
repeat	NN	O
tract	NN	O
that	WDT	O
was	VBD	O
thought	VBN	O
to	TO	O
be	VB	O
invariant	JJ	O
.	.	O

Many	JJ	O
of	IN	O
these	DT	O
experiments	NNS	O
found	VBD	O
an	DT	O
overlap	NN	O
between	IN	O
the	DT	O
normal	JJ	O
and	CC	O
disease	JJ	O
size	NN	O
ranges	NNS	O
.	.	O

Subsequent	JJ	O
findings	NNS	O
that	IN	O
the	DT	O
CCG	NNP	O
repeats	NNS	O
vary	VBP	O
by	IN	O
8	CD	O
trinucleotide	JJ	O
lengths	NNS	O
suggested	VBD	O
that	IN	O
the	DT	O
limits	NNS	O
of	IN	O
the	DT	O
normal	JJ	O
and	CC	O
disease	JJ	O
size	NN	O
ranges	NNS	O
should	MD	O
be	VB	O
reevaluated	VBN	O
with	IN	O
assays	NNS	O
that	WDT	O
exclude	VBP	O
the	DT	O
CCG	NNP	O
polymorphism	NN	O
.	.	O

Since	IN	O
patients	NNS	O
with	IN	O
between	IN	O
30	CD	O
and	CC	O
40	CD	O
repeats	NNS	O
are	VBP	O
rare	JJ	O
,	,	O
a	DT	O
consortium	NN	O
was	VBD	O
assembled	VBN	O
to	TO	O
collect	VB	O
such	JJ	O
individuals	NNS	O
.	.	O

All	DT	O
178	CD	O
samples	NNS	O
were	VBD	O
reanalyzed	VBN	O
in	IN	O
Cambridge	NNP	O
by	IN	O
using	VBG	O
assays	NNS	O
specific	NN	O
for	IN	O
the	DT	O
CAG	NNP	O
repeats	NNS	O
.	.	O

We	PRP	O
have	VBP	O
optimized	VBN	O
methods	NNS	O
for	IN	O
reliable	JJ	O
sizing	NN	O
of	IN	O
CAG	NNP	O
repeats	NNS	O
and	CC	O
show	VBP	O
cases	NNS	O
that	WDT	O
demonstrate	VBP	O
the	DT	O
dangers	NNS	O
of	IN	O
using	VBG	O
PCR	NNP	O
assays	VBZ	O
that	IN	O
include	VBP	O
both	DT	O
the	DT	O
CAG	NNP	O
and	CC	O
CCG	NNP	O
polymorphisms	NNS	O
.	.	O

Seven	NNP	O
HD	NNP	S_Disease
patients	NNS	O
had	VBD	O
36	CD	O
repeats	NNS	O
,	,	O
which	WDT	O
confirms	VBZ	O
that	IN	O
this	DT	O
allele	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
disease	NN	O
.	.	O

Individuals	NNS	O
without	IN	O
apparent	NN	O
symptoms	NNS	O
or	CC	O
signs	NNS	O
of	IN	O
HD	NNP	S_Disease
were	VBD	O
found	VBN	O
at	IN	O
36	CD	O
repeats	NNS	O
(	(	O
aged	VBN	O
74	CD	O
,	,	O
78	CD	O
,	,	O
79	CD	O
,	,	O
and	CC	O
87	CD	O
years	NNS	O
)	)	O
,	,	O
37	CD	O
repeats	NNS	O
(	(	O
aged	VBN	O
69	CD	O
years	NNS	O
)	)	O
,	,	O
38	CD	O
repeats	NNS	O
(	(	O
aged	VBN	O
69	CD	O
and	CC	O
90	CD	O
years	NNS	O
)	)	O
,	,	O
and	CC	O
39	CD	O
repeats	NNS	O
(	(	O
aged	VBN	O
67	CD	O
,	,	O
90	CD	O
,	,	O
and	CC	O
95	CD	O
years	NNS	O
)	)	O
.	.	O

The	DT	O
detailed	JJ	O
case	NN	O
histories	NNS	O
of	IN	O
an	DT	O
exceptional	JJ	O
case	NN	O
from	IN	O
this	DT	O
series	NN	O
will	MD	O
be	VB	O
presented	VBN	O
a	DT	O
95	CD	O
-	:	O
year	NN	O
-	:	O
old	JJ	O
man	NN	O
with	IN	O
39	CD	O
repeats	NNS	O
who	WP	O
did	VBD	O
not	RB	O
have	VB	O
classical	JJ	O
features	NNS	O
of	IN	O
HD	NNP	S_Disease
.	.	O

The	DT	O
apparently	RB	O
healthy	JJ	O
survival	NN	O
into	IN	O
old	JJ	O
age	NN	O
of	IN	O
some	DT	O
individuals	NNS	O
with	IN	O
36	CD	O
-	:	O
39	CD	O
repeats	NNS	O
suggests	VBZ	O
that	IN	O
the	DT	O
HD	NNP	S_Disease
mutation	NN	O
may	MD	O
not	RB	O
always	RB	O
be	VB	O
fully	RB	O
penetrant	JJ	O
.	.	O
.	.	O

Identification	NN	O
and	CC	O
expression	NN	O
of	IN	O
eight	CD	O
novel	JJ	O
mutations	NNS	O
among	IN	O
non	JJ	O
-	:	O
Jewish	JJ	O
patients	NNS	O
with	IN	O
Canavan	NNP	B_Disease
disease	NN	E_Disease
.	.	O

Canavan	NNP	B_Disease
disease	NN	E_Disease
is	VBZ	O
inherited	VBN	O
as	IN	O
an	DT	O
autosomal	JJ	O
recessive	JJ	O
trait	NN	O
that	WDT	O
is	VBZ	O
caused	VBN	O
by	IN	O
the	DT	O
deficiency	NN	B_Disease
of	IN	I_Disease
aspartoacylase	NN	E_Disease
(	(	O
ASPA	NNP	O
)	)	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
patients	NNS	O
with	IN	O
Canavan	NNP	B_Disease
disease	NN	E_Disease
are	VBP	O
from	IN	O
an	DT	O
Ashkenazi	NNP	O
Jewish	NNP	O
background	NN	O
.	.	O

Mutations	NNS	O
in	IN	O
ASPA	NNP	O
that	WDT	O
lead	VBP	O
to	TO	O
loss	NN	O
of	IN	O
enzymatic	JJ	O
activity	NN	O
have	VBP	O
been	VBN	O
identified	VBN	O
,	,	O
and	CC	O
E285A	NNP	O
and	CC	O
Y231X	NNP	O
are	VBP	O
the	DT	O
two	CD	O
predominant	JJ	O
mutations	NNS	O
that	WDT	O
account	VBP	O
for	IN	O
97	CD	O
%	NN	O
of	IN	O
the	DT	O
mutant	JJ	O
chromosomes	NNS	O
in	IN	O
Ashkenazi	NNP	O
Jewish	JJ	O
patients	NNS	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
was	VBD	O
aimed	VBN	O
at	IN	O
finding	VBG	O
the	DT	O
molecular	JJ	O
basis	NN	O
of	IN	O
Canavan	NNP	B_Disease
disease	NN	E_Disease
in	IN	O
25	CD	O
independent	JJ	O
patients	NNS	O
of	IN	O
non	JJ	O
-	:	O
Jewish	JJ	O
background	NN	O
.	.	O

Eight	NNP	O
novel	NN	O
and	CC	O
three	CD	O
previously	RB	O
characterized	VBN	O
mutations	NNS	O
accounted	VBD	O
for	IN	O
80	CD	O
%	NN	O
(	(	O
40	CD	O
/	RB	O
50	CD	O
)	)	O
of	IN	O
mutant	JJ	O
chromosomes	NNS	O
.	.	O

The	DT	O
A305E	NNP	O
missense	NN	O
mutation	NN	O
accounted	VBD	O
for	IN	O
48	CD	O
%	NN	O
(	(	O
24	CD	O
/	RB	O
50	CD	O
)	)	O
of	IN	O
mutant	JJ	O
chromosomes	NNS	O
in	IN	O
patients	NNS	O
of	IN	O
western	JJ	O
European	JJ	O
descent	NN	O
,	,	O
while	IN	O
the	DT	O
two	CD	O
predominant	JJ	O
Jewish	JJ	O
mutations	NNS	O
each	DT	O
accounted	VBD	O
for	IN	O
a	DT	O
single	JJ	O
mutant	JJ	O
chromosome	NN	O
.	.	O

The	DT	O
eight	CD	O
novel	NN	O
mutations	NNS	O
identified	VBD	O
included	VBD	O
1	CD	O
-	:	O
and	CC	O
4	CD	O
-	:	O
bp	NN	O
deletions	NNS	O
(	(	O
32	CD	O
deltaT	NN	O
and	CC	O
876	CD	O
deltaAGAA	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
I16T	NNP	O
,	,	O
G27R	NNP	O
,	,	O
D114E	NNP	O
,	,	O
G123E	NNP	O
,	,	O
C152Y	NNP	O
,	,	O
and	CC	O
R168C	NNP	O
missense	NN	O
mutations	NNS	O
.	.	O

The	DT	O
homozygous	JJ	O
32	CD	O
deltaT	JJ	O
deletion	NN	O
was	VBD	O
identified	VBN	O
in	IN	O
the	DT	O
only	JJ	O
known	JJ	O
patient	NN	O
of	IN	O
African	NNP	O
-	:	O
American	JJ	O
origin	NN	O
with	IN	O
Canavan	NNP	B_Disease
disease	NN	E_Disease
.	.	O

The	DT	O
heterozygosity	NN	O
for	IN	O
876	CD	O
deltaAGAA	JJ	O
mutation	NN	O
was	VBD	O
identified	VBN	O
in	IN	O
three	CD	O
independent	JJ	O
patients	NNS	O
from	IN	O
England	NNP	O
.	.	O

Six	CD	O
single	JJ	O
-	:	O
base	NN	O
changes	NNS	O
leading	VBG	O
to	TO	O
missense	VB	O
mutations	NNS	O
were	VBD	O
identified	VBN	O
in	IN	O
patients	NNS	O
from	IN	O
Turkey	NNP	O
(	(	O
D114E	NNP	O
,	,	O
R168C	NNP	O
)	)	O
,	,	O
The	DT	O
Netherlands	NNP	O
(	(	O
I16T	NNP	O
)	)	O
,	,	O
Germany	NNP	O
(	(	O
G27R	NNP	O
)	)	O
,	,	O
Ireland	NNP	O
(	(	O
C152Y	NNP	O
)	)	O
,	,	O
and	CC	O
Canada	NNP	O
(	(	O
G123E	NNP	O
)	)	O
.	.	O

A	DT	O
PCR	NNP	O
-	:	O
based	VBN	O
protocol	NN	O
is	VBZ	O
described	VBN	O
that	IN	O
was	VBD	O
used	VBN	O
to	TO	O
introduce	VB	O
mutations	NNS	O
in	IN	O
wild	JJ	O
-	:	O
type	NN	O
cDNA	NN	O
.	.	O

In	IN	O
vitro	JJ	O
expression	NN	O
of	IN	O
mutant	JJ	O
cDNA	NN	O
clones	NNS	O
demonstrated	VBD	O
that	IN	O
all	DT	O
of	IN	O
these	DT	O
mutations	NNS	O
led	VBD	O
to	TO	O
a	DT	O
deficiency	NN	B_Disease
of	IN	I_Disease
ASPA	NNP	E_Disease
and	CC	O
should	MD	O
therefore	VB	O
result	NN	O
in	IN	O
Canavan	NNP	B_Disease
disease	NN	E_Disease
.	.	O
.	.	O

Identification	NN	O
and	CC	O
chromosomal	JJ	O
localization	NN	O
of	IN	O
Atm	NNP	O
,	,	O
the	DT	O
mouse	NN	O
homolog	NN	O
of	IN	O
the	DT	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
gene	NN	O
.	.	O

Atm	NNP	O
,	,	O
the	DT	O
mouse	NN	O
homolog	NN	O
of	IN	O
the	DT	O
human	JJ	O
ATM	NNP	O
gene	NN	O
defective	NN	O
in	IN	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
(	(	O
A	DT	B_Disease
-	:	I_Disease
T	NN	E_Disease
)	)	O
,	,	O
has	VBZ	O
been	VBN	O
identified	VBN	O
.	.	O

The	DT	O
entire	JJ	O
coding	NN	O
sequence	NN	O
of	IN	O
the	DT	O
Atm	NNP	O
transcript	NN	O
was	VBD	O
cloned	VBN	O
and	CC	O
found	VBN	O
to	TO	O
contain	VB	O
an	DT	O
open	JJ	O
reading	NN	O
frame	NN	O
encoding	VBG	O
a	DT	O
protein	NN	O
of	IN	O
3066	CD	O
amino	NN	O
acids	NNS	O
with	IN	O
84	CD	O
%	NN	O
overall	JJ	O
identity	NN	O
and	CC	O
91	CD	O
%	NN	O
similarity	NN	O
to	TO	O
the	DT	O
human	JJ	O
ATM	NNP	O
protein	NN	O
.	.	O

Variable	JJ	O
levels	NNS	O
of	IN	O
expression	NN	O
of	IN	O
Atm	NNP	O
were	VBD	O
observed	VBN	O
in	IN	O
different	JJ	O
tissues	NNS	O
.	.	O

Fluorescence	NN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
and	CC	O
linkage	NN	O
analysis	NN	O
located	VBD	O
the	DT	O
Atm	NNP	O
gene	NN	O
on	IN	O
mouse	NN	O
chromosome	NN	O
9	CD	O
,	,	O
band	NN	O
9C	CD	O
,	,	O
in	IN	O
a	DT	O
region	NN	O
homologous	JJ	O
to	TO	O
the	DT	O
ATM	NNP	O
region	NN	O
on	IN	O
human	JJ	O
chromosome	NN	O
11q22	CD	O
-	:	O
q23	NN	O
.	.	O
.	.	O

The	DT	O
mouse	NN	O
homolog	NN	O
of	IN	O
the	DT	O
Wiskott	NNP	B_Disease
-	:	I_Disease
Aldrich	NNP	I_Disease
syndrome	VBP	E_Disease
protein	NN	O
(	(	O
WASP	NNP	O
)	)	O
gene	NN	O
is	VBZ	O
highly	RB	O
conserved	VBN	O
and	CC	O
maps	NNS	O
near	IN	O
the	DT	O
scurfy	NN	O
(	(	O
sf	NN	O
)	)	O
mutation	NN	O
on	IN	O
the	DT	O
X	NNP	O
chromosome	NN	O
.	.	O

The	DT	O
mouse	NN	O
WASP	NNP	O
gene	NN	O
,	,	O
the	DT	O
homolog	NN	O
of	IN	O
the	DT	O
gene	NN	O
mutated	VBN	O
in	IN	O
Wiskott	NNP	B_Disease
-	:	I_Disease
Aldrich	NNP	I_Disease
syndrome	NN	E_Disease
,	,	O
has	VBZ	O
been	VBN	O
isolated	VBN	O
and	CC	O
sequenced	VBN	O
.	.	O

the	DT	O
predicted	VBN	O
amino	NN	O
acid	NN	O
sequence	NN	O
is	VBZ	O
86	CD	O
%	NN	O
identical	JJ	O
to	TO	O
the	DT	O
human	JJ	O
WASP	NNP	O
sequence	NN	O
.	.	O

A	DT	O
distinct	JJ	O
feature	NN	O
of	IN	O
the	DT	O
mouse	NN	O
gene	NN	O
is	VBZ	O
an	DT	O
expanded	JJ	O
polymorphic	JJ	O
GGA	NNP	O
trinucleotide	NN	O
repeat	NN	O
that	WDT	O
codes	VBZ	O
for	IN	O
polyglycine	NN	O
and	CC	O
varies	NNS	O
from	IN	O
15	CD	O
to	TO	O
17	CD	O
triplets	NNS	O
in	IN	O
different	JJ	O
Mus	NNP	O
musculus	NN	O
strains	NNS	O
.	.	O

The	DT	O
genomic	JJ	O
structure	NN	O
of	IN	O
the	DT	O
mouse	NN	O
WASP	NNP	O
gene	NN	O
is	VBZ	O
expressed	VBN	O
as	IN	O
an	DT	O
approximately	RB	O
2	CD	O
.	.	O

4	CD	O
-	:	O
kb	NN	O
mRNA	NN	O
in	IN	O
thymus	NN	O
and	CC	O
spleen	NN	O
.	.	O

Chromosomal	JJ	O
mapping	NN	O
in	IN	O
an	DT	O
interspecific	JJ	O
M	NNP	O
.	.	O

Musculus	NNP	O
/	NNP	O
M	NNP	O
.	.	O

spretus	NN	O
backcross	NN	O
placed	VBD	O
the	DT	O
Wasp	NNP	O
locus	NN	O
near	IN	O
the	DT	O
centromere	NN	O
of	IN	O
the	DT	O
mouse	NN	O
X	NNP	O
chromosome	NN	O
,	,	O
inseparable	JJ	O
from	IN	O
Gata1	NNP	O
,	,	O
Tcfe3	NNP	O
,	,	O
and	CC	O
scurfy	NN	O
(	(	O
sf	NN	O
)	)	O
.	.	O

This	DT	O
localization	NN	O
makes	VBZ	O
Wasp	NNP	O
a	DT	O
candidate	NN	O
for	IN	O
involvement	NN	O
in	IN	O
scurfy	NN	O
,	,	O
a	DT	O
T	NNP	O
cell	NN	O
-	:	O
mediated	VBN	O
fatal	JJ	B_Disease
lymphoreticular	JJ	I_Disease
disease	NN	E_Disease
of	IN	O
mice	NN	O
that	WDT	O
has	VBZ	O
previously	RB	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
mouse	NN	O
homolog	NN	O
of	IN	O
Wiskott	NNP	B_Disease
-	:	I_Disease
Aldrich	NNP	I_Disease
syndrome	NN	E_Disease
.	.	O

Northern	NNP	O
analysis	NN	O
of	IN	O
sf	JJ	O
tissue	NN	O
samples	NNS	O
indicated	VBD	O
the	DT	O
presence	NN	O
of	IN	O
WASP	NNP	O
mRNA	NN	O
in	IN	O
liver	NN	O
and	CC	O
skin	NN	O
,	,	O
presumably	RB	O
as	IN	O
a	DT	O
consequence	NN	O
of	IN	O
lymphocytic	JJ	O
infiltration	NN	O
,	,	O
but	CC	O
non	JJ	O
abnormalities	NNS	O
in	IN	O
the	DT	O
amount	NN	O
or	CC	O
size	NN	O
of	IN	O
mRNA	JJ	O
present	NN	O
.	.	O

Colchicine	NN	O
in	IN	O
breast	NN	O
milk	NN	O
of	IN	O
patients	NNS	O
with	IN	O
familial	JJ	B_Disease
Mediterranean	NNP	I_Disease
fever	NN	E_Disease
.	.	O

OBJECTIVE	NNP	O
.	.	O

To	TO	O
clarify	VB	O
whether	IN	O
colchicine	NN	O
is	VBZ	O
excreted	VBN	O
in	IN	O
breast	NN	O
milk	NN	O
,	,	O
and	CC	O
to	TO	O
compare	VB	O
its	PRP$	O
concentrations	NNS	O
in	IN	O
the	DT	O
serum	NN	O
and	CC	O
breast	NN	O
milk	NN	O
of	IN	O
lactating	VBG	O
women	NNS	O
who	WP	O
have	VBP	O
familial	JJ	B_Disease
Mediterranean	NNP	I_Disease
fever	NN	E_Disease
(	(	O
FMF	NNP	S_Disease
)	)	O
.	.	O

METHODS	NNP	O
.	.	O

Using	VBG	O
a	DT	O
specific	JJ	O
radioimmunoassay	NN	O
,	,	O
we	PRP	O
determined	VBD	O
colchicine	JJ	O
concentrations	NNS	O
in	IN	O
the	DT	O
serum	NN	O
and	CC	O
breast	NN	O
milk	NN	O
of	IN	O
4	CD	O
patients	NNS	O
at	IN	O
various	JJ	O
time	NN	O
points	NNS	O
,	,	O
following	VBG	O
oral	JJ	O
administration	NN	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O

The	DT	O
study	NN	O
evaluated	VBD	O
4	CD	O
patients	NNS	O
with	IN	O
FMF	NNP	S_Disease
who	WP	O
had	VBD	O
been	VBN	O
taking	VBG	O
colchicine	NN	O
on	IN	O
a	DT	O
long	JJ	O
-	:	O
term	NN	O
basis	NN	O
.	.	O

RESULTS	NNP	O
.	.	O

Colchicine	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
excreted	VBN	O
in	IN	O
breast	NN	O
milk	NN	O
.	.	O

Its	PRP$	O
levels	NNS	O
ranged	VBN	O
between	IN	O
1	CD	O
.	.	O

9	CD	O
and	CC	O
8	CD	O
.	.	O

6	CD	O
ng	JJ	O
/	NNP	O
ml	NN	O
,	,	O
which	WDT	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
found	VBN	O
in	IN	O
the	DT	O
serum	NN	O
(	(	O
parallel	JJ	O
concentration	NN	O
time	NN	O
curves	NNS	O
)	)	O
.	.	O

However	RB	O
,	,	O
there	EX	O
appeared	VBD	O
to	TO	O
be	VB	O
a	DT	O
considerable	JJ	O
variation	NN	O
in	IN	O
colchicine	NN	O
milk	NN	O
concentration	NN	O
among	IN	O
the	DT	O
different	JJ	O
patients	NNS	O
,	,	O
which	WDT	O
might	MD	O
be	VB	O
related	VBN	O
to	TO	O
individual	JJ	O
breast	NN	O
milk	NN	O
composition	NN	O
and	CC	O
,	,	O
possibly	RB	O
,	,	O
to	TO	O
other	JJ	O
nutritional	JJ	O
or	CC	O
metabolic	JJ	O
factors	NNS	O
.	.	O

CONCLUSION	NNP	O
.	.	O

The	DT	O
extensive	JJ	O
peripheral	JJ	O
tissue	NN	O
binding	NN	O
and	CC	O
relatively	RB	O
low	JJ	O
concentration	NN	O
of	IN	O
colchicine	NN	O
in	IN	O
breast	NN	O
milk	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
amount	NN	O
ingested	VBN	O
by	IN	O
the	DT	O
infant	NN	O
is	VBZ	O
small	JJ	O
.	.	O

Furthermore	RB	O
,	,	O
based	VBN	O
on	IN	O
our	PRP$	O
clinical	JJ	O
experience	NN	O
,	,	O
nursing	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
safe	JJ	O
for	IN	O
lactating	VBG	O
women	NNS	O
with	IN	O
FMF	NNP	S_Disease
who	WP	O
continue	VBP	O
to	TO	O
take	VB	O
colchicine	NN	O
.	.	O

Abnormal	NNP	O
myotonic	JJ	B_Disease
dystrophy	NN	E_Disease
protein	NN	O
kinase	NN	O
levels	NNS	O
produce	VBP	O
only	RB	O
mild	JJ	O
myopathy	NNS	S_Disease
in	IN	O
mice	NN	O
.	.	O

Myotonic	JJ	B_Disease
dystrophy	NN	E_Disease
(	(	O
DM	NNP	S_Disease
)	)	O
is	VBZ	O
commonly	RB	O
associated	VBN	O
with	IN	O
CTG	NNP	O
repeat	NN	O
expansions	NNS	O
within	IN	O
the	DT	O
gene	NN	O
for	IN	O
DM	NNP	O
-	:	O
protein	NN	O
kinase	NN	O
(	(	O
DMPK	NNP	O
)	)	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
altered	JJ	O
expression	NN	O
levels	NNS	O
of	IN	O
DMPK	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
ubiquitously	RB	O
expressed	VBN	O
in	IN	O
all	DT	O
muscle	NN	O
cell	NN	O
lineages	VBZ	O
during	IN	O
development	NN	O
,	,	O
was	VBD	O
examined	VBN	O
by	IN	O
disrupting	VBG	O
the	DT	O
endogenous	JJ	O
Dmpk	NNP	O
gene	NN	O
and	CC	O
overexpressing	VBG	O
a	DT	O
normal	JJ	O
human	JJ	O
DMPK	NNP	O
transgene	NN	O
in	IN	O
mice	NN	O
.	.	O

Nullizygous	NNP	O
(	(	O
-	:	O
/	SYM	O
-	:	O
)	)	O
mice	NN	O
showed	VBD	O
only	RB	O
inconsistent	JJ	O
and	CC	O
minor	JJ	O
size	NN	O
changes	NNS	O
in	IN	O
head	NN	O
and	CC	O
neck	NN	O
muscle	NN	O
fibres	NNS	O
at	IN	O
older	JJR	O
age	NN	O
,	,	O
animals	NNS	O
with	IN	O
the	DT	O
highest	JJS	O
DMPK	NNP	O
transgene	NN	O
expression	NN	O
showed	VBD	O
hypertrophic	JJ	B_Disease
cardiomyopathy	NN	E_Disease
and	CC	O
enhanced	VBD	O
neonatal	JJ	O
mortality	NN	O
.	.	O

However	RB	O
,	,	O
both	DT	O
models	NNS	O
lack	VBP	O
other	JJ	O
frequent	JJ	O
DM	NNP	S_Disease
symptoms	NNS	O
including	VBG	O
the	DT	O
fibre	NN	O
-	:	O
type	NN	O
dependent	JJ	O
atrophy	NN	S_Disease
,	,	O
myotonia	NN	S_Disease
,	,	O
cataract	NN	S_Disease
and	CC	O
male	JJ	B_Disease
-	:	I_Disease
infertility	NN	E_Disease
.	.	O

These	DT	O
results	NNS	O
strengthen	VBP	O
the	DT	O
contention	NN	O
that	WDT	O
simple	JJ	O
loss	NN	O
-	:	O
or	CC	O
gain	VB	O
-	:	O
of	IN	O
-	:	O
expression	NN	O
of	IN	O
DMPK	NNP	O
is	VBZ	O
not	RB	O
the	DT	O
only	JJ	O
crucial	JJ	O
requirement	NN	O
for	IN	O
development	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O
.	.	O

Mice	NNP	O
lacking	VBG	O
the	DT	O
myotonic	JJ	B_Disease
dystrophy	NN	E_Disease
protein	NN	O
kinase	VBD	O
develop	VB	O
a	DT	O
late	JJ	O
onset	NN	O
progressive	JJ	O
myopathy	NN	S_Disease
.	.	O

Myotonic	JJ	B_Disease
dystrophy	NN	E_Disease
(	(	O
DM	NNP	S_Disease
)	)	O
is	VBZ	O
an	DT	O
autosomal	JJ	B_Disease
dominant	JJ	I_Disease
disorder	NN	E_Disease
resulting	VBG	O
from	IN	O
the	DT	O
expansion	NN	O
of	IN	O
a	DT	O
CTG	NNP	O
repeat	NN	O
in	IN	O
the	DT	O
3	CD	O
untranslated	JJ	O
region	NN	O
of	IN	O
a	DT	O
putative	JJ	O
protein	NN	O
kinase	NN	O
(	(	O
DMPK	NNP	O
)	)	O
.	.	O

To	TO	O
elucidate	VB	O
the	DT	O
role	NN	O
of	IN	O
DMPK	NNP	O
in	IN	O
DM	NNP	S_Disease
pathogenesis	NN	O
we	PRP	O
have	VBP	O
developed	VBN	O
Dmpk	NNP	B_Disease
deficient	NN	E_Disease
(	(	O
Dmpk	NNP	O
-	:	O
/	SYM	O
-	:	O
)	)	O
mice	NN	O
.	.	O

Dmpk	NNP	O
-	:	O
/	SYM	O
-	:	O
mice	NN	O
develop	VB	O
a	DT	O
late	JJ	O
-	:	O
onset	NN	O
,	,	O
progressive	JJ	B_Disease
skeletal	NN	I_Disease
myopathy	NN	E_Disease
that	WDT	O
shares	NNS	O
some	DT	O
pathological	JJ	O
features	NNS	O
with	IN	O
DM	NNP	S_Disease
.	.	O

Muscles	NNS	O
from	IN	O
mature	NN	O
mice	NN	O
show	NN	O
variation	NN	O
in	IN	O
fibre	JJ	O
size	NN	O
,	,	O
increased	VBD	O
fibre	JJ	B_Disease
degeneration	NN	E_Disease
and	CC	O
fibrosis	NN	S_Disease
.	.	O

Adult	NNP	O
Dmpk	NNP	O
-	:	O
/	SYM	O
-	:	O
mice	NN	O
show	NN	O
ultrastructural	JJ	O
changes	NNS	O
in	IN	O
muscle	NN	O
and	CC	O
a	DT	O
50	CD	O
%	NN	O
decrease	NN	O
in	IN	O
force	NN	O
generation	NN	O
compared	VBN	O
to	TO	O
young	JJ	O
mice	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
indicate	VBP	O
that	IN	O
DMPK	NNP	O
may	MD	O
be	VB	O
necessary	JJ	O
for	IN	O
the	DT	O
maintenance	NN	O
of	IN	O
skeletal	JJ	O
muscle	NN	O
structure	NN	O
and	CC	O
function	NN	O
and	CC	O
suggest	VBP	O
that	IN	O
a	DT	O
decrease	NN	O
in	IN	O
DMPK	NNP	O
levels	NNS	O
may	MD	O
contribute	VB	O
to	TO	O
DM	NNP	S_Disease
pathology	NN	O
.	.	O
.	.	O

The	DT	O
tumor	NN	S_Disease
suppressor	NN	O
gene	NN	O
Brca1	NNP	O
is	VBZ	O
required	VBN	O
for	IN	O
embryonic	JJ	O
cellular	JJ	O
proliferation	NN	O
in	IN	O
the	DT	O
mouse	NN	O
.	.	O

Mutations	NNS	O
of	IN	O
the	DT	O
BRCA1	NNP	O
gone	VBN	O
in	IN	O
humans	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
predisposition	NN	O
to	TO	O
breast	VB	B_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancers	NNS	E_Disease
.	.	O

We	PRP	O
show	VBP	O
here	RB	O
that	IN	O
Brca1	NNP	O
+	NNP	O
/	NNP	O
-	:	O
mice	NN	O
are	VBP	O
normal	JJ	O
and	CC	O
fertile	JJ	O
and	CC	O
lack	JJ	O
tumors	NNS	S_Disease
by	IN	O
age	NN	O
eleven	JJ	O
months	NNS	O
.	.	O

Homozygous	JJ	O
Brca1	NNP	O
(	(	O
5	CD	O
-	:	O
6	CD	O
)	)	O
mutant	NN	O
mice	NN	O
die	NN	O
before	IN	O
day	NN	O
7	CD	O
.	.	O

5	CD	O
of	IN	O
embryogenesis	NN	O
.	.	O

Mutant	JJ	O
embryos	NN	O
are	VBP	O
poorly	RB	O
developed	VBN	O
,	,	O
with	IN	O
no	DT	O
evidence	NN	O
of	IN	O
mesoderm	JJ	O
formation	NN	O
.	.	O

The	DT	O
extraembryonic	JJ	O
region	NN	O
is	VBZ	O
abnormal	JJ	O
,	,	O
but	CC	O
aggregation	NN	O
with	IN	O
wild	JJ	O
-	:	O
type	NN	O
tetraploid	JJ	O
embryos	NN	O
does	VBZ	O
not	RB	O
rescue	VB	O
the	DT	O
lethality	NN	O
.	.	O

In	IN	O
vivo	NN	O
,	,	O
mutant	JJ	O
embryos	NN	O
do	VBP	O
not	RB	O
exhibit	VB	O
increased	JJ	O
apoptosis	NN	O
but	CC	O
show	NN	O
reduced	VBD	O
cell	NN	O
proliferation	NN	O
accompanied	VBN	O
by	IN	O
decreased	JJ	O
expression	NN	O
of	IN	O
cyclin	NN	O
E	NNP	O
and	CC	O
mdm	SYM	O
-	:	O
2	CD	O
,	,	O
a	DT	O
regulator	NN	O
of	IN	O
p53	NN	O
activity	NN	O
.	.	O

The	DT	O
expression	NN	O
of	IN	O
cyclin	NN	O
-	:	O
dependent	JJ	O
kinase	NN	O
inhibitor	NN	O
p21	NN	O
is	VBZ	O
dramatically	RB	O
increased	VBN	O
in	IN	O
the	DT	O
mutant	JJ	O
embryos	NN	O
.	.	O

Buttressing	VBG	O
these	DT	O
in	IN	O
vivo	NN	O
observations	NNS	O
is	VBZ	O
the	DT	O
fact	NN	O
that	IN	O
mutant	JJ	O
blastocyst	NN	O
growth	NN	O
is	VBZ	O
grossly	RB	O
impaired	VBN	O
in	IN	O
vitro	NN	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
death	NN	O
of	IN	O
Brca1	NNP	O
(	(	O
5	CD	O
-	:	O
6	CD	O
)	)	O
mutant	NN	O
embryos	NN	O
prior	RB	O
to	TO	O
gastrulation	NN	O
may	MD	O
be	VB	O
due	JJ	O
to	TO	O
a	DT	O
failure	NN	O
of	IN	O
the	DT	O
proliferative	JJ	O
burst	NN	O
required	VBN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
the	DT	O
different	JJ	O
germ	NN	O
layers	NNS	O
.	.	O

Increased	VBN	O
coronary	JJ	B_Disease
heart	NN	I_Disease
disease	NN	E_Disease
in	IN	O
Japanese	JJ	O
-	:	O
American	JJ	O
men	NNS	O
with	IN	O
mutation	NN	O
in	IN	O
the	DT	O
cholesteryl	NN	O
ester	NN	O
transfer	NN	O
protein	NN	O
gene	NN	O
despite	IN	O
increased	VBN	O
HDL	NNP	O
levels	NNS	O
.	.	O

Plasma	NNP	O
high	JJ	O
density	NN	O
lipoprotein	NN	O
(	(	O
HDL	NNP	O
)	)	O
levels	NNS	O
are	VBP	O
strongly	RB	O
genetically	RB	O
determined	VBN	O
and	CC	O
show	VB	O
a	DT	O
general	JJ	O
inverse	NN	O
relationship	NN	O
with	IN	O
coronary	JJ	B_Disease
heart	NN	I_Disease
disease	NN	E_Disease
(	(	O
CHD	NNP	S_Disease
)	)	O
.	.	O

The	DT	O
cholesteryl	NN	O
ester	NN	O
transfer	NN	O
protein	NN	O
(	(	O
CETP	NNP	O
)	)	O
mediates	VBZ	O
the	DT	O
transfer	NN	O
of	IN	O
cholesteryl	NN	O
esters	NNS	O
from	IN	O
HDL	NNP	O
to	TO	O
other	JJ	O
lipoproteins	NNS	O
and	CC	O
is	VBZ	O
a	DT	O
key	JJ	O
participant	NN	O
in	IN	O
the	DT	O
reverse	NN	O
transport	NN	O
of	IN	O
cholesterol	NN	O
from	IN	O
the	DT	O
periphery	NN	O
to	TO	O
the	DT	O
liver	NN	O
.	.	O

A	DT	O
high	JJ	O
prevalence	NN	O
of	IN	O
two	CD	O
different	JJ	O
CETP	NNP	O
gene	NN	O
mutations	NNS	O
(	(	O
D442G	NNP	O
,	,	O
5	CD	O
.	.	O

1	CD	O
%	NN	O
;	:	O
intron	CC	O
14G	CD	O
A	NNP	O
,	,	O
0	CD	O
.	.	O

5	CD	O
%	NN	O
)	)	O
,	,	O
was	VBD	O
found	VBN	O
in	IN	O
3	CD	O
,	,	O
469	CD	O
men	NNS	O
of	IN	O
Japanese	JJ	O
ancestry	NN	O
in	IN	O
the	DT	O
Honolulu	NNP	O
Heart	NNP	O
Program	NNP	O
and	CC	O
mutations	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
decreased	JJ	O
CETP	NNP	O
(	(	O
-	:	O
35	CD	O
%	NN	O
)	)	O
and	CC	O
increased	VBD	O
HDL	NNP	O
chol	NN	O
levels	NNS	O
(	(	O
+	VB	O
10	CD	O
%	NN	O
for	IN	O
D442G	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
overall	JJ	O
prevalence	NN	O
of	IN	O
definite	JJ	O
CHD	NNP	S_Disease
was	VBD	O
21	CD	O
%	NN	O
in	IN	O
men	NNS	O
with	IN	O
mutations	NNS	O
and	CC	O
16	CD	O
%	NN	O
in	IN	O
men	NNS	O
without	IN	O
mutations	NNS	O
.	.	O

The	DT	O
relative	JJ	O
risk	NN	O
(	(	O
RR	NNP	O
)	)	O
of	IN	O
CHD	NNP	S_Disease
was	VBD	O
1	CD	O
.	.	O

43	CD	O
in	IN	O
men	NNS	O
with	IN	O
mutations	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.	.	O

05	CD	O
)	)	O
;	:	O
after	IN	O
adjustment	NN	O
for	IN	O
CHD	NNP	S_Disease
risk	NN	O
factors	NNS	O
,	,	O
the	DT	O
RR	NNP	O
was	VBD	O
1	CD	O
.	.	O

55	CD	O
(	(	O
P	NNP	O
=	NNP	O
.	.	O

02	CD	O
)	)	O
;	:	O
after	IN	O
additional	JJ	O
adjustment	NN	O
for	IN	O
HDL	NNP	O
levels	NNS	O
,	,	O
the	DT	O
RR	NNP	O
was	VBD	O
1	CD	O
.	.	O

68	CD	O
(	(	O
P	NNP	O
=	NNP	O
.	.	O

008	CD	O
)	)	O
.	.	O

Similar	JJ	O
RR	NNP	O
values	NNS	O
were	VBD	O
obtained	VBN	O
for	IN	O
the	DT	O
D442G	NNP	O
mutation	NN	O
alone	RB	O
.	.	O

Increased	VBN	O
CHD	NNP	S_Disease
in	IN	O
men	NNS	O
with	IN	O
mutations	NNS	O
was	VBD	O
primarily	RB	O
observed	VBN	O
for	IN	O
HDL	NNP	O
chol	NN	O
41	CD	O
-	:	O
60	CD	O
mg	NN	O
/	NNP	O
dl	NN	O
;	:	O
for	IN	O
HDL	NNP	O
chol	NN	O
>	VBD	O
60	CD	O
mg	NN	O
/	NNP	O
dl	VBZ	O
men	NNS	O
with	IN	O
and	CC	O
without	IN	O
mutations	NNS	O
had	VBD	O
low	JJ	O
CHD	NNP	S_Disease
prevalence	NN	O
.	.	O

Thus	RB	O
,	,	O
genetic	JJ	O
CETP	NNP	B_Disease
deficiency	NN	E_Disease
appears	VBZ	O
to	TO	O
be	VB	O
an	DT	O
independent	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
CHD	NNP	S_Disease
,	,	O
primarily	RB	O
due	JJ	O
to	TO	O
increased	VBN	O
CHD	NNP	S_Disease
prevalence	NN	O
in	IN	O
men	NNS	O
with	IN	O
the	DT	O
D442G	NNP	O
mutation	NN	O
and	CC	O
HDL	NNP	O
cholesterol	NN	O
between	IN	O
41	CD	O
and	CC	O
60	CD	O
mg	NN	O
/	NNP	O
dl	NN	O
.	.	O

The	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
both	DT	O
HDL	NNP	O
concentration	NN	O
and	CC	O
the	DT	O
dynamics	NNS	O
of	IN	O
cholesterol	NN	O
transport	NN	O
through	IN	O
HDL	NNP	O
(	(	O
i	NN	O
.	.	O

e	NN	O
.	.	O
,	,	O
reverse	VB	O
cholesterol	NN	O
transport	NN	O
)	)	O
determine	VBZ	O
the	DT	O
anti	JJ	O
-	:	O
atherogenicity	NN	O
of	IN	O
the	DT	O
HDL	NNP	O
fraction	NN	O
.	.	O

Mapping	VBG	O
the	DT	O
homolog	NN	O
of	IN	O
the	DT	O
human	JJ	O
Rb1	NNP	O
gene	NN	O
to	TO	O
chromosome	VB	O
14	CD	O
of	IN	O
higher	JJR	O
primates	NNS	O
.	.	O

The	DT	O
Rb1	NNP	O
gene	NN	O
has	VBZ	O
been	VBN	O
implicated	VBN	O
with	IN	O
retinoblastoma	NN	S_Disease
and	CC	O
is	VBZ	O
located	VBN	O
on	IN	O
human	JJ	O
Chromosome	NNP	O
(	(	O
Chr	NNP	O
)	)	O
13q14	CD	O
.	.	O

2	CD	O
2	CD	O
.	.	O

A	DT	O
unique	JJ	O
sequence	NN	O
human	JJ	O
Rb1	NNP	O
cosmid	NN	O
DNA	NNP	O
probe	NN	O
has	VBZ	O
been	VBN	O
used	VBN	O
to	TO	O
localize	VB	O
this	DT	O
region	NN	O
on	IN	O
apes	NNS	O
Chr	NNP	O
14	CD	O
by	IN	O
the	DT	O
FISH	NNP	O
technique	NN	O
.	.	O

The	DT	O
conservation	NN	O
of	IN	O
the	DT	O
Rb1	NNP	O
gene	NN	O
in	IN	O
higher	JJR	O
primates	NNS	O
at	IN	O
the	DT	O
corresponding	JJ	O
equivalent	JJ	O
chromosome	NN	O
locus	NN	O
(	(	O
14q14	CD	O
)	)	O
of	IN	O
the	DT	O
human	NN	O
may	MD	O
serve	VB	O
as	IN	O
a	DT	O
phylogenetic	JJ	O
marker	NN	O
to	TO	O
further	JJ	O
trace	NN	O
the	DT	O
evolutionary	JJ	O
pathway	NN	O
of	IN	O
human	JJ	O
descent	NN	O
.	.	O

Wiskott	NNP	B_Disease
-	:	I_Disease
Aldrich	JJ	I_Disease
syndrome	NN	E_Disease
:	:	O
no	DT	O
strict	JJ	O
genotype	NN	O
-	:	O
phenotype	NN	O
correlations	NNS	O
but	CC	O
clustering	VBG	O
of	IN	O
missense	JJ	O
mutations	NNS	O
in	IN	O
the	DT	O
amino	NN	O
-	:	O
terminal	JJ	O
part	NN	O
of	IN	O
the	DT	O
WASP	NNP	O
gene	NN	O
product	NN	O
.	.	O

The	DT	O
Wiskott	NNP	B_Disease
-	:	I_Disease
Aldrich	NNP	I_Disease
syndrome	VBP	E_Disease
protein	NN	O
(	(	O
WASP	NNP	O
)	)	O
gene	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
mutated	VBN	O
in	IN	O
patients	NNS	O
presenting	VBG	O
with	IN	O
WAS	NNP	S_Disease
and	CC	O
in	IN	O
patients	NNS	O
showing	VBG	O
X	NNP	B_Disease
-	:	I_Disease
linked	VBN	I_Disease
thrombocytopenia	NN	E_Disease
.	.	O

Mutation	NN	O
analysis	NN	O
in	IN	O
19	CD	O
families	NNS	O
of	IN	O
German	JJ	O
,	,	O
Swiss	JJ	O
and	CC	O
Turkish	JJ	O
descent	NN	O
by	IN	O
single	JJ	O
-	:	O
strand	NN	O
conformation	NN	O
polymorphism	NN	O
and	CC	O
sequencing	NN	O
resulted	VBD	O
in	IN	O
the	DT	O
detection	NN	O
of	IN	O
seven	CD	O
novel	NNS	O
and	CC	O
10	CD	O
known	VBN	O
mutations	NNS	O
.	.	O

A	DT	O
striking	JJ	O
clustering	NN	O
of	IN	O
missense	JJ	O
mutations	NNS	O
in	IN	O
the	DT	O
first	JJ	O
four	CD	O
exons	NNS	O
contrasted	VBN	O
with	IN	O
a	DT	O
random	JJ	O
distribution	NN	O
of	IN	O
nonsense	JJ	O
mutations	NNS	O
.	.	O

More	JJR	O
than	IN	O
85	CD	O
%	NN	O
of	IN	O
all	DT	O
known	VBN	O
missense	NN	O
mutations	NNS	O
were	VBD	O
localized	VBN	O
in	IN	O
the	DT	O
amino	NN	O
-	:	O
terminal	JJ	O
stretch	NN	O
of	IN	O
the	DT	O
WASP	NNP	O
gene	NN	O
product	NN	O
;	:	O
this	DT	O
region	NN	O
contained	VBD	O
a	DT	O
mutational	JJ	O
hot	JJ	O
spot	NN	O
at	IN	O
codon	NN	O
86	CD	O
.	.	O

No	DT	O
genotype	NN	O
-	:	O
phenotype	NN	O
correlation	NN	O
emerged	VBD	O
after	IN	O
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
identified	JJ	O
mutations	NNS	O
with	IN	O
the	DT	O
resulting	VBG	O
clinical	JJ	O
picture	NN	O
for	IN	O
a	DT	O
classical	JJ	O
WAS	NNP	S_Disease
phenotype	NN	O
.	.	O

A	DT	O
substitution	NN	O
at	IN	O
codon	$	O
86	CD	O
resulted	VBN	O
in	IN	O
an	DT	O
extremely	RB	O
variable	JJ	O
expression	NN	O
of	IN	O
the	DT	O
disease	NN	O
in	IN	O
a	DT	O
large	JJ	O
Swiss	JJ	O
family	NN	O
.	.	O

An	DT	O
extended	JJ	O
homology	NN	O
search	NN	O
revealed	VBD	O
a	DT	O
distant	JJ	O
relationship	NN	O
of	IN	O
this	DT	O
stretch	NN	O
to	TO	O
the	DT	O
vasodilator	NN	O
-	:	O
stimulated	VBN	O
phosphoprotein	NN	O
(	(	O
VASP	NNP	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
involved	VBN	O
in	IN	O
the	DT	O
maintenance	NN	O
of	IN	O
cyto	NN	O
-	:	O
architecture	NN	O
by	IN	O
interacting	VBG	O
with	IN	O
actin	JJ	O
-	:	O
like	IN	O
filaments	NNS	O
.	.	O
.	.	O

Influence	NN	O
of	IN	O
PAX6	NNP	O
gene	NN	O
dosage	NN	O
on	IN	O
development	NN	O
:	:	O
overexpression	NN	O
causes	VBZ	O
severe	JJ	O
eye	NN	B_Disease
abnormalities	NNS	E_Disease
.	.	O

Aniridia	NNP	S_Disease
in	IN	O
man	NN	O
and	CC	O
Small	NNP	O
eye	NN	O
in	IN	O
mice	NNS	O
are	VBP	O
semidominant	JJ	B_Disease
developmental	JJ	I_Disease
disorders	NNS	E_Disease
caused	VBN	O
by	IN	O
mutations	NNS	O
within	IN	O
the	DT	O
paired	JJ	O
box	NN	O
gene	NN	O
PAX6	NNP	O
.	.	O

Whereas	NNP	O
heterozygotes	VBZ	O
suffer	VBP	O
from	IN	O
iris	JJ	B_Disease
hypoplasia	NN	E_Disease
,	,	O
homozygous	JJ	O
mice	NN	O
lack	NN	O
eyes	NNS	O
and	CC	O
nasal	JJ	O
cavities	NNS	O
and	CC	O
exhibit	NN	O
brain	NN	B_Disease
abnormalities	NNS	E_Disease
.	.	O

To	TO	O
investigate	VB	O
the	DT	O
role	NN	O
of	IN	O
gene	NN	O
dosage	NN	O
in	IN	O
more	JJR	O
detail	NN	O
,	,	O
we	PRP	O
have	VBP	O
generated	VBN	O
yeast	JJ	O
artificial	JJ	O
chromosome	NN	O
transgenic	JJ	O
mice	NN	O
carrying	VBG	O
the	DT	O
human	JJ	O
PAX6	NNP	O
locus	NN	O
.	.	O

When	WRB	O
crossed	VBN	O
onto	IN	O
the	DT	O
Small	NNP	O
eye	NN	O
background	NN	O
,	,	O
the	DT	O
transgene	NN	O
rescues	VBZ	O
the	DT	O
mutant	JJ	O
phenotype	NN	O
.	.	O

Strikingly	RB	O
,	,	O
mice	NNS	O
carrying	VBG	O
multiple	JJ	O
copies	NNS	O
on	IN	O
a	DT	O
wild	JJ	O
-	:	O
type	NN	O
background	NN	O
show	NN	O
specific	JJ	O
developmental	JJ	B_Disease
abnormalities	NNS	I_Disease
of	IN	I_Disease
the	DT	I_Disease
eye	NN	E_Disease
,	,	O
but	CC	O
not	RB	O
of	IN	O
other	JJ	O
tissues	NNS	O
expressing	VBG	O
the	DT	O
gene	NN	O
.	.	O

Thus	RB	O
,	,	O
at	IN	O
least	JJS	O
five	CD	O
different	JJ	O
eye	NN	O
phenotypes	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
changes	NNS	O
in	IN	O
PAX6	NNP	O
expression	NN	O
.	.	O

We	PRP	O
provide	VBP	O
evidence	NN	O
that	IN	O
not	RB	O
only	RB	O
reduced	VBN	O
,	,	O
but	CC	O
also	RB	O
increased	VBD	O
levels	NNS	O
of	IN	O
transcriptional	JJ	O
regulators	NNS	O
can	MD	O
cause	VB	O
developmental	JJ	B_Disease
defects	NNS	E_Disease
.	.	O
.	.	O

Heterodimer	NNP	O
formation	NN	O
and	CC	O
activity	NN	O
in	IN	O
the	DT	O
human	JJ	O
enzyme	NN	O
galactose	VBD	O
-	:	O
1	CD	O
-	:	O
phosphate	NN	O
uridylyltransferase	NN	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
fundamental	JJ	O
questions	NNS	O
concerning	VBG	O
expression	NN	O
and	CC	O
function	NN	O
of	IN	O
dimeric	JJ	O
enzymes	NNS	O
involves	VBZ	O
the	DT	O
impact	NN	O
of	IN	O
naturally	RB	O
occurring	VBG	O
mutations	NNS	O
on	IN	O
subunit	NN	O
assembly	NN	O
and	CC	O
heterodimer	NN	O
activity	NN	O
.	.	O

This	DT	O
question	NN	O
is	VBZ	O
of	IN	O
particular	JJ	O
interest	NN	O
for	IN	O
the	DT	O
human	JJ	O
enzyme	NN	O
galactose	SYM	O
-	:	O
l	NN	O
-	:	O
phosphate	NN	O
uridylyl	JJ	O
-	:	O
transferase	NN	O
(	(	O
GALT	NNP	O
)	)	O
,	,	O
impairment	NN	O
of	IN	O
which	WDT	O
results	NNS	O
in	IN	O
the	DT	O
inherited	JJ	B_Disease
metabolic	JJ	I_Disease
disorder	NN	E_Disease
galactosemia	NN	S_Disease
,	,	O
because	IN	O
many	JJ	O
if	IN	O
not	RB	O
most	JJS	O
patients	NNS	O
studied	VBN	O
to	TO	O
date	NN	O
are	VBP	O
compound	VBN	O
heterozygotes	NNS	O
rather	RB	O
than	IN	O
true	JJ	O
molecular	JJ	O
homozygotes	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
the	DT	O
broad	JJ	O
range	NN	O
of	IN	O
phenotypic	NN	O
severity	NN	O
observed	VBN	O
in	IN	O
these	DT	O
patients	NNS	O
raises	VBZ	O
the	DT	O
possibility	NN	O
that	IN	O
allelic	JJ	O
combination	NN	O
,	,	O
not	RB	O
just	RB	O
allelic	JJ	O
constitution	NN	O
,	,	O
may	MD	O
play	VB	O
some	DT	O
role	NN	O
in	IN	O
determining	VBG	O
outcome	NN	O
.	.	O

In	IN	O
the	DT	O
work	NN	O
described	VBD	O
herein	RB	O
,	,	O
we	PRP	O
have	VBP	O
selected	VBN	O
two	CD	O
distinct	JJ	O
naturally	RB	O
occurring	VBG	O
null	JJ	O
mutations	NNS	O
of	IN	O
GALT	NNP	O
,	,	O
Q188R	NNP	O
and	CC	O
R333W	NNP	O
,	,	O
and	CC	O
asked	VBD	O
the	DT	O
questions	NNS	O
(	(	O
i	NN	O
)	)	O
what	WDT	O
are	VBP	O
the	DT	O
impacts	NNS	O
of	IN	O
these	DT	O
mutations	NNS	O
on	IN	O
subunit	NN	O
assembly	NN	O
,	,	O
and	CC	O
(	(	O
ii	NN	O
)	)	O
if	IN	O
heterodimers	NNS	O
do	VBP	O
form	VB	O
,	,	O
are	VBP	O
they	PRP	O
active	JJ	O
?	.	O
To	TO	O
answer	VB	O
these	DT	O
questions	NNS	O
,	,	O
we	PRP	O
have	VBP	O
established	VBN	O
a	DT	O
yeast	NN	O
system	NN	O
for	IN	O
the	DT	O
coexpression	NN	O
of	IN	O
epitope	NN	O
-	:	O
tagged	JJ	O
alleles	NNS	O
of	IN	O
human	JJ	O
GALT	NNP	O
and	CC	O
investigated	VBN	O
both	PDT	O
the	DT	O
extent	NN	O
of	IN	O
specific	JJ	O
GALT	NNP	O
subunit	NN	O
interactions	NNS	O
and	CC	O
the	DT	O
activity	NN	O
of	IN	O
defined	JJ	O
heterodimer	NN	O
pools	NNS	O
.	.	O

We	PRP	O
have	VBP	O
found	VBN	O
that	IN	O
both	DT	O
homodimers	NNS	O
and	CC	O
heterodimers	NNS	O
do	VBP	O
form	VB	O
involving	VBG	O
each	DT	O
of	IN	O
the	DT	O
mutant	JJ	O
subunits	NNS	O
tested	VBN	O
and	CC	O
that	IN	O
both	DT	O
heterodimer	NN	O
pools	NNS	O
retain	VBP	O
substantial	JJ	O
enzymatic	JJ	O
activity	NN	O
.	.	O

These	DT	O
results	NNS	O
are	VBP	O
significant	JJ	O
not	RB	O
only	RB	O
in	IN	O
terms	NNS	O
of	IN	O
their	PRP$	O
implications	NNS	O
for	IN	O
furthering	VBG	O
our	PRP$	O
understanding	NN	O
of	IN	O
galactosemia	NN	S_Disease
and	CC	O
GALT	NNP	O
holoenzyme	NN	O
structure	NN	O
-	:	O
function	NN	O
relationships	NNS	O
but	CC	O
also	RB	O
because	IN	O
the	DT	O
system	NN	O
described	VBD	O
may	MD	O
serve	VB	O
as	IN	O
a	DT	O
model	NN	O
for	IN	O
similar	JJ	O
studies	NNS	O
of	IN	O
other	JJ	O
complexes	NNS	O
composed	VBN	O
of	IN	O
multiple	JJ	O
subunits	NNS	O
.	.	O
.	.	O

Cleavage	NN	O
of	IN	O
huntingtin	NN	O
by	IN	O
apopain	NN	O
,	,	O
a	DT	O
proapoptotic	JJ	O
cysteine	NN	O
protease	NN	O
,	,	O
is	VBZ	O
modulated	VBN	O
by	IN	O
the	DT	O
polyglutamine	NN	O
tract	NN	O
.	.	O

Apoptosis	NN	O
has	VBZ	O
recently	RB	O
been	VBN	O
recognized	VBN	O
as	IN	O
a	DT	O
mode	NN	O
of	IN	O
cell	NN	O
death	NN	O
in	IN	O
Huntington	NNP	B_Disease
disease	NN	E_Disease
(	(	O
HD	NNP	S_Disease
)	)	O
.	.	O

Apopain	NNP	O
,	,	O
a	DT	O
human	JJ	O
counterpart	NN	O
of	IN	O
the	DT	O
nematode	JJ	O
cysteine	NN	O
protease	NN	O
death	NN	O
-	:	O
gene	NN	O
product	NN	O
,	,	O
CED	NNP	O
-	:	O
3	CD	O
,	,	O
has	VBZ	O
a	DT	O
key	JJ	O
role	NN	O
in	IN	O
proteolytic	JJ	O
events	NNS	O
leading	VBG	O
to	TO	O
apoptosis	NN	O
.	.	O

Here	RB	O
we	PRP	O
show	VBP	O
that	IN	O
apoptotic	JJ	O
extracts	NNS	O
and	CC	O
apopain	VB	O
itself	PRP	O
specifically	RB	O
cleave	VBP	O
the	DT	O
HD	NNP	S_Disease
gene	NN	O
product	NN	O
,	,	O
huntingtin	NN	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
cleavage	NN	O
increases	NNS	O
with	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
huntingtin	NN	O
polyglutamine	NN	O
tract	NN	O
,	,	O
providing	VBG	O
an	DT	O
explanation	NN	O
for	IN	O
the	DT	O
gain	NN	O
-	:	O
of	IN	O
-	:	O
function	NN	O
associated	VBN	O
with	IN	O
CAG	NNP	O
expansion	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
show	VBP	O
that	IN	O
huntingtin	NN	O
is	VBZ	O
cleaved	VBN	O
by	IN	O
cysteine	NN	O
proteases	NNS	O
and	CC	O
suggest	VBP	O
that	IN	O
HD	NNP	S_Disease
might	MD	O
be	VB	O
a	DT	O
disorder	NN	B_Disease
of	IN	I_Disease
inappropriate	JJ	I_Disease
apoptosis	NN	E_Disease
.	.	O
.	.	O

The	DT	O
5	CD	O
'	POS	O
end	NN	O
of	IN	O
the	DT	O
BRCA1	NNP	O
gene	NN	O
lies	VBZ	O
within	IN	O
a	DT	O
duplicated	JJ	O
region	NN	O
of	IN	O
human	JJ	O
chromosome	NN	O
17q21	CD	O
.	.	O

To	TO	O
begin	VB	O
to	TO	O
address	VB	O
the	DT	O
hypothesis	NN	O
that	WDT	O
abnormal	JJ	O
regulation	NN	O
of	IN	O
the	DT	O
breast	NN	B_Disease
/	JJ	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
susceptibility	NN	O
gene	NN	O
BRCA1	NNP	O
is	VBZ	O
a	DT	O
critical	JJ	O
step	NN	O
in	IN	O
sporadic	JJ	O
breast	NN	O
/	NNP	O
ovarian	JJ	O
tumorigenesis	NN	O
,	,	O
we	PRP	O
have	VBP	O
determined	VBN	O
the	DT	O
detailed	JJ	O
structure	NN	O
of	IN	O
the	DT	O
BRCA1	NNP	O
genomic	JJ	O
region	NN	O
.	.	O

We	PRP	O
show	VBP	O
that	IN	O
this	DT	O
region	NN	O
of	IN	O
the	DT	O
genome	NN	O
contains	VBZ	O
a	DT	O
tandem	JJ	O
duplication	NN	O
of	IN	O
approximately	RB	O
30	CD	O
kilobases	NNS	O
,	,	O
which	WDT	O
results	NNS	O
in	IN	O
two	CD	O
copies	NNS	O
of	IN	O
BRCA1	NNP	O
exons	NNS	O
1	CD	O
and	CC	O
2	CD	O
,	,	O
of	IN	O
exons	NNS	O
1	CD	O
and	CC	O
3	CD	O
of	IN	O
the	DT	O
adjacent	JJ	O
1A1	CD	O
-	:	O
3B	CD	O
gene	NN	O
and	CC	O
of	IN	O
the	DT	O
previously	RB	O
reported	VBN	O
295	CD	O
base	NN	O
pair	NN	O
intergenic	JJ	O
region	NN	O
.	.	O

Sequence	NNP	O
analysis	NN	O
of	IN	O
the	DT	O
duplicated	JJ	O
exons	NNS	O
of	IN	O
BRCA1	NNP	O
and	CC	O
1A1	CD	O
-	:	O
3B	CD	O
and	CC	O
flanking	VBG	O
genomic	JJ	O
DNA	NN	O
reveals	NNS	O
maintenance	NN	O
of	IN	O
the	DT	O
intron	NN	O
-	:	O
exon	NN	O
structure	NN	O
and	CC	O
a	DT	O
high	JJ	O
degree	NN	O
of	IN	O
nucleotide	JJ	O
sequence	NN	O
identity	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
these	DT	O
are	VBP	O
non	JJ	O
-	:	O
processed	VBN	O
pseudogenes	NNS	O
and	CC	O
that	IN	O
the	DT	O
duplication	NN	O
is	VBZ	O
a	DT	O
recent	JJ	O
event	NN	O
in	IN	O
evolutionary	JJ	O
terms	NNS	O
.	.	O

We	PRP	O
also	RB	O
show	VBP	O
that	IN	O
a	DT	O
processed	JJ	O
pseudogene	NN	O
of	IN	O
the	DT	O
acidic	JJ	O
ribosomal	JJ	O
phosphoprotein	NN	O
P1	NNP	O
(	(	O
ARPP1	NNP	O
)	)	O
is	VBZ	O
inserted	VBN	O
directly	RB	O
upstream	JJ	O
of	IN	O
pseudo	JJ	O
-	:	O
BRCA1	NNP	O
exon	VBZ	O
1A	CD	O
.	.	O

We	PRP	O
believe	VBP	O
that	IN	O
these	DT	O
findings	NNS	O
could	MD	O
not	RB	O
only	RB	O
confound	VB	O
BRCA1	NNP	O
mutation	NN	O
analysis	NN	O
,	,	O
but	CC	O
could	MD	O
have	VB	O
implications	NNS	O
for	IN	O
the	DT	O
normal	JJ	O
and	CC	O
abnormal	JJ	O
regulation	NN	O
of	IN	O
BRCA1	NNP	O
transcription	NN	O
,	,	O
translation	NN	O
and	CC	O
function	NN	O
.	.	O
.	.	O

Deletion	NN	O
of	IN	O
small	JJ	O
nuclear	JJ	O
ribonucleoprotein	NN	O
polypeptide	IN	O
N	NNP	O
(	(	O
SNRPN	NNP	O
)	)	O
in	IN	O
Prader	NNP	B_Disease
-	:	I_Disease
Willi	NNP	I_Disease
syndrome	NN	E_Disease
detected	VBN	O
by	IN	O
fluorescence	NN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
:	:	O
two	CD	O
sibs	NN	O
with	IN	O
the	DT	O
typical	JJ	O
phenotype	NN	O
without	IN	O
a	DT	O
cytogenetic	JJ	O
deletion	NN	O
in	IN	O
chromosome	NN	O
15q	CD	O
.	.	O

The	DT	O
small	JJ	O
nuclear	JJ	O
ribonucleoprotein	NN	O
polypeptide	IN	O
N	NNP	O
(	(	O
SNRPN	NNP	O
)	)	O
gene	NN	O
is	VBZ	O
regarded	VBN	O
as	IN	O
one	CD	O
of	IN	O
the	DT	O
candidates	NNS	O
for	IN	O
Prader	NNP	B_Disease
-	:	I_Disease
Willi	NNP	I_Disease
syndrome	NN	E_Disease
(	(	O
PWS	NNP	S_Disease
)	)	O
.	.	O

We	PRP	O
describe	VBP	O
two	CD	O
sibs	NN	O
with	IN	O
typical	JJ	O
PWS	NNP	S_Disease
presenting	VBG	O
deletion	NN	O
of	IN	O
SNRPN	NNP	O
detected	VBN	O
by	IN	O
fluorescence	NN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
(	(	O
FISH	NNP	O
)	)	O
.	.	O

Neither	CC	O
a	DT	O
cytogenetically	RB	O
detectable	JJ	O
15q12	CD	O
deletion	NN	O
nor	CC	O
a	DT	O
deletion	NN	O
for	IN	O
the	DT	O
D15S11	NNP	O
,	,	O
D15S10	NNP	O
,	,	O
and	CC	O
GABRB3	NNP	O
cosmid	VBP	O
probes	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
either	DT	O
patient	NN	O
.	.	O

This	DT	O
implies	VBZ	O
a	DT	O
smaller	JJR	O
deletion	NN	O
limited	VBD	O
to	TO	O
the	DT	O
PWS	NNP	S_Disease
critical	JJ	O
region	NN	O
.	.	O

FISH	NN	O
with	IN	O
a	DT	O
SNRPN	NNP	O
probe	NN	O
will	MD	O
permit	VB	O
analysis	NN	O
of	IN	O
PWS	NNP	S_Disease
patients	NNS	O
with	IN	O
limited	JJ	O
deletions	NNS	O
not	RB	O
detectable	JJ	O
with	IN	O
other	JJ	O
probes	NNS	O
.	.	O
.	.	O

Expression	NN	O
of	IN	O
the	DT	O
von	NN	B_Disease
Hippel	NNP	I_Disease
-	:	I_Disease
Lindau	NNP	I_Disease
disease	VB	I_Disease
tumour	NN	E_Disease
suppressor	NN	O
gene	NN	O
during	IN	O
human	JJ	O
embryogenesis	NN	O
.	.	O

The	DT	O
von	NN	B_Disease
Hippel	NNP	I_Disease
-	:	I_Disease
Lindau	NNP	I_Disease
(	(	I_Disease
VHL	NNP	I_Disease
)	)	I_Disease
disease	NN	E_Disease
product	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
down	VB	O
-	:	O
regulate	NN	O
transcription	NN	O
by	IN	O
antagonizing	VBG	O
elongin	SYM	O
-	:	O
enhanced	JJ	O
transcriptional	JJ	O
elongation	NN	O
.	.	O

Germline	NNP	O
VHL	NNP	S_Disease
gene	NN	O
mutations	NNS	O
predispose	VBP	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
retinal	JJ	B_Disease
,	,	I_Disease
cerebellar	JJ	I_Disease
and	CC	I_Disease
spinal	JJ	I_Disease
haemangioblastomas	NN	E_Disease
,	,	O
renal	JJ	B_Disease
cell	NN	I_Disease
carcinoma	NN	E_Disease
and	CC	O
phaeochromocytoma	NN	S_Disease
.	.	O

In	IN	O
addition	NN	O
,	,	O
somatic	JJ	O
Inactivation	NN	O
of	IN	O
the	DT	O
VHL	NNP	S_Disease
gene	NN	O
is	VBZ	O
frequent	JJ	O
in	IN	O
sporadic	JJ	B_Disease
renal	JJ	I_Disease
cell	NN	I_Disease
carcinoma	NN	E_Disease
and	CC	O
haemangioblastoma	NN	S_Disease
.	.	O

Regulation	NN	O
of	IN	O
transcript	JJ	O
elongation	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
control	NN	O
mechanism	NN	O
for	IN	O
gene	NN	O
expression	NN	O
and	CC	O
the	DT	O
VHL	NNP	S_Disease
gene	NN	O
might	MD	O
modify	VB	O
the	DT	O
expression	NN	O
of	IN	O
proto	NN	O
-	:	O
oncogenes	NNS	O
and	CC	O
growth	NN	O
suppressor	NN	O
genes	NNS	O
during	IN	O
embryogenesis	NN	O
.	.	O

We	PRP	O
therefore	RB	O
investigated	VBD	O
the	DT	O
expression	NN	O
of	IN	O
VHL	NNP	S_Disease
mRNA	NN	O
during	IN	O
human	JJ	O
embryogenesis	NN	O
by	IN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
studies	NNS	O
at	IN	O
4	CD	O
,	,	O
6	CD	O
and	CC	O
10	CD	O
weeks	NNS	O
post	NN	O
conception	NN	O
.	.	O

Although	IN	O
VHL	NNP	S_Disease
mRNA	NN	O
was	VBD	O
expressed	VBN	O
in	IN	O
all	DT	O
three	CD	O
germ	NN	O
layers	NNS	O
,	,	O
strong	JJ	O
expression	NN	O
was	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
,	,	O
kidneys	NNS	O
,	,	O
testis	NN	O
and	CC	O
lung	NN	O
.	.	O

Within	IN	O
the	DT	O
kidney	NN	O
,	,	O
VHL	NNP	S_Disease
mRNA	NN	O
was	VBD	O
differentially	RB	O
expressed	VBN	O
within	IN	O
renal	JJ	O
tubules	NNS	O
suggesting	VBG	O
that	IN	O
the	DT	O
VHL	NNP	S_Disease
gene	NN	O
product	NN	O
may	MD	O
have	VB	O
a	DT	O
specific	JJ	O
role	NN	O
in	IN	O
kidney	NN	O
development	NN	O
.	.	O

Two	CD	O
alternatively	RB	O
spliced	VBD	O
VHL	NNP	S_Disease
mRNAs	NNS	O
characterized	VBN	O
by	IN	O
inclusion	NN	O
(	(	O
isoform	VB	O
I	PRP	O
)	)	O
or	CC	O
exclusion	NN	O
(	(	O
isoform	VB	O
II	NNP	O
)	)	O
of	IN	O
exon	$	O
2	CD	O
are	VBP	O
transcribed	VBN	O
in	IN	O
adult	NN	O
tissues	NNS	O
.	.	O

To	TO	O
investigate	VB	O
if	IN	O
the	DT	O
two	CD	O
isoforms	NNS	O
are	VBP	O
differentially	RB	O
expressed	VBN	O
during	IN	O
embryogenesis	NN	O
,	,	O
VHL	NNP	S_Disease
mRNA	NN	O
was	VBD	O
reverse	JJ	O
transcribed	NN	O
from	IN	O
13	CD	O
fetal	JJ	O
tissues	NNS	O
(	(	O
8	CD	O
-	:	O
10	CD	O
weeks	NNS	O
gestation	NN	O
)	)	O
.	.	O

The	DT	O
quantitative	JJ	O
distribution	NN	O
of	IN	O
VHL	NNP	S_Disease
mRNA	NN	O
within	IN	O
fetal	JJ	O
tissues	NNS	O
reflected	VBD	O
that	IN	O
seen	VBN	O
by	IN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
and	CC	O
the	DT	O
ratio	NN	O
of	IN	O
the	DT	O
two	CD	O
VHL	NNP	S_Disease
isoforms	NNS	O
was	VBD	O
similar	JJ	O
between	IN	O
tissues	NNS	O
.	.	O

Although	IN	O
the	DT	O
genes	NNS	O
regulated	VBN	O
by	IN	O
the	DT	O
VHL	NNP	S_Disease
gene	NN	O
product	NN	O
have	VBP	O
not	RB	O
yet	RB	O
been	VBN	O
identified	VBN	O
,	,	O
our	PRP$	O
findings	NNS	O
are	VBP	O
compatible	JJ	O
with	IN	O
the	DT	O
hypothesis	NN	O
that	WDT	O
VHL	NNP	S_Disease
-	:	O
mediated	VBD	O
control	NN	O
of	IN	O
transcriptional	JJ	O
elongation	NN	O
may	MD	O
have	VB	O
a	DT	O
role	NN	O
in	IN	O
normal	JJ	O
human	JJ	O
development	NN	O
.	.	O
.	.	O

Genetic	JJ	O
heterogeneity	NN	O
in	IN	O
hereditary	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
:	:	O
role	NN	O
of	IN	O
BRCA1	NNP	O
and	CC	O
BRCA2	NNP	O
.	.	O

The	DT	O
common	JJ	O
hereditary	JJ	O
forms	NNS	O
of	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
have	VBP	O
been	VBN	O
largely	RB	O
attributed	VBN	O
to	TO	O
the	DT	O
inheritance	NN	O
of	IN	O
mutations	NNS	O
in	IN	O
the	DT	O
BRCA1	NNP	O
or	CC	O
BRCA2	NNP	O
genes	NNS	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
not	RB	O
yet	RB	O
clear	JJ	O
what	WP	O
proportion	NN	O
of	IN	O
hereditary	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
is	VBZ	O
explained	VBN	O
by	IN	O
BRCA1	NNP	O
and	CC	O
BRCA2	NNP	O
or	CC	O
by	IN	O
some	DT	O
other	JJ	O
unidentified	JJ	O
susceptibility	NN	O
gene	NN	O
(	(	O
s	JJ	O
)	)	O
.	.	O

We	PRP	O
describe	VBP	O
the	DT	O
proportion	NN	O
of	IN	O
hereditary	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
explained	VBN	O
by	IN	O
BRCA1	NNP	O
or	CC	O
BRCA2	NNP	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
North	JJ	O
American	JJ	O
hereditary	NN	B_Disease
breast	NN	I_Disease
cancers	NNS	E_Disease
and	CC	O
assess	VB	O
the	DT	O
evidence	NN	O
for	IN	O
additional	JJ	O
susceptibility	NN	O
genes	NNS	O
that	WDT	O
may	MD	O
confer	VB	O
hereditary	JJ	B_Disease
breast	NN	I_Disease
or	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
risk	NN	O
.	.	O

Twenty	NNP	O
-	:	O
three	CD	O
families	NNS	O
were	VBD	O
identified	VBN	O
through	IN	O
two	CD	O
high	JJ	O
-	:	O
risk	NN	O
breast	NN	B_Disease
cancer	NN	E_Disease
research	NN	O
programs	NNS	O
.	.	O

Genetic	JJ	O
analysis	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
establish	VB	O
linkage	NN	O
between	IN	O
the	DT	O
breast	NN	B_Disease
or	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
cases	NNS	O
and	CC	O
markers	NNS	O
on	IN	O
chromosomes	NNS	O
17q	CD	O
(	(	O
BRCA1	NNP	O
)	)	O
and	CC	O
13q	CD	O
(	(	O
BRCA2	NNP	O
)	)	O
.	.	O

Mutation	NN	O
analysis	NN	O
in	IN	O
the	DT	O
BRCA1	NNP	O
and	CC	O
BRCA2	NNP	O
genes	NNS	O
was	VBD	O
also	RB	O
undertaken	VBN	O
in	IN	O
all	DT	O
families	NNS	O
.	.	O

The	DT	O
pattern	NN	O
of	IN	O
hereditary	JJ	B_Disease
cancer	NN	E_Disease
in	IN	O
14	CD	O
(	(	O
61	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
23	CD	O
families	NNS	O
studied	VBN	O
was	VBD	O
attributed	VBN	O
to	TO	O
BRCA1	NNP	O
by	IN	O
a	DT	O
combination	NN	O
of	IN	O
linkage	NN	O
and	CC	O
mutation	NN	O
analyses	NNS	O
.	.	O

No	DT	O
families	NNS	O
were	VBD	O
attributed	VBN	O
to	TO	O
BRCA2	NNP	O
.	.	O

Five	CD	O
families	NNS	O
(	(	O
22	CD	O
%	NN	O
)	)	O
provided	VBD	O
evidence	NN	O
against	IN	O
linkage	NN	O
to	TO	O
both	DT	O
BRCA1	NNP	O
and	CC	O
BRCA2	NNP	O
.	.	O

No	DT	O
BRCA1	NNP	O
or	CC	O
BRCA2	NNP	O
mutations	NNS	O
were	VBD	O
detected	VBN	O
in	IN	O
these	DT	O
five	CD	O
families	NNS	O
.	.	O

The	DT	O
BRCA1	NNP	O
or	CC	O
BRCA2	NNP	O
status	NN	O
of	IN	O
four	CD	O
families	NNS	O
(	(	O
17	CD	O
%	NN	O
)	)	O
could	MD	O
not	RB	O
be	VB	O
determined	VBN	O
.	.	O

BRCA1	NNP	O
and	CC	O
BRCA2	NNP	O
probably	RB	O
explain	VBP	O
the	DT	O
majority	NN	O
of	IN	O
hereditary	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
that	WDT	O
exists	VBZ	O
in	IN	O
the	DT	O
North	JJ	O
American	JJ	O
population	NN	O
.	.	O

However	RB	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
additional	JJ	O
genes	NNS	O
may	MD	O
yet	RB	O
be	VB	O
found	VBN	O
that	IN	O
explain	VBP	O
some	DT	O
proportion	NN	O
of	IN	O
hereditary	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
.	.	O
.	.	O

An	DT	O
intronic	JJ	O
mutation	NN	O
in	IN	O
a	DT	O
lariat	JJ	O
branchpoint	NN	O
sequence	NN	O
is	VBZ	O
a	DT	O
direct	JJ	O
cause	NN	O
of	IN	O
an	DT	O
inherited	JJ	B_Disease
human	JJ	I_Disease
disorder	NN	E_Disease
(	(	O
fish	JJ	B_Disease
-	:	I_Disease
eye	NN	I_Disease
disease	NN	E_Disease
)	)	O
.	.	O

The	DT	O
first	JJ	O
step	NN	O
in	IN	O
the	DT	O
splicing	NN	O
of	IN	O
an	DT	O
intron	NN	O
from	IN	O
nuclear	JJ	O
precursors	NNS	O
of	IN	O
mRNA	NN	O
results	NNS	O
in	IN	O
the	DT	O
formation	NN	O
of	IN	O
a	DT	O
lariat	JJ	O
structure	NN	O
.	.	O

A	DT	O
distinct	JJ	O
intronic	JJ	O
nucleotide	NN	O
sequence	NN	O
,	,	O
known	VBN	O
as	IN	O
the	DT	O
branchpoint	NN	O
region	NN	O
,	,	O
plays	VBZ	O
a	DT	O
central	JJ	O
role	NN	O
in	IN	O
this	DT	O
process	NN	O
.	.	O

We	PRP	O
here	RB	O
describe	VBZ	O
a	DT	O
point	NN	O
mutation	NN	O
in	IN	O
such	JJ	O
a	DT	O
sequence	NN	O
.	.	O

Three	CD	O
sisters	NNS	O
were	VBD	O
shown	VBN	O
to	TO	O
suffer	VB	O
from	IN	O
fish	JJ	B_Disease
-	:	I_Disease
eye	NN	I_Disease
disease	NN	E_Disease
(	(	O
FED	NNP	S_Disease
)	)	O
,	,	O
a	DT	O
disorder	NN	O
which	WDT	O
is	VBZ	O
caused	VBN	O
by	IN	O
mutations	NNS	O
in	IN	O
the	DT	O
gene	NN	O
coding	VBG	O
for	IN	O
lecithin	JJ	O
cholesterol	NN	O
acyltransferase	NN	O
(	(	O
LCAT	NNP	O
)	)	O
.	.	O

Sequencing	VBG	O
of	IN	O
the	DT	O
LCAT	NNP	O
gene	NN	O
of	IN	O
all	DT	O
three	CD	O
probands	NNS	O
revealed	VBD	O
compound	NN	O
heterozygosity	NN	O
for	IN	O
a	DT	O
missense	JJ	O
mutation	NN	O
in	IN	O
exon	NN	O
4	CD	O
which	WDT	O
is	VBZ	O
reported	VBN	O
to	TO	O
underlie	VB	O
the	DT	O
FED	NNP	S_Disease
phenotype	NN	O
,	,	O
and	CC	O
a	DT	O
point	NN	O
mutation	NN	O
located	VBN	O
in	IN	O
intron	NN	O
4	CD	O
(	(	O
IVS4	NNP	O
T	NNP	O
-	:	O
22C	CD	O
)	)	O
.	.	O

By	IN	O
performing	VBG	O
in	IN	O
vitro	JJ	O
expression	NN	O
of	IN	O
LCAT	NNP	O
minigenes	NNS	O
and	CC	O
reverse	VB	O
transcriptase	NN	O
PCR	NNP	O
on	IN	O
mRNA	NN	O
isolated	VBN	O
from	IN	O
leukocytes	NNS	O
of	IN	O
the	DT	O
patient	NN	O
,	,	O
this	DT	O
gene	NN	O
defect	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
cause	VB	O
a	DT	O
null	JJ	O
allele	NN	O
as	IN	O
the	DT	O
result	NN	O
of	IN	O
complete	JJ	O
intron	NN	O
retention	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
we	PRP	O
demonstrated	VBD	O
that	IN	O
a	DT	O
point	NN	O
mutation	NN	O
in	IN	O
a	DT	O
lariat	JJ	O
branchpoint	NN	O
consensus	NN	O
sequence	NN	O
causes	VBZ	O
a	DT	O
null	JJ	O
allele	NN	O
in	IN	O
a	DT	O
patient	NN	O
with	IN	O
FED	NNP	S_Disease
.	.	O

In	IN	O
addition	NN	O
,	,	O
our	PRP$	O
finding	VBG	O
illustrates	VBZ	O
the	DT	O
importance	NN	O
of	IN	O
this	DT	O
sequence	NN	O
for	IN	O
normal	JJ	O
human	JJ	O
mRNA	NN	O
processing	NN	O
.	.	O

Finally	RB	O
,	,	O
this	DT	O
report	NN	O
provides	VBZ	O
a	DT	O
widely	RB	O
applicable	JJ	O
strategy	NN	O
which	WDT	O
ensures	VBZ	O
fast	RB	O
and	CC	O
effective	JJ	O
screening	NN	O
for	IN	O
intronic	JJ	O
defects	NNS	O
that	WDT	O
underlie	VBP	O
differential	JJ	O
gene	NN	O
expression	NN	O
.	.	O
.	.	O

Mutations	NNS	O
associated	VBN	O
with	IN	O
variant	JJ	O
phenotypes	NNS	O
in	IN	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
.	.	O

We	PRP	O
have	VBP	O
identified	VBN	O
14	CD	O
families	NNS	O
with	IN	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
(	(	O
A	DT	B_Disease
-	:	I_Disease
T	NN	E_Disease
)	)	O
in	IN	O
which	WDT	O
mutation	NN	O
of	IN	O
the	DT	O
ATM	NNP	O
gene	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
less	RBR	O
severe	JJ	O
clinical	JJ	O
and	CC	O
cellular	JJ	O
phenotype	NN	O
(	(	O
approximately	RB	O
10	CD	O
%	NN	O
-	:	O
15	CD	O
%	NN	O
of	IN	O
A	NNP	B_Disease
-	:	I_Disease
T	NN	E_Disease
families	NNS	O
identified	VBN	O
in	IN	O
the	DT	O
United	NNP	O
Kingdom	NNP	O
)	)	O
.	.	O

In	IN	O
10	CD	O
of	IN	O
these	DT	O
families	NNS	O
,	,	O
all	PDT	O
the	DT	O
homozygotes	NNS	O
have	VBP	O
a	DT	O
137	CD	O
-	:	O
bp	NN	O
insertion	NN	O
in	IN	O
their	PRP$	O
cDNA	NN	O
caused	VBN	O
by	IN	O
a	DT	O
point	NN	O
mutation	NN	O
in	IN	O
a	DT	O
sequence	NN	O
resembling	VBG	O
a	DT	O
splice	NN	O
-	:	O
donor	NN	O
site	NN	O
.	.	O

The	DT	O
second	JJ	O
A	NNP	B_Disease
-	:	I_Disease
T	NN	E_Disease
allele	NN	O
has	VBZ	O
a	DT	O
different	JJ	O
mutation	NN	O
in	IN	O
each	DT	O
patient	NN	O
.	.	O

We	PRP	O
show	VBP	O
that	IN	O
the	DT	O
less	JJR	O
severe	JJ	O
phenotype	NN	O
in	IN	O
these	DT	O
patients	NNS	O
is	VBZ	O
caused	VBN	O
by	IN	O
some	DT	O
degree	NN	O
of	IN	O
normal	JJ	O
splicing	NN	O
,	,	O
which	WDT	O
occurs	VBZ	O
as	IN	O
an	DT	O
alternative	JJ	O
product	NN	O
from	IN	O
the	DT	O
insertion	NN	O
-	:	O
containing	VBG	O
allele	NN	O
.	.	O

The	DT	O
level	NN	O
of	IN	O
the	DT	O
137	CD	O
-	:	O
bp	NN	O
PCR	NNP	O
product	NN	O
containing	VBG	O
the	DT	O
insertion	NN	O
was	VBD	O
lowest	JJS	O
in	IN	O
two	CD	O
patients	NNS	O
who	WP	O
showed	VBD	O
a	DT	O
later	JJ	O
onset	NN	O
of	IN	O
cerebellar	JJ	B_Disease
ataxia	NN	E_Disease
.	.	O

A	DT	O
further	JJ	O
four	CD	O
families	NNS	O
who	WP	O
do	VBP	O
not	RB	O
have	VB	O
this	DT	O
insertion	NN	O
have	VBP	O
been	VBN	O
identified	VBN	O
.	.	O

Mutations	NNS	O
detected	VBN	O
in	IN	O
two	CD	O
of	IN	O
four	CD	O
of	IN	O
these	DT	O
are	VBP	O
missense	JJ	O
mutations	NNS	O
,	,	O
normally	RB	O
rare	JJ	O
in	IN	O
A	NNP	B_Disease
-	:	I_Disease
T	NN	E_Disease
patients	NNS	O
.	.	O

The	DT	O
demonstration	NN	O
of	IN	O
mutations	NNS	O
giving	VBG	O
rise	NN	O
to	TO	O
a	DT	O
slightly	RB	O
milder	JJR	O
phenotype	NN	O
in	IN	O
A	NNP	B_Disease
-	:	I_Disease
T	NN	E_Disease
raises	VBZ	O
the	DT	O
interesting	JJ	O
question	NN	O
of	IN	O
what	WP	O
range	NN	O
of	IN	O
phenotypes	NNS	O
might	MD	O
occur	VB	O
in	IN	O
individuals	NNS	O
in	IN	O
whom	WP	O
both	DT	O
mutations	NNS	O
are	VBP	O
milder	NN	O
.	.	O

One	CD	O
possibility	NN	O
might	MD	O
be	VB	O
that	IN	O
individuals	NNS	O
who	WP	O
are	VBP	O
compound	VBN	O
heterozygotes	NNS	O
for	IN	O
ATM	NNP	O
mutations	NNS	O
are	VBP	O
more	RBR	O
common	JJ	O
than	IN	O
we	PRP	O
realize	VBP	O
.	.	O
.	.	O

Mutation	NN	O
of	IN	O
the	DT	O
VHL	NNP	O
gene	NN	O
is	VBZ	O
associated	VBN	O
exclusively	RB	O
with	IN	O
the	DT	O
development	NN	O
of	IN	O
non	JJ	B_Disease
-	:	I_Disease
papillary	JJ	I_Disease
renal	NN	I_Disease
cell	NN	I_Disease
carcinomas	NN	E_Disease
.	.	O

To	TO	O
define	VB	O
the	DT	O
possible	JJ	O
role	NN	O
of	IN	O
the	DT	O
VHL	NNP	S_Disease
gene	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
sporadic	JJ	B_Disease
renal	JJ	I_Disease
cell	NN	I_Disease
carcinomas	NN	E_Disease
,	,	O
91	CD	O
different	JJ	O
parenchymal	JJ	B_Disease
tumours	NN	I_Disease
of	IN	I_Disease
the	DT	I_Disease
kidney	NN	E_Disease
have	VBP	O
been	VBN	O
investigated	VBN	O
for	IN	O
mutation	NN	O
of	IN	O
the	DT	O
VHL	NNP	S_Disease
gene	NN	O
by	IN	O
single	JJ	O
strand	NN	O
conformation	NN	O
polymorphism	NN	O
(	(	O
SSCP	NNP	O
)	)	O
and	CC	O
/	$	O
or	CC	O
heteroduplex	NN	O
(	(	O
HD	NNP	O
)	)	O
techniques	NNS	O
.	.	O

Chromosome	NNP	O
3p	CD	O
deletion	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
98	CD	O
per	IN	O
cent	NN	O
of	IN	O
non	JJ	B_Disease
-	:	I_Disease
papillary	JJ	I_Disease
renal	NN	I_Disease
cell	NN	I_Disease
carcinomas	NN	E_Disease
and	CC	O
in	IN	O
25	CD	O
per	IN	O
cent	NN	O
of	IN	O
chromophobe	NN	O
renal	JJ	B_Disease
cell	NN	I_Disease
carcinomas	NN	E_Disease
.	.	O

In	IN	O
22	CD	O
of	IN	O
the	DT	O
43	CD	O
non	SYM	B_Disease
-	:	I_Disease
papillary	JJ	I_Disease
renal	NN	I_Disease
cell	NN	I_Disease
carcinomas	NN	E_Disease
,	,	O
abnormally	RB	O
migrating	VBG	O
DNA	NNP	O
bands	NNS	O
were	VBD	O
detected	VBN	O
by	IN	O
SSCP	NNP	O
and	CC	O
/	NNP	O
or	CC	O
HD	NNP	O
analysis	NN	O
.	.	O

No	DT	O
mobility	NN	O
shift	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
23	CD	O
chromophobe	NN	O
renal	NN	B_Disease
cell	NN	I_Disease
carcinomas	NN	E_Disease
.	.	O

In	IN	O
addition	NN	O
,	,	O
15	CD	O
papillary	JJ	B_Disease
renal	NN	I_Disease
cell	NN	I_Disease
tumours	NNS	E_Disease
and	CC	O
ten	JJ	O
renal	JJ	B_Disease
oncocytomas	NN	E_Disease
,	,	O
which	WDT	O
are	VBP	O
characterized	VBN	O
by	IN	O
genetic	JJ	O
changes	NNS	O
other	JJ	O
than	IN	O
loss	NN	O
of	IN	O
chromosome	NN	O
3p	CD	O
sequences	NNS	O
,	,	O
were	VBD	O
analysed	VBN	O
for	IN	O
mutation	NN	O
of	IN	O
the	DT	O
VHL	NNP	S_Disease
gene	NN	O
.	.	O

None	NN	O
of	IN	O
these	DT	O
tumours	NNS	S_Disease
showed	VBD	O
abnormal	JJ	O
migration	NN	O
patterns	NNS	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	DT	O
mutation	NN	O
of	IN	O
the	DT	O
VHL	NNP	S_Disease
gene	NN	O
is	VBZ	O
associated	VBN	O
exclusively	RB	O
with	IN	O
the	DT	O
development	NN	O
of	IN	O
non	JJ	B_Disease
-	:	I_Disease
papillary	JJ	I_Disease
renal	NN	I_Disease
cell	NN	I_Disease
carcinoma	NN	E_Disease
.	.	O
.	.	O

The	DT	O
Emery	NNP	B_Disease
-	:	I_Disease
Dreifuss	NNP	I_Disease
muscular	JJ	I_Disease
dystrophy	NN	E_Disease
protein	NN	O
,	,	O
emerin	NN	O
,	,	O
is	VBZ	O
a	DT	O
nuclear	JJ	O
membrane	NN	O
protein	NN	O
.	.	O

A	DT	O
large	JJ	O
fragment	NN	O
of	IN	O
emerin	JJ	O
cDNA	NN	O
was	VBD	O
prepared	VBN	O
by	IN	O
PCR	NNP	O
and	CC	O
expressed	VBD	O
as	IN	O
a	DT	O
recombinant	JJ	O
protein	NN	O
in	IN	O
Escherichia	NNP	O
coli	NN	O
.	.	O

Using	VBG	O
this	DT	O
as	IN	O
immunogen	NN	O
,	,	O
we	PRP	O
prepared	VBD	O
a	DT	O
panel	NN	O
of	IN	O
12	CD	O
monoclonal	JJ	O
antibodies	NNS	O
which	WDT	O
recognise	VBP	O
at	IN	O
least	JJS	O
four	CD	O
different	JJ	O
epitopes	NNS	O
on	IN	O
emerin	NN	O
in	IN	O
order	NN	O
to	TO	O
ensure	VB	O
that	IN	O
emerin	NN	O
can	MD	O
be	VB	O
distinguished	VBN	O
from	IN	O
non	JJ	O
-	:	O
specific	JJ	O
cross	NN	O
-	:	O
reacting	NN	O
proteins	NNS	O
.	.	O

All	PDT	O
the	DT	O
mAbs	NN	O
recognised	VBD	O
a	DT	O
34	CD	O
kDa	NN	O
protein	NN	O
in	IN	O
all	DT	O
tissues	NNS	O
tested	VBN	O
,	,	O
though	IN	O
minor	JJ	O
emerin	SYM	O
-	:	O
related	JJ	O
bands	NNS	O
were	VBD	O
also	RB	O
detected	VBN	O
in	IN	O
some	DT	O
tissues	NNS	O
.	.	O

Immunofluorescence	NN	O
microscopy	NN	O
showed	VBD	O
that	IN	O
emerin	NN	O
is	VBZ	O
located	VBN	O
at	IN	O
the	DT	O
nuclear	JJ	O
rim	NN	O
in	IN	O
all	DT	O
tissues	NNS	O
examined	VBN	O
.	.	O

A	DT	O
muscle	NN	O
biopsy	NN	O
from	IN	O
an	DT	O
Emery	NNP	B_Disease
-	:	I_Disease
Dreifuss	NNP	I_Disease
muscular	JJ	I_Disease
dystrophy	NN	E_Disease
(	(	O
EMDM	NNP	S_Disease
)	)	O
patient	NN	O
showed	VBD	O
complete	JJ	O
absence	NN	O
of	IN	O
emerin	NN	O
by	IN	O
both	DT	O
Western	NNP	O
blotting	NN	O
and	CC	O
immunohistochemistry	NN	O
,	,	O
suggesting	VBG	O
a	DT	O
simple	JJ	O
diagnostic	JJ	O
antibody	NN	O
test	NN	O
for	IN	O
EDMD	NNP	S_Disease
families	NNS	O
.	.	O

Biochemical	JJ	O
fractionation	NN	O
of	IN	O
brain	NN	O
and	CC	O
liver	NN	O
tissues	NNS	O
showed	VBD	O
that	IN	O
emerin	NN	O
was	VBD	O
present	JJ	O
in	IN	O
nuclei	JJ	O
purified	VBN	O
by	IN	O
centrifugation	NN	O
through	IN	O
65	CD	O
%	NN	O
sucrose	NN	O
and	CC	O
was	VBD	O
absent	NN	O
from	IN	O
soluble	JJ	O
fractions	NNS	O
(	(	O
post	NN	O
-	:	O
100	CD	O
,	,	O
000	CD	O
g	NN	O
)	)	O
.	.	O

From	IN	O
these	DT	O
results	NNS	O
,	,	O
together	RB	O
with	IN	O
sequence	NN	O
and	CC	O
structural	JJ	O
homologies	NNS	O
between	IN	O
emerin	NN	O
,	,	O
thymopoietins	NNS	O
and	CC	O
the	DT	O
nuclear	JJ	O
lamina	SYM	O
-	:	O
associated	VBN	O
protein	NN	O
,	,	O
LAP2	NNP	O
,	,	O
we	PRP	O
suggest	VBP	O
that	IN	O
emerin	NN	O
will	MD	O
prove	VB	O
to	TO	O
be	VB	O
one	CD	O
member	NN	O
of	IN	O
a	DT	O
family	NN	O
of	IN	O
inner	JJ	O
nuclear	JJ	O
membrane	NN	O
proteins	NNS	O
.	.	O
.	.	O

Mutation	NN	O
of	IN	O
MSH3	NNP	O
in	IN	O
endometrial	JJ	B_Disease
cancer	NN	E_Disease
and	CC	O
evidence	NN	O
for	IN	O
its	PRP$	O
functional	JJ	O
role	NN	O
in	IN	O
heteroduplex	JJ	O
repair	NN	O
.	.	O

Many	JJ	O
human	JJ	O
tumours	NNS	S_Disease
have	VBP	O
length	VBN	O
alterations	NNS	O
in	IN	O
repetitive	JJ	O
sequence	NN	O
elements	NNS	O
.	.	O

Although	IN	O
this	DT	O
microsatellite	JJ	B_Disease
instability	NN	E_Disease
has	VBZ	O
been	VBN	O
attributed	VBN	O
to	TO	O
mutations	NNS	O
in	IN	O
four	CD	O
DNA	NNP	O
mismatch	NN	O
repair	NN	O
genes	NNS	O
in	IN	O
hereditary	JJ	B_Disease
nonpolyposis	NN	I_Disease
colorectal	NN	I_Disease
cancer	NN	E_Disease
(	(	O
HNPCC	NNP	S_Disease
)	)	O
kindreds	NNS	O
,	,	O
many	JJ	O
sporadic	JJ	B_Disease
tumours	NNS	E_Disease
exhibit	VBP	O
instability	NN	O
but	CC	O
no	DT	O
detectable	JJ	O
mutations	NNS	O
in	IN	O
these	DT	O
genes	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
therefore	RB	O
of	IN	O
interest	NN	O
to	TO	O
identify	VB	O
other	JJ	O
genes	NNS	O
that	WDT	O
contribute	VBP	O
to	TO	O
this	DT	O
instability	NN	O
.	.	O

In	IN	O
yeast	NN	O
,	,	O
mutations	NNS	O
in	IN	O
several	JJ	O
genes	NNS	O
,	,	O
including	VBG	O
RTH	NNP	O
and	CC	O
MSH3	NNP	O
,	,	O
cause	NN	O
microsatellite	JJ	O
instability	NN	O
.	.	O

Thus	RB	O
,	,	O
we	PRP	O
screened	VBD	O
16	CD	O
endometrial	JJ	B_Disease
carcinomas	NN	E_Disease
with	IN	O
microsatellite	JJ	O
instability	NN	O
for	IN	O
alterations	NNS	O
in	IN	O
FEN1	NNP	O
(	(	O
the	DT	O
human	JJ	O
homolog	NN	O
of	IN	O
RTH	NNP	O
)	)	O
and	CC	O
in	IN	O
MSH3	NNP	O
(	(	O
refs	VB	O
12	CD	O
-	:	O
14	CD	O
)	)	O
.	.	O

Although	IN	O
we	PRP	O
found	VBD	O
no	DT	O
FEN1	NNP	O
mutations	NNS	O
,	,	O
a	DT	O
frameshift	NN	O
mutation	NN	O
in	IN	O
MSH3	NNP	O
was	VBD	O
observed	VBN	O
in	IN	O
an	DT	O
endometrial	JJ	B_Disease
carcinoma	NN	E_Disease
and	CC	O
in	IN	O
an	DT	O
endometrial	JJ	B_Disease
carcinoma	NN	E_Disease
cell	NN	O
line	NN	O
.	.	O

Extracts	NNS	O
of	IN	O
the	DT	O
cell	NN	O
line	NN	O
were	VBD	O
deficient	JJ	O
in	IN	O
repair	NN	O
of	IN	O
DNA	NNP	O
substrates	VBZ	O
containing	VBG	O
mismatches	NNS	O
or	CC	O
extra	JJ	O
nucleotides	NNS	O
.	.	O

Introducing	VBG	O
chromosome	NN	O
5	CD	O
,	,	O
encoding	VBG	O
the	DT	O
MSH3	NNP	O
gene	NN	O
,	,	O
into	IN	O
the	DT	O
mutant	JJ	O
cell	NN	O
line	NN	O
increased	VBD	O
the	DT	O
stability	NN	O
of	IN	O
some	DT	O
but	CC	O
not	RB	O
all	DT	O
microsatellites	NNS	O
.	.	O

Extracts	NNS	O
of	IN	O
these	DT	O
cells	NNS	O
repaired	VBD	O
certain	JJ	O
substrates	NNS	O
containing	VBG	O
extra	JJ	O
nucleotides	NNS	O
,	,	O
but	CC	O
were	VBD	O
deficient	JJ	O
in	IN	O
repair	NN	O
of	IN	O
those	DT	O
containing	VBG	O
mismatches	NNS	O
or	CC	O
other	JJ	O
extra	JJ	O
nucleotides	NNS	O
.	.	O

A	DT	O
subsequent	JJ	O
search	NN	O
revealed	VBD	O
a	DT	O
second	JJ	O
gene	NN	O
mutation	NN	O
in	IN	O
HHUA	NNP	O
cells	NNS	O
,	,	O
a	DT	O
missense	JJ	O
mutation	NN	O
in	IN	O
the	DT	O
MSH6	NNP	O
gene	NN	O
.	.	O

Together	RB	O
the	DT	O
data	NN	O
suggest	NN	O
that	IN	O
the	DT	O
MSH3	NNP	O
gene	NN	O
encodes	VBZ	O
a	DT	O
product	NN	O
that	WDT	O
functions	NNS	O
in	IN	O
repair	NN	O
of	IN	O
some	DT	O
but	CC	O
not	RB	O
all	DT	O
pre	SYM	O
-	:	O
mutational	JJ	O
intermediates	NNS	O
,	,	O
its	PRP$	O
mutation	NN	O
in	IN	O
tumours	NNS	S_Disease
can	MD	O
result	VB	O
in	IN	O
genomic	JJ	O
instability	NN	O
and	CC	O
,	,	O
as	IN	O
in	IN	O
yeast	NN	O
,	,	O
MSH3	NNP	O
and	CC	O
MSH6	NNP	O
are	VBP	O
partially	RB	O
redundant	JJ	O
for	IN	O
mismatch	NN	O
repair	NN	O
.	.	O
.	.	O

Comparative	JJ	O
genome	NN	O
mapping	NN	O
of	IN	O
the	DT	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
region	NN	O
in	IN	O
mouse	NN	O
,	,	O
rat	NN	O
,	,	O
and	CC	O
Syrian	JJ	O
hamster	NN	O
.	.	O

Chromosomal	JJ	O
locations	NNS	O
of	IN	O
the	DT	O
Atm	NNP	O
(	(	O
ataxia	SYM	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
(	(	O
AT	NNP	S_Disease
)	)	O
-	:	O
mutated	VBN	O
)	)	O
and	CC	O
Acat1	NNP	O
(	(	O
mitochondrial	JJ	O
acetoacetyl	NN	O
-	:	O
CoA	NNP	O
thiolase	NN	O
)	)	O
genes	NNS	O
in	IN	O
mouse	NN	O
,	,	O
rat	NN	O
,	,	O
and	CC	O
Syrian	JJ	O
hamster	NN	O
were	VBD	O
determined	VBN	O
by	IN	O
direct	JJ	O
R	NNP	O
-	:	O
banding	VBG	O
FISH	NNP	O
.	.	O

Both	DT	O
genes	NNS	O
were	VBD	O
colocalized	VBN	O
to	TO	O
the	DT	O
C	NNP	O
-	:	O
D	NNP	O
band	NN	O
of	IN	O
mouse	NN	O
chromosome	NN	O
9	CD	O
,	,	O
the	DT	O
proximal	JJ	O
end	NN	O
of	IN	O
q24	NN	O
.	.	O

1	CD	O
of	IN	O
rat	NN	O
chromosome	NN	O
8	CD	O
,	,	O
and	CC	O
qa4	SYM	O
-	:	O
qa5	NN	O
of	IN	O
Syrian	JJ	O
hamster	NN	O
chromosome	NN	O
12	CD	O
.	.	O

The	DT	O
regions	NNS	O
in	IN	O
the	DT	O
mouse	NN	O
and	CC	O
rat	NN	O
were	VBD	O
homologous	JJ	O
to	TO	O
human	JJ	O
chromosome	NN	O
11q	CD	O
.	.	O

Fine	NNP	O
genetic	JJ	O
linkage	NN	O
mapping	NN	O
of	IN	O
the	DT	O
mouse	NN	O
AT	NNP	S_Disease
region	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
the	DT	O
interspecific	JJ	O
backcross	NN	O
mice	NN	O
.	.	O

Atm	NNP	O
,	,	O
Acat1	NNP	O
,	,	O
and	CC	O
Npat	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
new	JJ	O
gene	NN	O
isolated	VBN	O
from	IN	O
the	DT	O
AT	NNP	O
region	NN	O
,	,	O
and	CC	O
12	CD	O
flanking	VBG	O
microsatellite	JJ	O
DNA	NN	O
markers	NNS	O
were	VBD	O
examined	VBN	O
.	.	O

No	DT	O
recombinations	NNS	O
were	VBD	O
found	VBN	O
among	IN	O
the	DT	O
Atm	NNP	O
,	,	O
Npat	NNP	O
,	,	O
Acat1	NNP	O
,	,	O
and	CC	O
D9Mit6	NNP	O
loci	NN	O
,	,	O
and	CC	O
these	DT	O
loci	NNS	O
were	VBD	O
mapped	VBN	O
2	CD	O
.	.	O

0	CD	O
cM	JJ	O
distal	NN	O
to	TO	O
D9Mit99	NNP	O
and	CC	O
1	CD	O
.	.	O

3	CD	O
cM	NN	O
proximal	NN	O
to	TO	O
D9Mit102	NNP	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
linkage	NN	O
map	NN	O
of	IN	O
mouse	NN	O
chromosome	NN	O
9	CD	O
(	(	O
MMU9	NNP	O
)	)	O
and	CC	O
that	IN	O
of	IN	O
human	JJ	O
chromosome	NN	O
11	CD	O
(	(	O
HSA11	NNP	O
)	)	O
indicates	VBZ	O
that	IN	O
there	EX	O
is	VBZ	O
a	DT	O
chromosomal	JJ	O
rearrangement	NN	O
due	JJ	O
to	TO	O
an	DT	O
inversion	NN	O
between	IN	O
Ets1	NNP	O
and	CC	O
Atm	NNP	O
-	:	O
Npat	NNP	O
-	:	O
Acat1	NN	O
and	CC	O
that	IN	O
the	DT	O
inversion	NN	O
of	IN	O
MMU9	NNP	O
originated	VBD	O
from	IN	O
the	DT	O
chromosomal	JJ	O
breakage	NN	O
at	IN	O
the	DT	O
boundary	NN	O
between	IN	O
Gria4	NNP	O
and	CC	O
Atm	NNP	O
-	:	O
Npat	NNP	O
-	:	O
Acat1	NN	O
on	IN	O
HSA11	NNP	O
.	.	O

This	DT	O
type	NN	O
of	IN	O
inversion	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
conserved	VBN	O
in	IN	O
the	DT	O
three	CD	O
rodent	NN	O
species	NNS	O
,	,	O
mouse	NN	O
,	,	O
rat	NN	O
,	,	O
and	CC	O
Syrian	JJ	O
hamster	NN	O
,	,	O
using	VBG	O
additional	JJ	O
comparative	JJ	O
mapping	NN	O
data	NNS	O
with	IN	O
the	DT	O
Rck	NNP	O
gene	NN	O

An	DT	O
animal	JJ	O
model	NN	O
for	IN	O
Norrie	NNP	B_Disease
disease	NN	E_Disease
(	(	O
ND	NNP	S_Disease
)	)	O
:	:	O
gene	NN	O
targeting	NN	O
of	IN	O
the	DT	O
mouse	NN	O
ND	NNP	S_Disease
gene	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
elucidate	VB	O
the	DT	O
cellular	JJ	O
and	CC	O
molecular	JJ	O
processes	NNS	O
which	WDT	O
are	VBP	O
involved	VBN	O
in	IN	O
Norrie	NNP	B_Disease
disease	NN	E_Disease
(	(	O
ND	NNP	S_Disease
)	)	O
,	,	O
we	PRP	O
have	VBP	O
used	VBN	O
gene	NN	O
targeting	VBG	O
technology	NN	O
to	TO	O
generate	VB	O
ND	NNP	S_Disease
mutant	JJ	O
mice	NN	O
.	.	O

The	DT	O
murine	NN	O
homologue	NN	O
of	IN	O
the	DT	O
ND	NNP	S_Disease
gene	NN	O
was	VBD	O
cloned	VBN	O
and	CC	O
shown	VBN	O
to	TO	O
encode	VB	O
a	DT	O
polypeptide	NN	O
that	WDT	O
shares	NNS	O
94	CD	O
%	NN	O
of	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
with	IN	O
its	PRP$	O
human	JJ	O
counterpart	NN	O
.	.	O

RNA	NNP	O
in	IN	O
situ	JJ	O
hybridization	NN	O
revealed	VBD	O
expression	NN	O
in	IN	O
retina	NN	O
,	,	O
brain	NN	O
and	CC	O
the	DT	O
olfactory	NN	O
bulb	NN	O
and	CC	O
epithelium	NN	O
of	IN	O
2	CD	O
week	NN	O
old	JJ	O
mice	NN	O
.	.	O

Hemizygous	JJ	O
mice	NN	O
carrying	VBG	O
a	DT	O
replacement	NN	O
mutation	NN	O
in	IN	O
exon	JJ	O
2	CD	O
of	IN	O
the	DT	O
ND	NNP	S_Disease
gene	NN	O
developed	VBD	O
retrolental	JJ	O
structures	NNS	O
in	IN	O
the	DT	O
vitreous	JJ	O
body	NN	O
and	CC	O
showed	VBD	O
an	DT	O
overall	JJ	O
disorganization	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
ganglion	NN	O
cell	NN	O
layer	NN	O
.	.	O

The	DT	O
outer	NN	O
plexiform	NN	O
layer	NN	O
disappears	VBZ	O
occasionally	RB	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
juxtaposed	JJ	O
inner	NN	O
and	CC	O
outer	NN	O
nuclear	JJ	O
layer	NN	O
.	.	O

At	IN	O
the	DT	O
same	JJ	O
regions	NNS	O
,	,	O
the	DT	O
outer	NN	O
segments	NNS	O
of	IN	O
the	DT	O
photoreceptor	NN	O
cell	NN	O
layer	NN	O
are	VBP	O
no	RB	O
longer	RBR	O
present	JJ	O
.	.	O

These	DT	O
ocular	JJ	O
findings	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
observations	NNS	O
in	IN	O
ND	NNP	S_Disease
patients	NNS	O
and	CC	O
the	DT	O
generated	VBN	O
mouse	NN	O
line	NN	O
provides	VBZ	O
a	DT	O
faithful	JJ	O
model	NN	O
for	IN	O
study	NN	O
of	IN	O
early	JJ	O
pathogenic	JJ	O
events	NNS	O
in	IN	O
this	DT	O
severe	JJ	O
X	NNP	B_Disease
-	:	I_Disease
linked	VBD	I_Disease
recessive	JJ	I_Disease
neurological	JJ	I_Disease
disorder	NN	E_Disease
.	.	O
.	.	O

The	DT	O
hybrid	JJ	O
PAX3	NNP	O
-	:	O
FKHR	NNP	O
fusion	NN	O
protein	NN	O
of	IN	O
alveolar	JJ	B_Disease
rhabdomyosarcoma	NN	E_Disease
transforms	NNS	O
fibroblasts	NNS	O
in	IN	O
culture	NN	O
.	.	O

Pediatric	NNP	B_Disease
alveolar	JJ	I_Disease
rhabdomyosarcoma	NN	E_Disease
is	VBZ	O
characterized	VBN	O
by	IN	O
a	DT	O
chromosomal	JJ	O
translocation	NN	O
that	WDT	O
fuses	VBZ	O
parts	NNS	O
of	IN	O
the	DT	O
PAX3	NNP	O
and	CC	O
FKHR	NNP	O
genes	NNS	O
.	.	O

PAX3	NNP	O
codes	NNS	O
for	IN	O
a	DT	O
transcriptional	JJ	O
regulator	NN	O
that	WDT	O
controls	VBZ	O
developmental	JJ	O
programs	NNS	O
,	,	O
and	CC	O
FKHR	NNP	O
codes	NNS	O
for	IN	O
a	DT	O
forkhead	JJ	O
-	:	O
winged	VBD	O
helix	NN	O
protein	NN	O
,	,	O
also	RB	O
a	DT	O
likely	JJ	O
transcription	NN	O
factor	NN	O
.	.	O

The	DT	O
PAX3	NNP	O
-	:	O
FKHR	NNP	O
fusion	NN	O
product	NN	O
retains	VBZ	O
the	DT	O
DNA	NN	O
binding	VBG	O
domains	NNS	O
of	IN	O
the	DT	O
PAX3	NNP	O
protein	NN	O
and	CC	O
the	DT	O
putative	JJ	O
activator	NN	O
domain	NN	O
of	IN	O
the	DT	O
FKHR	NNP	O
protein	NN	O
.	.	O

The	DT	O
PAX3	NNP	O
-	:	O
FKHR	NNP	O
protein	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
function	VB	O
as	IN	O
a	DT	O
transcriptional	JJ	O
activator	NN	O
.	.	O

Using	VBG	O
the	DT	O
RCAS	NNP	O
retroviral	JJ	O
vector	NN	O
,	,	O
we	PRP	O
have	VBP	O
introduced	VBN	O
the	DT	O
PAX3	NNP	O
-	:	O
FKHR	NNP	O
gene	NN	O
into	IN	O
chicken	JJ	O
embryo	NN	O
fibroblasts	NNS	O
.	.	O

Expression	NN	O
of	IN	O
the	DT	O
PAX3	NNP	O
-	:	O
FKHR	NNP	O
protein	NN	O
in	IN	O
these	DT	O
cells	NNS	O
leads	VBZ	O
to	TO	O
transformation	VB	O
the	DT	O
cells	NNS	O
become	VBP	O
enlarged	JJ	O
,	,	O
grow	VB	O
tightly	RB	O
packed	VBN	O
and	CC	O
in	IN	O
multiple	JJ	O
layers	NNS	O
,	,	O
and	CC	O
acquire	VB	O
the	DT	O
ability	NN	O
for	IN	O
anchorage	NN	O
-	:	O
independent	JJ	O
growth	NN	O
.	.	O

This	DT	O
cellular	JJ	O
transformation	NN	O
in	IN	O
vitro	NN	O
will	MD	O
facilitate	VB	O
studies	NNS	O
on	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
PAX3	NNP	O
-	:	O
FKHR	NNP	O
-	:	O
induced	JJ	O
oncogenesis	NN	O
.	.	O
.	.	O

Somatic	JJ	O
-	:	O
cell	NN	O
selection	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
determinant	NN	O
of	IN	O
the	DT	O
blood	NN	O
-	:	O
cell	NN	O
phenotype	NN	O
in	IN	O
heterozygotes	NNS	O
for	IN	O
glucose	JJ	O
-	:	O
6	CD	O
-	:	O
phosphate	NN	O
dehydrogenase	NN	O
mutations	NNS	O
causing	VBG	O
severe	JJ	O
enzyme	JJ	B_Disease
deficiency	NN	E_Disease
.	.	O

X	LS	O
-	:	O
chromosome	NN	O
inactivation	NN	O
in	IN	O
mammals	NNS	O
is	VBZ	O
regarded	VBN	O
as	IN	O
an	DT	O
essentially	RB	O
random	JJ	O
process	NN	O
,	,	O
but	CC	O
the	DT	O
resulting	JJ	O
somatic	JJ	O
-	:	O
cell	NN	O
mosaicism	NN	O
creates	VBZ	O
the	DT	O
opportunity	NN	O
for	IN	O
cell	NN	O
selection	NN	O
.	.	O

In	IN	O
most	JJS	O
people	NNS	O
with	IN	O
red	JJ	O
-	:	O
blood	NN	O
-	:	O
cell	NN	O
glucose	JJ	B_Disease
-	:	I_Disease
6	CD	I_Disease
-	:	I_Disease
phosphate	NN	I_Disease
dehydrogenase	NN	I_Disease
(	(	I_Disease
G6PD	NNP	I_Disease
)	)	I_Disease
deficiency	NN	E_Disease
,	,	O
the	DT	O
enzyme	NN	O
-	:	O
deficient	NN	O
phenotype	NN	O
is	VBZ	O
only	RB	O
moderately	RB	O
expressed	VBN	O
in	IN	O
nucleated	JJ	O
cells	NNS	O
.	.	O

However	RB	O
,	,	O
in	IN	O
a	DT	O
small	JJ	O
subset	NN	O
of	IN	O
hemizygous	JJ	O
males	NNS	O
who	WP	O
suffer	VBP	O
from	IN	O
chronic	JJ	B_Disease
nonspherocytic	JJ	I_Disease
hemolytic	JJ	I_Disease
anemia	NN	E_Disease
,	,	O
the	DT	O
underlying	JJ	O
mutations	NNS	O
(	(	O
designated	JJ	O
class	NN	O
I	PRP	O
)	)	O
cause	NN	O
more	RBR	O
-	:	O
severe	JJ	O
G6PD	NNP	B_Disease
deficiency	NN	E_Disease
,	,	O
and	CC	O
this	DT	O
might	MD	O
provide	VB	O
an	DT	O
opportunity	NN	O
for	IN	O
selection	NN	O
in	IN	O
heterozygous	JJ	O
females	NNS	O
during	IN	O
development	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
test	VB	O
this	DT	O
possibility	NN	O
we	PRP	O
have	VBP	O
analyzed	VBN	O
four	CD	O
heterozygotes	NNS	O
for	IN	O
class	NN	O
I	PRP	O
G6PD	VBP	O
mutations	NNS	O
two	CD	O
with	IN	O
G6PD	NNP	O
Portici	NNP	O
(	(	O
1178G	CD	O
-	:	O
-	:	O
>	VB	O
A	DT	O
)	)	O
and	CC	O
two	CD	O
with	IN	O
G6PD	NNP	O
Bari	NNP	O
(	(	O
1187C	CD	O
-	:	O
-	:	O
>	NN	O
T	NNP	O
)	)	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
in	IN	O
fractionated	JJ	O
blood	NN	O
cell	NN	O
types	NNS	O
(	(	O
including	VBG	O
erythroid	NN	O
,	,	O
myeloid	NN	O
,	,	O
and	CC	O
lymphoid	NN	O
cell	NN	O
lineages	NNS	O
)	)	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
excess	NN	O
of	IN	O
G6PD	NNP	O
-	:	O
normal	JJ	O
cells	NNS	O
.	.	O

The	DT	O
significant	JJ	O
concordance	NN	O
that	IN	O
we	PRP	O
have	VBP	O
observed	VBN	O
in	IN	O
the	DT	O
degree	NN	O
of	IN	O
imbalance	NN	O
in	IN	O
the	DT	O
different	JJ	O
blood	NN	O
-	:	O
cell	NN	O
lineages	VBZ	O
indicates	VBZ	O
that	IN	O
a	DT	O
selective	JJ	O
mechanism	NN	O
is	VBZ	O
likely	JJ	O
to	TO	O
operate	VB	O
at	IN	O
the	DT	O
level	NN	O
of	IN	O
pluripotent	JJ	O
blood	NN	O
stem	NN	O
cells	NNS	O
.	.	O

Thus	RB	O
,	,	O
it	PRP	O
appears	VBZ	O
that	IN	O
severe	JJ	O
G6PD	NNP	B_Disease
deficiency	NN	E_Disease
affects	VBZ	O
adversely	RB	O
the	DT	O
proliferation	NN	O
or	CC	O
the	DT	O
survival	NN	O
of	IN	O
nucleated	JJ	O
blood	NN	O
cells	NNS	O
and	CC	O
that	IN	O
this	DT	O
phenotypic	NN	O
characteristic	NN	O
is	VBZ	O
critical	JJ	O
during	IN	O
hematopoiesis	NN	O
.	.	O
.	.	O

Analysis	NN	O
of	IN	O
meiotic	JJ	O
segregation	NN	O
,	,	O
using	VBG	O
single	JJ	O
-	:	O
sperm	JJ	O
typing	NN	O
:	:	O
meiotic	JJ	O
drive	NN	O
at	IN	O
the	DT	O
myotonic	JJ	B_Disease
dystrophy	NN	E_Disease
locus	NN	O
.	.	O

Meiotic	JJ	O
drive	NN	O
at	IN	O
the	DT	O
myotonic	JJ	B_Disease
dystrophy	NN	E_Disease
(	(	O
DM	NNP	S_Disease
)	)	O
locus	NN	O
has	VBZ	O
recently	RB	O
been	VBN	O
suggested	VBN	O
as	IN	O
being	VBG	O
responsible	JJ	O
for	IN	O
maintaining	VBG	O
the	DT	O
frequency	NN	O
,	,	O
in	IN	O
the	DT	O
human	JJ	O
population	NN	O
,	,	O
of	IN	O
DM	NNP	S_Disease
chromosomes	NNS	O
capable	JJ	O
of	IN	O
expansion	NN	O
to	TO	O
the	DT	O
disease	NN	O
state	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
test	VB	O
this	DT	O
hypothesis	NN	O
,	,	O
we	PRP	O
have	VBP	O
studied	VBN	O
samples	NNS	O
of	IN	O
single	JJ	O
sperm	NN	O
from	IN	O
three	CD	O
individuals	NNS	O
heterozygous	JJ	O
at	IN	O
the	DT	O
DM	NNP	S_Disease
locus	NN	O
,	,	O
each	DT	O
with	IN	O
one	CD	O
allele	NN	O
larger	JJR	O
and	CC	O
one	CD	O
allele	NN	O
smaller	JJR	O
than	IN	O
19	CD	O
CTG	NNP	O
repeats	NNS	O
.	.	O

To	TO	O
guard	VB	O
against	IN	O
the	DT	O
possible	JJ	O
problem	NN	O
of	IN	O
differential	JJ	O
PCR	NNP	O
amplification	NN	O
rates	NNS	O
based	VBN	O
on	IN	O
the	DT	O
lengths	NNS	O
of	IN	O
the	DT	O
alleles	NNS	O
,	,	O
the	DT	O
sperm	NN	O
were	VBD	O
also	RB	O
typed	VBN	O
at	IN	O
another	DT	O
closely	RB	O
linked	VBN	O
marker	NN	O
whose	WP$	O
allele	JJ	O
size	NN	O
was	VBD	O
unrelated	JJ	O
to	TO	O
the	DT	O
allele	JJ	O
size	NN	O
at	IN	O
the	DT	O
DM	NNP	S_Disease
locus	NN	O
.	.	O

Using	VBG	O
statistical	JJ	O
models	NNS	O
specifically	RB	O
designed	VBN	O
to	TO	O
study	VB	O
single	JJ	O
-	:	O
sperm	JJ	O
segregation	NN	O
data	NNS	O
,	,	O
we	PRP	O
find	VBP	O
no	DT	O
evidence	NN	O
of	IN	O
meiotic	JJ	O
segregation	NN	O
distortion	NN	O
.	.	O

The	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
the	DT	O
two	CD	O
-	:	O
sided	VBD	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
for	IN	O
the	DT	O
estimate	NN	O
of	IN	O
the	DT	O
common	JJ	O
segregation	NN	O
probability	NN	O
for	IN	O
the	DT	O
three	CD	O
donors	NNS	O
is	VBZ	O
at	IN	O
or	CC	O
below	IN	O
.	.	O

515	CD	O
for	IN	O
all	DT	O
models	NNS	O
considered	VBN	O
,	,	O
and	CC	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
from	IN	O
.	.	O

5	CD	O
is	VBZ	O
detected	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
models	NNS	O
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
any	DT	O
greater	JJR	O
amount	NN	O
of	IN	O
segregation	NN	O
distortion	NN	O
at	IN	O
the	DT	O
myotonic	JJ	B_Disease
dystrophy	NN	E_Disease
locus	NN	O
must	MD	O
result	VB	O
from	IN	O
events	NNS	O
following	VBG	O
sperm	JJ	O
ejaculation	NN	O
.	.	O

LPP	NNP	O
,	,	O
the	DT	O
preferred	JJ	O
fusion	NN	O
partner	NN	O
gene	NN	O
of	IN	O
HMGIC	NNP	O
in	IN	O
lipomas	NN	S_Disease
,	,	O
is	VBZ	O
a	DT	O
novel	JJ	O
member	NN	O
of	IN	O
the	DT	O
LIM	NNP	O
protein	NN	O
gene	NN	O
family	NN	O
.	.	O

A	DT	O
major	JJ	O
cytogenetic	JJ	O
subgroup	NN	O
of	IN	O
lipomas	NN	S_Disease
is	VBZ	O
characterized	VBN	O
by	IN	O
recurrent	JJ	O
chromosome	NN	O
aberrations	NNS	O
,	,	O
mainly	RB	O
translocations	NNS	O
,	,	O
that	IN	O
involve	VBP	O
chromosome	NN	O
segment	NN	O
12q13	CD	O
-	:	O
q15	NN	O
.	.	O

Multiple	JJ	O
chromosomes	NNS	O
have	VBP	O
been	VBN	O
found	VBN	O
as	IN	O
the	DT	O
translocation	NN	O
partners	NNS	O
of	IN	O
chromosome	NN	O
12	CD	O
but	CC	O
3q27	CD	O
-	:	O
q28	NN	O
is	VBZ	O
preferentially	RB	O
involved	VBN	O
.	.	O

In	IN	O
previous	JJ	O
studies	NNS	O
,	,	O
it	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
that	IN	O
the	DT	O
high	JJ	O
mobility	NN	O
group	NN	O
(	(	O
HMG	NNP	O
)	)	O
protein	VBP	O
gene	NN	O
HMGIC	NNP	O
at	IN	O
12q15	CD	O
is	VBZ	O
consistently	RB	O
rearranged	VBN	O
as	IN	O
a	DT	O
consequence	NN	O
of	IN	O
these	DT	O
translocations	NNS	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
report	VBP	O
the	DT	O
identification	NN	O
and	CC	O
characterization	NN	O
of	IN	O
the	DT	O
chromosome	NN	O
3	CD	O
-	:	O
derived	VBN	O
translocation	NN	O
partner	NN	O
gene	NN	O
,	,	O
which	WDT	O
we	PRP	O
have	VBP	O
designated	VBN	O
LPP	NNP	O
(	(	O
lipoma	JJ	S_Disease
preferred	VBN	O
partner	NN	O
gene	NN	O
)	)	O
.	.	O

Using	VBG	O
3	CD	O
-	:	O
RACE	JJ	O
analysis	NN	O
of	IN	O
HMGIC	NNP	O
fusion	NN	O
transcripts	NNS	O
in	IN	O
lipoma	NN	S_Disease
cell	NN	O
line	NN	O
Li	NNP	O
-	:	O
501	CD	O
/	NN	O
SV40	NNP	O
,	,	O
ectopic	VBZ	O
genetic	JJ	O
sequences	NNS	O
were	VBD	O
obtained	VBN	O
,	,	O
which	WDT	O
by	IN	O
CASH	NNP	O
(	(	O
chromosome	JJ	O
assignment	NN	O
using	VBG	O
somatic	JJ	O
cell	NN	O
hybrids	NNS	O
)	)	O
and	CC	O
FISH	NNP	O
(	(	O
fluorescence	NN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
)	)	O
analysis	NN	O
were	VBD	O
found	VBN	O
to	TO	O
originate	VB	O
from	IN	O
chromosome	NN	O
segment	NN	O
3q27	CD	O
-	:	O
q28	NN	O
.	.	O

In	IN	O
Northern	NNP	O
blot	NN	O
analysis	NN	O
,	,	O
an	DT	O
mRNA	NN	O
of	IN	O
over	IN	O
10	CD	O
kb	NN	O
was	VBD	O
detected	VBN	O
by	IN	O
these	DT	O
ectopic	NNS	O
sequences	NNS	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
human	JJ	O
tissues	NNS	O
but	CC	O
not	RB	O
in	IN	O
brain	NN	O
and	CC	O
peripheral	JJ	O
blood	NN	O
leukocytes	NNS	O
.	.	O

Upon	IN	O
partial	JJ	O
cDNA	NN	O
cloning	NN	O
,	,	O
features	NNS	O
of	IN	O
the	DT	O
genetic	JJ	O
organization	NN	O
of	IN	O
LPP	NNP	O
were	VBD	O
established	VBN	O
.	.	O

The	DT	O
gene	NN	O
was	VBD	O
found	VBN	O
to	TO	O
span	VB	O
a	DT	O
genomic	JJ	O
region	NN	O
of	IN	O
over	IN	O
400	CD	O
kb	NNS	O
.	.	O

Nucleotide	NNP	O
sequence	NN	O
analysis	NN	O
of	IN	O
a	DT	O
composite	JJ	O
cDNA	NN	O
of	IN	O
LPP	NNP	O
revealed	VBD	O
an	DT	O
open	JJ	O
reading	NN	O
frame	NN	O
of	IN	O
1836	CD	O
nucleotides	NNS	O
encoding	VBG	O
a	DT	O
proline	NN	O
-	:	O
rich	JJ	O
protein	NN	O
containing	VBG	O
a	DT	O
leucine	JJ	O
-	:	O
zipper	NN	O
motif	NN	O
in	IN	O
its	PRP$	O
amino	NN	O
-	:	O
terminal	JJ	O
region	NN	O
and	CC	O
three	CD	O
LIM	NNP	O
domains	VBZ	O
in	IN	O
its	PRP$	O
carboxy	JJ	O
-	:	O
terminal	JJ	O
region	NN	O
.	.	O

The	DT	O
LPP	NNP	O
-	:	O
encoded	VBD	O
protein	NN	O
should	MD	O
be	VB	O
classified	VBN	O
as	IN	O
a	DT	O
novel	JJ	O
member	NN	O
of	IN	O
the	DT	O
group	NN	O
3	CD	O
proteins	NNS	O
of	IN	O
the	DT	O
LIM	NNP	O
protein	NN	O
gene	NN	O
family	NN	O
.	.	O

Using	VBG	O
reverse	JJ	O
transcriptase	NN	O
combined	VBN	O
with	IN	O
polymerase	NN	O
chain	NN	O
reactions	NNS	O
in	IN	O
the	DT	O
analysis	NN	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
lipoma	NN	S_Disease
cell	NN	O
lines	NNS	O
and	CC	O
primary	JJ	B_Disease
lipomas	NN	E_Disease
,	,	O
it	PRP	O
appeared	VBD	O
that	IN	O
LPP	NNP	O
is	VBZ	O
frequently	RB	O
rearranged	VBN	O
also	RB	O
in	IN	O
cases	NNS	O
without	IN	O
a	DT	O
cytogenetically	RB	O
detectable	JJ	O
involvement	NN	O
of	IN	O
3q27	CD	O
-	:	O
q28	NN	O
.	.	O

Two	CD	O
alternative	JJ	O
HMGIC	NNP	O
/	NNP	O
LPP	NNP	O
hybrid	JJ	O
transcripts	NNS	O
have	VBP	O
been	VBN	O
detected	VBN	O
;	:	O
the	DT	O
difference	NN	O
between	IN	O
them	PRP	O
is	VBZ	O
mainly	RB	O
the	DT	O
presence	NN	O
of	IN	O
either	CC	O
two	CD	O
or	CC	O
three	CD	O
LIM	NNP	O
domains	NNS	O
in	IN	O
the	DT	O
predicted	JJ	O
HMGI	NNP	O
-	:	O
C	NNP	O
/	NNP	O
LPP	NNP	O
fusion	NN	O
proteins	NNS	O
.	.	O
.	.	O

Absence	NN	O
of	IN	O
disease	NN	O
phenotype	NN	O
and	CC	O
intergenerational	JJ	O
stability	NN	O
of	IN	O
the	DT	O
CAG	NNP	O
repeat	NN	O
in	IN	O
transgenic	JJ	O
mice	NN	O
expressing	VBG	O
the	DT	O
human	JJ	O
Huntington	NNP	B_Disease
disease	NN	E_Disease
transcript	NN	O
.	.	O

The	DT	O
mutation	NN	O
underlying	VBG	O
Huntington	NNP	B_Disease
disease	NN	E_Disease
(	(	O
HD	NNP	S_Disease
)	)	O
is	VBZ	O
CAG	JJ	O
expansion	NN	O
in	IN	O
the	DT	O
first	JJ	O
exon	NN	O
of	IN	O
the	DT	O
HD	NNP	S_Disease
gene	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
investigate	VB	O
the	DT	O
role	NN	O
of	IN	O
CAG	NNP	O
expansion	NN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
HD	NNP	S_Disease
,	,	O
we	PRP	O
have	VBP	O
produced	VBN	O
transgenic	JJ	O
mice	NN	O
containing	VBG	O
the	DT	O
full	JJ	O
length	NN	O
human	JJ	O
HD	NNP	S_Disease
cDNA	NN	O
with	IN	O
44	CD	O
CAG	NNP	O
repeats	NNS	O
.	.	O

By	IN	O
1	CD	O
year	NN	O
,	,	O
these	DT	O
mice	NNS	O
have	VBP	O
no	DT	O
behavioral	JJ	B_Disease
abnormalities	NNS	E_Disease
and	CC	O
morphometric	JJ	O
analysis	NN	O
at	IN	O
6	CD	O
(	(	O
one	CD	O
animal	NN	O
)	)	O
and	CC	O
9	CD	O
(	(	O
two	CD	O
animals	NNS	O
)	)	O
months	NNS	O
age	NN	O
revealed	VBD	O
no	DT	O
changes	NNS	O
.	.	O

Despite	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
mRNA	NN	O
expression	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
the	DT	O
HD	NNP	S_Disease
gene	NN	O
product	NN	O
in	IN	O
any	DT	O
of	IN	O
these	DT	O
transgenic	JJ	O
mice	NN	O
.	.	O

In	IN	O
vitro	JJ	O
transfection	NN	O
studies	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
inclusion	NN	O
of	IN	O
120	CD	O
bp	NN	O
of	IN	O
the	DT	O
5	CD	O
UTR	NNP	O
in	IN	O
the	DT	O
cDNA	NN	O
construct	NN	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
frameshift	JJ	O
mutation	NN	O
at	IN	O
nucleotide	JJ	O
2349	CD	O
prevented	JJ	O
expression	NN	O
of	IN	O
the	DT	O
HD	NNP	S_Disease
cDNA	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
HD	NNP	S_Disease
is	VBZ	O
not	RB	O
mediated	VBN	O
through	IN	O
DNA	NNP	O
-	:	O
protein	NN	O
interaction	NN	O
and	CC	O
that	DT	O
presence	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
transcript	NN	O
with	IN	O
an	DT	O
expanded	VBN	O
CAG	NNP	O
repeat	NN	O
is	VBZ	O
insufficient	JJ	O
to	TO	O
cause	VB	O
the	DT	O
disease	NN	O
.	.	O

Rather	RB	O
,	,	O
translation	NN	O
of	IN	O
the	DT	O
CAG	NNP	O
is	VBZ	O
crucial	JJ	O
for	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
HD	NNP	S_Disease
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
that	DT	O
seen	VBN	O
in	IN	O
humans	NNS	O
,	,	O
the	DT	O
CAG	NNP	O
repeat	NN	O
in	IN	O
these	DT	O
mice	NN	O
was	VBD	O
remarkably	RB	O
stable	JJ	O
in	IN	O
97	CD	O
meioses	NNS	O
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
genomic	JJ	O
sequences	NNS	O
may	MD	O
play	VB	O
a	DT	O
critical	JJ	O
role	NN	O
in	IN	O
influencing	VBG	O
repeat	NN	O
instability	NN	O
.	.	O
.	.	O

FISH	NNP	O
studies	NNS	O
in	IN	O
a	DT	O
patient	NN	O
with	IN	O
sporadic	JJ	B_Disease
aniridia	NN	E_Disease
and	CC	O
t	NN	O
(	(	O
7	CD	O
;	:	O
11	CD	O
)	)	O
(	(	O
q31	UH	O
.	.	O
2	CD	O
;	:	O
p13	NN	O
)	)	O
.	.	O

A	DT	O
2	CD	O
year	NN	O
old	JJ	O
female	NN	O
presenting	VBG	O
with	IN	O
bilateral	JJ	B_Disease
sporadic	JJ	I_Disease
aniridia	NN	E_Disease
was	VBD	O
found	VBN	O
to	TO	O
have	VB	O
an	DT	O
apparently	RB	O
balanced	JJ	O
reciprocal	JJ	O
translocation	NN	O
with	IN	O
a	DT	O
chromosome	NN	O
11	CD	O
breakpoint	NN	O
within	IN	O
band	NN	O
p13	NN	O
.	.	O

Fluorescence	NN	O
in	IN	O
situ	JJ	O
hybridisation	NN	O
(	(	O
FISH	NNP	O
)	)	O
studies	NNS	O
with	IN	O
distal	JJ	O
11p13	CD	O
specific	JJ	O
cosmids	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
chromosome	NN	O
11	CD	O
breakpoint	NN	O
lay	NN	O
between	IN	O
the	DT	O
aniridia	NN	S_Disease
(	(	O
PAX6	NNP	O
)	)	O
locus	NN	O
and	CC	O
a	DT	O
region	NN	O
approximately	RB	O
100	CD	O
kb	NNS	O
distal	JJ	O
to	TO	O
PAX6	NNP	O
defined	VBN	O
by	IN	O
the	DT	O
cosmid	NN	O
FO2121	NNP	O
.	.	O

Although	IN	O
this	DT	O
patient	NN	O
did	VBD	O
not	RB	O
have	VB	O
a	DT	O
detectable	JJ	O
deletion	NN	O
within	IN	O
PAX6	NNP	O
,	,	O
her	PRP$	O
aniridia	NN	S_Disease
may	MD	O
have	VB	O
resulted	VBN	O
from	IN	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
distal	JJ	O
chromatin	NN	O
domain	NN	O
containing	VBG	O
either	CC	O
enhancers	NNS	O
or	CC	O
regulators	NNS	O
for	IN	O
PAX6	NNP	O
.	.	O

This	DT	O
case	NN	O
may	MD	O
therefore	RB	O
be	VB	O
another	DT	O
example	NN	O
of	IN	O
aniridia	NN	S_Disease
caused	VBN	O
by	IN	O
a	DT	O
position	NN	O
effect	NN	O
as	IN	O
recently	RB	O
described	VBN	O
in	IN	O
two	CD	O
familial	JJ	B_Disease
aniridia	NN	E_Disease
patients	NNS	O
in	IN	O
which	WDT	O
the	DT	O
phenotype	NN	O
cosegregated	VBD	O
with	IN	O
chromosome	NN	B_Disease
abnormalities	NNS	E_Disease
with	IN	O
11p13	CD	O
breakpoints	NNS	O
.	.	O
.	.	O

Muscle	NNP	O
expression	NN	O
of	IN	O
glucose	JJ	B_Disease
-	:	I_Disease
6	CD	I_Disease
-	:	I_Disease
phosphate	NN	I_Disease
dehydrogenase	NN	I_Disease
deficiency	NN	E_Disease
in	IN	O
different	JJ	O
variants	NNS	O
.	.	O

Muscle	NNP	O
expression	NN	O
of	IN	O
G6PD	NNP	B_Disease
deficiency	NN	E_Disease
has	VBZ	O
been	VBN	O
investigated	VBN	O
in	IN	O
Mediterranean	NNP	O
,	,	O
Seattle	NNP	O
-	:	O
like	NN	O
and	CC	O
A	NNP	O
-	:	O
variants	NNS	O
.	.	O

G6PD	NNP	O
activity	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
samples	NNS	O
obtained	VBN	O
from	IN	O
biopsies	NNS	O
on	IN	O
the	DT	O
quadriceps	JJ	O
muscle	NN	O
of	IN	O
seven	CD	O
males	NNS	O
and	CC	O
one	CD	O
female	NN	O
.	.	O

The	DT	O
type	NN	O
of	IN	O
genetic	JJ	O
variant	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
molecular	JJ	O
analysis	NN	O
of	IN	O
DNA	NNP	O
,	,	O
extracted	VBD	O
from	IN	O
blood	NN	O
samples	NNS	O
.	.	O

All	DT	O
variants	NNS	O
showed	VBD	O
the	DT	O
enzyme	NN	O
defect	NN	O
in	IN	O
muscle	NN	O
.	.	O

A	DT	O
statistically	RB	O
significant	JJ	O
relationship	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
activity	NN	O
of	IN	O
G6PD	NNP	O
between	IN	O
erythrocytes	NNS	O
and	CC	O
muscle	NN	O
of	IN	O
the	DT	O
male	JJ	O
subjects	NNS	O
(	(	O
r	VB	O
=	RB	O
0	CD	O
.	.	O

968	CD	O
;	:	O
p	NN	O
=	VBZ	O
0	CD	O
.	.	O

00008	CD	O
)	)	O
.	.	O

The	DT	O
equation	NN	O
for	IN	O
the	DT	O
best	JJS	O
fit	JJ	O
line	NN	O
was	VBD	O
Y	NNP	O
=	NNP	O
0	CD	O
.	.	O

390X	CD	O
+	JJ	O
0	CD	O
.	.	O

198	CD	O
198	CD	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
,	,	O
for	IN	O
a	DT	O
given	VBN	O
variant	NN	O
,	,	O
the	DT	O
extent	NN	O
of	IN	O
the	DT	O
enzyme	NN	O
defect	NN	O
in	IN	O
muscle	NN	O
may	MD	O
be	VB	O
determined	VBN	O
,	,	O
using	VBG	O
this	DT	O
equation	NN	O
,	,	O
from	IN	O
the	DT	O
G6PD	NNP	O
activity	NN	O
of	IN	O
erythrocytes	NNS	O

Gene	NNP	O
therapy	NN	O
for	IN	O
phenylketonuria	NN	S_Disease
.	.	O

Classical	JJ	O
phenylketonuria	NN	S_Disease
(	(	O
PKU	NNP	S_Disease
)	)	O
is	VBZ	O
an	DT	O
autosomal	JJ	B_Disease
recessive	JJ	I_Disease
disorder	NN	E_Disease
caused	VBN	O
by	IN	O
a	DT	O
deficiency	NN	B_Disease
of	IN	I_Disease
hepatic	JJ	I_Disease
phenylalanine	NN	I_Disease
hydroxylase	NN	E_Disease
(	(	O
PAH	NNP	O
)	)	O
.	.	O

Limitations	NNS	O
of	IN	O
the	DT	O
current	JJ	O
dietary	JJ	O
treatment	NN	O
for	IN	O
PKU	NNP	S_Disease
have	VBP	O
led	VBN	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
potential	JJ	O
treatments	NNS	O
based	VBN	O
on	IN	O
somatic	JJ	O
gene	NN	O
transfer	NN	O
.	.	O

Three	CD	O
different	JJ	O
vector	NN	O
systems	NNS	O
have	VBP	O
been	VBN	O
examined	VBN	O
.	.	O

Vectors	NNS	O
derived	VBD	O
from	IN	O
a	DT	O
recombinant	JJ	O
retrovirus	NN	O
or	CC	O
a	DT	O
DNA	NN	O
/	JJ	O
protein	NN	O
complex	NN	O
can	MD	O
efficiently	RB	O
transduce	VB	O
the	DT	O
PAH	NNP	O
cDNA	NN	O
into	IN	O
PAH	NNP	B_Disease
-	:	I_Disease
deficient	NN	E_Disease
hepatocytes	NNS	O
in	IN	O
vitro	NN	O
,	,	O
but	CC	O
the	DT	O
application	NN	O
of	IN	O
these	DT	O
vector	NN	O
systems	NNS	O
is	VBZ	O
presently	RB	O
limited	VBN	O
by	IN	O
their	PRP$	O
low	JJ	O
transduction	NN	O
efficiency	NN	O
in	IN	O
vivo	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
a	DT	O
vector	NN	O
derived	VBN	O
from	IN	O
a	DT	O
recombinant	JJ	O
adenovirus	NN	O
can	MD	O
restore	VB	O
10	CD	O
%	NN	O
-	:	O
80	CD	O
%	NN	O
of	IN	O
normal	JJ	O
hepatic	JJ	O
PAH	NNP	O
activity	NN	O
into	IN	O
PAH	NNP	B_Disease
-	:	I_Disease
deficient	NN	E_Disease
mice	NN	O
,	,	O
which	WDT	O
completely	RB	O
normalizes	VBZ	O
serum	JJ	O
phenylalanine	NN	O
levels	NNS	O
.	.	O

This	DT	O
treatment	NN	O
is	VBZ	O
transient	JJ	O
and	CC	O
cannot	JJ	O
be	VB	O
effectively	RB	O
re	JJ	O
-	:	O
administered	VBN	O
due	JJ	O
to	TO	O
the	DT	O
presence	NN	O
of	IN	O
neutralizing	VBG	O
antibodies	NNS	O
directed	VBN	O
against	IN	O
the	DT	O
recombinant	JJ	O
adenoviral	JJ	O
vector	NN	O
.	.	O

However	RB	O
,	,	O
these	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
PKU	NNP	S_Disease
can	MD	O
be	VB	O
completely	RB	O
corrected	VBN	O
by	IN	O
somatic	JJ	O
gene	NN	O
therapy	NN	O
,	,	O
and	CC	O
provide	VB	O
some	DT	O
direction	NN	O
for	IN	O
the	DT	O
future	NN	O
development	NN	O
of	IN	O
adenoviral	JJ	O
vectors	NNS	O
.	.	O
.	.	O

Exon	NNP	O
-	:	O
intron	NN	O
structure	NN	O
of	IN	O
the	DT	O
human	JJ	O
neuronal	JJ	O
nicotinic	JJ	O
acetylcholine	NN	O
receptor	NN	O
alpha	VBD	O
4	CD	O
subunit	NN	O
(	(	O
CHRNA4	NNP	O
)	)	O
.	.	O

The	DT	O
human	JJ	O
neuronal	JJ	O
nicotinic	JJ	O
acetylcholine	NN	O
receptor	NN	O
alpha	VBD	O
4	CD	O
subunit	NN	O
gene	NN	O
(	(	O
CHRNA4	NNP	O
)	)	O
is	VBZ	O
located	VBN	O
in	IN	O
the	DT	O
candidate	NN	O
region	NN	O
for	IN	O
three	CD	O
different	JJ	O
phenotypes	NNS	O
benign	JJ	B_Disease
familial	JJ	I_Disease
neonatal	JJ	I_Disease
convulsions	NNS	E_Disease
,	,	O
autosomal	JJ	B_Disease
dominant	JJ	I_Disease
nocturnal	JJ	I_Disease
frontal	NN	I_Disease
lobe	NN	I_Disease
epilepsy	NN	E_Disease
,	,	O
and	CC	O
low	JJ	O
-	:	O
voltage	NN	O
EEG	NNP	O
.	.	O

Recently	RB	O
,	,	O
a	DT	O
missense	JJ	O
mutation	NN	O
in	IN	O
transmembrane	NN	O
domain	VBP	O
2	CD	O
of	IN	O
CHRNA4	NNP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
autosomal	JJ	B_Disease
dominant	JJ	I_Disease
nocturnal	JJ	I_Disease
frontal	NN	I_Disease
lobe	NN	I_Disease
epilepsy	NN	E_Disease
in	IN	O
one	CD	O
extended	VBD	O
pedigree	NN	O
.	.	O

We	PRP	O
have	VBP	O
determined	VBN	O
the	DT	O
genomic	JJ	O
organization	NN	O
of	IN	O
CHRNA4	NNP	O
,	,	O
which	WDT	O
consists	VBZ	O
of	IN	O
six	CD	O
exons	NNS	O
distributed	VBN	O
over	IN	O
approximately	RB	O
17	CD	O
kb	NNS	O
of	IN	O
genomic	JJ	O
DNA	NNP	O
.	.	O

The	DT	O
nucleotide	JJ	O
sequence	NN	O
obtained	VBN	O
from	IN	O
the	DT	O
genomic	JJ	O
regions	NNS	O
adjacent	VBP	O
to	TO	O
the	DT	O
exon	NN	O
boundaries	NNS	O
enabled	VBD	O
us	PRP	O
to	TO	O
develop	VB	O
a	DT	O
set	NN	O
of	IN	O
primer	NN	O
pairs	NNS	O
for	IN	O
PCR	NNP	O
amplification	NN	O
of	IN	O
the	DT	O
complete	JJ	O
coding	NN	O
region	NN	O
.	.	O

The	DT	O
sequence	NN	O
analysis	NN	O
provides	VBZ	O
the	DT	O
basis	NN	O
for	IN	O
a	DT	O
comprehensive	JJ	O
mutation	NN	O
screening	NN	O
of	IN	O
CHRNA4	NNP	O
in	IN	O
the	DT	O
above	JJ	O
-	:	O
mentioned	VBN	O
phenotypes	NNS	O
and	CC	O
possibly	RB	O
in	IN	O
other	JJ	O
types	NNS	O
of	IN	O
idiopathic	JJ	B_Disease
epilepsies	NNS	E_Disease
.	.	O
.	.	O

Ashkenazi	NNP	O
Jewish	NNP	O
population	NN	O
frequencies	NNS	O
for	IN	O
common	JJ	O
mutations	NNS	O
in	IN	O
BRCA1	NNP	O
and	CC	O
BRCA2	NNP	O
.	.	O

BRCA1	NNP	O
and	CC	O
BRCA2	NNP	O
are	VBP	O
the	DT	O
two	CD	O
major	JJ	O
identified	VBN	O
causes	NNS	O
of	IN	O
inherited	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
,	,	O
with	IN	O
mutations	NNS	O
in	IN	O
either	DT	O
gene	NN	O
conferring	VBG	O
up	RP	O
to	TO	O
80	CD	O
-	:	O
90	CD	O
%	NN	O
lifetime	NN	O
risk	NN	O
of	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
in	IN	O
carrier	NN	O
females	NNS	O
.	.	O

Mutations	NNS	O
in	IN	O
BRCA1	NNP	O
account	NN	O
for	IN	O
approximately	RB	O
45	CD	O
%	NN	O
of	IN	O
familial	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
and	CC	O
90	CD	O
%	NN	O
of	IN	O
inherited	JJ	B_Disease
breast	NN	I_Disease
/	JJ	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
,	,	O
whereas	JJ	O
mutations	NNS	O
in	IN	O
BRCA2	NNP	O
account	NN	O
for	IN	O
a	DT	O
comparable	JJ	O
percentage	NN	O
of	IN	O
inherited	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
cases	NNS	O
.	.	O

Over	IN	O
85	CD	O
distinct	JJ	O
BRCA1	NNP	O
mutations	NNS	O
and	CC	O
a	DT	O
growing	VBG	O
list	NN	O
of	IN	O
BRCA2	NNP	O
mutations	NNS	O
have	VBP	O
been	VBN	O
identified	VBN	O
,	,	O
with	IN	O
the	DT	O
majority	NN	O
resulting	VBG	O
in	IN	O
protein	NN	O
truncation	NN	O
.	.	O

A	DT	O
specific	JJ	O
BRCA1	NNP	O
mutation	NN	O
,	,	O
185delAG	CD	O
,	,	O
has	VBZ	O
a	DT	O
reported	VBN	O
increased	VBN	O
carrier	NN	O
frequency	NN	O
of	IN	O
approximately	RB	O
0	CD	O
.	.	O

9	CD	O
%	NN	O
in	IN	O
the	DT	O
Ashkenazi	NNP	O
Jewish	NNP	O
population	NN	O
,	,	O
but	CC	O
is	VBZ	O
also	RB	O
found	VBN	O
in	IN	O
rare	JJ	O
non	NN	O
-	:	O
Jewish	JJ	O
patients	NNS	O
with	IN	O
a	DT	O
different	JJ	O
haplotype	NN	O
.	.	O

The	DT	O
6174delT	CD	O
mutation	NN	O
in	IN	O
BRCA2	NNP	O
was	VBD	O
recently	RB	O
identified	VBN	O
as	IN	O
a	DT	O
frequent	JJ	O
mutation	NN	O
in	IN	O
8	CD	O
out	IN	O
of	IN	O
107	CD	O
Ashkenazi	NNP	O
Jewish	JJ	O
women	NNS	O
diagnosed	VBN	O
with	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
by	IN	O
age	NN	O
50	CD	O
(	(	O
ref	NN	O
.	.	O

8	CD	O
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
three	CD	O
Ashkenazi	NNP	O
male	NN	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
patients	NNS	O
.	.	O

We	PRP	O
have	VBP	O
conducted	VBN	O
a	DT	O
large	JJ	O
-	:	O
scale	NN	O
population	NN	O
study	NN	O
to	TO	O
investigate	VB	O
the	DT	O
prevalence	NN	O
of	IN	O
specific	JJ	O
BRCA1	NNP	O
and	CC	O
BRCA2	NNP	O
mutations	NNS	O
in	IN	O
Ashkenazi	NNP	O
Jewish	JJ	O
individuals	NNS	O
who	WP	O
were	VBD	O
unselected	VBN	O
for	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
.	.	O

BRCA1	NNP	O
mutation	NN	O
screening	VBG	O
on	IN	O
approximately	RB	O
3	CD	O
,	,	O
000	CD	O
Ashkenazi	NNP	O
Jewish	NNP	O
samples	NNS	O
determined	VBD	O
a	DT	O
carrier	NN	O
frequency	NN	O
of	IN	O
1	CD	O
.	.	O

09	CD	O
%	NN	O
for	IN	O
the	DT	O
185delAG	CD	O
mutation	NN	O
and	CC	O
0	CD	O
.	.	O

13	CD	O
%	NN	O
for	IN	O
the	DT	O
5382insC	CD	O
mutation	NN	O
.	.	O

BRCA2	NNP	O
analysis	NN	O
on	IN	O
3	CD	O
,	,	O
085	CD	O
individuals	NNS	O
from	IN	O
the	DT	O
same	JJ	O
population	NN	O
showed	VBD	O
a	DT	O
carrier	NN	O
frequency	NN	O
of	IN	O
1	CD	O
.	.	O

52	CD	O
%	NN	O
for	IN	O
the	DT	O
6174delT	CD	O
mutation	NN	O
.	.	O

This	DT	O
expanded	VBN	O
population	NN	O
-	:	O
based	VBN	O
study	NN	O
confirms	VBZ	O
that	IN	O
the	DT	O
BRCA1	NNP	O
185delAG	CD	O
mutation	NN	O
and	CC	O
the	DT	O
BRCA2	NNP	O
6174delT	CD	O
mutation	NN	O
constitute	VB	O
the	DT	O
two	CD	O
most	JJS	O
frequent	JJ	O
mutation	NN	O
alleles	NNS	O
predisposing	VBG	O
to	TO	O
hereditary	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
among	IN	O
the	DT	O
Ashkenazim	NNP	O
,	,	O
and	CC	O
suggests	VBZ	O
a	DT	O
relatively	RB	O
lower	JJR	O
penetrance	NN	O
for	IN	O
the	DT	O
6174delT	CD	O
mutation	NN	O
in	IN	O
BRCA2	NNP	O

Dual	JJ	O
roles	NNS	O
of	IN	O
ATM	NNP	O
in	IN	O
the	DT	O
cellular	JJ	O
response	NN	O
to	TO	O
radiation	NN	O
and	CC	O
in	IN	O
cell	NN	O
growth	NN	O
control	NN	O
.	.	O

The	DT	O
gene	NN	O
mutated	VBN	O
in	IN	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
(	(	O
AT	NNP	S_Disease
)	)	O
patients	NNS	O
,	,	O
denoted	VBN	O
ATM	NNP	O
,	,	O
encodes	VBZ	O
a	DT	O
putative	JJ	O
protein	NN	O
or	CC	O
lipid	JJ	O
kinase	NN	O
.	.	O

To	TO	O
elucidate	VB	O
the	DT	O
functions	NNS	O
of	IN	O
ATM	NNP	O
,	,	O
we	PRP	O
disrupted	VBD	O
the	DT	O
mouse	NN	O
ATM	NNP	O
gene	NN	O
through	IN	O
homologous	JJ	O
recombination	NN	O
in	IN	O
mice	NN	O
.	.	O

Consistent	JJ	O
with	IN	O
cellular	JJ	O
defects	NNS	O
of	IN	O
AT	NNP	S_Disease
patients	NNS	O
,	,	O
the	DT	O
ATM	NNP	O
-	:	O
/	SYM	O
-	:	O
cells	NNS	O
are	VBP	O
hypersensitive	JJ	O
to	TO	O
gamma	VB	O
-	:	O
irradiation	NN	O
and	CC	O
defective	JJ	O
in	IN	O
cell	NN	O
-	:	O
cycle	NN	O
arrest	NN	O
following	VBG	O
radiation	NN	O
,	,	O
correlating	VBG	O
with	IN	O
a	DT	O
defective	JJ	O
up	RP	O
-	:	O
regulation	NN	O
of	IN	O
p53	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
ATM	NNP	O
-	:	O
/	SYM	O
-	:	O
mouse	NN	O
thymocytes	NNS	O
are	VBP	O
more	RBR	O
resistant	JJ	O
to	TO	O
apoptosis	VB	O
induced	VBN	O
by	IN	O
gamma	JJ	O
-	:	O
irradiation	NN	O
than	IN	O
normal	JJ	O
thymocytes	NNS	O
.	.	O

ATM	NNP	O
-	:	O
/	SYM	O
-	:	O
fibroblasts	NNS	O
are	VBP	O
inefficient	JJ	O
in	IN	O
G1	NNP	O
to	TO	O
S	NNP	O
-	:	O
phase	NN	O
progression	NN	O
following	VBG	O
serum	JJ	O
stimulation	NN	O
and	CC	O
senesce	NN	O
after	IN	O
only	RB	O
a	DT	O
few	JJ	O
passages	NNS	O
in	IN	O
culture	NN	O
.	.	O

They	PRP	O
have	VBP	O
an	DT	O
increased	VBN	O
constitutive	JJ	O
level	NN	O
of	IN	O
p21CP1	JJ	O
/	NNP	O
WAF1	NNP	O
.	.	O

The	DT	O
ATM	NNP	O
protein	NN	O
is	VBZ	O
therefore	RB	O
critical	JJ	O
both	DT	O
for	IN	O
cellular	JJ	O
responses	NNS	O
to	TO	O
ionizing	VBG	O
radiation	NN	O
and	CC	O
for	IN	O
normal	JJ	O
cell	NN	O
-	:	O
cycle	NN	O
progression	NN	O
.	.	O

ATM	NNP	O
+	NNP	O
/	NNP	O
-	:	O
fibroblasts	NNS	O
and	CC	O
thymocytes	NNS	O
showed	VBD	O
intermediately	RB	O
defective	JJ	O
responses	NNS	O
to	TO	O
irradiation	VB	O
but	CC	O
no	DT	O
growth	NN	O
defect	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
the	DT	O
increased	JJ	O
cancer	NN	S_Disease
risk	NN	O
of	IN	O
AT	NNP	S_Disease
heterozygotes	NNS	O
could	MD	O
be	VB	O
attributable	JJ	O
to	TO	O
poor	JJ	O
checkpoint	NN	O
function	NN	O
.	.	O
.	.	O

Targeted	VBN	O
disruption	NN	O
of	IN	O
ATM	NNP	O
leads	VBZ	O
to	TO	O
growth	NN	B_Disease
retardation	NN	E_Disease
,	,	O
chromosomal	JJ	B_Disease
fragmentation	NN	I_Disease
during	IN	I_Disease
meiosis	NN	E_Disease
,	,	O
immune	JJ	B_Disease
defects	NNS	E_Disease
,	,	O
and	CC	O
thymic	JJ	B_Disease
lymphoma	NN	E_Disease
.	.	O

ATM	NNP	O
,	,	O
the	DT	O
gene	NN	O
mutated	VBN	O
in	IN	O
the	DT	O
inherited	JJ	B_Disease
human	JJ	I_Disease
disease	NN	E_Disease
ataxia	SYM	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
,	,	O
is	VBZ	O
a	DT	O
member	NN	O
of	IN	O
a	DT	O
family	NN	O
of	IN	O
kinases	NNS	O
involved	VBN	O
in	IN	O
DNA	NNP	O
metabolism	NN	O
and	CC	O
cell	NN	O
-	:	O
cycle	NN	O
checkpoint	NN	O
control	NN	O
.	.	O

To	TO	O
help	VB	O
clarify	VB	O
the	DT	O
physiological	JJ	O
roles	NNS	O
of	IN	O
the	DT	O
ATM	NNP	O
protein	NN	O
,	,	O
we	PRP	O
disrupted	VBD	O
the	DT	O
ATM	NNP	O
gene	NN	O
in	IN	O
mice	NNS	O
through	IN	O
homologous	JJ	O
recombination	NN	O
.	.	O

Initial	JJ	O
evaluation	NN	O
of	IN	O
the	DT	O
ATM	NNP	O
knockout	NN	O
animals	NNS	O
indicates	VBZ	O
that	IN	O
inactivation	NN	O
of	IN	O
the	DT	O
mouse	NN	O
ATM	NNP	O
gene	NN	O
recreates	VBZ	O
much	RB	O
of	IN	O
the	DT	O
phenotype	NN	O
of	IN	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
.	.	O

The	DT	O
homozygous	JJ	O
mutant	NN	O
(	(	O
ATM	NNP	O
-	:	O
/	SYM	O
-	:	O
)	)	O
mice	NN	O
are	VBP	O
viable	JJ	O
,	,	O
growth	NN	O
-	:	O
retarded	VBN	O
,	,	O
and	CC	O
infertile	NN	O
.	.	O

The	DT	O
infertility	NN	S_Disease
of	IN	O
ATM	NNP	O
-	:	O
/	SYM	O
-	:	O
mice	NN	O
results	NNS	O
from	IN	O
meiotic	JJ	O
failure	NN	O
.	.	O

Meiosis	NN	O
is	VBZ	O
arrested	VBN	O
at	IN	O
the	DT	O
zygotene	NN	O
/	NNP	O
pachytene	NN	O
stage	NN	O
of	IN	O
prophase	NN	O
I	PRP	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
abnormal	JJ	O
chromosomal	JJ	O
synapsis	NN	O
and	CC	O
subsequent	JJ	O
chromosome	NN	O
fragmentation	NN	O
.	.	O

Immune	NNP	B_Disease
defects	NNS	E_Disease
also	RB	O
are	VBP	O
evident	JJ	O
in	IN	O
ATM	NNP	O
-	:	O
/	SYM	O
-	:	O
mice	NN	O
,	,	O
including	VBG	O
reduced	JJ	O
numbers	NNS	O
of	IN	O
B220	NNP	O
+	NNP	O
CD43	NNP	O
-	:	O
pre	NN	O
-	:	O
B	NNP	O
cells	NNS	O
,	,	O
thymocytes	NNS	O
,	,	O
and	CC	O
peripheral	JJ	O
T	NNP	O
cells	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
functional	JJ	O
impairment	NN	O
of	IN	O
T	NNP	O
-	:	O
cell	NN	O
-	:	O
dependent	NN	O
immune	JJ	O
responses	NNS	O
.	.	O

The	DT	O
cerebella	NN	O
of	IN	O
ATM	NNP	O
-	:	O
/	SYM	O
-	:	O
mice	NN	O
appear	IN	O
normal	JJ	O
by	IN	O
histologic	JJ	O
examination	NN	O
at	IN	O
3	CD	O
to	TO	O
4	CD	O
months	NNS	O
and	CC	O
the	DT	O
mice	NNS	O
have	VBP	O
no	DT	O
gross	JJ	O
behavioral	JJ	B_Disease
abnormalities	NNS	E_Disease
.	.	O

The	DT	O
majority	NN	O
of	IN	O
mutant	JJ	O
mice	NNS	O
rapidly	RB	O
develop	VBP	O
thymic	JJ	B_Disease
lymphomas	NN	E_Disease
and	CC	O
die	NN	O
before	IN	O
4	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

These	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
ATM	NNP	O
gene	NN	O
product	NN	O
plays	VBZ	O
an	DT	O
essential	JJ	O
role	NN	O
in	IN	O
a	DT	O
diverse	JJ	O
group	NN	O
of	IN	O
cellular	JJ	O
processes	NNS	O
,	,	O
including	VBG	O
meiosis	NN	O
,	,	O
the	DT	O
normal	JJ	O
growth	NN	O
of	IN	O
somatic	JJ	O
tissues	NNS	O
,	,	O
immune	NN	O
development	NN	O
,	,	O
and	CC	O
tumor	NN	S_Disease
suppression	NN	O
.	.	O
.	.	O

Cloning	VBG	O
and	CC	O
characterization	NN	O
of	IN	O
human	JJ	O
very	RB	O
-	:	O
long	JJ	O
-	:	O
chain	NN	O
acyl	IN	O
-	:	O
CoA	NNP	O
dehydrogenase	NN	O
cDNA	NN	O
,	,	O
chromosomal	JJ	O
assignment	NN	O
of	IN	O
the	DT	O
gene	NN	O
and	CC	O
identification	NN	O
in	IN	O
four	CD	O
patients	NNS	O
of	IN	O
nine	CD	O
different	JJ	O
mutations	NNS	O
within	IN	O
the	DT	O
VLCAD	NNP	O
gene	NN	O
.	.	O

Very	RB	O
-	:	O
long	JJ	O
-	:	O
chain	NN	O
acyl	IN	O
-	:	O
CoA	NNP	O
dehydrogenase	NN	O
(	(	O
VLCAD	NNP	O
)	)	O
is	VBZ	O
one	CD	O
of	IN	O
four	CD	O
straight	JJ	O
-	:	O
chain	NN	O
acyl	IN	O
-	:	O
CoA	NNP	O
dehydrogenase	NN	O
(	(	O
ACD	NNP	O
)	)	O
enzymes	NNS	O
,	,	O
which	WDT	O
are	VBP	O
all	DT	O
nuclear	JJ	O
encoded	VBN	O
mitochondrial	JJ	O
flavoproteins	NNS	O
catalyzing	VBG	O
the	DT	O
initial	JJ	O
step	NN	O
in	IN	O
fatty	JJ	O
acid	NN	O
beta	SYM	O
-	:	O
oxidation	NN	O
.	.	O

We	PRP	O
have	VBP	O
used	VBN	O
the	DT	O
very	RB	O
fast	RB	O
,	,	O
Rapid	NNP	O
Amplification	NNP	O
of	IN	O
cDNA	NN	O
Ends	NNP	O
(	(	O
RACE	NNP	O
)	)	O
based	VBN	O
strategy	NN	O
to	TO	O
obtain	VB	O
the	DT	O
sequence	NN	O
of	IN	O
cDNAs	NN	O
encoding	VBG	O
human	JJ	O
VLCAD	NNP	O
from	IN	O
placenta	NN	O
and	CC	O
fibroblasts	NNS	O
.	.	O

Alignment	NN	O
of	IN	O
the	DT	O
predicted	VBN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
human	JJ	O
VLCAD	NNP	O
with	IN	O
those	DT	O
of	IN	O
the	DT	O
other	JJ	O
human	JJ	O
ACD	NNP	O
enzymes	NNS	O
revealed	VBD	O
extensive	JJ	O
sequence	NN	O
homology	NN	O
.	.	O

Moreover	RB	O
,	,	O
human	JJ	O
VLCAD	NNP	O
and	CC	O
human	JJ	O
acyl	NN	O
-	:	O
CoA	NNP	O
oxidase	NN	O
showed	VBD	O
extensive	JJ	O
sequence	NN	O
homology	NN	O
corroborating	VBG	O
the	DT	O
notion	NN	O
that	IN	O
these	DT	O
genes	NNS	O
are	VBP	O
evolutionarily	RB	O
related	VBN	O
.	.	O

Southern	NNP	O
blot	NN	O
analysis	NN	O
of	IN	O
genomic	JJ	O
DNA	NN	O
from	IN	O
hybrid	JJ	O
cell	NN	O
lines	NNS	O
was	VBD	O
used	VBN	O
to	TO	O
localize	VB	O
the	DT	O
VLCAD	NNP	O
gene	NN	O
to	TO	O
human	JJ	O
chromosome	NN	O
17p11	CD	O
.	.	O

2	CD	O
-	:	O
p11	NN	O
.	.	O

13105	CD	O
.	.	O

Using	VBG	O
Northern	NNP	O
and	CC	O
Western	NNP	O
blot	NN	O
analysis	NN	O
to	TO	O
investigate	VB	O
the	DT	O
tissue	NN	O
specific	JJ	O
distribution	NN	O
of	IN	O
VLCAD	NNP	O
mRNA	NN	O
and	CC	O
protein	NN	O
in	IN	O
several	JJ	O
human	JJ	O
tissues	NNS	O
we	PRP	O
showed	VBD	O
that	IN	O
VLCAD	NNP	O
is	VBZ	O
most	RBS	O
abundant	JJ	O
in	IN	O
heart	NN	O
and	CC	O
skeletal	JJ	O
muscle	NN	O
.	.	O

This	DT	O
agrees	VBZ	O
well	RB	O
with	IN	O
the	DT	O
fact	NN	O
that	IN	O
cardiac	NN	O
and	CC	O
muscle	NN	O
symptoms	NNS	O
are	VBP	O
characteristic	JJ	O
for	IN	O
patients	NNS	O
with	IN	O
VLCAD	NNP	B_Disease
deficiency	NN	E_Disease
.	.	O

Northern	NNP	O
blot	NN	O
analysis	NN	O
and	CC	O
sequencing	NN	O
of	IN	O
cloned	JJ	O
PCR	NNP	O
amplified	VBD	O
VLCAD	NNP	O
cDNA	NN	O
from	IN	O
four	CD	O
unrelated	JJ	O
patients	NNS	O
with	IN	O
VLCAD	NNP	B_Disease
deficiency	NN	E_Disease
showed	VBD	O
that	IN	O
VLCAD	NNP	O
mRNA	NN	O
was	VBD	O
undetectable	JJ	O
in	IN	O
one	CD	O
patient	NN	O
and	CC	O
that	IN	O
the	DT	O
other	JJ	O
three	CD	O
have	VBP	O
mutations	NNS	O
in	IN	O
both	DT	O
VLCAD	NNP	O
alleles	NNS	O
.	.	O

Western	JJ	O
blot	NN	O
analysis	NN	O
of	IN	O
patient	NN	O
fibroblasts	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
identified	JJ	O
mutations	NNS	O
result	VBP	O
in	IN	O
severely	RB	O
reduced	JJ	O
amounts	NNS	O
of	IN	O
VLCAD	NNP	O
protein	NN	O
.	.	O

Molecular	JJ	O
bases	NNS	O
of	IN	O
combined	JJ	B_Disease
subtotal	JJ	I_Disease
deficiencies	NNS	I_Disease
of	IN	I_Disease
C6	NNP	I_Disease
and	CC	I_Disease
C7	NNP	E_Disease
:	:	O
their	PRP$	O
effects	NNS	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
C6	NNP	B_Disease
and	CC	I_Disease
C7	NNP	I_Disease
deficiencies	NNS	E_Disease
.	.	O

Combined	VBN	B_Disease
subtotal	JJ	I_Disease
deficiency	NN	I_Disease
of	IN	I_Disease
C6	NNP	I_Disease
and	CC	I_Disease
C7	NNP	E_Disease
,	,	O
in	IN	O
which	WDT	O
both	DT	O
proteins	NNS	O
are	VBP	O
expressed	VBN	O
at	IN	O
very	RB	O
low	JJ	O
levels	NNS	O
,	,	O
has	VBZ	O
been	VBN	O
observed	VBN	O
in	IN	O
homozygous	JJ	O
form	NN	O
in	IN	O
two	CD	O
families	NNS	O
.	.	O

A	DT	O
defect	NN	O
at	IN	O
the	DT	O
5	CD	O
splice	NN	O
donor	NN	O
site	NN	O
of	IN	O
intron	JJ	O
15	CD	O
of	IN	O
the	DT	O
C6	NNP	O
gene	NN	O
explains	VBZ	O
the	DT	O
low	JJ	O
molecular	JJ	O
weight	NN	O
of	IN	O
the	DT	O
C6	NNP	O
protein	NN	O
and	CC	O
is	VBZ	O
probably	RB	O
responsible	JJ	O
for	IN	O
its	PRP$	O
low	JJ	O
expressed	VBN	O
concentration	NN	O
.	.	O

The	DT	O
C7	NNP	O
defect	NN	O
is	VBZ	O
more	RBR	O
enigmatic	JJ	O
the	DT	O
protein	NN	O
is	VBZ	O
of	IN	O
normal	JJ	O
molecular	JJ	O
weight	NN	O
,	,	O
low	JJ	O
circulating	VBG	O
concentration	NN	O
,	,	O
and	CC	O
altered	VBD	O
isoelectric	JJ	O
point	NN	O
.	.	O

An	DT	O
Arg	NNP	O
>	NNP	O
Ser	NNP	O
codon	NN	O
substitution	NN	O
in	IN	O
exon	JJ	O
11	CD	O
is	VBZ	O
the	DT	O
only	JJ	O
molecular	JJ	O
alteration	NN	O
within	IN	O
the	DT	O
mature	NN	O
C7	NNP	O
protein	NN	O
.	.	O

These	DT	O
defects	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
a	DT	O
characteristic	JJ	O
set	NN	O
of	IN	O
polymorphic	JJ	O
DNA	NNP	O
markers	NNS	O
in	IN	O
the	DT	O
C6	NNP	O
/	NNP	O
C7	NNP	O
region	NN	O
,	,	O
forming	VBG	O
a	DT	O
distinct	JJ	O
haplotype	NN	O
.	.	O

The	DT	O
haplotype	NN	O
has	VBZ	O
been	VBN	O
found	VBN	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
number	NN	O
of	IN	O
other	JJ	O
haplotypes	NNS	O
containing	VBG	O
defective	JJ	O
genes	NNS	O
that	WDT	O
lead	VBP	O
either	DT	O
to	TO	O
C6	NNP	B_Disease
or	CC	I_Disease
C7	NNP	I_Disease
deficiency	NN	E_Disease
,	,	O
but	CC	O
with	IN	O
different	JJ	O
consequences	NNS	O
.	.	O

Where	WRB	O
it	PRP	O
is	VBZ	O
combined	VBN	O
with	IN	O
a	DT	O
C6	NNP	B_Disease
-	:	I_Disease
deficient	NN	E_Disease
gene	NN	O
,	,	O
the	DT	O
serum	NN	O
C7	NNP	O
levels	NNS	O
can	MD	O
be	VB	O
surprisingly	RB	O
high	JJ	O
,	,	O
possibly	RB	O
because	IN	O
there	EX	O
is	VBZ	O
no	DT	O
C6	NNP	O
generating	VBG	O
C56	NNP	O
to	TO	O
consume	VB	O
the	DT	O
C7	NNP	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
where	WRB	O
the	DT	O
C7	NNP	O
genes	NNS	O
are	VBP	O
both	DT	O
defective	JJ	O
(	(	O
but	CC	O
still	RB	O
partially	RB	O
functional	JJ	O
)	)	O
,	,	O
there	EX	O
may	MD	O
be	VB	O
a	DT	O
profound	JJ	O
deficit	NN	O
of	IN	O
circulating	VBG	O
C7	NNP	O
because	IN	O
there	EX	O
is	VBZ	O
ample	JJ	O
C6	NNP	O
to	TO	O
produce	VB	O
C56	NNP	O
and	CC	O
consume	VB	O
the	DT	O
already	RB	O
small	JJ	O
amount	NN	O
of	IN	O
C7	NNP	O
.	.	O

Each	DT	O
molecular	JJ	O
defect	NN	O
has	VBZ	O
also	RB	O
been	VBN	O
found	VBN	O
in	IN	O
isolation	NN	O
and	CC	O
has	VBZ	O
the	DT	O
expected	VBN	O
effect	NN	O
.	.	O
.	.	O

Genetic	JJ	O
bases	NNS	O
of	IN	O
human	JJ	O
complement	NN	B_Disease
C7	NNP	I_Disease
deficiency	NN	E_Disease
.	.	O

Complement	NNP	B_Disease
C7	NNP	I_Disease
deficiency	NN	E_Disease
(	(	O
C7D	NNP	S_Disease
)	)	O
is	VBZ	O
associated	VBN	O
frequently	RB	O
with	IN	O
recurrent	JJ	O
bacterial	JJ	B_Disease
infections	NNS	E_Disease
,	,	O
especially	RB	O
meningitis	NNS	S_Disease
caused	VBN	O
by	IN	O
Neisseria	NNP	B_Disease
meningitidis	NN	E_Disease
.	.	O

We	PRP	O
report	VBP	O
in	IN	O
this	DT	O
work	NN	O
the	DT	O
molecular	JJ	O
bases	NNS	O
of	IN	O
C7D	NNP	S_Disease
in	IN	O
two	CD	O
unrelated	JJ	O
Japanese	JJ	O
males	NNS	O
.	.	O

We	PRP	O
used	VBD	O
exon	SYM	O
-	:	O
specific	JJ	O
PCR	NNP	O
/	NNP	O
single	JJ	O
-	:	O
strand	NN	O
conformation	NN	O
polymorphism	NN	O
analysis	NN	O
as	IN	O
a	DT	O
screening	JJ	O
step	NN	O
for	IN	O
mutations	NNS	O
.	.	O

Subsequent	JJ	O
direct	JJ	O
sequencing	NN	O
of	IN	O
the	DT	O
target	NN	O
exons	NNS	O
identified	VBN	O
homozygous	JJ	O
mutations	NNS	O
in	IN	O
exon	JJ	O
16	CD	O
of	IN	O
case	NN	O
1	CD	O
and	CC	O
in	IN	O
exon	JJ	O
15	CD	O
of	IN	O
case	NN	O
2	CD	O
.	.	O

The	DT	O
mutation	NN	O
of	IN	O
case	NN	O
1	CD	O
was	VBD	O
a	DT	O
homozygous	JJ	O
T	NNP	O
to	TO	O
A	DT	O
transversion	NN	O
at	IN	O
nucleotide	JJ	O
2250	CD	O
,	,	O
the	DT	O
third	JJ	O
nucleotide	NN	O
of	IN	O
the	DT	O
codon	NN	O
TGT	NNP	O
for	IN	O
Cys728	NNP	O
,	,	O
leading	VBG	O
to	TO	O
a	DT	O
stop	JJ	O
codon	NN	O
TGA	NNP	O
(	(	O
C728X	NNP	O
)	)	O
.	.	O

In	IN	O
case	NN	O
2	CD	O
,	,	O
a	DT	O
homozygous	JJ	O
2	CD	O
-	:	O
bp	NN	O
deletion	NN	O
(	(	O
2137delTG	CD	O
/	RB	O
2138delGT	CD	O
/	JJ	O
2139delTG	CD	O
)	)	O
caused	VBD	O
a	DT	O
frameshift	NN	O
,	,	O
generating	VBG	O
a	DT	O
premature	NN	O
termination	NN	O
codon	VBZ	O
4	CD	O
to	TO	O
6	CD	O
nucleotides	NNS	O
downstream	NN	O
.	.	O

Family	RB	O
study	NN	O
in	IN	O
case	NN	O
1	CD	O
confirmed	VBD	O
the	DT	O
genetic	JJ	O
nature	NN	O
of	IN	O
the	DT	O
defect	NN	O
.	.	O

Moreover	RB	O
,	,	O
we	PRP	O
detected	VBD	O
a	DT	O
novel	JJ	O
polymorphism	NN	O
in	IN	O
intron	NN	O
11	CD	O
that	IN	O
presumably	NN	O
is	VBZ	O
linked	VBN	O
to	TO	O
the	DT	O
mutation	NN	O
responsible	JJ	O
for	IN	O
C7D	NNP	S_Disease
in	IN	O
case	NN	O
1	CD	O
.	.	O

Our	PRP$	O
results	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
C7D	NNP	S_Disease
is	VBZ	O
heterogeneous	JJ	O
like	IN	O
most	JJS	O
of	IN	O
the	DT	O
other	JJ	O
deficiencies	NNS	B_Disease
of	IN	I_Disease
complement	JJ	I_Disease
components	NNS	E_Disease
.	.	O
.	.	O

HPRT	NNP	B_Disease
-	:	I_Disease
APRT	NNP	I_Disease
-	:	I_Disease
deficient	NN	E_Disease
mice	NNS	O
are	VBP	O
not	RB	O
a	DT	O
model	NN	O
for	IN	O
lesch	JJ	B_Disease
-	:	I_Disease
nyhan	JJ	I_Disease
syndrome	NN	E_Disease
.	.	O

Complete	JJ	B_Disease
hypoxanthine	NN	I_Disease
-	:	I_Disease
guanine	NN	I_Disease
phosphoribosyl	NN	I_Disease
-	:	I_Disease
transferase	NN	I_Disease
(	(	I_Disease
HPRT	NNP	I_Disease
)	)	I_Disease
deficiency	NN	E_Disease
in	IN	O
humans	NNS	O
results	NNS	O
in	IN	O
the	DT	O
Lesch	NNP	B_Disease
-	:	I_Disease
Nyhan	NNP	I_Disease
syndrome	NN	E_Disease
which	WDT	O
is	VBZ	O
characterized	VBN	O
,	,	O
among	IN	O
other	JJ	O
features	NNS	O
,	,	O
by	IN	O
compulsive	JJ	O
self	NN	O
-	:	O
injurious	JJ	O
behavior	NN	O
.	.	O

HPRT	NNP	B_Disease
-	:	I_Disease
deficient	NN	E_Disease
mice	NN	O
generated	VBD	O
using	VBG	O
mouse	NN	O
embryonic	JJ	O
stem	NN	O
cells	NNS	O
exhibit	VBP	O
none	NN	O
of	IN	O
the	DT	O
behavioral	JJ	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
Lesch	NNP	B_Disease
-	:	I_Disease
Nyhan	NNP	I_Disease
syndrome	NN	E_Disease
.	.	O

Administration	NN	O
of	IN	O
drugs	NNS	O
that	WDT	O
inhibit	VBP	O
adenine	JJ	O
phosphoribosyltransferase	NN	O
(	(	O
APRT	NNP	O
)	)	O
in	IN	O
HPRT	NNP	B_Disease
-	:	I_Disease
deficient	NN	E_Disease
mice	NN	O
has	VBZ	O
produced	VBN	O
the	DT	O
suggestion	NN	O
that	IN	O
deficiency	NN	B_Disease
of	IN	I_Disease
APRT	NNP	E_Disease
in	IN	O
combination	NN	O
with	IN	O
HPRT	NNP	B_Disease
-	:	I_Disease
deficiency	NN	E_Disease
in	IN	O
mice	NN	O
may	MD	O
lead	VB	O
to	TO	O
self	VB	O
-	:	O
mutilation	NN	O
behavior	NN	O
[	NNP	O
C	NNP	O
.	.	O

L	NNP	O
.	.	O

Wu	NNP	O
and	CC	O
D	NNP	O
.	.	O

W	NNP	O
.	.	O

Melton	NNP	O
(	(	O
1993	CD	O
)	)	O
Nature	NN	O
Genet	NNP	O
.	.	O

3	CD	O
,	,	O
235	CD	O
-	:	O
240	CD	O
]	NN	O
.	.	O

To	TO	O
test	VB	O
this	DT	O
proposition	NN	O
,	,	O
we	PRP	O
bred	VBD	O
HPRT	NNP	B_Disease
-	:	I_Disease
APRT	NNP	I_Disease
-	:	I_Disease
deficient	NN	E_Disease
mice	NN	O
.	.	O

Although	IN	O
the	DT	O
doubly	RB	O
-	:	O
deficient	NN	O
mice	NN	O
excrete	JJ	O
adenine	NN	O
and	CC	O
its	PRP$	O
highly	RB	O
insoluble	JJ	O
derivative	NN	O
,	,	O
2	CD	O
,	,	O
8	CD	O
-	:	O
dihydroxyadenine	NN	O
,	,	O
which	WDT	O
are	VBP	O
also	RB	O
associated	VBN	O
with	IN	O
human	JJ	O
APRT	NNP	B_Disease
deficiency	NN	E_Disease
,	,	O
additional	JJ	O
abnormalities	NNS	O
or	CC	O
any	DT	O
self	JJ	O
-	:	O
injurious	JJ	O
behavior	NN	O
were	VBD	O
not	RB	O
detected	VBN	O
.	.	O

Thus	RB	O
,	,	O
APRT	NNP	B_Disease
-	:	I_Disease
HPRT	NNP	I_Disease
-	:	I_Disease
deficient	NN	E_Disease
mice	NN	O
,	,	O
which	WDT	O
are	VBP	O
devoid	NNS	O
of	IN	O
any	DT	O
purine	JJ	O
salvage	NN	O
pathways	NNS	O
,	,	O
show	VBP	O
no	DT	O
novel	JJ	O
phenotype	NN	O
and	CC	O
are	VBP	O
not	RB	O
a	DT	O
model	NN	O
for	IN	O
the	DT	O
behavioral	JJ	B_Disease
abnormalities	NNS	E_Disease
associated	VBN	O
with	IN	O
the	DT	O
Lesch	NNP	B_Disease
-	:	I_Disease
Nyhan	NNP	I_Disease
syndrome	NN	E_Disease
as	IN	O
previously	RB	O
suggested	VBN	O

Somatic	JJ	O
alterations	NNS	O
of	IN	O
the	DT	O
DPC4	NNP	O
gene	NN	O
in	IN	O
human	JJ	O
colorectal	NN	B_Disease
cancers	NNS	E_Disease
in	IN	O
vivo	NN	O
.	.	O

BACKGROUND	NNP	O
&	CC	O
AIMS	NNP	O
The	DT	O
chromosome	NN	O
region	NN	O
18q21	CD	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
frequently	RB	O
deleted	VBN	O
in	IN	O
colorectal	JJ	B_Disease
cancers	NNS	E_Disease
,	,	O
and	CC	O
such	JJ	O
frequent	JJ	O
allelic	JJ	O
loss	NN	O
is	VBZ	O
a	DT	O
hallmark	NN	O
of	IN	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
tumor	NN	O
-	:	O
suppressor	NN	O
gene	NN	O
.	.	O

The	DT	O
DPC4	NNP	O
gene	NN	O
,	,	O
which	WDT	O
is	VBZ	O
located	VBN	O
at	IN	O
18q21	CD	O
,	,	O
has	VBZ	O
been	VBN	O
identified	VBN	O
as	IN	O
a	DT	O
tumor	NN	O
-	:	O
suppressor	NN	O
gene	NN	O
from	IN	O
examination	NN	O
of	IN	O
pancreatic	JJ	B_Disease
cancers	NNS	E_Disease
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
it	PRP	O
might	MD	O
also	RB	O
be	VB	O
altered	VBN	O
in	IN	O
colorectal	JJ	B_Disease
cancers	NNS	E_Disease
.	.	O

METHODS	NNP	O
Mutation	NNP	O
analyses	NNS	O
of	IN	O
the	DT	O
DPC4	NNP	O
gene	NN	O
were	VBD	O
performed	VBN	O
on	IN	O
complementary	JJ	O
DNA	NN	O
samples	NNS	O
from	IN	O
31	CD	O
primary	JJ	O
colorectal	JJ	B_Disease
cancer	NN	E_Disease
specimens	VBZ	O
using	VBG	O
a	DT	O
combination	NN	O
of	IN	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
,	,	O
single	JJ	O
-	:	O
strand	NN	O
conformation	NN	O
polymorphism	NN	O
,	,	O
and	CC	O
DNA	NNP	O
sequencing	NN	O
.	.	O

RESULTS	NNP	O
Four	NNP	O
missense	NN	O
mutations	NNS	O
producing	VBG	O
amino	NN	O
acid	JJ	O
substitutions	NNS	O
and	CC	O
a	DT	O
somatic	JJ	O
12	CD	O
-	:	O
base	NN	O
pair	NN	O
deletion	NN	O
in	IN	O
the	DT	O
coding	JJ	O
region	NN	O
of	IN	O
the	DT	O
DPC4	NNP	O
gene	NN	O
were	VBD	O
detected	VBN	O
in	IN	O
the	DT	O
31	CD	O
cancers	NNS	S_Disease
(	(	O
16	CD	O
%	NN	O
;	:	O
5	CD	O
of	IN	O
31	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
The	DT	O
DPC4	NNP	O
gene	NN	O
may	MD	O
play	VB	O
a	DT	O
role	NN	O
as	IN	O
a	DT	O
tumor	NN	O
-	:	O
suppressor	NN	O
gene	NN	O
in	IN	O
a	DT	O
fraction	NN	O
of	IN	O
colorectal	JJ	B_Disease
cancers	NNS	E_Disease
;	:	O
however	RB	O
,	,	O
while	IN	O
allelic	JJ	O
loss	NN	O
at	IN	O
18q21	CD	O
is	VBZ	O
very	RB	O
often	RB	O
seen	VBN	O
in	IN	O
colorectal	JJ	B_Disease
cancers	NNS	E_Disease
,	,	O
only	RB	O
a	DT	O
minority	NN	O
show	NN	O
DPC4	NNP	O
mutations	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
there	EX	O
might	MD	O
be	VB	O
another	DT	O
tumor	NN	O
-	:	O
suppressor	NN	O
gene	NN	O
in	IN	O
this	DT	O
chromosome	NN	O
region	NN	O
.	.	O
.	.	O

Pleiotropic	NNP	O
defects	NNS	O
in	IN	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
protein	SYM	O
-	:	O
deficient	NN	O
mice	NN	O
.	.	O

We	PRP	O
have	VBP	O
generated	VBN	O
a	DT	O
mouse	NN	O
model	NN	O
for	IN	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
by	IN	O
using	VBG	O
gene	NN	O
targeting	VBG	O
to	TO	O
generate	VB	O
mice	NN	O
that	WDT	O
do	VBP	O
not	RB	O
express	VB	O
the	DT	O
Atm	NNP	O
protein	NN	O
.	.	O

Atm	NNP	O
-	:	O
deficient	NN	O
mice	NN	O
are	VBP	O
retarded	VBN	O
in	IN	O
growth	NN	O
,	,	O
do	VBP	O
not	RB	O
produce	VB	O
mature	JJ	O
sperm	NN	O
,	,	O
and	CC	O
exhibit	NN	O
severe	JJ	O
defects	NNS	O
in	IN	O
T	NNP	O
cell	NN	O
maturation	NN	O
while	IN	O
going	VBG	O
on	IN	O
to	TO	O
develop	VB	O
thymomas	NN	S_Disease
.	.	O

Atm	NNP	O
-	:	O
deficient	NN	O
fibroblasts	NNS	O
grow	VBP	O
poorly	RB	O
in	IN	O
culture	NN	O
and	CC	O
display	VB	O
a	DT	O
high	JJ	O
level	NN	O
of	IN	O
double	JJ	O
-	:	O
stranded	VBD	O
chromosome	NN	O
breaks	NNS	O
.	.	O

Atm	NNP	O
-	:	O
deficient	NN	O
thymocytes	VBZ	O
undergo	RB	O
spontaneous	JJ	O
apoptosis	NN	O
in	IN	O
vitro	NN	O
significantly	RB	O
more	RBR	O
than	IN	O
controls	NNS	O
.	.	O

Atm	NNP	O
-	:	O
deficient	NN	O
mice	NN	O
then	RB	O
exhibit	VBD	O
many	JJ	O
of	IN	O
the	DT	O
same	JJ	O
symptoms	NNS	O
found	VBN	O
in	IN	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
patients	NNS	O
and	CC	O
in	IN	O
cells	NNS	O
derived	VBN	O
from	IN	O
them	PRP	O
.	.	O

Furthermore	RB	O
,	,	O
we	PRP	O
demonstrate	VBP	O
that	IN	O
the	DT	O
Atm	NNP	O
protein	NN	O
exists	VBZ	O
as	IN	O
two	CD	O
discrete	JJ	O
molecular	JJ	O
species	NNS	O
,	,	O
and	CC	O
that	IN	O
loss	NN	O
of	IN	O
one	CD	O
or	CC	O
of	IN	O
both	DT	O
of	IN	O
these	DT	O
can	MD	O
lead	VB	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O
.	.	O

The	DT	O
DCC	NNP	O
protein	NN	O
and	CC	O
prognosis	NN	O
in	IN	O
colorectal	JJ	B_Disease
cancer	NN	E_Disease
.	.	O

BACKGROUND	NNP	O
Allelic	NNP	O
loss	NN	O
of	IN	O
chromosome	NN	O
18q	CD	O
predicts	VBZ	O
a	DT	O
poor	JJ	O
outcome	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stage	NN	B_Disease
II	NNP	I_Disease
colorectal	NN	I_Disease
cancer	NN	E_Disease
.	.	O

Although	IN	O
the	DT	O
specific	JJ	O
gene	NN	O
inactivated	VBN	O
by	IN	O
this	DT	O
allelic	JJ	O
loss	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
elucidated	VBN	O
,	,	O
the	DT	O
DCC	NNP	O
(	(	O
deleted	VBN	O
in	IN	O
colorectal	JJ	B_Disease
cancer	NN	E_Disease
)	)	O
gene	NN	O
is	VBZ	O
a	DT	O
candidate	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
whether	IN	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
DCC	NNP	O
protein	NN	O
in	IN	O
tumor	NN	S_Disease
cells	NNS	O
is	VBZ	O
a	DT	O
prognostic	JJ	O
marker	NN	O
in	IN	O
colorectal	JJ	B_Disease
carcinoma	NN	E_Disease
.	.	O

METHODS	NNP	O
The	DT	O
expression	NN	O
of	IN	O
DCC	NNP	O
was	VBD	O
evaluated	VBN	O
immunohistochemically	RB	O
in	IN	O
132	CD	O
paraffin	NN	O
-	:	O
embedded	VBD	O
samples	NNS	O
from	IN	O
patients	NNS	O
with	IN	O
curatively	RB	O
resected	VBN	O
stage	NN	B_Disease
II	NNP	I_Disease
and	CC	I_Disease
III	NNP	I_Disease
colorectal	JJ	I_Disease
carcinomas	NN	E_Disease
.	.	O

The	DT	O
Cox	NNP	O
proportional	JJ	O
-	:	O
hazards	NNS	O
model	NN	O
was	VBD	O
used	VBN	O
to	TO	O
adjust	VB	O
for	IN	O
covariates	NNS	O
including	VBG	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
tumor	NN	S_Disease
site	NN	O
,	,	O
degree	NN	O
of	IN	O
tumor	NN	S_Disease
differentiation	NN	O
,	,	O
and	CC	O
use	NN	O
of	IN	O
adjuvant	JJ	O
therapy	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
expression	NN	O
of	IN	O
DCC	NNP	O
was	VBD	O
a	DT	O
strong	JJ	O
positive	JJ	O
predictive	JJ	O
factor	NN	O
for	IN	O
survival	NN	O
in	IN	O
both	DT	O
stage	NN	B_Disease
II	NNP	I_Disease
and	CC	I_Disease
stage	NN	I_Disease
III	NNP	I_Disease
colorectal	JJ	I_Disease
carcinomas	NN	E_Disease
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
stage	NN	O
II	NNP	O
disease	NN	O
whose	WP$	O
tumors	NNS	S_Disease
expressed	VBD	O
DCC	NNP	O
,	,	O
the	DT	O
five	CD	O
-	:	O
year	NN	O
survival	NN	O
rate	NN	O
was	VBD	O
94	CD	O
.	.	O

3	CD	O
percent	NN	O
,	,	O
whereas	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
DCC	NNP	B_Disease
-	:	I_Disease
negative	JJ	I_Disease
tumors	NNS	E_Disease
,	,	O
the	DT	O
survival	NN	O
rate	NN	O
was	VBD	O
61	CD	O
.	.	O

6	CD	O
percent	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0	CD	O
.	.	O

001	CD	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
stage	NN	B_Disease
III	NNP	I_Disease
disease	NN	E_Disease
,	,	O
the	DT	O
respective	JJ	O
survival	NN	O
rates	NNS	O
were	VBD	O
59	CD	O
.	.	O

3	CD	O
percent	NN	O
and	CC	O
33	CD	O
.	.	O

2	CD	O
percent	NN	O
(	(	O
P	NNP	O
=	VBZ	O
0	CD	O
.	.	O

03	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
DCC	NNP	O
is	VBZ	O
a	DT	O
prognostic	JJ	O
marker	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stage	NN	B_Disease
II	NNP	I_Disease
or	CC	I_Disease
stage	NN	I_Disease
III	NNP	I_Disease
colorectal	JJ	I_Disease
cancer	NN	E_Disease
.	.	O

In	IN	O
stage	NN	B_Disease
II	NNP	I_Disease
colorectal	NN	I_Disease
carcinomas	NN	E_Disease
,	,	O
the	DT	O
absence	NN	O
of	IN	O
DCC	NNP	O
identifies	VBZ	O
a	DT	O
subgroup	NN	O
of	IN	O
patients	NNS	O
with	IN	O
lesions	NNS	O
that	WDT	O
behave	VBP	O
like	IN	O
stage	NN	B_Disease
III	NNP	I_Disease
cancers	NNS	E_Disease
.	.	O

These	DT	O
findings	NNS	O
may	MD	O
thus	RB	O
have	VB	O
therapeutic	JJ	O
implications	NNS	O
in	IN	O
this	DT	O
group	NN	O
of	IN	O
patients	NNS	O

Association	NNP	O
of	IN	O
anxiety	NN	B_Disease
-	:	I_Disease
related	JJ	I_Disease
traits	NNS	E_Disease
with	IN	O
a	DT	O
polymorphism	NN	O
in	IN	O
the	DT	O
serotonin	NN	O
transporter	NN	O
gene	NN	O
regulatory	JJ	O
region	NN	O
.	.	O

Transporter	NNP	O
-	:	O
facilitated	VBD	O
uptake	NN	O
of	IN	O
serotonin	NN	O
(	(	O
5	CD	O
-	:	O
hydroxytryptamine	NN	O
or	CC	O
5	CD	O
-	:	O
HT	NN	O
)	)	O
has	VBZ	O
been	VBN	O
implicated	VBN	O
in	IN	O
anxiety	NN	S_Disease
in	IN	O
humans	NNS	O
and	CC	O
animal	JJ	O
models	NNS	O
and	CC	O
is	VBZ	O
the	DT	O
site	NN	O
of	IN	O
action	NN	O
of	IN	O
widely	RB	O
used	VBN	O
uptake	JJ	O
-	:	O
inhibiting	NN	O
antidepressant	NN	O
and	CC	O
antianxiety	NN	O
drugs	NNS	O
.	.	O

Human	NNP	O
5	CD	O
-	:	O
HT	NN	O
transporter	NN	O
(	(	O
5	CD	O
-	:	O
HTT	NN	O
)	)	O
gene	NN	O
transcription	NN	O
is	VBZ	O
modulated	VBN	O
by	IN	O
a	DT	O
common	JJ	O
polymorphism	NN	O
in	IN	O
its	PRP$	O
upstream	JJ	O
regulatory	JJ	O
region	NN	O
.	.	O

The	DT	O
short	JJ	O
variant	NN	O
of	IN	O
the	DT	O
polymorphism	NN	O
reduces	VBZ	O
the	DT	O
transcriptional	JJ	O
efficiency	NN	O
of	IN	O
the	DT	O
5	CD	O
-	:	O
HTT	NNP	O
gene	NN	O
promoter	NN	O
,	,	O
resulting	VBG	O
in	IN	O
decreased	JJ	O
5	CD	O
-	:	O
HTT	NNP	O
expression	NN	O
and	CC	O
5	CD	O
-	:	O
HT	NNP	O
uptake	VBP	O
in	IN	O
lymphoblasts	NNS	O
.	.	O

Association	NNP	O
studies	NNS	O
in	IN	O
two	CD	O
independent	JJ	O
samples	NNS	O
totaling	VBG	O
505	CD	O
individuals	NNS	O
revealed	VBD	O
that	IN	O
the	DT	O
5	CD	O
-	:	O
HTT	NNP	O
polymorphism	NN	O
accounts	NNS	O
for	IN	O
3	CD	O
to	TO	O
4	CD	O
percent	NN	O
of	IN	O
total	JJ	O
variation	NN	O
and	CC	O
7	CD	O
to	TO	O
9	CD	O
percent	NN	O
of	IN	O
inherited	JJ	O
variance	NN	O
in	IN	O
anxiety	NN	B_Disease
-	:	I_Disease
related	JJ	I_Disease
personality	NN	I_Disease
traits	NNS	E_Disease
in	IN	O
individuals	NNS	O
as	RB	O
well	RB	O
as	IN	O
sibships	NNS	O
.	.	O
.	.	O

Phenotypic	NNP	O
and	CC	O
genotypic	VB	O
overlap	NN	O
between	IN	O
atelosteogenesis	NN	B_Disease
type	NN	I_Disease
2	CD	E_Disease
and	CC	O
diastrophic	JJ	B_Disease
dysplasia	NN	E_Disease
.	.	O

Mutations	NNS	O
in	IN	O
the	DT	O
diastrophic	JJ	B_Disease
dysplasia	NN	E_Disease
sulfate	NN	O
transporter	NN	O
gene	NN	O
DTDST	NNP	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
a	DT	O
family	NN	O
of	IN	O
chondrodysplasias	NN	S_Disease
that	WDT	O
comprises	VBZ	O
,	,	O
in	IN	O
order	NN	O
of	IN	O
increasing	VBG	O
severity	NN	O
,	,	O
diastrophic	JJ	B_Disease
dysplasia	NN	E_Disease
(	(	O
DTD	NNP	S_Disease
)	)	O
,	,	O
atelosteogenesis	NN	B_Disease
type	NN	I_Disease
2	CD	E_Disease
(	(	O
AO2	NNP	S_Disease
)	)	O
,	,	O
and	CC	O
achondrogenesis	NN	B_Disease
type	NN	I_Disease
1B	CD	E_Disease
(	(	O
ACG1B	NNP	S_Disease
)	)	O
.	.	O

To	TO	O
learn	VB	O
more	JJR	O
about	IN	O
the	DT	O
molecular	JJ	O
basis	NN	O
of	IN	O
DTDST	NNP	B_Disease
chondrodysplasias	NN	E_Disease
and	CC	O
about	IN	O
genotype	JJ	O
-	:	O
phenotype	NN	O
correlations	NNS	O
,	,	O
we	PRP	O
studied	VBD	O
fibroblast	JJ	O
cultures	NNS	O
of	IN	O
three	CD	O
new	JJ	O
patients	NNS	O
one	CD	O
with	IN	O
AO	NNP	B_Disease
-	:	I_Disease
2	CD	E_Disease
,	,	O
one	CD	O
with	IN	O
DTD	NNP	S_Disease
,	,	O
and	CC	O
one	CD	O
with	IN	O
an	DT	O
intermediate	JJ	O
phenotype	NN	O
(	(	O
AO2	NNP	S_Disease
/	NNP	O
DTD	NNP	S_Disease
)	)	O
.	.	O

Reduced	VBN	O
incorporation	NN	O
of	IN	O
inorganic	JJ	O
sulfate	NN	O
into	IN	O
macromolecules	NNS	O
was	VBD	O
found	VBN	O
in	IN	O
all	DT	O
three	CD	O
.	.	O

Each	DT	O
of	IN	O
the	DT	O
three	CD	O
patients	NNS	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
heterozygous	JJ	O
for	IN	O
a	DT	O
c862t	JJ	O
transition	NN	O
predicting	VBG	O
a	DT	O
R279W	NNP	O
substitution	NN	O
in	IN	O
the	DT	O
third	JJ	O
extracellular	JJ	O
loop	NN	O
of	IN	O
DTDST	NNP	O
.	.	O

In	IN	O
two	CD	O
patients	NNS	O
(	(	O
DTD	NNP	S_Disease
and	CC	O
AO2	NNP	S_Disease
/	NNP	O
DTD	NNP	S_Disease
)	)	O
,	,	O
no	DT	O
other	JJ	O
structural	JJ	O
mutation	NN	O
was	VBD	O
found	VBN	O
,	,	O
but	CC	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
amplification	NN	O
and	CC	O
single	JJ	O
-	:	O
strand	NN	O
conformation	NN	O
polymorphism	NN	O
analysis	NN	O
of	IN	O
fibroblast	NN	O
cDNA	NN	O
showed	VBD	O
reduced	VBN	O
mRNA	NN	O
levels	NNS	O
of	IN	O
the	DT	O
wild	JJ	O
-	:	O
type	NN	O
DTDST	NNP	O
allele	IN	O
these	DT	O
two	CD	O
patients	NNS	O
may	MD	O
be	VB	O
compound	VBN	O
heterozygotes	NNS	O
for	IN	O
the	DT	O
"	NNP	O
Finnish	NNP	O
"	NNP	O
mutation	NN	O
(	(	O
as	IN	O
yet	RB	O
uncharacterized	VBN	O
at	IN	O
the	DT	O
DNA	NNP	O
level	NN	O
)	)	O
,	,	O
which	WDT	O
causes	VBZ	O
reduced	JJ	O
expression	NN	O
of	IN	O
DTDST	NNP	O
.	.	O

The	DT	O
third	JJ	O
patient	NN	O
(	(	O
with	IN	O
AO2	NNP	S_Disease
)	)	O
had	VBD	O
the	DT	O
R279W	NNP	O
mutation	NN	O
compounded	VBD	O
with	IN	O
a	DT	O
novel	JJ	O
mutation	NN	O
,	,	O
the	DT	O
deletion	NN	O
of	IN	O
cytosine	NN	O
418	CD	O
(	(	O
delta	JJ	O
c418	NN	O
)	)	O
,	,	O
predicting	VBG	O
a	DT	O
frameshift	NN	O
with	IN	O
premature	JJ	O
termination	NN	O
.	.	O

Also	RB	O
the	DT	O
delta	NN	O
c418	NN	O
allele	NN	O
was	VBD	O
underrepresented	VBN	O
in	IN	O
the	DT	O
cDNA	NN	O
,	,	O
in	IN	O
accordance	NN	O
with	IN	O
previous	JJ	O
observations	NNS	O
that	IN	O
premature	NN	O
stop	VB	O
codons	NNS	O
reduce	VB	O
mRNA	NN	O
levels	NNS	O
.	.	O

The	DT	O
presence	NN	O
of	IN	O
the	DT	O
DTDST	NNP	O
R279W	NNP	O
mutation	NN	O
in	IN	O
a	DT	O
total	NN	O
of	IN	O
11	CD	O
patients	NNS	O
with	IN	O
AO2	NNP	S_Disease
or	CC	O
DTD	NNP	S_Disease
emphasizes	VBZ	O
the	DT	O
overlap	NN	O
between	IN	O
these	DT	O
conditions	NNS	O
.	.	O

This	DT	O
mutation	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
found	VBN	O
so	RB	O
far	RB	O
in	IN	O
8	CD	O
analyzed	JJ	O
ACG1B	NNP	S_Disease
patients	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
it	PRP	O
allows	VBZ	O
some	DT	O
residual	JJ	O
activity	NN	O
of	IN	O
the	DT	O
sulfate	NN	O
transporter	NN	O
.	.	O
.	.	O

Identification	NN	O
of	IN	O
WASP	NNP	O
mutations	NNS	O
,	,	O
mutation	NN	O
hotspots	NNS	O
and	CC	O
genotype	JJ	O
-	:	O
phenotype	NN	O
disparities	NNS	O
in	IN	O
24	CD	O
patients	NNS	O
with	IN	O
the	DT	O
Wiskott	NNP	B_Disease
-	:	I_Disease
Aldrich	NNP	I_Disease
syndrome	NN	E_Disease
.	.	O

The	DT	O
Wiskott	NNP	B_Disease
-	:	I_Disease
Aldrich	NNP	I_Disease
syndrome	NN	E_Disease
(	(	O
WAS	NNP	S_Disease
)	)	O
,	,	O
an	DT	O
X	NNP	B_Disease
-	:	I_Disease
linked	VBN	I_Disease
immunodeficiency	NN	I_Disease
disease	NN	E_Disease
caused	VBN	O
by	IN	O
mutation	NN	O
in	IN	O
the	DT	O
recently	RB	O
isolated	VBN	O
gene	NN	O
encoding	VBG	O
WAS	NNP	S_Disease
protein	NN	O
(	(	O
WASP	NNP	O
)	)	O
,	,	O
is	VBZ	O
known	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
extensive	JJ	O
clinical	JJ	O
heterogeneity	NN	O
.	.	O

Cumulative	JJ	O
mutation	NN	O
data	NNS	O
have	VBP	O
revealed	VBN	O
that	IN	O
WASP	NNP	O
genotypes	NNS	O
are	VBP	O
also	RB	O
highly	RB	O
variable	JJ	O
among	IN	O
WAS	JJ	S_Disease
patients	NNS	O
,	,	O
but	CC	O
the	DT	O
relationship	NN	O
of	IN	O
phenotype	NN	O
with	IN	O
genotype	NN	O
in	IN	O
this	DT	O
disease	NN	O
remains	VBZ	O
unclear	JJ	O
.	.	O

To	TO	O
address	VB	O
this	DT	O
issue	NN	O
we	PRP	O
characterized	VBD	O
WASP	NNP	O
mutations	NNS	O
in	IN	O
24	CD	O
unrelated	JJ	O
WAS	NNP	S_Disease
patients	NNS	O
,	,	O
including	VBG	O
18	CD	O
boys	NNS	O
with	IN	O
severe	JJ	O
classical	NN	O
WAS	NNP	S_Disease
and	CC	O
6	CD	O
boys	NNS	O
expressing	VBG	O
mild	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
disease	NN	O
,	,	O
and	CC	O
then	RB	O
examined	VBD	O
the	DT	O
degree	NN	O
of	IN	O
correlation	NN	O
of	IN	O
these	DT	O
as	RB	O
well	RB	O
as	IN	O
all	DT	O
previously	RB	O
published	VBN	O
WASP	NNP	O
mutations	NNS	O
with	IN	O
disease	NN	O
severity	NN	O
.	.	O

By	IN	O
analysis	NN	O
of	IN	O
these	DT	O
compiled	VBN	O
mutation	NN	O
data	NNS	O
,	,	O
we	PRP	O
demonstrated	VBD	O
clustering	VBG	O
of	IN	O
WASP	NNP	O
mutations	NNS	O
within	IN	O
the	DT	O
four	CD	O
most	JJS	O
N	NNP	O
-	:	O
terminal	JJ	O
exons	NNS	O
of	IN	O
the	DT	O
gene	NN	O
and	CC	O
also	RB	O
identified	VBD	O
several	JJ	O
sites	NNS	O
within	IN	O
this	DT	O
region	NN	O
as	IN	O
hotspots	NNS	O
for	IN	O
WASP	NNP	O
mutation	NN	O
.	.	O

These	DT	O
characteristics	NNS	O
were	VBD	O
observed	VBN	O
,	,	O
however	RB	O
,	,	O
in	IN	O
both	DT	O
severe	JJ	O
and	CC	O
mild	JJ	O
cases	NNS	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

Similarly	RB	O
,	,	O
while	IN	O
the	DT	O
cumulative	JJ	O
data	NNS	O
revealed	VBD	O
a	DT	O
predominance	NN	O
of	IN	O
missense	JJ	O
mutations	NNS	O
among	IN	O
the	DT	O
WASP	NNP	O
gene	NN	O
lesions	NNS	O
observed	VBN	O
in	IN	O
boys	NNS	O
with	IN	O
isolated	JJ	B_Disease
thrombocytopenia	NN	E_Disease
,	,	O
missense	JJ	O
mutations	NNS	O
were	VBD	O
not	RB	O
exclusively	RB	O
associated	VBN	O
with	IN	O
milder	NN	O
WAS	NNP	S_Disease
phenotypes	NNS	O
,	,	O
but	CC	O
also	RB	O
comprised	VBD	O
a	DT	O
substantial	JJ	O
portion	NN	O
(	(	O
38	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
WASP	NNP	O
gene	NN	O
defects	NNS	O
found	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
disease	NN	O
.	.	O

These	DT	O
findings	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
detection	NN	O
of	IN	O
identical	JJ	O
WASP	NNP	O
mutations	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
disparate	JJ	O
phenotypes	NNS	O
,	,	O
reveal	VB	O
a	DT	O
lack	NN	O
of	IN	O
phenotype	JJ	O
concordance	NN	O
with	IN	O
genotype	NN	O
in	IN	O
WAS	NNP	S_Disease
and	CC	O
thus	RB	O
imply	VB	O
that	DT	O
phenotypic	NN	O
outcome	NN	O
in	IN	O
this	DT	O
disease	NN	O
cannot	NN	O
be	VB	O
reliably	RB	O
predicted	VBN	O
solely	RB	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
WASP	NNP	O
genotypes	NNS	O
.	.	O
.	.	O

Germline	NNP	O
mutations	NNS	O
in	IN	O
the	DT	O
3	CD	O
'	POS	O
part	NN	O
of	IN	O
APC	NNP	S_Disease
exon	FW	O
15	CD	O
do	VBP	O
not	RB	O
result	VB	O
in	IN	O
truncated	JJ	O
proteins	NNS	O
and	CC	O
are	VBP	O
associated	VBN	O
with	IN	O
attenuated	JJ	O
adenomatous	JJ	B_Disease
polyposis	NN	I_Disease
coli	NN	E_Disease
.	.	O

Familial	NNP	B_Disease
adenomatous	JJ	I_Disease
polyposis	NN	E_Disease
(	(	O
FAP	NNP	S_Disease
)	)	O
is	VBZ	O
an	DT	O
inherited	JJ	O
predisposition	NN	O
to	TO	O
colorectal	JJ	B_Disease
cancer	NN	E_Disease
characterized	VBN	O
by	IN	O
the	DT	O
development	NN	O
of	IN	O
numerous	JJ	O
adenomatous	JJ	B_Disease
polyps	NNS	E_Disease
predominantly	RB	O
in	IN	O
the	DT	O
colorectal	JJ	O
region	NN	O
.	.	O

Germline	NNP	O
mutations	NNS	O
in	IN	O
the	DT	O
adenomatous	JJ	B_Disease
polyposis	NN	I_Disease
coli	NN	E_Disease
(	(	O
APC	NNP	S_Disease
)	)	O
gene	NN	O
are	VBP	O
responsible	JJ	O
for	IN	O
most	JJS	O
cases	NNS	O
of	IN	O
FAP	NNP	S_Disease
.	.	O

Mutations	NNS	O
at	IN	O
the	DT	O
5	CD	O
end	NN	O
of	IN	O
APC	NNP	S_Disease
are	VBP	O
known	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
a	DT	O
relatively	RB	O
mild	JJ	O
form	NN	O
of	IN	O
the	DT	O
disease	NN	O
,	,	O
called	VBN	O
attenuated	VBD	B_Disease
adenomatous	JJ	I_Disease
polyposis	NN	I_Disease
coli	NN	E_Disease
(	(	O
AAPC	NNP	S_Disease
)	)	O
.	.	O

We	PRP	O
identified	VBD	O
a	DT	O
frameshift	JJ	O
mutation	NN	O
in	IN	O
the	DT	O
3	CD	O
part	NN	O
of	IN	O
exon	NN	O
15	CD	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
stop	JJ	O
codon	NN	O
at	IN	O
1862	CD	O
,	,	O
in	IN	O
a	DT	O
large	JJ	O
Dutch	NN	O
kindred	VBD	O
with	IN	O
AAPC	NNP	S_Disease
.	.	O

Western	JJ	O
blot	NN	O
analysis	NN	O
of	IN	O
lymphoblastoid	NN	O
cell	NN	O
lines	NNS	O
derived	VBN	O
from	IN	O
affected	JJ	O
family	NN	O
members	NNS	O
from	IN	O
this	DT	O
kindred	VBN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
from	IN	O
a	DT	O
previously	RB	O
reported	VBN	O
Swiss	JJ	O
family	NN	O
carrying	VBG	O
a	DT	O
frameshift	NN	O
mutation	NN	O
at	IN	O
codon	NN	O
1987	CD	O
and	CC	O
displaying	VBG	O
a	DT	O
similar	JJ	O
attenuated	JJ	O
phenotype	NN	O
,	,	O
showed	VBD	O
only	RB	O
the	DT	O
wild	JJ	O
-	:	O
type	NN	O
APC	NNP	S_Disease
protein	NN	O
.	.	O

Our	PRP$	O
study	NN	O
indicates	VBZ	O
that	IN	O
chain	NN	O
-	:	O
terminating	NN	O
mutations	NNS	O
located	VBN	O
in	IN	O
the	DT	O
3	CD	O
part	NN	O
of	IN	O
APC	NNP	S_Disease
do	VBP	O
not	RB	O
result	VB	O
in	IN	O
detectable	JJ	O
truncated	JJ	O
polypeptides	NNS	O
and	CC	O
we	PRP	O
hypothesize	VBP	O
that	IN	O
this	DT	O
is	VBZ	O
likely	JJ	O
to	TO	O
be	VB	O
the	DT	O
basis	NN	O
for	IN	O
the	DT	O
observed	JJ	O
AAPC	NNP	S_Disease
phenotype	NN	O
.	.	O
.	.	O

Complete	JJ	O
genomic	JJ	O
sequence	NN	O
and	CC	O
analysis	NN	O
of	IN	O
117	CD	O
kb	NN	O
of	IN	O
human	JJ	O
DNA	NNP	O
containing	VBG	O
the	DT	O
gene	NN	O
BRCA1	NNP	O
.	.	O

Over	IN	O
100	CD	O
distinct	JJ	O
disease	NN	O
-	:	O
associated	VBN	O
mutations	NNS	O
have	VBP	O
been	VBN	O
identified	VBN	O
in	IN	O
the	DT	O
breast	NN	B_Disease
-	:	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
susceptibility	NN	O
gene	NN	O
BRCA1	NNP	O
.	.	O

Loss	NNP	O
of	IN	O
the	DT	O
wild	JJ	O
-	:	O
type	NN	O
allele	NN	O
in	IN	O
>	JJ	O
90	CD	O
%	NN	O
of	IN	O
tumors	NNS	S_Disease
from	IN	O
patients	NNS	O
with	IN	O
inherited	JJ	O
BRCA1	NNP	O
mutations	NNS	O
indicates	VBZ	O
tumor	JJ	S_Disease
suppressive	JJ	O
function	NN	O
.	.	O

The	DT	O
low	JJ	O
incidence	NN	O
of	IN	O
somatic	JJ	O
mutations	NNS	O
suggests	VBZ	O
that	IN	O
BRCA1	NNP	O
inactivation	NN	O
in	IN	O
sporadic	JJ	O
tumors	NNS	S_Disease
occurs	VBN	O
by	IN	O
alternative	JJ	O
mechanisms	NNS	O
,	,	O
such	JJ	O
as	IN	O
interstitial	JJ	O
chromosomal	JJ	O
deletion	NN	O
or	CC	O
reduced	JJ	O
transcription	NN	O
.	.	O

To	TO	O
identify	VB	O
possible	JJ	O
features	NNS	O
of	IN	O
the	DT	O
BRCA1	NNP	O
genomic	JJ	O
region	NN	O
that	WDT	O
may	MD	O
contribute	VB	O
to	TO	O
chromosomal	JJ	O
instability	NN	O
as	RB	O
well	RB	O
as	IN	O
potential	JJ	O
transcriptional	JJ	O
regulatory	JJ	O
elements	NNS	O
,	,	O
a	DT	O
117	CD	O
,	,	O
143	CD	O
-	:	O
bp	NN	O
DNA	NNP	O
sequence	NN	O
encompassing	VBG	O
BRCA1	NNP	O
was	VBD	O
obtained	VBN	O
by	IN	O
random	JJ	O
sequencing	NN	O
of	IN	O
four	CD	O
cosmids	NNS	O
identified	VBN	O
from	IN	O
a	DT	O
human	JJ	O
chromosome	NN	O
17	CD	O
specific	JJ	O
library	NN	O
.	.	O

The	DT	O
24	CD	O
exons	NNS	O
of	IN	O
BRCA1	NNP	O
span	VBP	O
an	DT	O
81	CD	O
-	:	O
kb	NN	O
region	NN	O
that	WDT	O
has	VBZ	O
an	DT	O
unusually	RB	O
high	JJ	O
density	NN	O
of	IN	O
Alu	NNP	O
repetitive	JJ	O
DNA	NNP	O
(	(	O
41	CD	O
.	.	O

5	CD	O
%	NN	O
)	)	O
,	,	O
but	CC	O
relatively	RB	O
low	JJ	O
density	NN	O
(	(	O
4	CD	O
.	.	O

8	CD	O
%	NN	O
)	)	O
of	IN	O
other	JJ	O
repetitive	JJ	O
sequences	NNS	O
.	.	O

BRCA1	NNP	O
intron	NN	O
lengths	NNS	O
range	VBP	O
in	IN	O
size	NN	O
from	IN	O
403	CD	O
bp	NN	O
to	TO	O
9	CD	O
.	.	O

2	CD	O
kb	NN	O
and	CC	O
contain	VB	O
the	DT	O
intragenic	JJ	O
microsatellite	NN	O
markers	NNS	O
D17S1323	NNP	O
,	,	O
D17S1322	NNP	O
,	,	O
and	CC	O
D17S855	NNP	O
,	,	O
which	WDT	O
localize	VBP	O
to	TO	O
introns	NNS	O
12	CD	O
,	,	O
19	CD	O
,	,	O
and	CC	O
20	CD	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
BRCA1	NNP	O
,	,	O
the	DT	O
contig	NN	O
contains	VBZ	O
two	CD	O
complete	JJ	O
genes	NNS	O
Rho7	NNP	O
,	,	O
a	DT	O
member	NN	O
of	IN	O
the	DT	O
rho	JJ	O
family	NN	O
of	IN	O
GTP	NNP	O
binding	VBG	O
proteins	NNS	O
,	,	O
and	CC	O
VAT1	NNP	O
,	,	O
an	DT	O
abundant	JJ	O
membrane	NN	O
protein	NN	O
of	IN	O
cholinergic	JJ	O
synaptic	JJ	O
vesicles	NNS	O
.	.	O

Partial	JJ	O
sequences	NNS	O
of	IN	O
the	DT	O
1A1	CD	O
-	:	O
3B	CD	O
B	NNP	O
-	:	O
box	NN	O
protein	NN	O
pseudogene	NN	O
and	CC	O
IFP	NNP	O
35	CD	O
,	,	O
an	DT	O
interferon	NN	O
induced	VBD	O
leucine	JJ	O
zipper	NN	O
protein	NN	O
,	,	O
reside	VB	O
within	IN	O
the	DT	O
contig	NN	O
.	.	O

An	DT	O
L21	NNP	O
ribosomal	NN	O
protein	NN	O
pseudogene	NN	O
is	VBZ	O
embedded	VBN	O
in	IN	O
BRCA1	NNP	O
intron	NN	O
13	CD	O
.	.	O

The	DT	O
order	NN	O
of	IN	O
genes	NNS	O
on	IN	O
the	DT	O
chromosome	NN	O
is	VBZ	O
centromere	JJ	O
-	:	O
1FP	CD	O
35	CD	O
-	:	O
VAT1	NNP	O
-	:	O
Rho7	NNP	O
-	:	O
BRCA1	NNP	O
-	:	O
1A1	CD	O
-	:	O
3B	CD	O
-	:	O
telomere	NN	O

Identification	NN	O
of	IN	O
a	DT	O
RING	NNP	O
protein	NN	O
that	WDT	O
can	MD	O
interact	VB	O
in	IN	O
vivo	NN	O
with	IN	O
the	DT	O
BRCA1	NNP	O
gene	NN	O
product	NN	O
.	.	O

The	DT	O
hereditary	JJ	B_Disease
breast	NN	I_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
gene	NN	O
,	,	O
BRCA1	NNP	O
,	,	O
encodes	VBZ	O
a	DT	O
large	JJ	O
polypeptide	NN	O
that	WDT	O
contains	VBZ	O
the	DT	O
cysteine	NN	O
-	:	O
rich	JJ	O
RING	NNP	O
motif	NN	O
,	,	O
a	DT	O
zinc	NN	O
-	:	O
binding	NN	O
domain	NN	O
found	VBD	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
regulatory	JJ	O
proteins	NNS	O
.	.	O

Here	RB	O
we	PRP	O
describe	VBP	O
a	DT	O
novel	JJ	O
protein	NN	O
that	WDT	O
interacts	VBZ	O
in	IN	O
vivo	NN	O
with	IN	O
the	DT	O
N	NNP	O
-	:	O
terminal	JJ	O
region	NN	O
of	IN	O
BRCA1	NNP	O
.	.	O

This	DT	O
BRCA1	NNP	O
-	:	O
associated	VBD	O
RING	NNP	O
domain	NN	O
(	(	O
BARD1	NNP	O
)	)	O
protein	NN	O
contains	VBZ	O
an	DT	O
N	NNP	O
-	:	O
terminal	JJ	O
RING	NN	O
motif	NN	O
,	,	O
three	CD	O
tandem	NN	O
ankyrin	NN	O
repeats	NNS	O
,	,	O
and	CC	O
a	DT	O
C	NNP	O
-	:	O
terminal	JJ	O
sequence	NN	O
with	IN	O
significant	JJ	O
homology	NN	O
to	TO	O
the	DT	O
phylogenetically	RB	O
conserved	VBN	O
BRCT	NNP	O
domains	VBZ	O
that	IN	O
lie	NN	O
near	IN	O
the	DT	O
C	NNP	O
terminus	NN	O
of	IN	O
BRCA1	NNP	O
.	.	O

The	DT	O
BARD1	NNP	O
/	NNP	O
BRCA1	NNP	O
interaction	NN	O
is	VBZ	O
disrupted	VBN	O
by	IN	O
BRCA1	NNP	O
missense	NN	O
mutations	NNS	O
that	WDT	O
segregate	VBP	O
with	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
susceptibility	NN	O
,	,	O
indicating	VBG	O
that	IN	O
BARD1	NNP	O
may	MD	O
be	VB	O
involved	VBN	O
in	IN	O
mediating	VBG	O
tumour	JJ	S_Disease
suppression	NN	O
by	IN	O
BRCA1	NNP	O
.	.	O
.	.	O

Detection	NN	O
of	IN	O
heterozygous	JJ	O
mutations	NNS	O
in	IN	O
BRCA1	NNP	O
using	VBG	O
high	JJ	O
density	NN	O
oligonucleotide	VBP	O
arrays	NNS	O
and	CC	O
two	CD	O
-	:	O
colour	NN	O
fluorescence	NN	O
analysis	NN	O
.	.	O

The	DT	O
ability	NN	O
to	TO	O
scan	VB	O
a	DT	O
large	JJ	O
gene	NN	O
rapidly	RB	O
and	CC	O
accurately	RB	O
for	IN	O
all	DT	O
possible	JJ	O
heterozygous	JJ	O
mutations	NNS	O
in	IN	O
large	JJ	O
numbers	NNS	O
of	IN	O
patient	NN	O
samples	NNS	O
will	MD	O
be	VB	O
critical	JJ	O
for	IN	O
the	DT	O
future	NN	O
of	IN	O
medicine	NN	O
.	.	O

We	PRP	O
have	VBP	O
designed	VBN	O
high	JJ	O
-	:	O
density	NN	O
arrays	VBZ	O
consisting	VBG	O
of	IN	O
over	IN	O
96	CD	O
,	,	O
600	CD	O
oligonucleotides	NNS	O
20	CD	O
-	:	O
nucleotides	NNS	O
(	(	O
nt	NN	O
)	)	O
in	IN	O
length	NN	O
to	TO	O
screen	VB	O
for	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
heterozygous	JJ	O
mutations	NNS	O
in	IN	O
the	DT	O
3	CD	O
.	.	O

45	CD	O
-	:	O
kilobases	NNS	O
(	(	O
kb	NN	O
)	)	O
exon	VBZ	O
11	CD	O
of	IN	O
the	DT	O
hereditary	JJ	B_Disease
breast	NN	I_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
gene	NN	O
BRCA1	NNP	O
.	.	O

Reference	NN	O
and	CC	O
test	NN	O
samples	NNS	O
were	VBD	O
co	JJ	O
-	:	O
hybridized	VBN	O
to	TO	O
these	DT	O
arrays	NNS	O
and	CC	O
differences	NNS	O
in	IN	O
hybridization	NN	O
patterns	NNS	O
quantitated	VBN	O
by	IN	O
two	CD	O
-	:	O
colour	NN	O
analysis	NN	O
.	.	O

Fourteen	NNP	O
of	IN	O
fifteen	JJ	O
patient	NN	O
samples	NNS	O
with	IN	O
known	JJ	O
mutations	NNS	O
were	VBD	O
accurately	RB	O
diagnosed	VBN	O
,	,	O
and	CC	O
no	DT	O
false	JJ	O
positive	JJ	O
mutations	NNS	O
were	VBD	O
identified	VBN	O
in	IN	O
20	CD	O
control	NN	O
samples	NNS	O
.	.	O

Eight	CD	O
single	JJ	O
nucleotide	RB	O
polymorphisms	NNS	O
were	VBD	O
also	RB	O
readily	RB	O
detected	VBN	O
.	.	O

DNA	NN	O
chip	NN	O
-	:	O
based	VBN	O
assays	NNS	O
may	MD	O
provide	VB	O
a	DT	O
valuable	JJ	O
new	JJ	O
technology	NN	O
for	IN	O
high	JJ	O
-	:	O
throughput	NN	O
cost	NN	O
-	:	O
efficient	JJ	O
detection	NN	O
of	IN	O
genetic	JJ	O
alterations	NNS	O
.	.	O

Autosomal	NNP	O
dominant	JJ	O
primary	JJ	O
hyperparathyroidism	NN	B_Disease
and	CC	I_Disease
jaw	JJ	I_Disease
tumor	NN	I_Disease
syndrome	NN	E_Disease
associated	VBN	O
with	IN	O
renal	JJ	B_Disease
hamartomas	NN	E_Disease
and	CC	O
cystic	JJ	B_Disease
kidney	NN	I_Disease
disease	NN	E_Disease
:	:	O
linkage	NN	O
to	TO	O
1q21	CD	O
-	:	O
q32	NN	O
and	CC	O
loss	NN	O
of	IN	O
the	DT	O
wild	JJ	O
type	NN	O
allele	NN	O
in	IN	O
renal	JJ	B_Disease
hamartomas	NN	E_Disease
.	.	O

Hereditary	JJ	B_Disease
hyperparathyroidism	NN	I_Disease
-	:	I_Disease
jaw	NN	I_Disease
tumor	NN	I_Disease
syndrome	NN	E_Disease
(	(	O
HPT	NNP	B_Disease
-	:	I_Disease
JT	NN	E_Disease
)	)	O
is	VBZ	O
an	DT	O
autosomal	JJ	B_Disease
dominant	JJ	I_Disease
disease	NN	E_Disease
(	(	O
OMIM	NNP	O
145001	CD	O
)	)	O
that	WDT	O
has	VBZ	O
recently	RB	O
been	VBN	O
mapped	VBN	O
to	TO	O
chromosomal	VB	O
region	NN	O
1q21	CD	O
-	:	O
q32	NN	O
(	(	O
HRPT2	NNP	O
)	)	O
.	.	O

Here	RB	O
we	PRP	O
report	VBP	O
two	CD	O
families	NNS	O
with	IN	O
HPT	NNP	B_Disease
-	:	I_Disease
JT	NNP	I_Disease
syndrome	NN	E_Disease
in	IN	O
which	WDT	O
adult	VBP	B_Disease
renal	JJ	I_Disease
hamartomas	NN	E_Disease
or	CC	O
cystic	JJ	B_Disease
kidney	NN	I_Disease
disease	NN	E_Disease
were	VBD	O
prominent	JJ	O
associated	VBN	O
features	NNS	O
,	,	O
possibly	RB	O
representing	VBG	O
a	DT	O
new	JJ	O
phenotypic	NN	O
variant	NN	O
of	IN	O
the	DT	O
HPT	NNP	B_Disease
-	:	I_Disease
JT	NNP	I_Disease
syndrome	NN	E_Disease
.	.	O

In	IN	O
the	DT	O
first	JJ	O
family	NN	O
,	,	O
renal	JJ	B_Disease
lesions	NNS	E_Disease
were	VBD	O
present	JJ	O
in	IN	O
five	CD	O
out	IN	O
of	IN	O
six	CD	O
affected	JJ	O
individuals	NNS	O
,	,	O
whereas	NNS	O
HPT	NNP	S_Disease
and	CC	O
JT	NNP	S_Disease
were	VBD	O
seen	VBN	O
in	IN	O
four	CD	O
and	CC	O
two	CD	O
cases	NNS	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
second	JJ	O
family	NN	O
,	,	O
JT	NNP	S_Disease
was	VBD	O
found	VBN	O
in	IN	O
three	CD	O
of	IN	O
the	DT	O
five	CD	O
affected	JJ	O
individuals	NNS	O
and	CC	O
two	CD	O
affected	VBD	O
members	NNS	O
also	RB	O
exhibited	VBD	O
polycystic	JJ	B_Disease
kidney	NN	I_Disease
disease	NN	E_Disease
.	.	O

The	DT	O
possibility	NN	O
of	IN	O
the	DT	O
latter	JJ	O
cosegregating	NN	O
as	IN	O
a	DT	O
separate	JJ	O
autosomal	JJ	O
dominant	JJ	O
gene	NN	O
can	MD	O
not	RB	O
be	VB	O
ruled	VBN	O
out	RP	O
.	.	O

A	DT	O
sex	NN	O
-	:	O
dependent	JJ	O
penetrance	NN	O
of	IN	O
primary	JJ	B_Disease
HPT	NNP	E_Disease
,	,	O
resulting	VBG	O
in	IN	O
predominantly	RB	O
male	JJ	O
-	:	O
affected	JJ	O
cases	NNS	O
was	VBD	O
evident	JJ	O
in	IN	O
the	DT	O
two	CD	O
families	NNS	O
.	.	O

Twenty	NNP	O
microsatellite	NN	O
markers	NNS	O
in	IN	O
the	DT	O
HRPT2	NNP	O
region	NN	O
were	VBD	O
typed	VBN	O
,	,	O
in	IN	O
addition	NN	O
to	TO	O
markers	NNS	O
in	IN	O
the	DT	O
multiple	JJ	B_Disease
endocrine	NN	I_Disease
neoplasia	NN	I_Disease
(	(	I_Disease
MEN	NNP	I_Disease
)	)	I_Disease
types	VBZ	I_Disease
1	CD	I_Disease
and	CC	I_Disease
2	CD	E_Disease
regions	NNS	O
at	IN	O
11q13	CD	O
and	CC	O
10q11	CD	O
.	.	O

The	DT	O
disease	NN	O
in	IN	O
these	DT	O
two	CD	O
kindreds	NNS	O
was	VBD	O
linked	VBN	O
to	TO	O
five	CD	O
markers	NNS	O
in	IN	O
the	DT	O
1q21	CD	O
-	:	O
q32	NN	O
region	NN	O
(	(	O
logarithm	JJ	O
-	:	O
of	IN	O
-	:	O
odds	NNS	O
scores	VBZ	O
3	CD	O
.	.	O

2	CD	O
-	:	O
4	CD	O
2	CD	O
-	:	O
4	CD	O
.	.	O

2	CD	O
)	)	O
,	,	O
whereas	JJ	O
linkage	NN	O
to	TO	O
the	DT	O
MEN1	NNP	S_Disease
and	CC	O
MEN2	NNP	S_Disease
regions	NNS	O
was	VBD	O
excluded	VBN	O
.	.	O

Meiotic	JJ	O
recombinations	NNS	O
detected	VBN	O
in	IN	O
affected	JJ	O
individuals	NNS	O
placed	VBD	O
the	DT	O
locus	NN	O
telomeric	NN	O
of	IN	O
D1S215	NNP	O
,	,	O
thus	RB	O
narrowing	VBG	O
the	DT	O
HRPT2	NNP	O
region	NN	O
from	IN	O
>	$	O
60	CD	O
to	TO	O
approximately	RB	O
34	CD	O
centimorgans	NNS	O
.	.	O

Loss	NNP	O
of	IN	O
heterozygosity	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
seven	CD	O
renal	JJ	B_Disease
hamartomas	NNS	E_Disease
from	IN	O
two	CD	O
affected	JJ	O
individuals	NNS	O
in	IN	O
the	DT	O
first	JJ	O
family	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
a	DT	O
jaw	NN	B_Disease
tumor	NN	E_Disease
and	CC	O
a	DT	O
parathyroid	JJ	B_Disease
tumor	NN	E_Disease
from	IN	O
the	DT	O
second	JJ	O
family	NN	O
.	.	O

All	DT	O
renal	JJ	B_Disease
hamartomas	NN	E_Disease
showed	VBD	O
loss	NN	O
of	IN	O
heterozygosity	NN	O
at	IN	O
the	DT	O
1q21	CD	O
-	:	O
q32	JJ	O
region	NN	O
.	.	O

The	DT	O
losses	NNS	O
invariably	RB	O
involved	VBD	O
the	DT	O
wild	JJ	O
type	NN	O
allele	NN	O
derived	VBN	O
from	IN	O
the	DT	O
unaffected	JJ	O
parent	NN	O
,	,	O
suggesting	VBG	O
the	DT	O
inactivation	NN	O
of	IN	O
a	DT	O
tumor	NN	S_Disease
suppressor	NN	O
gene	NN	O
in	IN	O
this	DT	O
region	NN	O

Independent	NNP	O
origin	NN	O
of	IN	O
single	JJ	O
and	CC	O
double	JJ	O
mutations	NNS	O
in	IN	O
the	DT	O
human	JJ	O
glucose	NN	O
6	CD	O
-	:	O
phosphate	NN	O
dehydrogenase	NN	O
gene	NN	O
.	.	O

The	DT	O
vast	JJ	O
majority	NN	O
of	IN	O
both	DT	O
polymorphic	JJ	O
and	CC	O
sporadic	JJ	O
G6PD	NNP	O
variants	NNS	O
are	VBP	O
due	JJ	O
to	TO	O
single	JJ	O
missense	NN	O
mutations	NNS	O
.	.	O

In	IN	O
the	DT	O
four	CD	O
polymorphic	JJ	O
variants	NNS	O
that	WDT	O
have	VBP	O
two	CD	O
point	NN	O
mutations	NNS	O
,	,	O
one	CD	O
of	IN	O
the	DT	O
mutations	NNS	O
is	VBZ	O
always	RB	O
376	CD	O
A	NNP	O
-	:	O
-	:	O
>	NN	O
G	NNP	O
(	(	O
126	CD	O
Asn	NNP	O
-	:	O
-	:	O
>	JJ	O
Asp	NNP	O
)	)	O
,	,	O
which	WDT	O
on	IN	O
its	PRP$	O
own	JJ	O
gives	VBZ	O
rise	NN	O
to	TO	O
the	DT	O
nondeficient	JJ	O
polymorphic	JJ	O
variant	NN	O
,	,	O
G6PD	NNP	O
A	NNP	O
.	.	O

In	IN	O
a	DT	O
study	NN	O
of	IN	O
G6PD	NNP	B_Disease
deficient	NN	E_Disease
patients	NNS	O
who	WP	O
presented	VBD	O
with	IN	O
clinical	JJ	O
favism	NN	S_Disease
in	IN	O
Spain	NNP	O
,	,	O
we	PRP	O
have	VBP	O
found	VBN	O
a	DT	O
new	JJ	O
polymorphic	JJ	O
variant	NN	O
that	IN	O
we	PRP	O
have	VBP	O
called	VBN	O
G6PD	NNP	O
Malaga	NNP	O
,	,	O
whose	WP$	O
only	JJ	O
abnormality	NN	O
is	VBZ	O
a	DT	O
542	CD	O
A	NNP	O
-	:	O
-	:	O
>	NN	O
T	NNP	O
(	(	O
181	CD	O
Asp	NNP	O
-	:	O
-	:	O
>	NN	O
Val	NNP	O
)	)	O
mutation	NN	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
same	JJ	O
mutation	NN	O
as	IN	O
previously	RB	O
found	VBN	O
in	IN	O
association	NN	O
with	IN	O
the	DT	O
mutation	NN	O
of	IN	O
G6PD	NNP	O
A	NNP	O
in	IN	O
the	DT	O
double	JJ	O
mutant	NN	O
,	,	O
G6PD	NNP	O
Santamaria	NNP	O
.	.	O

G6PD	NNP	O
Malaga	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
enzyme	JJ	B_Disease
deficiency	NN	E_Disease
(	(	O
class	NN	O
III	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
enzymic	JJ	O
properties	NNS	O
of	IN	O
G6PD	NNP	O
Malaga	NNP	O
and	CC	O
G6PD	NNP	O
Santamaria	NNP	O
are	VBP	O
quite	RB	O
similar	JJ	O
,	,	O
indicating	VBG	O
that	IN	O
in	IN	O
this	DT	O
case	NN	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
two	CD	O
mutations	NNS	O
are	VBP	O
additive	JJ	O
rather	RB	O
than	IN	O
synergistic	JJ	O
.	.	O

G6PD	NNP	O
Santamaria	NNP	O
might	MD	O
have	VB	O
been	VBN	O
produced	VBN	O
by	IN	O
recombination	NN	O
between	IN	O
G6PD	NNP	O
A	NNP	O
and	CC	O
G6PD	NNP	O
Malaga	NNP	O
;	:	O
however	RB	O
haplotype	NN	O
analysis	NN	O
,	,	O
including	VBG	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
new	JJ	O
silent	JJ	O
polymorphism	NN	O
,	,	O
suggests	VBZ	O
that	IN	O
the	DT	O
same	JJ	O
542	CD	O
A	NNP	O
-	:	O
-	:	O
>	NN	O
T	NNP	O
mutation	NN	O
has	VBZ	O
taken	VBN	O
place	NN	O
independently	RB	O
in	IN	O
a	DT	O
G6PD	NNP	O
B	NNP	O
gene	NN	O
to	TO	O
give	VB	O
G6PD	NNP	O
Malaga	NNP	O
and	CC	O
in	IN	O
a	DT	O
G6PD	NNP	O
A	NNP	O
gene	NN	O
to	TO	O
give	VB	O
G6PD	NNP	O
Santamaria	NNP	O
.	.	O

These	DT	O
findings	NNS	O
help	VBP	O
to	TO	O
outline	VB	O
the	DT	O
relationship	NN	O
and	CC	O
evolution	NN	O
of	IN	O
mutations	NNS	O
in	IN	O
the	DT	O
human	JJ	O
G6PD	NNP	O
locus	NN	O
.	.	O
.	.	O

BRCA1	NNP	O
R841W	NNP	O
:	:	O
a	DT	O
strong	JJ	O
candidate	NN	O
for	IN	O
a	DT	O
common	JJ	O
mutation	NN	O
with	IN	O
moderate	JJ	O
phenotype	NN	O
.	.	O

BRCA1	NNP	O
mutations	NNS	O
cause	VBP	O
increased	VBN	O
risk	NN	O
for	IN	O
breast	NN	B_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
,	,	O
frequently	RB	O
of	IN	O
early	JJ	O
onset	NN	O
.	.	O

Many	JJ	O
different	JJ	O
mutations	NNS	O
occur	VBP	O
in	IN	O
BRCA1	NNP	O
,	,	O
including	VBG	O
several	JJ	O
examples	NNS	O
of	IN	O
recurrent	NN	O
mutations	NNS	O
,	,	O
each	DT	O
of	IN	O
which	WDT	O
accounts	NNS	O
for	IN	O
a	DT	O
significant	JJ	O
number	NN	O
of	IN	O
families	NNS	O
with	IN	O
heritable	JJ	O
cancer	NN	S_Disease
predisposition	NN	O
.	.	O

These	DT	O
common	JJ	O
mutations	NNS	O
have	VBP	O
an	DT	O
etiological	JJ	O
role	NN	O
in	IN	O
many	JJ	O
breast	NN	B_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
cases	NNS	O
and	CC	O
provide	VB	O
the	DT	O
opportunity	NN	O
to	TO	O
examine	VB	O
genotype	JJ	O
-	:	O
phenotype	NN	O
correlations	NNS	O
and	CC	O
genotype	JJ	O
-	:	O
environment	NN	O
interactions	NNS	O
in	IN	O
individuals	NNS	O
with	IN	O
the	DT	O
identical	JJ	O
BRCA1	NNP	O
lesion	NN	O
.	.	O

We	PRP	O
report	VBP	O
a	DT	O
novel	JJ	O
missense	NN	O
change	NN	O
in	IN	O
BRCA1	NNP	O
,	,	O
2640	CD	O
C	NNP	O
-	:	O
-	:	O
>	NN	O
T	NNP	O
(	(	O
R841W	NNP	O
)	)	O
,	,	O
found	VBN	O
in	IN	O
3	CD	O
cases	NNS	O
from	IN	O
a	DT	O
subject	JJ	O
group	NN	O
of	IN	O
305	CD	O
breast	NN	B_Disease
and	CC	I_Disease
79	CD	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
cases	NNS	O
from	IN	O
Orange	NNP	O
County	NNP	O
,	,	O
CA	NNP	O
.	.	O

These	DT	O
are	VBP	O
consecutive	JJ	O
,	,	O
population	NN	O
-	:	O
based	VBN	O
cases	NNS	O
not	RB	O
selected	VBN	O
for	IN	O
age	NN	O
or	CC	O
family	NN	O
history	NN	O
.	.	O

In	IN	O
all	DT	O
three	CD	O
cases	NNS	O
,	,	O
there	EX	O
is	VBZ	O
a	DT	O
strong	JJ	O
family	NN	O
history	NN	O
of	IN	O
breast	NN	B_Disease
,	,	I_Disease
ovarian	JJ	I_Disease
,	,	I_Disease
or	CC	I_Disease
other	JJ	I_Disease
cancers	NNS	E_Disease
possibly	RB	O
related	VBN	O
to	TO	O
a	DT	O
BRCA1	NNP	O
defect	NN	O
and	CC	O
family	NN	O
members	NNS	O
showed	VBD	O
a	DT	O
high	JJ	O
concordance	NN	O
of	IN	O
cancer	NN	S_Disease
incidence	NN	O
with	IN	O
the	DT	O
presence	NN	O
of	IN	O
R841W	NNP	O
.	.	O

The	DT	O
age	NN	O
of	IN	O
cancer	NN	S_Disease
onset	NN	O
was	VBD	O
not	RB	O
always	RB	O
distinct	VBP	O
from	IN	O
typical	JJ	O
sporadic	JJ	O
cases	NNS	O
.	.	O

Testing	VBG	O
of	IN	O
a	DT	O
sample	NN	O
of	IN	O
413	CD	O
unrelated	JJ	O
individuals	NNS	O
to	TO	O
examine	VB	O
the	DT	O
hypothesis	NN	O
that	WDT	O
R841W	NNP	O
might	MD	O
be	VB	O
a	DT	O
rare	JJ	O
polymorphism	NN	O
detected	VBD	O
one	CD	O
additional	JJ	O
instance	NN	O
in	IN	O
a	DT	O
woman	NN	O
with	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
diagnosed	VBN	O
at	IN	O
age	NN	O
77	CD	O
years	NNS	O
,	,	O
and	CC	O
cancer	NN	S_Disease
in	IN	O
one	CD	O
parent	NN	O
.	.	O

R841W	NN	O
is	VBZ	O
likely	JJ	O
to	TO	O
be	VB	O
an	DT	O
etiologically	RB	O
significant	JJ	O
lesion	NN	O
with	IN	O
involvement	NN	O
in	IN	O
close	JJ	O
to	TO	O
1	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
of	IN	O
0	CD	O
-	:	O
1	CD	O
.	.	O

7	CD	O
%	NN	O
)	)	O
of	IN	O
all	DT	O
breast	NN	B_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancers	NNS	E_Disease
in	IN	O
this	DT	O
population	NN	O
.	.	O

Ataxia	NNP	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
:	:	O
founder	NN	O
effect	NN	O
among	IN	O
north	JJ	O
African	JJ	O
Jews	NNP	O
.	.	O

The	DT	O
ATM	NNP	O
gene	NN	O
is	VBZ	O
responsible	JJ	O
for	IN	O
the	DT	O
autosomal	JJ	B_Disease
recessive	JJ	I_Disease
disorder	NN	E_Disease
ataxia	SYM	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
(	(	O
A	DT	B_Disease
-	:	I_Disease
T	NN	E_Disease
)	)	O
,	,	O
characterized	VBN	O
by	IN	O
cerebellar	JJ	B_Disease
degeneration	NN	E_Disease
,	,	O
immunodeficiency	NN	S_Disease
and	CC	O
cancer	NN	B_Disease
predisposition	NN	E_Disease
.	.	O

A	DT	B_Disease
-	:	I_Disease
T	NN	E_Disease
carriers	NNS	O
were	VBD	O
reported	VBN	O
to	TO	O
be	VB	O
moderately	RB	O
cancer	NN	B_Disease
-	:	I_Disease
prone	NN	E_Disease
.	.	O

A	DT	O
wide	JJ	O
variety	NN	O
of	IN	O
A	NNP	B_Disease
-	:	I_Disease
T	NN	E_Disease
mutations	NNS	O
,	,	O
most	JJS	O
of	IN	O
which	WDT	O
are	VBP	O
unique	JJ	O
to	TO	O
single	JJ	O
families	NNS	O
,	,	O
were	VBD	O
identified	VBN	O
in	IN	O
various	JJ	O
ethnic	JJ	O
groups	NNS	O
,	,	O
precluding	VBG	O
carrier	NN	O
screening	VBG	O
with	IN	O
mutation	NN	O
-	:	O
specific	JJ	O
assays	NNS	O
.	.	O

However	RB	O
,	,	O
a	DT	O
single	JJ	O
mutation	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
32	CD	O
/	JJ	O
33	CD	O
defective	JJ	O
ATM	NNP	O
alleles	NNS	O
in	IN	O
Jewish	NNP	O
A	NNP	B_Disease
-	:	I_Disease
T	NNP	E_Disease
families	NNS	O
of	IN	O
North	JJ	O
African	JJ	O
origin	NN	O
,	,	O
coming	VBG	O
from	IN	O
various	JJ	O
regions	NNS	O
of	IN	O
Morocco	NNP	O
and	CC	O
Tunisia	NNP	O
.	.	O

This	DT	O
mutation	NN	O
,	,	O
103C	CD	O
-	:	O
-	:	O
>	NN	O
T	NNP	O
,	,	O
results	NNS	O
in	IN	O
a	DT	O
stop	JJ	O
codon	NN	O
at	IN	O
position	NN	O
35	CD	O
of	IN	O
the	DT	O
ATM	NNP	O
protein	NN	O
.	.	O

In	IN	O
keeping	VBG	O
with	IN	O
the	DT	O
nature	NN	O
of	IN	O
this	DT	O
mutation	NN	O
,	,	O
various	JJ	O
antibodies	NNS	O
directed	VBN	O
against	IN	O
the	DT	O
ATM	NNP	O
protein	NN	O
failed	VBD	O
to	TO	O
defect	VB	O
this	DT	O
protein	NN	O
in	IN	O
patient	JJ	O
cells	NNS	O
.	.	O

A	DT	O
rapid	JJ	O
carrier	NN	O
detection	NN	O
assay	RB	O
detected	VBD	O
this	DT	O
mutation	NN	O
in	IN	O
three	CD	O
out	IN	O
of	IN	O
488	CD	O
ATM	NNP	O
alleles	NNS	O
of	IN	O
Jewish	JJ	O
Moroccan	NNP	O
or	CC	O
Tunisian	JJ	O
origin	NN	O
.	.	O

This	DT	O
founder	NN	O
effect	NN	O
provides	VBZ	O
a	DT	O
unique	JJ	O
opportunity	NN	O
for	IN	O
population	NN	O
-	:	O
based	VBN	O
screening	NN	O
for	IN	O
A	NNP	B_Disease
-	:	I_Disease
T	NN	E_Disease
carriers	NNS	O
in	IN	O
a	DT	O
large	JJ	O
Jewish	NNP	O
community	NN	O
.	.	O
.	.	O

Mutation	NNP	O
analysis	NN	O
of	IN	O
BRCA1	NNP	O
and	CC	O
BRCA2	NNP	O
in	IN	O
a	DT	O
male	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
population	NN	O
.	.	O

A	DT	O
population	NN	O
-	:	O
based	VBN	O
series	NN	O
of	IN	O
54	CD	O
male	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
cases	NNS	O
from	IN	O
Southern	NNP	O
California	NNP	O
were	VBD	O
analyzed	VBN	O
for	IN	O
germ	JJ	O
-	:	O
line	NN	O
mutations	NNS	O
in	IN	O
the	DT	O
inherited	JJ	B_Disease
breast	NN	I_Disease
/	JJ	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
genes	NNS	O
,	,	O
BRCA1	NNP	O
and	CC	O
BRCA2	NNP	O
.	.	O

Nine	NNP	O
(	(	O
17	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
breast	NN	B_Disease
and	CC	I_Disease
/	NN	I_Disease
or	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
in	IN	O
at	IN	O
least	JJS	O
one	CD	O
first	JJ	O
-	:	O
degree	NN	O
relative	NN	O
.	.	O

A	DT	O
further	JJ	O
seven	CD	O
(	(	O
13	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
reported	VBD	O
breast	JJ	B_Disease
/	JJ	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
in	IN	O
at	IN	O
least	JJS	O
one	CD	O
second	JJ	O
-	:	O
degree	NN	O
relative	NN	O
and	CC	O
in	IN	O
no	DT	O
first	JJ	O
-	:	O
degree	NN	O
relatives	NNS	O
.	.	O

No	DT	O
germ	JJ	O
-	:	O
line	NN	O
BRCA1	NNP	O
mutations	NNS	O
were	VBD	O
found	VBN	O
.	.	O

Two	CD	O
male	JJ	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
patients	NNS	O
(	(	O
4	CD	O
%	NN	O
of	IN	O
the	DT	O
total	NN	O
)	)	O
were	VBD	O
found	VBN	O
to	TO	O
carry	VB	O
novel	JJ	O
truncating	VBG	O
mutations	NNS	O
in	IN	O
the	DT	O
BRCA2	NNP	O
gene	NN	O
.	.	O

Only	RB	O
one	CD	O
of	IN	O
the	DT	O
two	CD	O
male	NN	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
patients	NNS	O
carrying	VBG	O
a	DT	O
BRCA2	NNP	O
mutation	NN	O
had	VBD	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
cancer	NN	S_Disease
,	,	O
with	IN	O
one	CD	O
case	NN	O
of	IN	O
ovarian	JJ	B_Disease
cancer	NN	E_Disease
in	IN	O
a	DT	O
first	JJ	O
-	:	O
degree	NN	O
relative	NN	O
.	.	O

The	DT	O
remaining	VBG	O
eight	CD	O
cases	NNS	O
(	(	O
89	CD	O
%	NN	O
)	)	O
of	IN	O
male	NN	B_Disease
breast	NN	I_Disease
cancer	NN	E_Disease
with	IN	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
breast	NN	B_Disease
/	JJ	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
in	IN	O
first	JJ	O
-	:	O
degree	NN	O
relatives	NNS	O
remain	VBP	O
unaccounted	JJ	O
for	IN	O
by	IN	O
mutations	NNS	O
in	IN	O
either	CC	O
the	DT	O
BRCA1	NNP	O
gene	NN	O
or	CC	O
the	DT	O
BRCA2	NNP	O
gene	NN	O
.	.	O
.	.	O

Molecular	JJ	O
basis	NN	O
for	IN	O
Duarte	NNP	B_Disease
and	CC	I_Disease
Los	NNP	I_Disease
Angeles	NNP	I_Disease
variant	NN	I_Disease
galactosemia	NN	E_Disease
.	.	O

Human	NNP	O
orythrocytes	VBZ	O
that	WDT	O
are	VBP	O
homozygous	JJ	O
for	IN	O
the	DT	O
Duarte	NNP	B_Disease
enzyme	NN	I_Disease
variant	NN	I_Disease
of	IN	I_Disease
galactosemia	NN	E_Disease
(	(	O
D	NNP	O
/	NNP	O
D	NNP	O
)	)	O
have	VBP	O
a	DT	O
characteristic	JJ	O
isoform	NN	O
on	IN	O
isoelectric	JJ	O
focusing	NN	O
and	CC	O
50	CD	O
%	NN	O
reduction	NN	O
in	IN	O
galactose	JJ	O
-	:	O
1	CD	O
-	:	O
phosphate	NN	O
uridyltransferase	NN	O
(	(	O
GALT	NNP	O
)	)	O
enzyme	NN	O
activity	NN	O
.	.	O

The	DT	O
Duarte	NNP	O
biochemical	JJ	O
phenotype	NN	O
has	VBZ	O
a	DT	O
molecular	JJ	O
genotype	NN	O
of	IN	O
N314D	NNP	O
/	NNP	O
N314D	NNP	O
.	.	O

The	DT	O
characteristic	JJ	O
Duarte	NNP	O
isoform	NN	O
is	VBZ	O
also	RB	O
associated	VBN	O
with	IN	O
a	DT	O
variant	NN	O
called	VBN	O
the	DT	O
"	NNP	O
Los	NNP	O
Angeles	NNP	O
(	(	O
LA	NNP	O
)	)	O
phenotype	NN	O
,	,	O
"	NNP	O
which	WDT	O
has	VBZ	O
increased	VBN	O
GALT	NNP	O
enzyme	JJ	O
activity	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
GALT	NNP	O
enzyme	JJ	O
activity	NN	O
and	CC	O
screened	VBD	O
the	DT	O
GALT	NNP	O
genes	NNS	O
of	IN	O
145	CD	O
patients	NNS	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
N314D	NNP	O
-	:	O
containing	NN	O
alleles	NNS	O
.	.	O

We	PRP	O
found	VBD	O
seven	CD	O
with	IN	O
the	DT	O
LA	NNP	O
biochemical	JJ	O
phenotype	NN	O
,	,	O
and	CC	O
all	DT	O
had	VBD	O
a	DT	O
1721C	CD	O
-	:	O
-	:	O
>	NN	O
T	NNP	O
transition	NN	O
in	IN	O
exon	JJ	O
7	CD	O
in	IN	O
cis	NN	O
with	IN	O
the	DT	O
N314D	NNP	O
missense	NN	O
mutation	NN	O
.	.	O

The	DT	O
1721C	CD	O
-	:	O
-	:	O
>	NN	O
T	NNP	O
transition	NN	O
is	VBZ	O
a	DT	O
neutral	JJ	O
polymorphism	NN	O
for	IN	O
leucine	NN	O
at	IN	O
amino	NN	O
acid	NN	O
218	CD	O
(	(	O
L218L	NNP	O
)	)	O
.	.	O

In	IN	O
pedigree	JJ	O
analyses	NNS	O
,	,	O
this	DT	O
1721C	CD	O
-	:	O
-	:	O
>	NN	O
T	NNP	O
transition	NN	O
segregated	VBD	O
with	IN	O
the	DT	O
LA	NNP	O
phenotype	NN	O
of	IN	O
increased	JJ	O
GALT	NNP	O
activity	NN	O
in	IN	O
three	CD	O
different	JJ	O
biochemical	JJ	O
phenotypes	NNS	O
(	(	O
LA	NNP	O
/	NNP	O
N	NNP	O
,	,	O
LA	NNP	O
/	NNP	O
G	NNP	O
,	,	O
and	CC	O
LA	NNP	O
/	NNP	O
D	NNP	O
)	)	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
mechanism	NN	O
for	IN	O
increased	JJ	O
activity	NN	O
of	IN	O
the	DT	O
LA	NNP	O
variant	NN	O
,	,	O
we	PRP	O
compared	VBN	O
GALT	NNP	O
mRNA	NN	O
,	,	O
protein	NN	O
abundance	NN	O
,	,	O
and	CC	O
enzyme	VB	O
thermal	JJ	O
stability	NN	O
in	IN	O
lymphoblast	NN	O
cell	NN	O
lines	NNS	O
of	IN	O
D	NNP	O
and	CC	O
LA	NNP	O
phenotypes	NNS	O
with	IN	O
comparable	JJ	O
genotypes	NNS	O
.	.	O

GALT	NNP	O
protein	VBD	O
abundance	NN	O
was	VBD	O
increased	VBN	O
in	IN	O
LA	NNP	O
compared	VBN	O
to	TO	O
D	NNP	O
alleles	NNS	O
,	,	O
but	CC	O
mRNA	NN	O
was	VBD	O
similar	JJ	O
among	IN	O
all	DT	O
genotypes	NNS	O
.	.	O

When	WRB	O
LA	NNP	O
/	NNP	O
D	NNP	O
and	CC	O
D	NNP	O
/	NNP	O
D	NNP	O
GALT	NNP	O
biochemical	JJ	O
phenotypes	NNS	O
were	VBD	O
compared	VBN	O
to	TO	O
N	NNP	O
/	NNP	O
N	NNP	O
GALT	NNP	O
phenotypes	NNS	O
,	,	O
both	DT	O
had	VBD	O
50	CD	O
%	NN	O
,	,	O
as	IN	O
compared	VBN	O
to	TO	O
21	CD	O
%	NN	O
,	,	O
reduction	NN	O
in	IN	O
GALT	NNP	O
activity	NN	O
in	IN	O
the	DT	O
wild	JJ	O
type	NN	O
(	(	O
N	NNP	O
/	NNP	O
N	NNP	O
)	)	O
after	IN	O
exposure	NN	O
at	IN	O
identical	JJ	O
initial	JJ	O
enzyme	NN	O
activity	NN	O
to	TO	O
50	CD	O
degrees	NNS	O
C	NNP	O
for	IN	O
15	CD	O
min	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
codon	NN	O
change	NN	O
N314D	NNP	O
in	IN	O
cis	NN	O
with	IN	O
the	DT	O
base	NN	O
-	:	O
pair	NN	O
transition	NN	O
1721C	CD	O
-	:	O
-	:	O
>	NN	O
T	NNP	O
produces	VBZ	O
the	DT	O
LA	NNP	B_Disease
variant	NN	I_Disease
of	IN	I_Disease
galactosemia	NN	E_Disease
and	CC	O
that	IN	O
this	DT	O
nucleotide	JJ	O
change	NN	O
increases	NNS	O
GALT	NNP	O
activity	NN	O
by	IN	O
increasing	VBG	O
GALT	NNP	O
protein	NN	O
abundance	NN	O
without	IN	O
increasing	VBG	O
transcription	NN	O
or	CC	O
decreasing	VBG	O
thermal	JJ	O
lability	NN	O
.	.	O

A	DT	O
favorable	JJ	O
codon	NN	O
bias	NN	O
for	IN	O
the	DT	O
mutated	JJ	O
codon	NN	O
with	IN	O
consequently	RB	O
increased	VBN	O
translation	NN	O
rates	NNS	O
is	VBZ	O
postulated	VBN	O
as	IN	O
the	DT	O
mechanism	NN	O
.	.	O
.	.	O

The	DT	O
TSG101	NNP	O
tumor	NN	S_Disease
susceptibility	NN	O
gene	NN	O
is	VBZ	O
located	VBN	O
in	IN	O
chromosome	NN	O
11	CD	O
band	NN	O
p15	NN	O
and	CC	O
is	VBZ	O
mutated	VBN	O
in	IN	O
human	JJ	O
breast	NN	B_Disease
cancer	NN	E_Disease
.	.	O

Recent	JJ	O
work	NN	O
has	VBZ	O
identified	VBN	O
a	DT	O
mouse	NN	O
gene	NN	O
(	(	O
tsg101	JJ	O
)	)	O
whose	WP$	O
inactivation	NN	O
in	IN	O
fibroblasts	NNS	O
results	NNS	O
in	IN	O
cellular	JJ	O
transformation	NN	O
and	CC	O
the	DT	O
ability	NN	O
to	TO	O
produce	VB	O
metastatic	JJ	B_Disease
tumors	NNS	E_Disease
in	IN	O
nude	JJ	O
mice	NN	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
report	VBP	O
that	IN	O
the	DT	O
human	JJ	O
homolog	NN	O
,	,	O
TSG101	NNP	O
,	,	O
which	WDT	O
we	PRP	O
isolated	VBD	O
and	CC	O
mapped	VBD	O
to	TO	O
chromosome	VB	O
11	CD	O
,	,	O
bands	VBZ	O
15	CD	O
.	.	O

1	CD	O
-	:	O
15	CD	O
1	CD	O
-	:	O
15	CD	O
.	.	O

2	CD	O
,	,	O
a	DT	O
region	NN	O
proposed	VBN	O
to	TO	O
contain	VB	O
tumor	NN	S_Disease
suppressor	NN	O
gene	NN	O
(	(	O
s	PRP	O
)	)	O
,	,	O
is	VBZ	O
mutated	VBN	O
at	IN	O
high	JJ	O
frequency	NN	O
in	IN	O
human	JJ	O
breast	NN	B_Disease
cancer	NN	E_Disease
.	.	O

In	IN	O
7	CD	O
of	IN	O
15	CD	O
uncultured	JJ	O
primary	JJ	O
human	JJ	O
breast	NN	B_Disease
carcinomas	NN	E_Disease
,	,	O
intragenic	JJ	O
deletions	NNS	O
were	VBD	O
shown	VBN	O
in	IN	O
TSG101	NNP	O
genomic	JJ	O
DNA	NNP	O
and	CC	O
transcripts	NNS	O
by	IN	O
gel	NN	O
and	CC	O
sequence	NN	O
analysis	NN	O
,	,	O
and	CC	O
mutations	NNS	O
affecting	VBG	O
two	CD	O
TSG101	NNP	O
alleles	NNS	O
were	VBD	O
identified	VBN	O
in	IN	O
four	CD	O
of	IN	O
these	DT	O
cancers	NNS	S_Disease
.	.	O

No	DT	O
TSG101	NNP	O
defects	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
matched	JJ	O
normal	JJ	O
breast	NN	O
tissue	NN	O
from	IN	O
the	DT	O
breast	NN	B_Disease
cancer	NN	E_Disease
patients	NNS	O
.	.	O

These	DT	O
findings	NNS	O
strongly	RB	O
implicate	VBP	O
TSG101	NNP	O
mutations	NNS	O
in	IN	O
human	JJ	O
breast	NN	B_Disease
cancer	NN	E_Disease

Moderate	NNP	O
intergenerational	JJ	O
and	CC	O
somatic	JJ	O
instability	NN	O
of	IN	O
a	DT	O
55	CD	O
-	:	O
CTG	NN	O
repeat	NN	O
in	IN	O
transgenic	JJ	O
mice	NN	O
.	.	O

Myotonic	JJ	B_Disease
dystrophy	NN	E_Disease
(	(	O
DM	NNP	S_Disease
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
the	DT	O
expansion	NN	O
of	IN	O
a	DT	O
(	(	O
CTG	NNP	O
)	)	O
n	FW	O
trinucleotide	JJ	O
repeat	NN	O
in	IN	O
the	DT	O
3	CD	O
untranslated	JJ	O
region	NN	O
(	(	O
UTR	NNP	O
)	)	O
of	IN	O
the	DT	O
DM	NNP	S_Disease
protein	NN	O
kinase	NN	O
gene	NN	O
(	(	O
DMPK	NNP	O
)	)	O
.	.	O

The	DT	O
(	(	O
CTG	NNP	O
)	)	O
n	FW	O
repeat	NN	O
is	VBZ	O
polymorphic	JJ	O
and	CC	O
varies	NNS	O
in	IN	O
size	NN	O
between	IN	O
5	CD	O
and	CC	O
37	CD	O
repeats	NNS	O
in	IN	O
unaffected	JJ	O
individuals	NNS	O
whereas	VBP	O
in	IN	O
affected	JJ	O
patients	NNS	O
there	EX	O
are	VBP	O
between	IN	O
50	CD	O
and	CC	O
4	CD	O
,	,	O
000	CD	O
CTGs	NNP	O
.	.	O

The	DT	O
size	NN	O
of	IN	O
the	DT	O
(	(	O
CTG	NNP	O
)	)	O
n	RB	O
repeat	NN	O
,	,	O
which	WDT	O
increases	VBZ	O
through	IN	O
generations	NNS	O
,	,	O
generally	RB	O
correlates	VBZ	O
with	IN	O
clinical	JJ	O
severity	NN	O
and	CC	O
age	NN	O
of	IN	O
onset	NN	O
.	.	O

The	DT	O
instability	NN	O
of	IN	O
the	DT	O
CTG	NNP	O
repeat	NN	O
appears	VBZ	O
to	TO	O
depend	VB	O
on	IN	O
its	PRP$	O
size	NN	O
as	RB	O
well	RB	O
as	IN	O
on	IN	O
the	DT	O
sex	NN	O
of	IN	O
the	DT	O
transmitting	JJ	O
parent	NN	O
.	.	O

Moreover	RB	O
,	,	O
mitotic	JJ	O
instability	NN	O
analysis	NN	O
of	IN	O
different	JJ	O
human	JJ	O
DM	NNP	S_Disease
tissues	NN	O
shows	NNS	O
length	VBP	O
mosaicism	NN	O
between	IN	O
different	JJ	O
cell	NN	O
lineages	NNS	O
.	.	O

The	DT	O
molecular	JJ	O
mechanisms	NN	O
of	IN	O
triplet	NN	O
instability	NN	O
remain	VBP	O
elusive	JJ	O
.	.	O

To	TO	O
investigate	VB	O
the	DT	O
role	NN	O
of	IN	O
genomic	JJ	O
sequences	NNS	O
in	IN	O
instability	NN	O
,	,	O
we	PRP	O
produced	VBD	O
transgenic	JJ	O
mice	NN	O
containing	VBG	O
a	DT	O
45	CD	O
-	:	O
kb	NN	O
genomic	JJ	O
segment	NN	O
with	IN	O
a	DT	O
55	CD	O
-	:	O
CTG	NNP	O
repeat	NN	O
cloned	VBD	O
from	IN	O
a	DT	O
mildly	RB	O
affected	JJ	O
patient	NN	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
other	JJ	O
mouse	NN	O
models	NNS	O
containing	VBG	O
CAG	NNP	O
repeats	NNS	O
within	IN	O
cDNAs	NN	O
,	,	O
these	DT	O
mice	NN	O
showed	VBD	O
both	DT	O
intergenerational	JJ	O
and	CC	O
somatic	JJ	O
repeat	NN	O
instability	NN	O
.	.	O
.	.	O

Missense	JJ	O
mutations	NNS	O
in	IN	O
the	DT	O
Fas	NNP	O
gene	NN	O
resulting	VBG	O
in	IN	O
autoimmune	JJ	B_Disease
lymphoproliferative	JJ	I_Disease
syndrome	NN	E_Disease
:	:	O
a	DT	O
molecular	JJ	O
and	CC	O
immunological	JJ	O
analysis	NN	O
.	.	O

Programmed	NNP	O
cell	NN	O
death	NN	O
(	(	O
or	CC	O
apoptosis	NN	O
)	)	O
is	VBZ	O
a	DT	O
physiological	JJ	O
process	NN	O
essential	JJ	O
to	TO	O
the	DT	O
normal	JJ	O
development	NN	O
and	CC	O
homeostatic	JJ	O
maintenance	NN	O
of	IN	O
the	DT	O
immune	NN	O
system	NN	O
.	.	O

The	DT	O
Fas	NNP	O
/	NNP	O
Apo	NNP	O
-	:	O
1	CD	O
receptor	NN	O
plays	VBZ	O
a	DT	O
crucial	JJ	O
role	NN	O
in	IN	O
the	DT	O
regulation	NN	O
of	IN	O
apoptosis	NN	O
,	,	O
as	IN	O
demonstrated	VBN	O
by	IN	O
lymphoproliferation	NN	O
in	IN	O
MRL	NNP	O
-	:	O
lpr	NN	O
/	JJ	O
lpr	JJ	O
mice	NN	O
and	CC	O
by	IN	O
the	DT	O
recently	RB	O
described	VBN	O
autoimmune	JJ	B_Disease
lymphoproliferative	JJ	I_Disease
syndrome	NN	E_Disease
(	(	O
ALPS	NNP	S_Disease
)	)	O
in	IN	O
humans	NNS	O
,	,	O
both	DT	O
of	IN	O
which	WDT	O
are	VBP	O
due	JJ	O
to	TO	O
mutations	NNS	O
in	IN	O
the	DT	O
Fas	NNP	O
gene	NN	O
.	.	O

We	PRP	O
describe	VBP	O
a	DT	O
novel	JJ	O
family	NN	O
with	IN	O
ALPS	NNP	S_Disease
in	IN	O
which	WDT	O
three	CD	O
affected	VBD	O
siblings	NNS	O
carry	VBP	O
two	CD	O
distinct	JJ	O
missense	NN	O
mutations	NNS	O
on	IN	O
both	DT	O
the	DT	O
Fas	NNP	O
gene	NN	O
alleles	NNS	O
and	CC	O
show	VBP	O
lack	NN	O
of	IN	O
Fas	NNP	O
-	:	O
induced	JJ	O
apoptosis	NN	O
.	.	O

The	DT	O
children	NNS	O
share	NN	O
common	JJ	O
clinical	JJ	O
features	NNS	O
including	VBG	O
splenomegaly	NN	S_Disease
and	CC	O
lymphadenopathy	JJ	S_Disease
,	,	O
but	CC	O
only	RB	O
one	CD	O
developed	VBD	O
severe	JJ	O
autoimmune	JJ	B_Disease
manifestations	NNS	E_Disease
.	.	O

In	IN	O
all	DT	O
three	CD	O
siblings	NNS	O
,	,	O
we	PRP	O
demonstrated	VBD	O
the	DT	O
presence	NN	O
of	IN	O
anergic	JJ	O
CD3	NNP	O
+	NNP	O
CD4	NNP	O
-	:	O
CD8	NNP	O
-	:	O
(	(	O
double	JJ	O
negative	JJ	O
,	,	O
[	JJ	O
DN	NNP	O
]	NNP	O
)	)	O
T	NNP	O
cells	NNS	O
;	:	O
moreover	RB	O
,	,	O
a	DT	O
chronic	JJ	O
lymphocyte	NN	O
activation	NN	O
was	VBD	O
found	VBN	O
,	,	O
as	IN	O
demonstrated	VBN	O
by	IN	O
the	DT	O
presence	NN	O
of	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
HLA	NNP	O
-	:	O
DR	NNP	O
expression	NN	O
on	IN	O
peripheral	JJ	O
CD3	NNP	O
+	NNP	O
cells	NNS	O
and	CC	O
by	IN	O
the	DT	O
presence	NN	O
of	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
serum	NN	O
activation	NN	O
markers	NNS	O
such	JJ	O
as	IN	O
soluble	JJ	O
interleukin	JJ	O
-	:	O
2	CD	O
receptor	NN	O
(	(	O
slL	JJ	O
-	:	O
2R	CD	O
)	)	O
and	CC	O
soluble	JJ	O
CD30	NNP	O
(	(	O
sCD30	NN	O
)	)	O
.	.	O
.	.	O

The	DT	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
gene	NN	O
product	NN	O
,	,	O
a	DT	O
constitutively	RB	O
expressed	VBN	O
nuclear	JJ	O
protein	NN	O
that	WDT	O
is	VBZ	O
not	RB	O
up	RP	O
-	:	O
regulated	VBN	O
following	VBG	O
genome	JJ	O
damage	NN	O
.	.	O

The	DT	O
product	NN	O
of	IN	O
the	DT	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
gene	NN	O
(	(	O
ATM	NNP	O
)	)	O
was	VBD	O
identified	VBN	O
by	IN	O
using	VBG	O
an	DT	O
antiserum	NN	O
developed	VBD	O
to	TO	O
a	DT	O
peptide	NN	O
corresponding	VBG	O
to	TO	O
the	DT	O
deduced	VBN	O
amino	NN	O
acid	NN	O
sequence	NN	O
.	.	O

The	DT	O
ATM	NNP	O
protein	NN	O
is	VBZ	O
a	DT	O
single	JJ	O
,	,	O
high	JJ	O
-	:	O
molecular	JJ	O
weight	NN	O
protein	NN	O
predominantly	RB	O
confined	VBN	O
to	TO	O
the	DT	O
nucleus	NN	O
of	IN	O
human	JJ	O
fibroblasts	NNS	O
,	,	O
but	CC	O
is	VBZ	O
present	JJ	O
in	IN	O
both	DT	O
nuclear	JJ	O
and	CC	O
microsomal	JJ	O
fractions	NNS	O
from	IN	O
human	JJ	O
lymphoblast	NN	O
cells	NNS	O
and	CC	O
peripheral	JJ	O
blood	NN	O
lymphocytes	NNS	O
.	.	O

ATM	NNP	O
protein	NN	O
levels	NNS	O
and	CC	O
localization	NN	O
remain	VBP	O
constant	JJ	O
throughout	IN	O
all	DT	O
stages	NNS	O
of	IN	O
the	DT	O
cell	NN	O
cycle	NN	O
.	.	O

Truncated	VBN	O
ATM	NNP	O
protein	NN	O
was	VBD	O
not	RB	O
detected	VBN	O
in	IN	O
lymphoblasts	NNS	O
from	IN	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
patients	NNS	O
homozygous	JJ	O
for	IN	O
mutations	NNS	O
leading	VBG	O
to	TO	O
premature	VB	O
protein	JJ	O
termination	NN	O
.	.	O

Exposure	NN	O
of	IN	O
normal	JJ	O
human	JJ	O
cells	NNS	O
to	TO	O
gamma	VB	O
-	:	O
irradiation	NN	O
and	CC	O
the	DT	O
radiomimetic	JJ	O
drug	NN	O
neocarzinostatin	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
ATM	NNP	O
protein	NN	O
levels	NNS	O
,	,	O
in	IN	O
contrast	NN	O
to	TO	O
a	DT	O
noted	JJ	O
rise	NN	O
in	IN	O
p53	NN	O
levels	NNS	O
over	IN	O
the	DT	O
same	JJ	O
time	NN	O
interval	NN	O
.	.	O

These	DT	O
findings	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
a	DT	O
role	NN	O
for	IN	O
the	DT	O
ATM	NNP	O
protein	NN	O
in	IN	O
ensuring	VBG	O
the	DT	O
fidelity	NN	O
of	IN	O
DNA	NNP	O
repair	NN	O
and	CC	O
cell	NN	O
cycle	NN	O
regulation	NN	O
following	VBG	O
genome	JJ	O
damage	NN	O
.	.	O
.	.	O

Type	NNP	O
III	NNP	O
collagen	NN	O
is	VBZ	O
crucial	JJ	O
for	IN	O
collagen	NN	O
I	PRP	O
fibrillogenesis	VBP	O
and	CC	O
for	IN	O
normal	JJ	O
cardiovascular	JJ	O
development	NN	O
.	.	O

Type	NNP	O
III	NNP	O
collagen	NN	O
is	VBZ	O
a	DT	O
fibrillar	JJ	O
forming	NN	O
collagen	NN	O
comprising	VBG	O
three	CD	O
alpha1	NN	O
(	(	O
III	NNP	O
)	)	O
chains	NNS	O
and	CC	O
is	VBZ	O
expressed	VBN	O
in	IN	O
early	JJ	O
embryos	NN	O
and	CC	O
throughout	IN	O
embryogenesis	NN	O
.	.	O

In	IN	O
the	DT	O
adult	NN	O
,	,	O
type	NN	O
III	NNP	O
collagen	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
component	NN	O
of	IN	O
the	DT	O
extracellular	JJ	O
matrix	NN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
internal	JJ	O
organs	NNS	O
and	CC	O
skin	NN	O
.	.	O

Mutations	NNS	O
in	IN	O
the	DT	O
COL3A1	NNP	O
gene	NN	O
have	VBP	O
been	VBN	O
implicated	VBN	O
as	IN	O
a	DT	O
cause	NN	O
of	IN	O
type	NN	B_Disease
IV	NNP	I_Disease
Ehlers	NNP	I_Disease
-	:	I_Disease
Danlos	NNP	I_Disease
syndrome	NN	E_Disease
,	,	O
a	DT	O
disease	NN	O
leading	VBG	O
to	TO	O
aortic	JJ	B_Disease
rupture	NN	E_Disease
in	IN	O
early	JJ	O
adult	NN	O
life	NN	O
.	.	O

To	TO	O
directly	RB	O
study	VB	O
the	DT	O
role	NN	O
of	IN	O
Col3a1	NNP	O
in	IN	O
development	NN	O
and	CC	O
disease	NN	O
,	,	O
we	PRP	O
have	VBP	O
inactivated	VBN	O
the	DT	O
Col3a1	NNP	O
gene	NN	O
in	IN	O
embryonic	JJ	O
stem	NN	O
cells	NNS	O
by	IN	O
homologous	JJ	O
recombination	NN	O
.	.	O

The	DT	O
mutated	JJ	O
allele	NN	O
was	VBD	O
transmitted	VBN	O
through	IN	O
the	DT	O
mouse	NN	O
germ	JJ	O
line	NN	O
and	CC	O
homozygous	JJ	O
mutant	NN	O
animals	NNS	O
were	VBD	O
derived	VBN	O
from	IN	O
heterozygous	JJ	O
intercrosses	NNS	O
.	.	O

About	RB	O
10	CD	O
%	NN	O
of	IN	O
the	DT	O
homozygous	JJ	O
mutant	NN	O
animals	NNS	O
survived	VBD	O
to	TO	O
adulthood	VB	O
but	CC	O
have	VB	O
a	DT	O
much	JJ	O
shorter	JJR	O
life	NN	O
span	NNS	O
compared	VBN	O
with	IN	O
wild	JJ	O
-	:	O
type	NN	O
mice	NN	O
.	.	O

The	DT	O
major	JJ	O
cause	NN	O
of	IN	O
death	NN	O
of	IN	O
mutant	JJ	O
mice	NN	O
was	VBD	O
rupture	NN	O
of	IN	O
the	DT	O
major	JJ	O
blood	NN	O
vessels	NNS	O
,	,	O
similar	JJ	O
to	TO	O
patients	NNS	O
with	IN	O
type	JJ	B_Disease
IV	NNP	I_Disease
Ehlers	NNP	I_Disease
-	:	I_Disease
Danlos	NNP	I_Disease
syndrome	NN	E_Disease
.	.	O

Ultrastructural	JJ	O
analysis	NN	O
of	IN	O
tissues	NNS	O
from	IN	O
mutant	JJ	O
mice	NN	O
revealed	VBD	O
that	IN	O
type	NN	O
III	NNP	O
collagen	NN	O
is	VBZ	O
essential	JJ	O
for	IN	O
normal	JJ	O
collagen	NN	O
I	PRP	O
fibrillogenesis	VBP	O
in	IN	O
the	DT	O
cardiovascular	JJ	O
system	NN	O
and	CC	O
other	JJ	O
organs	NNS	O
.	.	O
.	.	O

Nonsense	NNP	O
mutation	NN	O
in	IN	O
exon	JJ	O
3	CD	O
of	IN	O
the	DT	O
proteolipid	JJ	O
protein	NN	O
gene	NN	O
(	(	O
PLP	NNP	O
)	)	O
in	IN	O
a	DT	O
family	NN	O
with	IN	O
an	DT	O
unusual	JJ	O
form	NN	O
of	IN	O
Pelizaeus	NNP	B_Disease
-	:	I_Disease
Merzbacher	PRP$	I_Disease
disease	NN	E_Disease
.	.	O

We	PRP	O
report	VBP	O
a	DT	O
G	NNP	O
-	:	O
-	:	O
>	VB	O
A	DT	O
transition	NN	O
at	IN	O
nucleotide	JJ	O
431	CD	O
of	IN	O
the	DT	O
proteolipid	JJ	O
protein	NN	O
gene	NN	O
(	(	O
PLP	NNP	O
)	)	O
results	NNS	O
in	IN	O
a	DT	O
nonsense	JJ	O
codon	NN	O
in	IN	O
a	DT	O
family	NN	O
with	IN	O
an	DT	O
unusual	JJ	O
form	NN	O
of	IN	O
Pelizaeus	NNP	B_Disease
-	:	I_Disease
Merzbacher	PRP$	I_Disease
disease	NN	E_Disease
(	(	O
PMD	NNP	S_Disease
)	)	O
.	.	O

The	DT	O
mutation	NN	O
,	,	O
which	WDT	O
creates	VBZ	O
a	DT	O
second	JJ	O
AluI	NNP	O
restriction	NN	O
site	NN	O
,	,	O
results	NNS	O
in	IN	O
a	DT	O
nonsense	JJ	O
mutation	NN	O
in	IN	O
PLP	NNP	O
.	.	O

The	DT	O
clinical	JJ	O
picture	NN	O
resembles	VBZ	O
somewhat	RB	O
that	IN	O
of	IN	O
X	NNP	B_Disease
-	:	I_Disease
linked	VBN	I_Disease
spastic	JJ	I_Disease
paraplegia	NN	E_Disease
(	(	O
SPG	NNP	S_Disease
)	)	O
.	.	O

It	PRP	O
differs	VBZ	O
from	IN	O
this	DT	O
and	CC	O
both	DT	O
the	DT	O
classical	JJ	O
and	CC	O
connatal	JJ	O
forms	NNS	O
of	IN	O
PMD	NNP	S_Disease
in	IN	O
that	DT	O
it	PRP	O
is	VBZ	O
relatively	RB	O
mild	JJ	O
in	IN	O
form	NN	O
,	,	O
onset	NN	O
is	VBZ	O
delayed	VBN	O
beyond	IN	O
age	NN	O
2	CD	O
years	NNS	O
,	,	O
nystagmus	NN	S_Disease
is	VBZ	O
absent	JJ	O
,	,	O
tremors	NNS	S_Disease
are	VBP	O
prominent	JJ	O
,	,	O
mental	JJ	B_Disease
retardation	NN	E_Disease
is	VBZ	O
not	RB	O
severe	JJ	O
,	,	O
some	DT	O
patients	NNS	O
show	VBP	O
dementia	JJ	S_Disease
or	CC	O
personality	NN	B_Disease
disorders	NNS	E_Disease
,	,	O
the	DT	O
disease	NN	O
is	VBZ	O
progressive	JJ	O
rather	RB	O
than	IN	O
static	JJ	O
in	IN	O
some	DT	O
,	,	O
and	CC	O
several	JJ	O
females	NNS	O
show	VBP	O
signs	NNS	O
of	IN	O
disease	NN	O
.	.	O

The	DT	O
nonsense	JJ	O
mutation	NN	O
,	,	O
which	WDT	O
is	VBZ	O
in	IN	O
exon	JJ	O
3B	CD	O
,	,	O
should	MD	O
block	VB	O
the	DT	O
synthesis	NN	O
of	IN	O
normal	JJ	O
PLP	NNP	O
but	CC	O
spare	JJ	O
DM20	NNP	O
,	,	O
the	DT	O
isoform	NN	O
whose	WP$	O
persistence	NN	O
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
mild	JJ	O
forms	NNS	O
of	IN	O
PLP	NNP	B_Disease
-	:	I_Disease
associated	JJ	I_Disease
disease	NN	E_Disease
in	IN	O
both	DT	O
humans	NNS	O
and	CC	O
mice	NN	O
.	.	O
.	.	O

Common	JJ	O
BRCA1	NNP	O
variants	NNS	O
and	CC	O
susceptibility	NN	O
to	TO	O
breast	VB	B_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
in	IN	O
the	DT	O
general	JJ	O
population	NN	O
.	.	O

Most	JJS	O
multiple	JJ	O
case	NN	O
families	NNS	O
of	IN	O
young	JJ	O
onset	VBN	O
breast	NN	B_Disease
cancer	NN	E_Disease
and	CC	O
ovarian	JJ	B_Disease
cancer	NN	E_Disease
are	VBP	O
thought	VBN	O
to	TO	O
be	VB	O
due	JJ	O
to	TO	O
highly	RB	O
penetrant	JJ	O
mutations	NNS	O
in	IN	O
the	DT	O
predisposing	NN	O
genes	NNS	O
BRCA1	NNP	O
and	CC	O
BRCA2	NNP	O
.	.	O

However	RB	O
,	,	O
these	DT	O
mutations	NNS	O
are	VBP	O
uncommon	JJ	O
in	IN	O
the	DT	O
population	NN	O
and	CC	O
they	PRP	O
probably	RB	O
account	VBP	O
for	IN	O
only	RB	O
a	DT	O
few	JJ	O
percent	NN	O
of	IN	O
all	DT	O
breast	NN	B_Disease
cancer	NN	E_Disease
incidence	NN	O
.	.	O

A	DT	O
much	RB	O
larger	JJR	O
fraction	NN	O
of	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
might	MD	O
,	,	O
in	IN	O
principle	NN	O
,	,	O
be	VB	O
due	JJ	O
to	TO	O
common	JJ	O
variants	NNS	O
which	WDT	O
confer	VBP	O
more	JJR	O
modest	JJ	O
individual	JJ	O
risks	NNS	O
.	.	O

There	EX	O
are	VBP	O
several	JJ	O
common	JJ	O
polymorphisms	NNS	O
in	IN	O
the	DT	O
BRCA1	NNP	O
gene	NN	O
which	WDT	O
generate	VBP	O
amino	NN	O
acid	JJ	O
substitutions	NNS	O
.	.	O

We	PRP	O
have	VBP	O
examined	VBN	O
the	DT	O
frequency	NN	O
of	IN	O
four	CD	O
of	IN	O
these	DT	O
polymorphisms	NNS	O
Gln356Arg	NNP	O
,	,	O
Pro871Leu	NNP	O
,	,	O
Glu1038Gly	NNP	O
and	CC	O
Ser1613Gly	NNP	O
in	IN	O
large	JJ	O
series	NN	O
of	IN	O
breast	NN	B_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
cases	NNS	O
and	CC	O
matched	JJ	O
controls	NNS	O
.	.	O

Due	JJ	O
to	TO	O
strong	JJ	O
linkage	NN	O
disequilibrium	NN	O
,	,	O
these	DT	O
four	CD	O
sites	NNS	O
generate	VBP	O
only	RB	O
three	CD	O
haplotypes	NNS	O
with	IN	O
a	DT	O
frequency	NN	O
>	$	O
1	CD	O
.	.	O

3	CD	O
%	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
haplotypes	NNS	O
,	,	O
defined	VBN	O
by	IN	O
the	DT	O
alleles	NNS	O
Gln356Pro871Glu1038Ser1613	NNP	O
and	CC	O
Gln356Leu871Gly1038Gly1613	NNP	O
,	,	O
have	VBP	O
frequencies	NNS	O
of	IN	O
0	CD	O
.	.	O

57	CD	O
and	CC	O
0	CD	O
.	.	O

32	CD	O
respectively	RB	O
,	,	O
and	CC	O
these	DT	O
frequencies	NNS	O
do	VBP	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
patient	JJ	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Thus	RB	O
the	DT	O
most	RBS	O
common	JJ	O
polymorphisms	NN	O
of	IN	O
the	DT	O
BRCA1	NNP	O
gene	NN	O
do	VBP	O
not	RB	O
make	VB	O
a	DT	O
significant	JJ	O
contribution	NN	O
to	TO	O
breast	VB	B_Disease
or	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
risk	NN	O
.	.	O

However	RB	O
,	,	O
our	PRP$	O
data	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
Arg356	NNP	O
allele	NN	O
may	MD	O
have	VB	O
a	DT	O
different	JJ	O
genotype	NN	O
distribution	NN	O
in	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
patients	NNS	O
from	IN	O
that	DT	O
in	IN	O
controls	NNS	O
(	(	O
Arg356	NNP	O
homozygotes	NNS	O
are	VBP	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
control	NN	O
groups	NNS	O
,	,	O
P	NNP	O
=	VBZ	O
0	CD	O
.	.	O

01	CD	O
)	)	O
,	,	O
indicating	VBG	O
that	IN	O
it	PRP	O
may	MD	O
be	VB	O
protective	JJ	O
against	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
.	.	O

If	IN	O
this	DT	O
finding	NN	O
can	MD	O
be	VB	O
confirmed	VBN	O
,	,	O
it	PRP	O
may	MD	O
provide	VB	O
an	DT	O
insight	NN	O
into	IN	O
the	DT	O
structural	JJ	O
features	NNS	O
of	IN	O
the	DT	O
BRCA1	NNP	O
protein	NN	O
that	WDT	O
are	VBP	O
important	JJ	O
for	IN	O
its	PRP$	O
function	NN	O
.	.	O

Kniest	NNP	B_Disease
dysplasia	NN	E_Disease
:	:	O
Dr	NNP	O
.	.	O

W	NNP	O
.	.	O

Kniest	NNP	O
,	,	O
his	PRP$	O
patient	NN	O
,	,	O
the	DT	O
molecular	JJ	O
defect	NN	O
.	.	O

Kniest	NNP	B_Disease
dysplasia	NN	E_Disease
is	VBZ	O
a	DT	O
severe	JJ	O
chondrodysplasia	NN	S_Disease
caused	VBN	O
by	IN	O
the	DT	O
defective	JJ	B_Disease
formation	NN	I_Disease
of	IN	I_Disease
type	NN	I_Disease
II	NNP	I_Disease
collagen	NN	E_Disease
.	.	O

We	PRP	O
report	VBP	O
about	IN	O
Dr	NNP	O
.	.	O

Kniest	NNP	O
,	,	O
who	WP	O
first	RB	O
described	VBD	O
the	DT	O
condition	NN	O
in	IN	O
1952	CD	O
,	,	O
and	CC	O
his	PRP$	O
patient	NN	O
,	,	O
who	WP	O
,	,	O
at	IN	O
the	DT	O
age	NN	O
of	IN	O
50	CD	O
years	NNS	O
is	VBZ	O
severely	RB	B_Disease
handicapped	VBN	E_Disease
with	IN	O
short	JJ	B_Disease
stature	NN	E_Disease
,	,	O
restricted	VBD	B_Disease
joint	JJ	I_Disease
mobility	NN	E_Disease
,	,	O
and	CC	O
blindness	NN	S_Disease
but	CC	O
is	VBZ	O
mentally	RB	O
alert	JJ	O
and	CC	O
leads	VBZ	O
an	DT	O
active	JJ	O
life	NN	O
.	.	O

Molecular	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
patients	NNS	O
DNA	NNP	O
showed	VBD	O
a	DT	O
single	JJ	O
base	NN	O
(	(	O
G	NNP	O
)	)	O
deletion	NN	O
involving	VBG	O
the	DT	O
GT	NNP	O
dinucleotide	NN	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
intron	NN	O
18	CD	O
destroying	VBG	O
a	DT	O
splice	JJ	O
site	NN	O
of	IN	O
the	DT	O
COL2A1	NNP	O
gene	NN	O
.	.	O

This	DT	O
is	VBZ	O
in	IN	O
accordance	NN	O
with	IN	O
molecular	JJ	O
findings	NNS	O
in	IN	O
other	JJ	O
patients	NNS	O
with	IN	O
Kniest	NNP	B_Disease
dysplasia	NN	E_Disease
and	CC	O
confirms	NNS	O
,	,	O
in	IN	O
the	DT	O
original	JJ	O
patient	NN	O
,	,	O
that	IN	O
the	DT	O
disorder	NN	O
is	VBZ	O
caused	VBN	O
by	IN	O
small	JJ	O
inframe	NN	O
deletions	NNS	O
often	RB	O
due	JJ	O
to	TO	O
exon	VB	O
skipping	VBG	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
COL2A1	NNP	O
splice	NN	O
site	NN	O
mutations	NNS	O
.	.	O
.	.	O

Cloning	NN	O
of	IN	O
the	DT	O
homogentisate	NN	O
1	CD	O
,	,	O
2	CD	O
-	:	O
dioxygenase	NN	O
gene	NN	O
,	,	O
the	DT	O
key	JJ	O
enzyme	NN	O
of	IN	O
alkaptonuria	NN	S_Disease
in	IN	O
mouse	NN	O
.	.	O

We	PRP	O
determined	VBD	O
48	CD	O
amino	NN	O
acid	NN	O
residues	NNS	O
from	IN	O
five	CD	O
peptides	NNS	O
from	IN	O
the	DT	O
homogeneous	JJ	O
monomer	NN	O
of	IN	O
homogentisate	NN	O
1	CD	O
,	,	O
2	CD	O
-	:	O
dioxygenase	NN	O
(	(	O
HGO	NNP	O
;	:	O
E	NNP	O
.	.	O

C	NNP	O
.	.	O

1	CD	O
.	.	O

13	CD	O
.	.	O

11	CD	O
.	.	O

15	CD	O
)	)	O
of	IN	O
mouse	NN	O
liver	NN	O
.	.	O

After	IN	O
digestion	NN	O
with	IN	O
trypsin	NN	O
,	,	O
peptides	NNS	O
were	VBD	O
separated	VBN	O
by	IN	O
reversed	JJ	O
phase	NN	O
chromatography	NN	O
and	CC	O
amino	NN	O
acid	NN	O
sequenced	VBD	O
.	.	O

The	DT	O
deduced	JJ	O
codon	NN	O
sequence	NN	O
of	IN	O
three	CD	O
peptides	NNS	O
was	VBD	O
used	VBN	O
to	TO	O
derive	VB	O
degenerated	JJ	O
oligomeres	NNS	O
.	.	O

By	IN	O
combining	VBG	O
these	DT	O
oligos	NNS	O
,	,	O
we	PRP	O
were	VBD	O
able	JJ	O
to	TO	O
amplify	VB	O
fragments	NNS	O
from	IN	O
100	CD	O
to	TO	O
300	CD	O
bases	NNS	O
(	(	O
b	NN	O
)	)	O
from	IN	O
mouse	NN	O
liver	NN	O
cDNA	NN	O
by	IN	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
after	IN	O
reverse	JJ	O
transcription	NN	O
(	(	O
RT	NNP	O
-	:	O
PCR	NN	O
)	)	O
.	.	O

A	DT	O
fragment	NN	O
of	IN	O
200	CD	O
b	NN	O
was	VBD	O
cloned	VBN	O
and	CC	O
used	VBN	O
as	IN	O
a	DT	O
probe	NN	O
to	TO	O
screen	VB	O
a	DT	O
mouse	NN	O
liver	NN	O
cDNA	NN	O
library	NN	O
.	.	O

One	CD	O
clone	NN	O
from	IN	O
this	DT	O
library	NN	O
contained	VBD	O
the	DT	O
complete	JJ	O
cDNA	NN	O
-	:	O
insert	NN	O
for	IN	O
HGO	NNP	O
as	IN	O
determined	VBN	O
by	IN	O
sequencing	VBG	O
.	.	O

The	DT	O
cDNA	NN	O
encodes	VBZ	O
for	IN	O
a	DT	O
protein	NN	O
of	IN	O
50	CD	O
kDa	NNS	O
,	,	O
as	IN	O
predicted	VBN	O
.	.	O

The	DT	O
cDNA	NN	O
of	IN	O
mouse	NN	O
HGO	NNP	O
has	VBZ	O
an	DT	O
overall	JJ	O
identity	NN	O
of	IN	O
41	CD	O
%	NN	O
to	TO	O
the	DT	O
corresponding	JJ	O
gene	NN	O
hmgA	NN	O
from	IN	O
Aspergillus	NNP	O
.	.	O

Sequence	NN	O
similarities	NNS	O
to	TO	O
human	NNS	O
expressed	VBN	O
sequence	NN	O
tags	NN	O
(	(	O
EST	NNP	O
)	)	O
clones	NNS	O
ranged	VBD	O
from	IN	O
70	CD	O
%	NN	O
to	TO	O
20	CD	O
%	NN	O
.	.	O

The	DT	O
positions	NNS	O
of	IN	O
122	CD	O
conserved	VBD	O
amino	NN	O
acids	NNS	O
could	MD	O
be	VB	O
determined	VBN	O
by	IN	O
multiple	JJ	O
sequence	NN	O
alignment	NN	O
.	.	O

We	PRP	O
identified	VBD	O
one	CD	O
first	JJ	O
intron	NN	O
of	IN	O
928	CD	O
b	NN	O
in	IN	O
the	DT	O
mouse	NN	O
gene	NN	O
.	.	O

The	DT	O
gene	NN	O
for	IN	O
HGO	NNP	O
seems	VBZ	O
to	TO	O
be	VB	O
expressed	VBN	O
in	IN	O
various	JJ	O
tissues	NNS	O
,	,	O
as	IN	O
shown	VBN	O
by	IN	O
RT	NNP	O
-	:	O
PCR	NN	O
on	IN	O
different	JJ	O
cDNAs	NN	O
.	.	O

FISH	NN	O
experiments	NNS	O
with	IN	O
the	DT	O
whole	JJ	O
murine	NN	O
cDNA	NN	O
as	IN	O
probe	NN	O
clearly	RB	O
revealed	VBD	O
signals	NNS	O
at	IN	O
the	DT	O
human	JJ	O
chromosomal	JJ	O
band	NN	O
3q13	CD	O
.	.	O

3	LS	O
-	:	O
q21	NN	O
.	.	O

This	DT	O
corresponds	VBZ	O
well	RB	O
to	TO	O
the	DT	O
previous	JJ	O
assignment	NN	O
of	IN	O
the	DT	O
locus	NN	O
for	IN	O
the	DT	O
human	JJ	O
alkaptonuria	NN	S_Disease
gene	NN	O
(	(	O
AKU	NNP	O
)	)	O
to	TO	O
the	DT	O
same	JJ	O
chromosomal	JJ	O
region	NN	O
by	IN	O
multipoint	NN	O
linkage	NN	O
analysis	NN	O
.	.	O

We	PRP	O
therefore	VBP	O
conclude	VBP	O
that	IN	O
the	DT	O
HGO	NNP	O
cDNA	NN	O
encodes	VBZ	O
the	DT	O
gene	NN	O
responsible	JJ	O
for	IN	O
alkaptonuria	NN	S_Disease
.	.	O

PTEN	NNP	O
,	,	O
a	DT	O
putative	JJ	O
protein	NN	O
tyrosine	NN	O
phosphatase	NN	O
gene	NN	O
mutated	VBN	O
in	IN	O
human	JJ	O
brain	NN	B_Disease
,	,	I_Disease
breast	NN	I_Disease
,	,	I_Disease
and	CC	I_Disease
prostate	NN	I_Disease
cancer	NN	E_Disease
.	.	O

Mapping	NN	O
of	IN	O
homozygous	JJ	O
deletions	NNS	O
on	IN	O
human	JJ	O
chromosome	NN	O
10q23	CD	O
has	VBZ	O
led	VBN	O
to	TO	O
the	DT	O
isolation	NN	O
of	IN	O
a	DT	O
candidate	NN	O
tumor	NN	S_Disease
suppressor	NN	O
gene	NN	O
,	,	O
PTEN	NNP	O
,	,	O
that	WDT	O
appears	VBZ	O
to	TO	O
be	VB	O
mutated	VBN	O
at	IN	O
considerable	JJ	O
frequency	NN	O
in	IN	O
human	JJ	O
cancers	NNS	S_Disease
.	.	O

In	IN	O
preliminary	JJ	O
screens	NNS	O
,	,	O
mutations	NNS	O
of	IN	O
PTEN	NNP	O
were	VBD	O
detected	VBN	O
in	IN	O
31	CD	O
%	NN	O
(	(	O
13	CD	O
/	RB	O
42	CD	O
)	)	O
of	IN	O
glioblastoma	NN	S_Disease
cell	NN	O
lines	NNS	O
and	CC	O
xenografts	NNS	O
,	,	O
100	CD	O
%	NN	O
(	(	O
4	CD	O
/	RB	O
4	CD	O
)	)	O
of	IN	O
prostate	NN	B_Disease
cancer	NN	E_Disease
cell	NN	O
lines	NNS	O
,	,	O
6	CD	O
%	NN	O
(	(	O
4	CD	O
/	RB	O
65	CD	O
)	)	O
of	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
cell	NN	O
lines	NNS	O
and	CC	O
xenografts	NNS	O
,	,	O
and	CC	O
17	CD	O
%	NN	O
(	(	O
3	CD	O
/	RB	O
18	CD	O
)	)	O
of	IN	O
primary	JJ	B_Disease
glioblastomas	NN	E_Disease
.	.	O

The	DT	O
predicted	JJ	O
PTEN	NNP	O
product	NN	O
has	VBZ	O
a	DT	O
protein	NN	O
tyrosine	NN	O
phosphatase	NN	O
domain	NN	O
and	CC	O
extensive	JJ	O
homology	NN	O
to	TO	O
tensin	VB	O
,	,	O
a	DT	O
protein	NN	O
that	WDT	O
interacts	VBZ	O
with	IN	O
actin	JJ	O
filaments	NNS	O
at	IN	O
focal	JJ	O
adhesions	NNS	O
.	.	O

These	DT	O
homologies	NNS	O
suggest	VBP	O
that	IN	O
PTEN	NNP	O
may	MD	O
suppress	VB	O
tumor	NN	S_Disease
cell	NN	O
growth	NN	O
by	IN	O
antagonizing	VBG	O
protein	JJ	O
tyrosine	NN	O
kinases	NNS	O
and	CC	O
may	MD	O
regulate	VB	O
tumor	NN	S_Disease
cell	NN	O
invasion	NN	O
and	CC	O
metastasis	NN	S_Disease
through	IN	O
interactions	NNS	O
at	IN	O
focal	JJ	O
adhesions	NNS	O
.	.	O
.	.	O

Heterogeneity	NN	O
in	IN	O
Schwartz	NNP	B_Disease
-	:	I_Disease
Jampel	NNP	I_Disease
chondrodystrophic	JJ	I_Disease
myotonia	NN	E_Disease
.	.	O

The	DT	O
Schwartz	NNP	B_Disease
-	:	I_Disease
Jampel	NNP	I_Disease
syndrome	NN	E_Disease
(	(	O
SJS	NNP	S_Disease
;	:	O
chondrodystrophic	JJ	B_Disease
myotonia	NN	E_Disease
;	:	O
McK	NNP	O
255	CD	O
,	,	O
800	CD	O
)	)	O
is	VBZ	O
a	DT	O
recessively	RB	B_Disease
inherited	JJ	I_Disease
condition	NN	E_Disease
defined	VBN	O
by	IN	O
myotonia	NN	S_Disease
,	,	O
short	JJ	B_Disease
stature	NN	E_Disease
,	,	O
and	CC	O
bone	NN	B_Disease
dysplasia	NN	E_Disease
.	.	O

Genetic	JJ	O
linkage	NN	O
between	IN	O
SJS	NNP	S_Disease
and	CC	O
chromosomal	JJ	O
region	NN	O
1q36	CD	O
-	:	O
34	CD	O
has	VBZ	O
been	VBN	O
observed	VBN	O
in	IN	O
several	JJ	O
families	NNS	O
,	,	O
but	CC	O
the	DT	O
gene	NN	O
has	VBZ	O
not	RB	O
yet	RB	O
been	VBN	O
identified	VBN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
clinical	JJ	O
and	CC	O
radiological	JJ	O
features	NNS	O
in	IN	O
81	CD	O
patients	NNS	O
from	IN	O
the	DT	O
literature	NN	O
and	CC	O
5	CD	O
own	JJ	O
patients	NNS	O
trying	VBG	O
to	TO	O
identify	VB	O
distinct	JJ	O
subgroups	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
we	PRP	O
tested	VBD	O
genetic	JJ	O
linkage	NN	O
to	TO	O
the	DT	O
SJS	NNP	S_Disease
locus	NN	O
on	IN	O
chromosome	NN	O
1	CD	O
in	IN	O
one	CD	O
family	NN	O
with	IN	O
two	CD	O
affected	JJ	O
sibs	NN	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
a	DT	O
group	NN	O
of	IN	O
patients	NNS	O
have	VBP	O
mild	VBN	O
skeletal	JJ	O
changes	NNS	O
which	WDT	O
may	MD	O
be	VB	O
secondary	JJ	O
consequences	NNS	O
of	IN	O
myotonia	NN	S_Disease
,	,	O
while	IN	O
another	DT	O
group	NN	O
of	IN	O
patients	NNS	O
appear	VBP	O
to	TO	O
have	VB	O
primary	JJ	O
bone	NN	B_Disease
dysplasia	NN	E_Disease
with	IN	O
myotonia	NN	S_Disease
.	.	O

Within	IN	O
this	DT	O
latter	JJ	O
group	NN	O
,	,	O
there	EX	O
are	VBP	O
differences	NNS	O
in	IN	O
age	NN	O
of	IN	O
manifestation	NN	O
,	,	O
clinical	JJ	O
course	NN	O
and	CC	O
pattern	NN	O
of	IN	O
bone	NN	O
changes	NNS	O
.	.	O

We	PRP	O
tentatively	RB	O
isolate	VBP	O
three	CD	O
different	JJ	O
types	NNS	O
of	IN	O
SJS	NNP	B_Disease
type	NN	I_Disease
1A	CD	E_Disease
,	,	O
usually	RB	O
recognized	VBN	O
in	IN	O
childhood	NN	O
,	,	O
with	IN	O
moderate	JJ	O
bone	NN	B_Disease
dysplasia	NN	E_Disease
,	,	O
corresponding	VBG	O
to	TO	O
the	DT	O
original	JJ	O
descriptions	NNS	O
of	IN	O
Schwartz	NNP	O
,	,	O
Jampel	NNP	O
and	CC	O
Aberfeld	NNP	O
;	:	O
type	NN	O
1B	CD	O
,	,	O
similar	JJ	O
to	TO	O
type	VB	O
1A	CD	O
but	CC	O
recognizable	JJ	O
at	IN	O
birth	NN	O
,	,	O
with	IN	O
more	RBR	O
pronounced	JJ	O
bone	NN	B_Disease
dysplasia	NN	E_Disease
resembling	VBG	O
Kniest	NNP	B_Disease
dysplasia	NN	E_Disease
;	:	O
and	CC	O
type	VB	O
2	CD	O
,	,	O
manifest	NN	O
at	IN	O
birth	NN	O
,	,	O
with	IN	O
increased	VBN	O
mortality	NN	O
and	CC	O
bone	NN	B_Disease
dysplasia	NN	E_Disease
resembling	VBG	O
Pyle	NNP	B_Disease
disease	NN	E_Disease
.	.	O

Genetic	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
family	NN	O
with	IN	O
two	CD	O
sibs	NNS	O
affected	VBN	O
by	IN	O
SJS	NNP	B_Disease
type	NN	I_Disease
2	CD	E_Disease
showed	VBD	O
evidence	NN	O
against	IN	O
linkage	NN	O
to	TO	O
chromosome	VB	O
1p36	CD	O
-	:	O
34	CD	O
.	.	O

CONCLUSIONS	NNP	O
SJS	NNP	S_Disease
is	VBZ	O
clinically	RB	O
and	CC	O
radiologically	RB	O
heterogeneous	JJ	O
.	.	O

The	DT	O
causes	NNS	O
of	IN	O
heterogeneity	NN	O
are	VBP	O
not	RB	O
known	VBN	O
yet	RB	O
but	CC	O
are	VBP	O
likely	JJ	O
to	TO	O
include	VB	O
both	DT	O
different	JJ	O
mutations	NNS	O
at	IN	O
the	DT	O
SJS	NNP	S_Disease
locus	NN	O
on	IN	O
chromosome	NN	O
1	CD	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
second	JJ	O
SJS	NNP	S_Disease
locus	NN	O
.	.	O

A	DT	O
tentative	JJ	O
clinico	NN	O
-	:	O
radiological	JJ	O
classification	NN	O
can	MD	O
be	VB	O
useful	JJ	O
for	IN	O
the	DT	O
characterization	NN	O
of	IN	O
patients	NNS	O
and	CC	O
the	DT	O
development	NN	O
of	IN	O
genotype	NN	O
-	:	O
phenotype	NN	O
correlations	NNS	O
.	.	O
.	.	O

A	DT	O
clinical	JJ	O
overview	NN	O
of	IN	O
WT1	NNP	O
gene	NN	O
mutations	NNS	O
.	.	O

Mutations	NNS	O
in	IN	O
the	DT	O
WT1	NNP	O
gene	NN	O
were	VBD	O
anticipated	VBN	O
to	TO	O
explain	VB	O
the	DT	O
genetic	JJ	O
basis	NN	O
of	IN	O
the	DT	O
childhood	NN	O
kidney	NN	B_Disease
cancer	NN	E_Disease
,	,	O
Wilms	NNP	B_Disease
tumour	NN	E_Disease
(	(	O
WT	NNP	S_Disease
)	)	O
.	.	O

Six	CD	O
years	NNS	O
on	IN	O
,	,	O
we	PRP	O
review	VBP	O
100	CD	O
reports	NNS	O
of	IN	O
intragenic	JJ	O
WT1	NNP	O
mutations	NNS	O
and	CC	O
examine	VB	O
the	DT	O
accompanying	VBG	O
clinical	JJ	O
phenotypes	NNS	O
.	.	O

While	IN	O
only	RB	O
5	CD	O
%	NN	O
of	IN	O
sporadic	JJ	B_Disease
Wilms	NNP	I_Disease
tumours	NNS	E_Disease
have	VBP	O
intragenic	JJ	O
WT1	NNP	O
mutations	NNS	O
,	,	O
>	VBP	O
90	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
the	DT	O
Denys	NNP	B_Disease
-	:	I_Disease
Drash	NNP	I_Disease
syndrome	NN	E_Disease
(	(	O
renal	JJ	B_Disease
nephropathy	NN	E_Disease
,	,	O
gonadal	JJ	B_Disease
anomaly	NN	E_Disease
,	,	O
predisposition	NN	B_Disease
to	TO	I_Disease
WT	NNP	E_Disease
)	)	O
carry	VBP	O
constitutional	JJ	O
intragenic	JJ	O
WT1	NNP	O
mutations	NNS	O
.	.	O

WT1	NNP	O
mutations	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
reported	VBN	O
in	IN	O
juvenile	NN	B_Disease
granulosa	NN	I_Disease
cell	NN	I_Disease
tumour	NN	E_Disease
,	,	O
non	SYM	B_Disease
-	:	I_Disease
asbestos	NN	I_Disease
related	JJ	I_Disease
mesothelioma	NN	E_Disease
,	,	O
desmoplastic	JJ	B_Disease
small	JJ	I_Disease
round	NN	I_Disease
cell	NN	I_Disease
tumour	NN	E_Disease
and	CC	O
,	,	O
most	RBS	O
recently	RB	O
,	,	O
acute	JJ	B_Disease
myeloid	NN	I_Disease
leukemia	NN	E_Disease
.	.	O
.	.	O

A	DT	O
mutation	NN	O
in	IN	O
autosomal	JJ	B_Disease
dominant	JJ	I_Disease
myotonia	NN	I_Disease
congenita	NN	E_Disease
affects	VBZ	O
pore	IN	O
properties	NNS	O
of	IN	O
the	DT	O
muscle	NN	O
chloride	NN	O
channel	NN	O
.	.	O

Autosomal	NNP	B_Disease
dominant	JJ	I_Disease
myotonia	NN	I_Disease
congenita	NN	E_Disease
is	VBZ	O
an	DT	O
inherited	JJ	B_Disease
disorder	NN	I_Disease
of	IN	I_Disease
skeletal	JJ	I_Disease
muscle	NN	E_Disease
caused	VBN	O
by	IN	O
mutations	NNS	O
in	IN	O
a	DT	O
voltage	NN	O
-	:	O
gated	VBN	O
Cl	NNP	O
-	:	O
channel	NN	O
gene	NN	O
(	(	O
CLCN1	NNP	O
,	,	O
7q35	CD	O
)	)	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
report	VBP	O
that	IN	O
a	DT	O
mutation	NN	O
predicting	VBG	O
the	DT	O
substitution	NN	O
of	IN	O
Gly	NNP	O
230	CD	O
by	IN	O
glutamic	JJ	O
acid	NN	O
(	(	O
G230E	NNP	O
)	)	O
between	IN	O
segments	NNS	O
D3	NNP	O
and	CC	O
D4	NNP	O
dramatically	RB	O
alters	VBZ	O
the	DT	O
pore	NN	O
properties	NNS	O
of	IN	O
a	DT	O
recombinant	JJ	O
human	JJ	O
muscle	NN	O
Cl	NNP	O
-	:	O
channel	NN	O
(	(	O
hCIC	JJ	O
-	:	O
1	CD	O
)	)	O
expressed	VBN	O
in	IN	O
a	DT	O
mammalian	JJ	O
cell	NN	O
line	NN	O
(	(	O
tsA201	NN	O
)	)	O
.	.	O

The	DT	O
G230E	NNP	O
mutation	NN	O
causes	VBZ	O
substantial	JJ	O
changes	NNS	O
in	IN	O
anion	NN	O
and	CC	O
cation	NN	O
selectivity	NN	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
fundamental	JJ	O
change	NN	O
in	IN	O
rectification	NN	O
of	IN	O
the	DT	O
current	JJ	O
-	:	O
voltage	NN	O
relationship	NN	O
.	.	O

Whereas	NNP	O
wild	SYM	O
-	:	O
type	NN	O
channels	NNS	O
are	VBP	O
characterized	VBN	O
by	IN	O
pronounced	JJ	O
inward	JJ	O
rectification	NN	O
and	CC	O
a	DT	O
Cl	NNP	O
>	NNP	O
thiocyanate	NN	O
>	NNP	O
Br	NNP	O
>	NNP	O
NO	NNP	O
(	(	O
3	CD	O
)	)	O
>	NN	O
I	PRP	O
>	VBP	O
CH	NNP	O
(	(	O
3	CD	O
)	)	O
SO	NNP	O
(	(	O
3	CD	O
)	)	O
selectivity	NN	O
,	,	O
G230E	NNP	O
exhibits	VBZ	O
outward	JJ	O
rectification	NN	O
at	IN	O
positive	JJ	O
potentials	NNS	O
and	CC	O
a	DT	O
thiocyanate	NN	O
>	NN	O
NO	NNP	O
(	(	O
3	CD	O
)	)	O
>	NN	O
I	PRP	O
>	VBP	O
Br	NNP	O
>	NNP	O
Cl	NNP	O
>	NNP	O
CH	NNP	O
(	(	O
3	CD	O
)	)	O
SO	NNP	O
(	(	O
3	CD	O
)	)	O
selectivity	NN	O
.	.	O

Furthermore	RB	O
,	,	O
the	DT	O
cation	NN	O
-	:	O
to	TO	O
-	:	O
anion	NN	O
permeability	NN	O
ratio	NN	O
of	IN	O
the	DT	O
mutant	NN	O
is	VBZ	O
much	RB	O
greater	JJR	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
wild	JJ	O
-	:	O
type	NN	O
channel	NN	O
.	.	O

Voltage	NNP	O
-	:	O
dependent	NN	O
blocks	NNS	O
by	IN	O
intracellular	JJ	O
and	CC	O
extracellular	JJ	O
iodide	NN	O
help	NN	O
to	TO	O
distinguish	VB	O
two	CD	O
distinct	JJ	O
ion	NN	O
binding	VBG	O
sites	NNS	O
within	IN	O
the	DT	O
hClC	NN	O
-	:	O
1	CD	O
conduction	NN	O
pathway	NN	O
.	.	O

Both	DT	O
binding	VBG	O
sites	NNS	O
are	VBP	O
preserved	VBN	O
in	IN	O
the	DT	O
mutant	NN	O
but	CC	O
have	VBP	O
decreased	VBN	O
affinities	NNS	O
for	IN	O
iodide	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
Gly	NNP	O
230	CD	O
is	VBZ	O
critical	JJ	O
for	IN	O
normal	JJ	O
ion	NN	O
conductance	NN	O
in	IN	O
hClC	JJ	O
-	:	O
1	CD	O
and	CC	O
that	IN	O
this	DT	O
residue	JJ	O
resides	NNS	O
within	IN	O
the	DT	O
channel	NN	O
pore	NN	O
.	.	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
PAX6	NNP	O
mutation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
simple	JJ	O
aniridia	NN	S_Disease
:	:	O
an	DT	O
evaluation	NN	O
of	IN	O
mutation	NN	O
detection	NN	O
in	IN	O
12	CD	O
cases	NNS	O
.	.	O

Twelve	NNP	O
aniridia	NN	S_Disease
patients	NNS	O
,	,	O
five	CD	O
with	IN	O
a	DT	O
family	NN	O
history	NN	O
and	CC	O
seven	CD	O
presumed	VBD	O
to	TO	O
be	VB	O
sporadic	JJ	O
,	,	O
were	VBD	O
exhaustively	RB	O
screened	VBN	O
in	IN	O
order	NN	O
to	TO	O
test	VB	O
what	WP	O
proportion	NN	O
of	IN	O
people	NNS	O
with	IN	O
aniridia	NN	S_Disease
,	,	O
uncomplicated	VBN	O
by	IN	O
associated	JJ	O
anomalies	NNS	O
,	,	O
carry	VBP	O
mutations	NNS	O
in	IN	O
the	DT	O
human	JJ	O
PAX6	NNP	O
gene	NN	O
.	.	O

Mutations	NNS	O
were	VBD	O
detected	VBN	O
in	IN	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
cases	NNS	O
.	.	O

Three	CD	O
mutation	NN	O
detection	NN	O
techniques	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
if	IN	O
one	CD	O
method	NN	O
was	VBD	O
superior	JJ	O
for	IN	O
this	DT	O
gene	NN	O
.	.	O

The	DT	O
protein	NN	O
truncation	NN	O
test	NN	O
(	(	O
PTT	NNP	O
)	)	O
was	VBD	O
used	VBN	O
on	IN	O
RT	NNP	O
-	:	O
PCR	NN	O
products	NNS	O
,	,	O
SSCP	NNP	O
on	IN	O
genomic	JJ	O
PCR	NNP	O
amplifications	NNS	O
,	,	O
and	CC	O
chemical	JJ	O
cleavage	NN	O
of	IN	O
mismatch	NN	O
on	IN	O
both	DT	O
RT	NNP	O
-	:	O
PCR	NN	O
and	CC	O
genomic	JJ	O
amplifications	NNS	O
.	.	O

For	IN	O
RT	NNP	O
-	:	O
PCR	NN	O
products	NNS	O
,	,	O
only	RB	O
the	DT	O
translated	JJ	O
portion	NN	O
of	IN	O
the	DT	O
gene	NN	O
was	VBD	O
screened	VBN	O
.	.	O

On	IN	O
genomic	JJ	O
products	NNS	O
exons	NNS	O
1	CD	O
to	TO	O
13	CD	O
(	(	O
including	VBG	O
740	CD	O
bp	NN	O
of	IN	O
the	DT	O
3	CD	O
untranslated	JJ	O
sequence	NN	O
and	CC	O
all	DT	O
intron	NN	O
/	NNP	O
exon	NNP	O
boundaries	NNS	O
)	)	O
were	VBD	O
screened	VBN	O
,	,	O
as	IN	O
was	VBD	O
a	DT	O
neuroretina	JJ	O
specific	JJ	O
enhancer	NN	O
in	IN	O
intron	NN	O
4	CD	O
.	.	O

Ten	CD	O
of	IN	O
the	DT	O
possible	JJ	O
12	CD	O
mutations	NNS	O
in	IN	O
the	DT	O
five	CD	O
familial	JJ	O
cases	NNS	O
and	CC	O
five	CD	O
of	IN	O
the	DT	O
sporadic	JJ	O
patients	NNS	O
were	VBD	O
found	VBN	O
,	,	O
all	DT	O
of	IN	O
which	WDT	O
conformed	VBD	O
to	TO	O
a	DT	O
functional	JJ	O
outcome	NN	O
of	IN	O
haploinsufficiency	NN	O
.	.	O

Five	CD	O
were	VBD	O
splice	NN	O
site	NN	O
mutations	NNS	O
(	(	O
one	CD	O
in	IN	O
the	DT	O
donor	JJ	O
site	NN	O
of	IN	O
intron	NN	O
4	CD	O
,	,	O
two	CD	O
in	IN	O
the	DT	O
donor	JJ	O
site	NN	O
of	IN	O
intron	NN	O
6	CD	O
,	,	O
one	CD	O
in	IN	O
each	DT	O
of	IN	O
the	DT	O
acceptor	NN	O
sites	NNS	O
of	IN	O
introns	NNS	O
8	CD	O
and	CC	O
9	CD	O
)	)	O
and	CC	O
five	CD	O
were	VBD	O
nonsense	JJ	O
mutations	NNS	O
in	IN	O
exons	NNS	O
8	CD	O
,	,	O
9	CD	O
,	,	O
10	CD	O
,	,	O
11	CD	O
,	,	O
and	CC	O
12	CD	O
.	.	O

SSCP	NNP	O
analysis	NN	O
of	IN	O
individually	RB	O
amplified	JJ	O
exons	NNS	O
,	,	O
with	IN	O
which	WDT	O
nine	CD	O
of	IN	O
the	DT	O
10	CD	O
mutations	NNS	O
were	VBD	O
seen	VBN	O
,	,	O
was	VBD	O
the	DT	O
most	RBS	O
useful	JJ	O
detection	NN	O
method	NN	O
for	IN	O
PAX6	NNP	O
.	.	O
.	.	O

Insulin	NNP	O
gene	NN	O
region	NN	O
contributes	NNS	O
to	TO	O
genetic	JJ	O
susceptibility	NN	O
to	TO	O
,	,	O
but	CC	O
may	MD	O
not	RB	O
to	TO	O
low	JJ	O
incidence	NN	O
of	IN	O
,	,	O
insulin	FW	B_Disease
-	:	I_Disease
dependent	NN	I_Disease
diabetes	VBZ	I_Disease
mellitus	NNS	E_Disease
in	IN	O
Japanese	JJ	O
.	.	O

In	IN	O
the	DT	O
Caucasian	JJ	O
population	NN	O
,	,	O
it	PRP	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
that	IN	O
the	DT	O
insulin	NN	O
gene	NN	O
(	(	O
INS	NNP	O
)	)	O
region	NN	O
contains	VBZ	O
the	DT	O
insulin	NN	B_Disease
-	:	I_Disease
dependent	NN	I_Disease
diabetes	VBZ	I_Disease
mellitus	JJ	E_Disease
locus	NN	O
(	(	O
IDDM2	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
Japanese	JJ	O
population	NN	O
,	,	O
however	RB	O
,	,	O
there	EX	O
has	VBZ	O
been	VBN	O
no	DT	O
report	NN	O
demonstrating	VBG	O
the	DT	O
contribution	NN	O
of	IN	O
IDDM2	NNP	O
to	TO	O
the	DT	O
pathogenesis	NN	O
of	IN	O
IDDM	NNP	S_Disease
.	.	O

We	PRP	O
conducted	VBD	O
an	DT	O
association	NN	O
study	NN	O
of	IN	O
IDDM	NNP	S_Disease
in	IN	O
a	DT	O
large	JJ	O
number	NN	O
of	IN	O
Japanese	JJ	O
subjects	NNS	O
with	IN	O
multiple	JJ	O
polymorphisms	NNS	O
in	IN	O
INS	NNP	O
region	NN	O
.	.	O

We	PRP	O
found	VBD	O
a	DT	O
significant	JJ	O
association	NN	O
of	IN	O
the	DT	O
INS	NNP	O
region	NN	O
with	IN	O
IDDM	NNP	S_Disease
.	.	O

Alleles	NNS	O
positively	RB	O
associated	VBN	O
with	IN	O
IDDM	NNP	S_Disease
in	IN	O
INS	NNP	O
region	NN	O
were	VBD	O
the	DT	O
same	JJ	O
as	IN	O
those	DT	O
positively	JJ	O
-	:	O
associated	VBN	O
with	IN	O
IDDM	NNP	S_Disease
in	IN	O
Caucasian	NNP	O
population	NN	O
,	,	O
although	IN	O
positively	RB	O
-	:	O
associated	VBN	O
alleles	NNS	O
are	VBP	O
very	RB	O
common	JJ	O
(	(	O
allele	JJ	O
frequencies	NNS	O
>	VBP	O
0	CD	O
.	.	O

9	CD	O
)	)	O
in	IN	O
the	DT	O
Japanese	JJ	O
general	JJ	O
population	NN	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
IDDM2	NNP	O
is	VBZ	O
involved	VBN	O
in	IN	O
the	DT	O
genetic	JJ	O
susceptibility	NN	O
to	TO	O
IDDM	NNP	S_Disease
in	IN	O
Japanese	NNP	O
.	.	O

The	DT	O
high	JJ	O
frequencies	NNS	O
of	IN	O
disease	NN	O
-	:	O
associated	VBN	O
alleles	NNS	O
in	IN	O
the	DT	O
general	JJ	O
population	NN	O
suggest	VBP	O
that	IN	O
IDDM2	NNP	O
locus	NN	O
is	VBZ	O
not	RB	O
responsible	JJ	O
for	IN	O
the	DT	O
low	JJ	O
incidence	NN	O
of	IN	O
IDDM	NNP	S_Disease
in	IN	O
Japanese	NNP	O
.	.	O

The	DT	O
human	JJ	O
complement	NN	O
C9	NNP	O
gene	NN	O
:	:	O
identification	NN	O
of	IN	O
two	CD	O
mutations	NNS	O
causing	VBG	O
deficiency	NN	O
and	CC	O
revision	NN	O
of	IN	O
the	DT	O
gene	NN	O
structure	NN	O
.	.	O

The	DT	O
ninth	JJ	O
component	NN	O
of	IN	O
human	JJ	O
complement	NN	O
(	(	O
C9	NNP	O
)	)	O
is	VBZ	O
the	DT	O
last	JJ	O
of	IN	O
the	DT	O
terminal	JJ	O
complement	NN	O
components	NNS	O
creating	VBG	O
the	DT	O
membrane	NN	O
attack	NN	O
complex	NN	O
.	.	O

C9	NNP	O
is	VBZ	O
a	DT	O
single	JJ	O
-	:	O
chain	NN	O
serum	NN	O
protein	NN	O
that	WDT	O
is	VBZ	O
encoded	VBN	O
by	IN	O
a	DT	O
gene	NN	O
located	VBN	O
on	IN	O
chromosome	NN	O
5p	CD	O
.	.	O

Deficiency	NN	B_Disease
of	IN	I_Disease
terminal	JJ	I_Disease
complement	NN	I_Disease
components	NNS	E_Disease
is	VBZ	O
generally	RB	O
associated	VBN	O
with	IN	O
recurrent	NN	O
neisseria	NNS	B_Disease
infections	NNS	E_Disease
.	.	O

We	PRP	O
studied	VBD	O
a	DT	O
previously	RB	O
described	VBN	O
Swiss	JJ	O
family	NN	O
with	IN	O
inherited	JJ	B_Disease
C9	NNP	I_Disease
deficiency	NN	E_Disease
.	.	O

To	TO	O
identify	VB	O
the	DT	O
genetic	JJ	O
basis	NN	O
of	IN	O
C9	NNP	B_Disease
deficiency	NN	E_Disease
,	,	O
we	PRP	O
developed	VBD	O
an	DT	O
approach	NN	O
using	VBG	O
exon	JJ	O
-	:	O
specific	JJ	O
PCR	NNP	O
and	CC	O
direct	JJ	O
DNA	NNP	O
sequencing	NN	O
.	.	O

As	IN	O
a	DT	O
cause	NN	O
of	IN	O
C9	NNP	B_Disease
deficiency	NN	E_Disease
,	,	O
we	PRP	O
found	VBD	O
two	CD	O
different	JJ	O
point	NN	O
mutations	NNS	O
,	,	O
both	DT	O
generating	VBG	O
TGA	NNP	O
stop	JJ	O
codons	NNS	O
in	IN	O
the	DT	O
coding	NN	O
sequence	NN	O
.	.	O

One	CD	O
mutation	NN	O
,	,	O
a	DT	O
C	NNP	O
to	TO	O
A	NNP	O
exchange	NN	O
,	,	O
was	VBD	O
detected	VBN	O
in	IN	O
exon	JJ	O
2	CD	O
at	IN	O
cDNA	NN	O
position	NN	O
166	CD	O
,	,	O
the	DT	O
other	JJ	O
,	,	O
a	DT	O
C	NNP	O
to	TO	O
T	NNP	O
exchange	NN	O
,	,	O
was	VBD	O
located	VBN	O
in	IN	O
exon	JJ	O
4	CD	O
(	(	O
cDNA	JJ	O
position	NN	O
464	CD	O
)	)	O
.	.	O

In	IN	O
family	NN	O
studies	NNS	O
of	IN	O
three	CD	O
first	JJ	O
-	:	O
degree	NN	O
relatives	NNS	O
with	IN	O
heterozygous	JJ	O
C9	NNP	B_Disease
deficiency	NN	E_Disease
,	,	O
we	PRP	O
demonstrated	VBD	O
that	IN	O
the	DT	O
two	CD	O
mutations	NNS	O
are	VBP	O
segregating	VBG	O
independently	RB	O
.	.	O

Therefore	RB	O
,	,	O
these	DT	O
mutations	NNS	O
are	VBP	O
sufficient	JJ	O
to	TO	O
explain	VB	O
the	DT	O
complete	JJ	O
deficiency	NN	O
of	IN	O
both	CC	O
the	DT	O
probands	NNS	O
studied	VBN	O
.	.	O

DNA	NN	O
sequencing	NN	O
of	IN	O
the	DT	O
exon	JJ	O
-	:	O
intron	NN	O
junctions	NNS	O
revealed	VBD	O
a	DT	O
number	NN	O
of	IN	O
revisions	NNS	O
regarding	VBG	O
the	DT	O
boundaries	NNS	O
between	IN	O
exons	NNS	O
4	CD	O
,	,	O
5	CD	O
,	,	O
and	CC	O
6	CD	O
as	RB	O
well	RB	O
as	IN	O
between	IN	O
exons	NNS	O
10	CD	O
and	CC	O
11	CD	O
.	.	O

No	DT	O
additional	JJ	O
introns	NNS	O
were	VBD	O
detected	VBN	O
in	IN	O
exons	NNS	O
6	CD	O
and	CC	O
10	CD	O
.	.	O

Furthermore	RB	O
,	,	O
DNA	NNP	O
marker	NN	O
studies	NNS	O
were	VBD	O
conducted	VBN	O
using	VBG	O
known	VBN	O
polymorphisms	NNS	O
of	IN	O
the	DT	O
C6	NNP	O
,	,	O
C7	NNP	O
,	,	O
and	CC	O
C9	NNP	O
genes	NNS	O
,	,	O
confirming	VBG	O
the	DT	O
linkage	NN	O
of	IN	O
the	DT	O
observed	JJ	O
C9	NNP	O
mutations	NNS	O
with	IN	O
defined	JJ	O
haplotypes	NNS	O
.	.	O
.	.	O

BRCA1	NNP	O
mutations	NNS	O
in	IN	O
women	NNS	O
attending	VBG	O
clinics	NNS	O
that	WDT	O
evaluate	VBP	O
the	DT	O
risk	NN	O
of	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
.	.	O

BACKGROUND	NNP	O
To	TO	O
define	VB	O
the	DT	O
incidence	NN	O
of	IN	O
BRCA1	NNP	O
mutations	NNS	O
among	IN	O
patients	NNS	O
seen	VBN	O
in	IN	O
clinics	NNS	O
that	WDT	O
evaluate	VBP	O
the	DT	O
risk	NN	O
of	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
,	,	O
we	PRP	O
analyzed	VBD	O
DNA	NNP	O
samples	NNS	O
from	IN	O
women	NNS	O
seen	VBN	O
in	IN	O
this	DT	O
setting	NN	O
and	CC	O
constructed	VBN	O
probability	NN	O
tables	NNS	O
to	TO	O
provide	VB	O
estimates	NNS	O
of	IN	O
the	DT	O
likelihood	NN	O
of	IN	O
finding	VBG	O
a	DT	O
BRCA1	NNP	O
mutation	NN	O
in	IN	O
individual	JJ	O
families	NNS	O
.	.	O

METHODS	NNP	O
Clinical	NNP	O
information	NN	O
,	,	O
family	NN	O
histories	NNS	O
,	,	O
and	CC	O
blood	NN	O
for	IN	O
DNA	NN	O
analysis	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
263	CD	O
women	NNS	O
with	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
.	.	O

Conformation	NNP	O
-	:	O
sensitive	JJ	O
gel	NN	O
electrophoresis	NN	O
and	CC	O
DNA	NNP	O
sequencing	NN	O
were	VBD	O
used	VBN	O
to	TO	O
identify	VB	O
BRCA1	NNP	O
mutations	NNS	O
.	.	O

RESULTS	NNP	O
BRCA1	NNP	O
mutations	NNS	O
were	VBD	O
identified	VBN	O
in	IN	O
16	CD	O
percent	NN	O
of	IN	O
women	NNS	O
with	IN	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
.	.	O

Only	RB	O
7	CD	O
percent	NN	O
of	IN	O
women	NNS	O
from	IN	O
families	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
but	CC	O
not	RB	O
ovarian	JJ	B_Disease
cancer	NN	E_Disease
had	VBD	O
BRCA1	NNP	O
mutations	NNS	O
.	.	O

The	DT	O
rates	NNS	O
were	VBD	O
higher	JJR	O
among	IN	O
women	NNS	O
from	IN	O
families	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
both	DT	O
breast	NN	B_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
.	.	O

Among	IN	O
family	NN	O
members	NNS	O
,	,	O
an	DT	O
average	JJ	O
age	NN	O
of	IN	O
less	JJR	O
than	IN	O
55	CD	O
years	NNS	O
at	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
,	,	O
the	DT	O
presence	NN	O
of	IN	O
ovarian	JJ	B_Disease
cancer	NN	E_Disease
,	,	O
the	DT	O
presence	NN	O
of	IN	O
breast	NN	B_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
in	IN	O
the	DT	O
same	JJ	O
woman	NN	O
,	,	O
and	CC	O
Ashkenazi	NNP	O
Jewish	NNP	O
ancestry	NN	O
were	VBD	O
all	DT	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
detecting	VBG	O
a	DT	O
BRCA1	NNP	O
mutation	NN	O
.	.	O

No	DT	O
association	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
presence	NN	O
of	IN	O
bilateral	JJ	O
breast	NN	B_Disease
cancer	NN	E_Disease
or	CC	O
the	DT	O
number	NN	O
of	IN	O
breast	NN	B_Disease
cancers	NNS	E_Disease
in	IN	O
a	DT	O
family	NN	O
and	CC	O
the	DT	O
detection	NN	O
of	IN	O
a	DT	O
BRCA1	NNP	O
mutation	NN	O
,	,	O
or	CC	O
between	IN	O
the	DT	O
position	NN	O
of	IN	O
the	DT	O
mutation	NN	O
in	IN	O
the	DT	O
BRCA1	NNP	O
gene	NN	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
ovarian	JJ	B_Disease
cancer	NN	E_Disease
in	IN	O
a	DT	O
family	NN	O
.	.	O

CONCLUSIONS	NNP	O
Among	IN	O
women	NNS	O
with	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
and	CC	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
the	DT	O
disease	NN	O
,	,	O
the	DT	O
percentage	NN	O
with	IN	O
BRCA1	NNP	O
coding	VBG	O
-	:	O
region	NN	O
mutations	NNS	O
is	VBZ	O
less	JJR	O
than	IN	O
the	DT	O
45	CD	O
percent	NN	O
predicted	VBN	O
by	IN	O
genetic	JJ	O
-	:	O
linkage	NN	O
analysis	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
even	RB	O
in	IN	O
a	DT	O
referral	JJ	O
clinic	NN	O
specializing	VBG	O
in	IN	O
screening	VBG	O
women	NNS	O
from	IN	O
high	JJ	O
-	:	O
risk	NN	O
families	NNS	O
,	,	O
the	DT	O
majority	NN	O
of	IN	O
tests	NNS	O
for	IN	O
BRCA1	NNP	O
mutations	NNS	O
will	MD	O
be	VB	O
negative	JJ	O
and	CC	O
therefore	RB	O
uninformative	JJ	O
.	.	O
.	.	O

Mutations	NNS	O
in	IN	O
the	DT	O
arginine	NN	O
-	:	O
rich	JJ	O
protein	NN	O
gene	NN	O
(	(	O
ARP	NNP	O
)	)	O
in	IN	O
pancreatic	JJ	B_Disease
cancer	NN	E_Disease
.	.	O

The	DT	O
ARP	NNP	O
gene	NN	O
encodes	VBZ	O
a	DT	O
highly	RB	O
conserved	VBN	O
arginine	NN	O
-	:	O
rich	JJ	O
protein	NN	O
from	IN	O
chromosomal	JJ	O
band	NN	O
3p21	CD	O
.	.	O

1	CD	O
1	CD	O
.	.	O

At	IN	O
the	DT	O
cytogenetic	JJ	O
level	NN	O
this	DT	O
region	NN	O
is	VBZ	O
frequently	RB	O
deleted	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
different	JJ	O
solid	JJ	B_Disease
tumors	NNS	E_Disease
,	,	O
although	IN	O
not	RB	O
in	IN	O
pancreatic	JJ	B_Disease
cancer	NN	E_Disease
.	.	O

We	PRP	O
have	VBP	O
reported	VBN	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
specific	JJ	O
mutation	NN	O
(	(	O
ATG50	NNP	O
-	:	O
-	:	O
>	NN	O
AGG	NNP	O
)	)	O
or	CC	O
deletion	NN	O
of	IN	O
codon	JJ	O
50	CD	O
of	IN	O
the	DT	O
ARP	NNP	O
gene	NN	O
in	IN	O
different	JJ	O
tumor	NN	B_Disease
types	NNS	E_Disease
(	(	O
Shridhar	NNP	O
et	RB	O
al	RB	O
.	.	O
,	,	O
1996	CD	O
,	,	O
1996a	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
we	PRP	O
have	VBP	O
observed	VBN	O
mutations	NNS	O
involving	VBG	O
codon	NN	O
50	CD	O
in	IN	O
11	CD	O
of	IN	O
37	CD	O
pancreatic	JJ	B_Disease
tumors	NNS	E_Disease
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
codon	NN	O
50	CD	O
mutation	NN	O
is	VBZ	O
roughly	RB	O
the	DT	O
same	JJ	O
in	IN	O
pancreatic	JJ	B_Disease
tumors	NNS	E_Disease
as	IN	O
in	IN	O
the	DT	O
other	JJ	O
types	NNS	O
of	IN	O
tumors	NNS	S_Disease
previously	RB	O
examined	VBN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
we	PRP	O
have	VBP	O
detected	VBN	O
mutations	NNS	O
at	IN	O
codon	NN	O
51	CD	O
in	IN	O
multiple	JJ	O
PCR	NNP	O
subclones	NNS	O
in	IN	O
two	CD	O
other	JJ	O
pancreatic	JJ	B_Disease
tumors	NNS	E_Disease
.	.	O

Mutations	NNS	O
in	IN	O
the	DT	O
ARP	NNP	O
gene	NN	O
are	VBP	O
thus	RB	O
commonly	RB	O
observed	VBN	O
in	IN	O
pancreatic	JJ	B_Disease
cancer	NN	E_Disease
,	,	O
as	RB	O
well	RB	O
as	IN	O
many	JJ	O
other	JJ	O
cancers	NNS	S_Disease
.	.	O

Difficulties	NNS	O
in	IN	O
the	DT	O
ascertainment	NN	O
of	IN	O
C9	NNP	B_Disease
deficiency	NN	E_Disease
:	:	O
lessons	NNS	O
to	TO	O
be	VB	O
drawn	VBN	O
from	IN	O
a	DT	O
compound	NN	O
heterozygote	NN	O
C9	NNP	B_Disease
-	:	I_Disease
deficient	NN	E_Disease
subject	NN	O
.	.	O

A	DT	O
group	NN	O
of	IN	O
patients	NNS	O
with	IN	O
long	JJ	O
-	:	O
surviving	VBG	O
mismatched	VBN	O
kidney	NN	O
allografts	NNS	O
were	VBD	O
investigated	VBN	O
for	IN	O
complement	NN	O
function	NN	O
using	VBG	O
haemolytic	JJ	O
assays	NNS	O
in	IN	O
agarose	JJ	O
gels	NNS	O
.	.	O

One	CD	O
patient	NN	O
was	VBD	O
found	VBN	O
to	TO	O
have	VB	O
no	DT	O
alternative	JJ	O
pathway	NN	O
activity	NN	O
but	CC	O
a	DT	O
low	JJ	O
normal	JJ	O
classical	JJ	O
pathway	NN	O
.	.	O

Surprisingly	RB	O
,	,	O
investigation	NN	O
revealed	VBD	O
that	IN	O
the	DT	O
patients	NNS	O
complement	NN	O
was	VBD	O
normal	JJ	O
for	IN	O
all	DT	O
components	NNS	O
except	IN	O
C9	NNP	O
,	,	O
which	WDT	O
was	VBD	O
functionally	RB	O
absent	JJ	O
.	.	O

The	DT	O
patient	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
heterozygous	JJ	O
for	IN	O
DNA	NN	O
markers	NNS	O
in	IN	O
the	DT	O
C6	NNP	O
,	,	O
C7	NNP	O
and	CC	O
C9	NNP	O
region	NN	O
of	IN	O
chromosome	NN	O
5	CD	O
and	CC	O
therefore	RB	O
appears	VBZ	O
to	TO	O
be	VB	O
a	DT	O
compound	NN	O
heterozygote	NN	O
for	IN	O
two	CD	O
uncharacterized	JJ	O
C9	NNP	B_Disease
deficiency	NN	E_Disease
genes	NNS	O
.	.	O

Serological	JJ	O
analysis	NN	O
by	IN	O
ELISA	NNP	O
revealed	VBD	O
that	IN	O
he	PRP	O
has	VBZ	O
trace	NN	O
concentrations	NNS	O
of	IN	O
a	DT	O
non	JJ	O
-	:	O
functional	JJ	O
C9	NNP	O
molecule	NN	O
.	.	O

Western	JJ	O
blot	NN	O
analysis	NN	O
was	VBD	O
not	RB	O
sufficiently	RB	O
sensitive	JJ	O
to	TO	O
permit	VB	O
detection	NN	O
of	IN	O
this	DT	O
molecule	NN	O
.	.	O

We	PRP	O
hypothesize	VBP	O
that	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
heterozygous	JJ	O
for	IN	O
a	DT	O
complete	JJ	B_Disease
deficiency	NN	I_Disease
of	IN	I_Disease
C9	NNP	E_Disease
and	CC	O
for	IN	O
a	DT	O
gene	NN	O
directing	VBG	O
hyposynthesis	NN	O
of	IN	O
a	DT	O
defective	JJ	O
C9	NNP	O
.	.	O

We	PRP	O
also	RB	O
suggest	VBP	O
that	IN	O
C9	NNP	B_Disease
deficiency	NN	E_Disease
may	MD	O
be	VB	O
more	JJR	O
common	JJ	O
among	IN	O
Caucasians	NNPS	O
than	IN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
.	.	O
.	.	O

Screening	VBG	O
for	IN	O
ESR	NNP	O
mutations	NNS	O
in	IN	O
breast	NN	B_Disease
and	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
patients	NNS	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
leukocyte	JJ	O
DNA	NN	O
from	IN	O
143	CD	O
patients	NNS	O
with	IN	O
familial	JJ	O
clustering	NN	O
of	IN	O
breast	NN	B_Disease
and	CC	I_Disease
/	NN	I_Disease
or	CC	I_Disease
ovarian	JJ	I_Disease
cancer	NN	E_Disease
and	CC	O
tumour	VB	S_Disease
DNA	NN	O
from	IN	O
96	CD	O
breast	NN	B_Disease
carcinomas	NN	E_Disease
were	VBD	O
screened	VBN	O
for	IN	O
base	NN	O
mutations	NNS	O
in	IN	O
the	DT	O
estrogen	NN	O
receptor	NN	O
gene	NN	O
(	(	O
ESR	NNP	O
)	)	O
.	.	O

Three	CD	O
patients	NNS	O
with	IN	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
cancer	NN	S_Disease
were	VBD	O
carrying	VBG	O
a	DT	O
Gly160Cys	NNP	O
germline	NN	O
substitution	NN	O
.	.	O

This	DT	O
alteration	NN	O
was	VBD	O
also	RB	O
detected	VBN	O
in	IN	O
eight	CD	O
(	(	O
four	CD	O
females	NNS	O
and	CC	O
four	CD	O
males	NNS	O
)	)	O
of	IN	O
729	CD	O
controls	NNS	O
(	(	O
366	CD	O
female	NN	O
,	,	O
363	CD	O
males	NNS	O
)	)	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
substitution	NN	O
probably	RB	O
represents	VBZ	O
a	DT	O
polymorphism	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
the	DT	O
229	CD	O
female	NN	O
controls	NNS	O
in	IN	O
whom	WP	O
family	NN	O
history	NN	O
of	IN	O
cancer	NN	S_Disease
was	VBD	O
known	VBN	O
,	,	O
one	CD	O
of	IN	O
two	CD	O
who	WP	O
had	VBD	O
a	DT	O
sister	NN	O
with	IN	O
breast	NN	B_Disease
cancer	NN	E_Disease
was	VBD	O
carrying	VBG	O
the	DT	O
variant	JJ	O
allele	NN	O
.	.	O

Hence	NNP	O
,	,	O
a	DT	O
possible	JJ	O
clinical	JJ	O
significance	NN	O
of	IN	O
the	DT	O
glycine	NN	O
into	IN	O
cysteine	NN	O
cannot	NN	O
be	VB	O
completely	RB	O
ruled	VBN	O
out	RP	O
and	CC	O
should	MD	O
be	VB	O
further	RB	O
investigated	VBN	O
.	.	O

Somatic	JJ	O
mutations	NNS	O
were	VBD	O
not	RB	O
detected	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
tumours	NNS	S_Disease
studied	VBN	O
,	,	O
and	CC	O
the	DT	O
present	JJ	O
data	NNS	O
do	VBP	O
not	RB	O
provide	VB	O
support	NN	O
for	IN	O
somatic	JJ	O
ESR	NNP	O
base	NN	O
mutations	NNS	O
as	IN	O
an	DT	O
important	JJ	O
mechanism	NN	O
for	IN	O
hormonal	JJ	O
therapy	NN	O
resistance	NN	O
in	IN	O
estrogen	NN	B_Disease
receptor	NN	I_Disease
-	:	I_Disease
positive	JJ	I_Disease
breast	NN	I_Disease
carcinomas	NN	E_Disease
.	.	O
.	.	O

Molecular	JJ	O
bases	NNS	O
of	IN	O
C7	NNP	B_Disease
deficiency	NN	E_Disease
:	:	O
three	CD	O
different	JJ	O
defects	NNS	O
.	.	O

The	DT	O
molecular	JJ	O
basis	NN	O
of	IN	O
C7	NNP	B_Disease
deficiency	NN	E_Disease
has	VBZ	O
been	VBN	O
investigated	VBN	O
in	IN	O
two	CD	O
Irish	JJ	O
families	NNS	O
and	CC	O
a	DT	O
number	NN	O
of	IN	O
Israeli	NNP	O
families	NNS	O
of	IN	O
Moroccan	NNP	O
Sephardic	NNP	O
Jewish	NNP	O
origin	NN	O
.	.	O

Exon	NNP	O
PCR	NNP	O
and	CC	O
sequencing	VBG	O
revealed	VBD	O
a	DT	O
heterozygous	JJ	O
point	NN	O
mutation	NN	O
at	IN	O
the	DT	O
3	CD	O
splice	NN	O
acceptor	NN	O
site	NN	O
of	IN	O
intron	NN	O
1	CD	O
in	IN	O
one	CD	O
Irish	JJ	O
family	NN	O
.	.	O

In	IN	O
the	DT	O
other	JJ	O
Irish	JJ	O
family	NN	O
,	,	O
exons	NNS	O
7	CD	O
and	CC	O
8	CD	O
failed	VBD	O
to	TO	O
amplify	VB	O
and	CC	O
they	PRP	O
were	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
deleted	VBN	O
.	.	O

Marker	NNP	O
haplotype	NN	O
studies	NNS	O
of	IN	O
the	DT	O
C6	NNP	O
and	CC	O
C7	NNP	O
gene	NN	O
region	NN	O
and	CC	O
Southern	NNP	O
blots	NNS	O
show	VBP	O
that	IN	O
the	DT	O
Irish	NNP	O
family	NN	O
with	IN	O
the	DT	O
splice	NN	O
defect	NN	O
also	RB	O
segregate	NN	O
for	IN	O
the	DT	O
deletion	NN	O
,	,	O
which	WDT	O
is	VBZ	O
not	RB	O
easily	RB	O
detected	VBN	O
in	IN	O
heterozygotes	NNS	O
.	.	O

The	DT	O
Israeli	NNP	O
C7	NNP	B_Disease
-	:	I_Disease
deficient	NN	E_Disease
cases	NNS	O
all	DT	O
share	NN	O
a	DT	O
C7	NNP	O
haplotype	NN	O
and	CC	O
are	VBP	O
homozygous	JJ	O
for	IN	O
a	DT	O
mis	JJ	O
-	:	O
sense	NN	O
mutation	NN	O
in	IN	O
exon	JJ	O
9	CD	O
.	.	O

However	RB	O
,	,	O
one	CD	O
individual	NN	O
is	VBZ	O
heterozygous	JJ	O
for	IN	O
markers	NNS	O
at	IN	O
adjacent	JJ	O
C6	NNP	O
loci	NN	O
,	,	O
showing	VBG	O
that	IN	O
there	EX	O
has	VBZ	O
been	VBN	O
an	DT	O
intergenic	JJ	O
recombination	NN	O
and	CC	O
suggesting	VBG	O
that	IN	O
the	DT	O
deficiency	NN	O
mutation	NN	O
is	VBZ	O
of	IN	O
appreciable	JJ	O
antiquity	NN	O
.	.	O
.	.	O

Molecular	JJ	O
heterogeneity	NN	O
of	IN	O
classical	JJ	B_Disease
and	CC	I_Disease
Duarte	NNP	I_Disease
galactosemia	NN	E_Disease
:	:	O
mutation	NN	O
analysis	NN	O
by	IN	O
denaturing	VBG	O
gradient	JJ	O
gel	JJ	O
electrophoresis	NN	O
.	.	O

Classical	JJ	B_Disease
galactosemia	NN	E_Disease
is	VBZ	O
caused	VBN	O
by	IN	O
one	CD	O
common	JJ	O
missense	NN	O
mutation	NN	O
(	(	O
Q188R	NNP	O
)	)	O
and	CC	O
by	IN	O
several	JJ	O
rare	JJ	O
mutations	NNS	O
in	IN	O
the	DT	O
galactose	JJ	O
-	:	O
1	CD	O
-	:	O
phosphate	NN	O
uridyltransferase	NN	O
(	(	O
GALT	NNP	O
)	)	O
gene	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
variant	NN	O
of	IN	O
GALT	NNP	O
,	,	O
the	DT	O
Duarte	NNP	O
variant	NN	O
,	,	O
occurs	VBZ	O
as	IN	O
two	CD	O
types	NNS	O
,	,	O
Duarte	NNP	O
-	:	O
1	CD	O
(	(	O
D	NNP	O
-	:	O
1	CD	O
)	)	O
and	CC	O
Duarte	NNP	O
-	:	O
2	CD	O
(	(	O
D	NNP	O
-	:	O
2	CD	O
)	)	O
,	,	O
both	DT	O
of	IN	O
which	WDT	O
carry	VBP	O
the	DT	O
sequence	NN	O
change	NN	O
N314D	NNP	O
.	.	O

D	NNP	O
-	:	O
1	CD	O
increases	NNS	O
,	,	O
whereas	NNS	O
D	NNP	O
-	:	O
2	CD	O
decreases	NNS	O
GALT	NNP	O
activity	NN	O
.	.	O

To	TO	O
study	VB	O
the	DT	O
molecular	JJ	O
genetics	NNS	O
of	IN	O
classical	JJ	B_Disease
and	CC	I_Disease
Duarte	NNP	I_Disease
galactosemia	NN	E_Disease
,	,	O
we	PRP	O
analyzed	VBD	O
the	DT	O
GALT	NNP	O
mutations	NNS	O
in	IN	O
30	CD	O
families	NNS	O
with	IN	O
classical	JJ	B_Disease
galactosemia	NN	E_Disease
,	,	O
in	IN	O
10	CD	O
families	NNS	O
with	IN	O
the	DT	O
D	NNP	O
-	:	O
2	CD	O
variant	NN	O
and	CC	O
in	IN	O
3	CD	O
individuals	NNS	O
carrying	VBG	O
the	DT	O
D	NNP	O
-	:	O
1	CD	O
allele	NN	O
by	IN	O
denaturing	VBG	O
gradient	JJ	O
gel	NN	O
electrophoresis	NN	O
(	(	O
DGGE	NNP	O
)	)	O
.	.	O

DGGE	NNP	O
detected	VBD	O
59	CD	O
of	IN	O
the	DT	O
60	CD	O
classical	JJ	O
galactosemia	NN	S_Disease
alleles	NNS	O
.	.	O

Q188R	NNP	O
accounted	VBD	O
for	IN	O
60	CD	O
%	NN	O
,	,	O
K285N	NNP	O
accounted	VBD	O
for	IN	O
28	CD	O
%	NN	O
of	IN	O
these	DT	O
alleles	NNS	O
.	.	O

Eight	CD	O
novel	JJ	O
candidate	NN	O
galactosemia	NN	S_Disease
mutations	NNS	O
were	VBD	O
found	VBN	O
.	.	O

On	IN	O
all	DT	O
D	NNP	O
-	:	O
2	CD	O
alleles	NNS	O
N314D	NNP	O
occurred	VBD	O
in	IN	O
cis	NN	O
with	IN	O
two	CD	O
intronic	JJ	O
sequence	NN	O
changes	NNS	O
,	,	O
on	IN	O
the	DT	O
D	NNP	O
-	:	O
1	CD	O
alleles	NNS	O
in	IN	O
cis	NN	O
with	IN	O
a	DT	O
neutral	JJ	O
mutation	NN	O
in	IN	O
exon	JJ	O
7	CD	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
mutations	NNS	O
causing	VBG	O
galactosemia	NN	S_Disease
are	VBP	O
highly	RB	O
heterogeneous	JJ	O
and	CC	O
that	DT	O
K285N	NNP	O
is	VBZ	O
a	DT	O
second	JJ	O
common	JJ	O
galactosemia	NN	S_Disease
mutation	NN	O
in	IN	O
our	PRP$	O
population	NN	O
.	.	O
.	.	O

Isolation	NN	O
of	IN	O
full	JJ	O
-	:	O
length	NN	O
ATM	NNP	O
cDNA	NN	O
and	CC	O
correction	NN	O
of	IN	O
the	DT	O
ataxia	JJ	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
cellular	JJ	O
phenotype	NN	O
.	.	O

A	DT	O
gene	NN	O
mutated	VBN	O
in	IN	O
the	DT	O
human	JJ	O
genetic	JJ	B_Disease
disorder	NN	E_Disease
ataxia	NN	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
(	(	O
A	DT	B_Disease
-	:	I_Disease
T	NN	E_Disease
)	)	O
,	,	O
ATM	NNP	O
,	,	O
was	VBD	O
recently	RB	O
identified	VBN	O
by	IN	O
positional	JJ	O
cloning	NN	O
.	.	O

ATM	NNP	O
is	VBZ	O
a	DT	O
member	NN	O
of	IN	O
the	DT	O
phosphatidylinositol	NN	O
-	:	O
3	CD	O
-	:	O
kinase	NN	O
superfamily	RB	O
,	,	O
some	DT	O
of	IN	O
which	WDT	O
are	VBP	O
protein	JJ	O
kinases	NNS	O
and	CC	O
appear	VBP	O
to	TO	O
have	VB	O
important	JJ	O
roles	NNS	O
in	IN	O
cell	NN	O
cycle	NN	O
control	NN	O
and	CC	O
radiation	NN	O
signal	JJ	O
transduction	NN	O
.	.	O

We	PRP	O
describe	VBP	O
herein	RB	O
,	,	O
to	TO	O
our	PRP$	O
knowledge	NN	O
,	,	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
,	,	O
the	DT	O
cloning	NN	O
of	IN	O
a	DT	O
full	JJ	O
-	:	O
length	NN	O
cDNA	NN	O
for	IN	O
ATM	NNP	O
and	CC	O
correction	NN	O
of	IN	O
multiple	JJ	O
aspects	NNS	O
of	IN	O
the	DT	O
radio	NN	O
-	:	O
sensitive	JJ	O
phenotype	NN	O
of	IN	O
A	NNP	B_Disease
-	:	I_Disease
T	NN	E_Disease
cells	NNS	O
by	IN	O
transfection	NN	O
with	IN	O
this	DT	O
cDNA	NN	O
.	.	O

Overexpression	NN	O
of	IN	O
ATM	NNP	O
cDNA	NN	O
in	IN	O
A	NNP	B_Disease
-	:	I_Disease
T	NNP	E_Disease
cells	NNS	O
enhanced	VBD	O
the	DT	O
survival	NN	O
of	IN	O
these	DT	O
cells	NNS	O
in	IN	O
response	NN	O
to	TO	O
radiation	NN	O
exposure	NN	O
,	,	O
decreased	VBN	O
radiation	NN	O
-	:	O
induced	JJ	O
chromosome	NN	O
aberrations	NNS	O
,	,	O
reduced	VBD	O
radio	NN	O
-	:	O
resistant	JJ	O
DNA	NNP	O
synthesis	NN	O
,	,	O
and	CC	O
partially	RB	O
corrected	VBN	O
defective	JJ	O
cell	NN	O
cycle	NN	O
checkpoints	NNS	O
and	CC	O
induction	NN	O
of	IN	O
stress	NN	O
-	:	O
activated	VBN	O
protein	JJ	O
kinase	NN	O
.	.	O

This	DT	O
correction	NN	O
of	IN	O
the	DT	O
defects	NNS	O
in	IN	O
A	NNP	B_Disease
-	:	I_Disease
T	NNP	E_Disease
cells	NNS	O
provides	VBZ	O
further	JJ	O
evidence	NN	O
of	IN	O
the	DT	O
multiplicity	NN	O
of	IN	O
effector	NN	O
functions	NNS	O
of	IN	O
the	DT	O
ATM	NNP	O
protein	NN	O
and	CC	O
suggests	VBZ	O
possible	JJ	O
approaches	NNS	O
to	TO	O
gene	NN	O
therapy	NN	O
.	.	O
.	.	O

Fusion	NNP	O
genes	NNS	O
resulting	VBG	O
from	IN	O
alternative	JJ	O
chromosomal	JJ	O
translocations	NNS	O
are	VBP	O
overexpressed	VBN	O
by	IN	O
gene	NN	O
-	:	O
specific	JJ	O
mechanisms	NNS	O
in	IN	O
alveolar	JJ	B_Disease
rhabdomyosarcoma	NN	E_Disease
.	.	O

Chromosomal	JJ	O
translocations	NNS	O
identified	VBN	O
in	IN	O
hematopoietic	JJ	B_Disease
and	CC	I_Disease
solid	JJ	I_Disease
tumors	NNS	E_Disease
result	VBP	O
in	IN	O
deregulated	JJ	O
expression	NN	O
of	IN	O
protooncogenes	NNS	O
or	CC	O
creation	NN	O
of	IN	O
chimeric	JJ	O
proteins	NNS	O
with	IN	O
tumorigenic	JJ	O
potential	NN	O
.	.	O

In	IN	O
the	DT	O
pediatric	JJ	O
solid	JJ	B_Disease
tumor	NN	E_Disease
alveolar	JJ	B_Disease
rhabdomyosarcoma	NN	E_Disease
,	,	O
a	DT	O
consistent	JJ	O
t	NN	O
(	(	O
2	CD	O
;	:	O
13	CD	O
)	)	O
(	(	O
q35	NN	O
;	:	O
q14	CC	O
)	)	O
or	CC	O
variant	JJ	O
t	NN	O
(	(	O
1	CD	O
;	:	O
13	CD	O
)	)	O
(	(	O
p36	NN	O
;	:	O
q14	CC	O
)	)	O
translocation	NN	O
generates	VBZ	O
PAX3	NNP	O
-	:	O
FKHR	NN	O
or	CC	O
PAX7	NNP	O
-	:	O
FKHR	NNP	O
fusion	NN	O
proteins	NNS	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
this	DT	O
report	NN	O
,	,	O
we	PRP	O
demonstrate	VBP	O
that	IN	O
in	IN	O
addition	NN	O
to	TO	O
functional	JJ	O
alterations	NNS	O
these	DT	O
translocations	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
fusion	NN	O
product	NN	O
overexpression	NN	O
.	.	O

Furthermore	RB	O
,	,	O
PAX3	NNP	O
-	:	O
FKHR	NN	O
and	CC	O
PAX7	NNP	O
-	:	O
FKHR	NNP	O
overexpression	NN	O
occurs	NNS	O
by	IN	O
distinct	JJ	O
mechanisms	NNS	O
.	.	O

Transcription	NN	O
of	IN	O
PAX3	NNP	O
-	:	O
FKHR	NNP	O
is	VBZ	O
increased	VBN	O
relative	JJ	O
to	TO	O
wild	VB	O
-	:	O
type	NN	O
PAX3	NNP	O
by	IN	O
a	DT	O
copy	NN	O
number	NN	O
-	:	O
independent	JJ	O
process	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
PAX7	NNP	O
-	:	O
FKHR	NNP	O
overexpression	NN	O
results	NNS	O
from	IN	O
fusion	JJ	O
gene	NN	O
amplification	NN	O
.	.	O

Thus	RB	O
,	,	O
gene	NN	O
-	:	O
specific	JJ	O
mechanisms	NNS	O
were	VBD	O
selected	VBN	O
to	TO	O
overexpress	VB	O
PAX3	NNP	O
-	:	O
FKHR	NN	O
and	CC	O
PAX7	NNP	O
-	:	O
FKHR	NN	O
in	IN	O
alveolar	JJ	B_Disease
rhabdomyosarcoma	NN	E_Disease
,	,	O
presumably	RB	O
due	JJ	O
to	TO	O
differences	NNS	O
in	IN	O
regulation	NN	O
between	IN	O
the	DT	O
wild	JJ	O
-	:	O
type	NN	O
loci	NN	O
.	.	O

We	PRP	O
postulate	VBP	O
that	IN	O
these	DT	O
overexpression	NN	O
mechanisms	NNS	O
ensure	VB	O
a	DT	O
critical	JJ	O
level	NN	O
of	IN	O
gene	NN	O
product	NN	O
for	IN	O
the	DT	O
oncogenic	JJ	O
effects	NNS	O
of	IN	O
these	DT	O
fusions	NNS	O
.	.	O
.	.	O

atm	NN	O
and	CC	O
p53	NN	O
cooperate	NN	O
in	IN	O
apoptosis	NN	O
and	CC	O
suppression	NN	O
of	IN	O
tumorigenesis	NN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
resistance	NN	O
to	TO	O
acute	VB	B_Disease
radiation	NN	I_Disease
toxicity	NN	E_Disease
.	.	O

Mutations	NNS	O
in	IN	O
atm	NN	O
and	CC	O
p53	NN	O
cause	VBP	O
the	DT	O
human	JJ	O
cancer	NN	B_Disease
-	:	I_Disease
associated	VBN	I_Disease
diseases	NNS	E_Disease
ataxia	VBP	B_Disease
-	:	I_Disease
telangiectasia	NN	E_Disease
and	CC	O
Li	NNP	B_Disease
-	:	I_Disease
Fraumeni	NNP	I_Disease
syndrome	NN	E_Disease
,	,	O
respectively	RB	O
.	.	O

The	DT	O
two	CD	O
genes	NNS	O
are	VBP	O
believed	VBN	O
to	TO	O
interact	VB	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
pathways	NNS	O
,	,	O
including	VBG	O
regulation	NN	O
of	IN	O
DNA	NNP	O
damage	NN	O
-	:	O
induced	VBN	O
cell	NN	O
-	:	O
cycle	NN	O
checkpoints	NNS	O
,	,	O
apoptosis	NN	O
and	CC	O
radiation	NN	O
sensitivity	NN	O
,	,	O
and	CC	O
cellular	JJ	O
proliferation	NN	O
.	.	O

Atm	NNP	O
-	:	O
null	JJ	O
mice	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
those	DT	O
null	JJ	O
for	IN	O
p53	NN	O
,	,	O
develop	VB	O
mainly	RB	O
T	NNP	B_Disease
-	:	I_Disease
cell	NN	I_Disease
lymphomas	NN	E_Disease
,	,	O
supporting	VBG	O
the	DT	O
view	NN	O
that	IN	O
these	DT	O
genes	NNS	O
have	VBP	O
similar	JJ	O
roles	NNS	O
in	IN	O
thymocyte	NN	O
development	NN	O
.	.	O

To	TO	O
study	VB	O
the	DT	O
interactions	NNS	O
of	IN	O
these	DT	O
two	CD	O
genes	NNS	O
on	IN	O
an	DT	O
organismal	JJ	O
level	NN	O
,	,	O
we	PRP	O
bred	VBD	O
mice	RB	O
heterozygous	JJ	O
for	IN	O
null	JJ	O
alleles	NNS	O
of	IN	O
both	DT	O
atm	NNS	O
and	CC	O
p53	NN	O
to	TO	O
produce	VB	O
all	DT	O
genotypic	NN	O
combinations	NNS	O
.	.	O

Mice	NNP	O
doubly	RB	O
null	RB	O
for	IN	O
atm	NN	O
and	CC	O
p53	NN	O
exhibited	VBD	O
a	DT	O
dramatic	JJ	O
acceleration	NN	O
of	IN	O
tumour	JJ	S_Disease
formation	NN	O
relative	NN	O
to	TO	O
singly	RB	O
null	JJ	O
mice	NN	O
,	,	O
indicating	VBG	O
that	IN	O
both	DT	O
genes	NNS	O
collaborate	VBP	O
in	IN	O
a	DT	O
significant	JJ	O
manner	NN	O
to	TO	O
prevent	VB	O
tumorigenesis	NN	O
.	.	O

With	IN	O
respect	NN	O
to	TO	O
their	PRP$	O
roles	NNS	O
in	IN	O
apoptosis	NN	O
,	,	O
loss	NN	O
of	IN	O
atm	NN	O
rendered	VBN	O
thymocytes	VBZ	O
only	RB	O
partly	RB	O
resistant	JJ	O
to	TO	O
irradiation	VB	O
-	:	O
induced	JJ	O
apoptosis	NN	O
,	,	O
whereas	JJ	O
additional	JJ	O
loss	NN	O
of	IN	O
p53	NN	O
engendered	VBD	O
complete	JJ	O
resistance	NN	O
.	.	O

This	DT	O
implies	VBZ	O
that	IN	O
the	DT	O
irradiation	NN	O
-	:	O
induced	JJ	O
atm	NN	O
and	CC	O
p53	NN	O
apoptotic	JJ	O
pathways	NNS	O
are	VBP	O
not	RB	O
completely	RB	O
congruent	JJ	O
.	.	O

Finally	RB	O
-	:	O
and	CC	O
in	IN	O
contrast	NN	O
to	TO	O
prior	VB	O
predictions	NNS	O
-	:	O
atm	NN	O
and	CC	O
p53	NN	O
do	VBP	O
not	RB	O
appear	VB	O
to	TO	O
interact	VB	O
in	IN	O
acute	JJ	B_Disease
radiation	NN	I_Disease
toxicity	NN	E_Disease
,	,	O
suggesting	VBG	O
a	DT	O
separate	JJ	O
atm	NN	O
effector	NN	O
pathway	NN	O
for	IN	O
this	DT	O
DNA	NNP	O
damage	NN	O
response	NN	O
and	CC	O
having	VBG	O
implications	NNS	O
for	IN	O
the	DT	O
prognosis	NN	O
and	CC	O
treatment	NN	O
of	IN	O
human	JJ	O
tumours	NNS	S_Disease
.	.	O
.	.	O

Trinucleotide	NNP	O
repeat	NN	O
expansion	NN	O
at	IN	O
the	DT	O
myotonic	JJ	B_Disease
dystrophy	NN	E_Disease
locus	NN	O
reduces	VBZ	O
expression	NN	O
of	IN	O
DMAHP	NNP	O
.	.	O

Myotonic	NNP	B_Disease
dystrophy	NN	E_Disease
,	,	O
or	CC	O
dystrophia	NN	B_Disease
myotonica	NN	E_Disease
(	(	O
DM	NNP	S_Disease
)	)	O
,	,	O
is	VBZ	O
an	DT	O
autosomal	JJ	B_Disease
dominant	JJ	I_Disease
multisystem	NN	I_Disease
disorder	NN	E_Disease
caused	VBN	O
by	IN	O
the	DT	O
expansion	NN	O
of	IN	O
a	DT	O
CTG	NNP	O
trinucleotide	NN	O
repeat	NN	O
in	IN	O
the	DT	O
3	CD	O
untranslated	JJ	O
region	NN	O
of	IN	O
the	DT	O
DMPK	NNP	O
protein	NN	O
kinase	VBD	O
gene	NN	O
on	IN	O
chromosome	NN	O
19q13	CD	O
.	.	O

3	CD	O
(	(	O
refs	VB	O
1	CD	O
-	:	O
3	CD	O
)	)	O
.	.	O

Although	IN	O
the	DT	O
DM	NNP	S_Disease
mutation	NN	O
was	VBD	O
identified	VBN	O
more	JJR	O
than	IN	O
five	CD	O
years	NNS	O
ago	RB	O
,	,	O
the	DT	O
pathogenic	JJ	O
mechanisms	NN	O
underlying	VBG	O
this	DT	O
most	RBS	O
prevalent	JJ	O
form	NN	O
of	IN	O
hereditary	JJ	O
adult	NN	O
neuromuscular	JJ	B_Disease
disease	NN	E_Disease
remain	VBP	O
elusive	JJ	O
.	.	O

Previous	JJ	O
work	NN	O
from	IN	O
our	PRP$	O
laboratory	NN	O
demonstrated	VBD	O
that	IN	O
a	DT	O
DNase	NNP	O
l	NN	O
-	:	O
hypersensitive	JJ	O
site	NN	O
located	VBN	O
adjacent	JJ	O
to	TO	O
the	DT	O
repeats	NNS	O
on	IN	O
the	DT	O
wild	JJ	O
-	:	O
type	NN	O
allele	NN	O
is	VBZ	O
eliminated	VBN	O
by	IN	O
repeat	NN	O
expansion	NN	O
,	,	O
indicating	VBG	O
that	IN	O
large	JJ	O
CTG	NNP	O
-	:	O
repeat	NN	O
arrays	NNS	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
a	DT	O
local	JJ	O
chromatin	NN	O
environment	NN	O
that	WDT	O
represses	VBZ	O
gene	NN	O
expression	NN	O
.	.	O

Here	RB	O
we	PRP	O
report	VBP	O
that	IN	O
the	DT	O
hypersensitive	JJ	O
site	NN	O
contains	VBZ	O
an	DT	O
enhancer	NN	O
element	NN	O
that	WDT	O
regulates	VBZ	O
transcription	NN	O
of	IN	O
the	DT	O
adjacent	JJ	O
DMAHP	NNP	O
homeobox	NN	O
gene	NN	O
.	.	O

Analysis	NN	O
of	IN	O
DMAHP	NNP	O
expression	NN	O
in	IN	O
the	DT	O
cells	NNS	O
of	IN	O
DM	NNP	S_Disease
patients	NNS	O
with	IN	O
loss	NN	O
of	IN	O
the	DT	O
hypersensitive	JJ	O
site	NN	O
revealed	VBD	O
a	DT	O
two	CD	O
-	:	O
to	TO	O
fourfold	VB	O
reduction	NN	O
in	IN	O
steady	JJ	O
-	:	O
state	NN	O
DMAHP	NNP	O
transcript	NN	O
levels	NNS	O
relative	VBP	O
to	TO	O
wild	VB	O
-	:	O
type	NN	O
controls	NNS	O
.	.	O

Allele	NNP	O
-	:	O
specific	JJ	O
analysis	NN	O
of	IN	O
DMAHP	NNP	O
expression	NN	O
showed	VBD	O
that	IN	O
steady	JJ	O
-	:	O
state	NN	O
transcript	NN	O
levels	NNS	O
from	IN	O
the	DT	O
expanded	VBN	O
allele	NN	O
were	VBD	O
greatly	RB	O
reduced	VBN	O
in	IN	O
comparison	NN	O
to	TO	O
those	DT	O
from	IN	O
the	DT	O
wild	JJ	O
-	:	O
type	NN	O
allele	NN	O
.	.	O

Together	RB	O
,	,	O
these	DT	O
results	NNS	O
demonstrate	VBP	O
that	IN	O
CTG	NNP	O
-	:	O
repeat	NN	O
expansions	NNS	O
can	MD	O
suppress	VB	O
local	JJ	O
gene	NN	O
expression	NN	O
and	CC	O
implicate	NN	O
DMAHP	NNP	O
in	IN	O
DM	NNP	S_Disease
pathogenesis	NN	O
.	.	O

Constitutively	RB	O
methylated	VBN	O
CpG	NNP	O
dinucleotides	NNS	O
as	IN	O
mutation	NN	O
hot	JJ	O
spots	NNS	O
in	IN	O
the	DT	O
retinoblastoma	NN	S_Disease
gene	NN	O
(	(	O
RB1	NNP	O
)	)	O
.	.	O

A	DT	O
wide	JJ	O
spectrum	NN	O
of	IN	O
mutations	NNS	O
,	,	O
ranging	VBG	O
from	IN	O
point	NN	O
mutations	NNS	O
to	TO	O
large	JJ	O
deletions	NNS	O
,	,	O
have	VBP	O
been	VBN	O
described	VBN	O
in	IN	O
the	DT	O
retinoblastoma	NN	S_Disease
gene	NN	O
(	(	O
RB1	NNP	O
)	)	O
.	.	O

Mutations	NNS	O
have	VBP	O
been	VBN	O
found	VBN	O
throughout	IN	O
the	DT	O
gene	NN	O
;	:	O
however	RB	O
,	,	O
these	DT	O
genetic	JJ	O
alterations	NNS	O
do	VBP	O
not	RB	O
appear	VB	O
to	TO	O
be	VB	O
homogeneously	RB	O
distributed	VBN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
a	DT	O
significant	JJ	O
proportion	NN	O
of	IN	O
disease	NN	O
-	:	O
causing	NN	O
mutations	NNS	O
results	NNS	O
in	IN	O
the	DT	O
premature	JJ	O
termination	NN	O
of	IN	O
protein	JJ	O
synthesis	NN	O
,	,	O
and	CC	O
the	DT	O
majority	NN	O
of	IN	O
these	DT	O
mutations	NNS	O
occur	VBP	O
as	IN	O
C	NNP	O
-	:	O
-	:	O
>	NN	O
T	NNP	O
transitions	NNS	O
at	IN	O
CpG	NNP	O
dinucleotides	NNS	O
(	(	O
CpGs	NNP	O
)	)	O
.	.	O

Such	JJ	O
recurrent	NN	O
CpG	NNP	O
mutations	NNS	O
,	,	O
including	VBG	O
those	DT	O
found	VBN	O
in	IN	O
RB1	NNP	O
,	,	O
are	VBP	O
likely	JJ	O
the	DT	O
result	NN	O
of	IN	O
the	DT	O
deamination	NN	O
of	IN	O
5	CD	O
-	:	O
methylcytosine	NN	O
within	IN	O
these	DT	O
CpGs	NNP	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
we	PRP	O
used	VBD	O
the	DT	O
sodiumbisulfite	JJ	O
conversion	NN	O
method	NN	O
to	TO	O
detect	VB	O
cytosine	JJ	O
methylation	NN	O
in	IN	O
representative	JJ	O
exons	NNS	O
of	IN	O
RB1	NNP	O
.	.	O

We	PRP	O
analyzed	VBD	O
DNA	NN	O
from	IN	O
a	DT	O
variety	NN	O
of	IN	O
tissues	NNS	O
and	CC	O
specifically	RB	O
targeted	VBD	O
CGA	NNP	O
codons	NNS	O
in	IN	O
RB1	NNP	O
,	,	O
where	WRB	O
recurrent	JJ	O
premature	NN	O
termination	NN	O
mutations	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
DNA	NNP	O
methylation	NN	O
within	IN	O
RB1	NNP	O
exons	NNS	O
8	CD	O
,	,	O
14	CD	O
,	,	O
25	CD	O
,	,	O
and	CC	O
27	CD	O
appeared	VBD	O
to	TO	O
be	VB	O
restricted	VBN	O
to	TO	O
CpGs	NNP	O
,	,	O
including	VBG	O
six	CD	O
CGA	NNP	O
codons	NNS	O
.	.	O

Other	JJ	O
codons	NNS	O
containing	VBG	O
methylated	VBN	O
cytosines	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
mutated	VBN	O
.	.	O

Therefore	RB	O
,	,	O
disease	VB	O
-	:	O
causing	NN	O
mutations	NNS	O
at	IN	O
CpGs	NNP	O
in	IN	O
RB1	NNP	O
appear	VBP	O
to	TO	O
be	VB	O
determined	VBN	O
by	IN	O
several	JJ	O
factors	NNS	O
,	,	O
including	VBG	O
the	DT	O
constitutive	JJ	O
presence	NN	O
of	IN	O
DNA	NNP	O
methylation	NN	O
at	IN	O
cytosines	NNS	O
within	IN	O
CpGs	NNP	O
,	,	O
the	DT	O
specific	JJ	O
codon	NN	O
within	IN	O
which	WDT	O
the	DT	O
methylated	JJ	O
cytosine	NN	O
is	VBZ	O
located	VBN	O
,	,	O
and	CC	O
the	DT	O
particular	JJ	O
region	NN	O
of	IN	O
the	DT	O
gene	NN	O
within	IN	O
which	WDT	O
that	IN	O
codon	NN	O
resides	NNS	O
.	.	O
.	.	O

The	DT	O
von	NN	B_Disease
Hippel	NNP	I_Disease
-	:	I_Disease
Lindau	NNP	I_Disease
tumor	NN	E_Disease
suppressor	NN	O
gene	NN	O
product	NN	O
interacts	NNS	O
with	IN	O
Sp1	NNP	O
to	TO	O
repress	VB	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
promoter	NN	O
activity	NN	O
.	.	O

The	DT	O
von	NN	B_Disease
Hippel	NNP	I_Disease
-	:	I_Disease
Lindau	NNP	I_Disease
tumor	NN	E_Disease
suppressor	NN	O
gene	NN	O
(	(	O
VHL	NNP	O
)	)	O
has	VBZ	O
a	DT	O
critical	JJ	O
role	NN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
clear	JJ	B_Disease
-	:	I_Disease
cell	NN	I_Disease
renal	JJ	I_Disease
cell	NN	I_Disease
carcinoma	NN	E_Disease
(	(	O
RCC	NNP	S_Disease
)	)	O
,	,	O
as	IN	O
VHL	NNP	O
mutations	NNS	O
have	VBP	O
been	VBN	O
found	VBN	O
in	IN	O
both	DT	O
von	NNP	B_Disease
Hippel	NNP	I_Disease
-	:	I_Disease
Lindau	NNP	I_Disease
disease	NN	I_Disease
-	:	I_Disease
associated	VBN	I_Disease
and	CC	I_Disease
sporadic	JJ	I_Disease
RCCs	NNP	E_Disease
.	.	O

Recent	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
(	(	O
VEGF	NNP	O
)	)	O
mRNA	NN	O
is	VBZ	O
upregulated	VBN	O
in	IN	O
RCC	NNP	B_Disease
-	:	I_Disease
and	CC	I_Disease
von	VB	I_Disease
Hippel	NNP	I_Disease
-	:	I_Disease
Lindau	NNP	I_Disease
disease	NN	I_Disease
-	:	I_Disease
associated	VBN	I_Disease
tumors	NNS	E_Disease
.	.	O

We	PRP	O
have	VBP	O
therefore	RB	O
assessed	VBN	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
VHL	NNP	O
gene	NN	O
product	NN	O
on	IN	O
VEGF	NNP	O
expression	NN	O
.	.	O

VEGF	NNP	O
promoter	NN	O
-	:	O
luciferase	NN	O
constructs	NNS	O
were	VBD	O
transiently	RB	O
cotransfected	VBN	O
with	IN	O
a	DT	O
wild	JJ	O
-	:	O
type	NN	O
VHL	NNP	O
(	(	O
wt	SYM	O
-	:	O
VHL	NN	O
)	)	O
vector	NN	O
in	IN	O
several	JJ	O
cell	NN	O
lines	NNS	O
,	,	O
including	VBG	O
293	CD	O
embryonic	JJ	O
kidney	NN	O
and	CC	O
RCC	NNP	S_Disease
cell	NN	O
lines	NNS	O
.	.	O

wt	SYM	O
-	:	O
VHL	NNP	O
protein	NN	O
inhibited	VBD	O
VEGF	NNP	O
promoter	NN	O
activity	NN	O
in	IN	O
a	DT	O
dose	JJ	O
-	:	O
dependent	NN	O
manner	NN	O
up	IN	O
to	TO	O
5	CD	O
-	:	O
to	TO	O
10	CD	O
-	:	O
fold	NN	O
.	.	O

Deletion	NN	O
analysis	NN	O
defined	VBD	O
a	DT	O
144	CD	O
-	:	O
bp	JJ	O
region	NN	O
of	IN	O
the	DT	O
VEGF	NNP	O
promoter	NN	O
necessary	JJ	O
for	IN	O
VHL	NNP	O
repression	NN	O
.	.	O

This	DT	O
VHL	NNP	O
-	:	O
responsive	JJ	O
element	NN	O
is	VBZ	O
GC	NNP	O
rich	JJ	O
and	CC	O
specifically	RB	O
binds	VBZ	O
the	DT	O
transcription	NN	O
factor	NN	O
Sp1	NNP	O
in	IN	O
crude	JJ	O
nuclear	JJ	O
extracts	NNS	O
.	.	O

In	IN	O
Drosophila	NNP	O
cells	NNS	O
,	,	O
cotransfected	VBD	O
VHL	NNP	O
represses	NNS	O
Sp1	NNP	O
-	:	O
mediated	VBN	O
activation	NN	O
but	CC	O
not	RB	O
basal	JJ	O
activity	NN	O
of	IN	O
the	DT	O
VEGF	NNP	O
promoter	NN	O
.	.	O

We	PRP	O
next	RB	O
demonstrated	VBD	O
in	IN	O
coimmunoprecipitates	NNS	O
that	IN	O
VHL	NNP	O
and	CC	O
Sp1	NNP	O
were	VBD	O
part	NN	O
of	IN	O
the	DT	O
same	JJ	O
complex	NN	O
and	CC	O
,	,	O
by	IN	O
using	VBG	O
a	DT	O
glutathione	NN	O
-	:	O
S	NNP	O
-	:	O
transferase	NN	O
-	:	O
VHL	NNP	O
fusion	NN	O
protein	NN	O
and	CC	O
purified	JJ	O
Sp1	NNP	O
,	,	O
that	IN	O
VHL	NNP	O
and	CC	O
Sp1	NNP	O
directly	RB	O
interact	VBP	O
.	.	O

Furthermore	RB	O
,	,	O
endogenous	JJ	O
VEGF	NNP	O
mRNA	NN	O
levels	NNS	O
were	VBD	O
suppressed	VBN	O
in	IN	O
permanent	JJ	O
RCC	NNP	S_Disease
cell	NN	O
lines	NNS	O
expressing	VBG	O
wt	SYM	O
-	:	O
VHL	NN	O
,	,	O
and	CC	O
nuclear	JJ	O
run	NN	O
-	:	O
on	IN	O
studies	NNS	O
indicated	VBD	O
that	IN	O
VHL	NNP	O
regulation	NN	O
of	IN	O
VEGF	NNP	O
occurs	VBZ	O
at	IN	O
least	JJS	O
partly	RB	O
at	IN	O
the	DT	O
transcriptional	JJ	O
level	NN	O
.	.	O

These	DT	O
observations	NNS	O
support	VBP	O
a	DT	O
new	JJ	O
mechanism	NN	O
for	IN	O
VHL	NNP	O
-	:	O
mediated	VBD	O
transcriptional	JJ	O
repression	NN	O
via	IN	O
a	DT	O
direct	JJ	O
inhibitory	NN	O
action	NN	O
on	IN	O
Sp1	NNP	O
and	CC	O
suggest	VBP	O
that	IN	O
loss	NN	O
of	IN	O
Sp1	NNP	O
inhibition	NN	O
may	MD	O
be	VB	O
important	JJ	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
von	NN	B_Disease
Hippel	NNP	I_Disease
-	:	I_Disease
Lindau	NNP	I_Disease
disease	NN	E_Disease
and	CC	O
RCC	NNP	S_Disease
.	.	O
.	.	O

Adult	NNP	B_Disease
onset	MD	I_Disease
globoid	VB	I_Disease
cell	NN	I_Disease
leukodystrophy	NN	E_Disease
(	(	O
Krabbe	NNP	B_Disease
disease	NN	E_Disease
)	)	O
:	:	O
analysis	NN	O
of	IN	O
galactosylceramidase	NN	O
cDNA	NN	O
from	IN	O
four	CD	O
Japanese	JJ	O
patients	NNS	O
.	.	O

We	PRP	O
examined	VBD	O
galactosylceramidase	NN	O
(	(	O
GALC	NNP	O
)	)	O
cDNA	NN	O
in	IN	O
four	CD	O
Japanese	JJ	O
patients	NNS	O
with	IN	O
adult	JJ	B_Disease
onset	VBN	I_Disease
globoid	NN	I_Disease
cell	NN	I_Disease
leukodystrophy	NN	E_Disease
(	(	O
Krabbe	NNP	B_Disease
disease	NN	E_Disease
;	:	O
AO	NNP	B_Disease
-	:	I_Disease
GLD	NN	E_Disease
)	)	O
by	IN	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
/	NNP	O
single	JJ	O
-	:	O
strand	NN	O
conformation	NN	O
polymorphism	NN	O
(	(	O
PCR	NNP	O
-	:	O
SSCP	NN	O
)	)	O
analysis	NN	O
,	,	O
subsequent	JJ	O
sequence	NN	O
determination	NN	O
,	,	O
and	CC	O
restriction	NN	O
enzyme	FW	O
digestion	NN	O
of	IN	O
PCR	NNP	O
products	NNS	O
,	,	O
initial	JJ	O
symptoms	NNS	O
were	VBD	O
the	DT	O
onset	NN	O
of	IN	O
slowly	RB	O
progressive	JJ	O
spastic	JJ	B_Disease
paraplegia	NN	E_Disease
from	IN	O
the	DT	O
middle	NN	O
of	IN	O
the	DT	O
second	JJ	O
decade	NN	O
,	,	O
and	CC	O
all	DT	O
patients	NNS	O
had	VBD	O
diminished	VBN	B_Disease
GALC	NNP	I_Disease
activity	NN	E_Disease
in	IN	O
their	PRP$	O
leukocytes	NNS	O
.	.	O

We	PRP	O
identified	VBD	O
three	CD	O
missense	NN	O
mutations	NNS	O
(	(	O
I66M	NNP	O
,	,	O
G270D	NNP	O
,	,	O
L618S	NNP	O
)	)	O
and	CC	O
one	CD	O
exon	NN	O
-	:	O
6	CD	O
skipping	NN	O
(	(	O
535	CD	O
-	:	O
573del	CD	O
)	)	O
.	.	O

Two	CD	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
only	RB	O
the	DT	O
I66M	NNP	O
mutant	NN	O
mRNA	NN	O
,	,	O
and	CC	O
one	CD	O
only	RB	O
the	DT	O
G27OD	NNP	O
mutant	NN	O
mRNA	NN	O
.	.	O

The	DT	O
fourth	JJ	O
patient	NN	O
carried	VBD	O
a	DT	O
compound	NN	O
heterozygous	JJ	O
mutation	NN	O
of	IN	O
535	CD	O
-	:	O
573del	CD	O
and	CC	O
L618S	NNP	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
enzymatic	JJ	O
activities	NNS	O
produced	VBN	O
by	IN	O
these	DT	O
mutations	NNS	O
,	,	O
we	PRP	O
constructed	VBD	O
mutated	VBN	O
GALC	NNP	O
cDNAs	NN	O
and	CC	O
expressed	VBD	O
them	PRP	O
in	IN	O
COS	NNP	O
-	:	O
1	CD	O
cells	NNS	O
.	.	O

Three	CD	O
mutations	NNS	O
,	,	O
viz	NN	O
.	.	O
,	,	O
G270D	NNP	O
,	,	O
L618S	NNP	O
,	,	O
and	CC	O
exon	SYM	O
-	:	O
6	CD	O
skipping	NN	O
(	(	O
535	CD	O
-	:	O
573del	CD	O
)	)	O
,	,	O
produced	VBD	O
diminished	JJ	B_Disease
GALC	NNP	I_Disease
activity	NN	E_Disease
as	IN	O
expected	VBN	O
.	.	O

The	DT	O
I66M	NNP	O
mutation	NN	O
in	IN	O
the	DT	O
wild	JJ	O
-	:	O
type	NN	O
GALC	NNP	O
cDNA	NN	O
(	(	O
I289	NNP	O
)	)	O
had	VBD	O
normal	JJ	O
activity	NN	O
,	,	O
but	CC	O
when	WRB	O
this	DT	O
mutation	NN	O
and	CC	O
the	DT	O
V289	NNP	O
polymorphism	NN	O
were	VBD	O
introduced	VBN	O
into	IN	O
the	DT	O
same	JJ	O
allele	NN	O
,	,	O
it	PRP	O
had	VBD	O
decreased	VBN	O
activity	NN	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
combination	NN	O
of	IN	O
a	DT	O
unique	JJ	O
mutation	NN	O
and	CC	O
polymorphism	NN	O
causes	NNS	O
conformational	JJ	O
change	NN	O
in	IN	O
the	DT	O
GALC	NNP	O
enzyme	NN	O
,	,	O
resulting	VBG	O
in	IN	O
low	JJ	O
enzymatic	JJ	O
activity	NN	O
.	.	O

AO	NNP	B_Disease
-	:	I_Disease
GLD	NNP	E_Disease
mutations	NNS	O
,	,	O
including	VBG	O
those	DT	O
found	VBN	O
here	RB	O
,	,	O
are	VBP	O
located	VBN	O
in	IN	O
the	DT	O
N	NNP	O
-	:	O
terminus	NN	O
(	(	O
I66M	NNP	O
,	,	O
G270D	NNP	O
,	,	O
535	CD	O
-	:	O
573del	CD	O
)	)	O
or	CC	O
C	NNP	O
-	:	O
terminus	NN	O
(	(	O
L618S	NNP	O
)	)	O
of	IN	O
the	DT	O
GALC	NNP	O
enzyme	NN	O
,	,	O
whereas	IN	O
the	DT	O
reported	JJ	O
mutations	NNS	O
in	IN	O
the	DT	O
infantile	JJ	O
form	NN	O
(	(	O
IF	NNP	B_Disease
-	:	I_Disease
GLD	NN	E_Disease
)	)	O
are	VBP	O
in	IN	O
the	DT	O
central	JJ	O
domain	NN	O
.	.	O

This	DT	O
difference	NN	O
in	IN	O
mutation	NN	O
sites	NNS	O
may	MD	O
affect	VB	O
the	DT	O
clinical	JJ	O
features	NNS	O
of	IN	O
GLD	NNP	S_Disease
.	.	O

